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Abstract 
 
This thesis describes the identification of sixty five secondary metabolites from thirteen 
separate organisms (three terrestrial and ten marine specimens). A total of twenty two new 
and forty two known secondary metabolites, as well as one new natural product derivative 
were identified by chemical profiling utilising HPLC-NMR and HPLC-MS together with 
traditional off-line isolation strategies. Of the new compounds identified, fourteen displayed 
antibiotic activity. For nine of the compounds identified the 2D NMR characterisation is now 
reported for the first time in addition to five carbon and one proton NMR chemical shift 
reassignments. The single X-ray crystallographic structures for three of the compounds 
identified were also reported. Five previously reported compounds are now reported as 
natural products for the first time. HPLC-NMR was vital in the identification of an unstable 
meroditerpenoid that could not be isolated by off-line approaches. This PhD study also 
resulted in the first report of the acquisition of a gHMBCAD NMR spectrum obtained in the 
stop-flow HPLC-NMR mode, without pre-concentration, microcoils or cryogenically cooled 
probes.  
 
Chapters 1-3 provide an introduction to natural products, isolation techniques as applied to 
natural products, an explanation and examples of dereplication strategies, an outline of the 
common NMR experiments used for natural product identification and a review of the recent 
advancements made in HPLC-NMR as well as its application to natural product 
identification.  
 
xv 
 
Chapter 4 details the limit of detection determined for five key NMR experiments in HPLC-
NMR, which were found to be within the 700 ng to 1 mg range, typical of that observed in 
natural product crude extracts. HPLC-NMR was subsequently successfully applied to a 
natural product crude extract for which complete 2D NMR data could be obtained for the 
major component. 
 
Chapter 5 outlines the constituents identified from the flowers and bulbs of the Australian 
plant, Macropidia fuliginosa. The flowers and bulbs produced very different chemistry, and a 
total of sixteen compounds were identified, including six new and ten previously reported 
compounds. The single X-ray crystal structure for three compounds is also presented. 
 
Chapter 6 describes the identification of eleven compounds including two new 
phenylphenalenones and two new chromenes from the bulbs of the Australian plant 
Haemodorum spicatum.  
 
Chapter 7 summarises the identification of three fatty acids from the yellow fungus 
Leucocoprinus birnbaumii. The positions of the double bonds were secured by ozonolysis 
methods.  
 
Chapter 8 outlines the dereplication of compounds from seven marine algae. Compounds 
were dereplicated using HPLC-NMR and HPLC-MS data in conjunction with the MarinLit 
database. Sixteen compounds were dereplicated including four new compounds. 
xvi 
 
Chapter 9 highlights the identification of four new and nine known meroditerpenoids from 
the brown alga Sargassum paradoxum. HPLC-NMR was vital for the identification of an 
unstable meroditerpenoid that oxidised during off-line isolation. 
 
Chapter 10 describes the dereplication and identification of phloroglucinols from two 
Cystophora species, including four new and eight known phloroglucinols. HPLC-NMR and 
HPLC-NMR was able to rapidly establish that both marine algae contained the same structure 
class of compounds.  
 
Chapter 11 summaries the relative configuration of elatenyne which was proposed on the 
basis of 1D nOe NMR and chemical derivatisation methods. 
  
xvii 
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 PART A - Introduction 
 
The chapters that encompass this section of the thesis (Chapters 1-4) include an 
overview of natural products, an outline and description of chemical profiling and 
dereplication, and the approaches adopted in this PhD thesis. Also included is the application 
of NMR to structurally identify natural products, recent advancements in HPLC-NMR and 
the limit of detection for a specific HPLC-NMR system. 
This section of the thesis comprises two journal publications and one book section of 
a book chapter as listed below: 
1. Brkljača, Robert, & Urban, Sylvia. (2014). Selected Applications of 
NMR Spectroscopy - Natural Products. In J. Fisher (Ed.), Modern 
NMR Techniques for Synthetic Chemistry. Florida, USA: CRC Press. 
2. Brkljača, Robert, & Urban, Sylvia. (2011). Recent Advancements in 
HPLC-NMR and Applications for Natural Product Profiling and 
Identification. Journal of Liquid Chromatography & Related 
Technologies, 34(12), 1063-1076.  
3. Brkljača, Robert, & Urban, Sylvia. (2015). Limit of Detection Studies 
for Application to Natural Product Identification using High 
Performance Liquid Chromatography Coupled to Nuclear Magnetic 
Resonance Spectroscopy. Journal of Chromatography A, 1375, 69-75.  
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CHAPTER 1 
Overview and background on Natural Products, Chemical 
Profiling/Dereplication and Strategies Adopted 
 
Natural Products 
Natural products, also known as secondary metabolites, are compounds produced by 
terrestrial and marine organisms. While it is not known exactly why these compounds are 
produced, it is thought that they may provide the organism with a possible chemical defence 
mechanism (Bennett & Wallsgrove, 1994; Pawlik, Chanas, Toonen, & Fenical, 1995) or to 
enhance the organisms overall fitness (reproduction, chemical communication, cell function) 
(Hay, 2009; Puglisi, Sneed, Sharp, Ritson-Williams, & Paul, 2014). Since historic times 
natural products have proved to be an important resource for the identification of potential 
new pharmaceuticals. Both terrestrial and marine sources have yielded a variety of 
compounds, displaying unique carbon skeletons and important therapeutic properties. 
Newman and Cragg reported that over the past 30 years (1981-2010), approximately 50% of 
the new drug entities have been discovered or are derived from a natural product origin 
(Newman & Cragg, 2012). Nature has the ability to create complex structural motifs which 
can also incorporate stereochemistry, which is difficult to recreate using synthetic and 
combinatorial chemistry. Natural products may also be used as drug leads, whereby an 
inactive or slightly active natural product is chemically modified to increase the potency or 
biological availability. Anti-cancer natural products represent the greatest number of new 
drug entities, however anti-bacterial and anti-viral natural products closely follow this 
Page 2
number (Newman & Cragg, 2012). In the area of anti-biotics, there is a pressing need for the 
discovery of new drugs. With the existence of drug resistant strains of bacteria, the discovery 
of new anti-biotics has never been more important. For instance the occurrence of resistant 
strains such as Pseudomonas aeruginosa and other multidrug resistant pathogens is well 
documented (Giamarellou & Poulakou, 2009; Igbinosa et al., 2012), and there is a need to 
discover new drugs to target these strains. In addition, the emergence of new diseases also 
necessitates the need for new drugs. Natural product sources, particularly marine 
invertebrates, provide an ideal avenue for potential new drug discovery. 
Terrestrial Organisms 
Terrestrial organisms such as plants and fungi have been studied extensively and have 
a large precedence historically in drug discovery. Plants and fungi are generally easily 
accessible and larger amounts can usually be collected, making them ideal for natural product 
discovery. One of the earliest success stories of a terrestrial based natural product is penicillin 
G (1) (Figure 1) which was isolated and identified from the Penicillium bacterium in 1928 
("American Chemical Society International Historic Chemical Landmarks. Discovery and 
Development of Penicillin,"). Taxol (2), an approved anti-cancer drug, from the bark of 
Taxus brevifolia, was isolated in its pure form in 1967, but difficulty in determining its 
identity meant that the complete structure was not reported until 1971 (Wani, Taylor, Wall, 
Coggon, & McPhail, 1971). Silybin (3), is an example of a plant derived natural product 
currently undergoing clinical trials as an anti-cancer agent (Butler, 2008; Provinciali et al., 
2007). 
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Figure 1: Chemical structures of penicillin (1), taxol (2) and silybin (3). 
Ethnopharmacology is the study of plants traditionally used by native people to treat 
certain illnesses, such as the treatments used by the Australian Aborigines and in traditional 
Chinese medicines. The herb, Artemisia annua had been used for centuries as a traditional 
Chinese medicine to treat malaria, and during the investigation of this herb in 1971, the active 
component responsible for the anti-malarial activity was identified as artemisinin (4) 
(Klayman, 1985) (Figure 2). 
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Figure 2: Chemical structure of artemisinin (4). 
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Terrestrial organisms generally produce different chemistry than their marine 
counterparts (Pietra, 2002), however there have been cases where natural products isolated 
from plants have also been isolated from marine sources, as in the case of δ-tocotrienol, 
which has been isolated from the plant Cinnamosma fragrans (Harinantenaina & Takaoka, 
2006), and the alga Cystophora siliquosa (Laird et al., 2010). It is estimated that 5-15% of 
higher plants have been evaluated for the chemistry they produce (Cragg & Newman, 2005). 
Plants and Fungi 
Plants are composed of different components, such as the bulbs (or roots), stems, 
leaves, flowers and, at times, fruit. When undertaking an investigation of a plant, it is 
important to evaluate all parts of the plant individually, as each component/part may contain 
different chemistry, and therefore, different biological activity. For instance the roots of 
Strobilanthes cusia have been found to produce (+)-9-O-β-D-glucopyranosyl lariciresinol 
(Tanaka et al., 2004) whilst the leaves produce strobilanthoside A (6) (Gu et al., 2014) 
(Figure 3).  
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Figure 3: Chemical structures of (+)-9-O-β-D-glucopyranosyl lariciresinol (5) and 
strobilanthoside A (6). 
Fungi can be classified into the micro- and the macro-fungi. The micro-fungi are most 
easily described as mould-type fungi, whereas the macro-fungi are described as mushrooms, 
or fungi that produce easily visible bodies. Chaetoviridin E (7) was identified from the micro-
fungus Chaetomium sp. and displays anti-microbial activity (Kingsland & Barrow, 2009), 
while the triterpene lactone, ganodermalactone F (8) was identified from the macro-fungus 
Ganoderma sp., displaying anti-malarial activity(Lakornwong et al., 2014) (Figure 4).  
 
Page 6
chaetoviridin E (7) ganodermalactone F (8)
OO
H
O
O
H
O
O
O
O
Cl
O
O
HO
 
Figure 4: Chemical structures of chaetoviridin E (7) and ganodermalactone F (8). 
Marine Invertebrates 
Marine invertebrates have been studied less extensively than terrestrial organisms.  
This has been mainly attributed to the difficulty in obtaining the specimens and because 
marine organisms are generally less stable and more difficult to preserve than terrestrial 
species (Jha & Zi-rong, 2004). It was not until the advent of SCUBA (1970s) and then later 
the introduction of remotely operated vehicles (ROVs) that access to marine specimens 
became easier and more popular (Cragg & Newman, 2013). The marine environment is 
particularly suited to natural product discovery as 70% of the earth is covered by oceans, and 
the biodiversity observed in the marine environment greatly exceeds that seen on land (Jaume 
& Duarte, 2006). In recent years, extreme environments such as deep sea mounts and 
geothermal vents have provided a wealth of new chemistry which can be attributed to the 
unique biodiversity and the number of species in these locations(Skropeta & Wei, 2014). 
Like terrestrial species, many marine invertebrates are sessile, but any natural product 
produced by marine invertebrates as a chemical defence must be exponentially more potent, 
as it undergoes dilution into the surrounding seawater (Haefner, 2003). The first study of a 
marine invertebrate to yield biologically active compounds was in 1951, which reported the 
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isolation of a nucleoside, spongothymidine (9), from the sponge Cryptotethia crypta 
(Bergman & Feeney, 1951) (Figure 5). 
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Figure 5: Chemical structure of the nucleoside identified from Cryptotethia crypta. 
 
Far fewer marine natural products have been approved as drugs. Research in this area 
has only been undertaken for the past 50 years, compared to natural products derived from 
terrestrial organisms which have been used for centuries across many civilisations and then 
studied extensively over the last century. The guidelines for drug approval (eg. FDA) have 
also changed significantly over the years, and in general have become more strict in 
approving a potential drug. This may have also affected the number of approved drugs in the 
recent decade/years. One of the first approved drugs from a marine organism was ziconotide 
(10) (Figure 6), a 25-amino acid peptide derived from the cone snail Conus magus(Mayer et 
al., 2010). Clinical studies continue to be carried out on marine natural products such as 
tetrodotoxin (11) (Figure 6) which is currently in phase 3 clinical trials to treat chronic pain 
("About TTX," ; "Marine pharmaceuticals: the clinical pipeline,"). A review published in 
2014 outlines other natural products in clinical trials (Butler, Robertson, & Cooper, 2014), 
which includes six compounds isolated or derived from marine invertebrates undergoing 
oncology trials, including plitidepsin (12) and bryostatin 1 (13).  
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Figure 6: Chemical structures of ziconotide (10), tetrodotoxin (11), plitidepsin (12) 
and bryostatin 1 (13). 
 
Marine Algae 
Marine algae are comprised of four primary phyla; the red (Rhodophyta), green 
(Chlorophyta), brown (Phaeophyta) and the blue-green algae (Cyanobacteria) (Kornprobst, 
2014). Each of these phyla displays unique features. Blue-green algae produce an abundant 
number of secondary metabolites containing nitrogen (approximately 80%) compared to the 
brown algae which display less than 5% of nitrogen containing secondary metabolites 
(Kornprobst, 2014). Terpenes constitute the largest chemical class present in marine 
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algae(Kornprobst, 2014), however the chemical classes present between different phyla of 
algae can vary significantly. Approximately 50% of the compounds reported from green 
algae are terpenes (Kornprobst, 2014), however the red algae produce a large number of 
halogen containing secondary metabolites (Choi, Pereira, & Gerwick, 2012). While each 
phylum of marine algae can display different chemistry, algae of the same phyla but from 
different genera, can also display different chemistry. Sargassum and Caulocystis represent 
two different genera belonging to the Phaeophyta (brown algae) phylum. The Sargassum 
genus is known to produce meroditerpenoid and phloroglucinol related compounds, while the 
Caulocystis genus produces acetogenin and resorcinol related compounds (MarinLit, 2015). 
A recent review evaluated the number of new natural products reported from marine 
organisms. In 2013, a total of 40 (3.4%) of the new compounds were discovered from marine 
algae (Blunt, Copp, Keyzers, Munro, & Prinsep, 2015). Figure 7 illustrates the number of 
new compounds per phyla, and clearly shows that the Chlorophyta have yielded the fewest 
number of new compounds. Interestingly the number of new compounds reported from 
Cyanobacteria and Rhodophyta had noticeably dropped compared to the previous year 
(Blunt, Copp, Keyzers, Munro, & Prinsep, 2014). Of the numerous bioactive compounds 
reported from marine algae, the cryptophycins represent a chemical class that displays potent 
anti-cancer activity (Smith, Zhang, Mooberry, Patterson, & Moore, 1994; Verma et al., 
2015). Cryptophycin (14) (Figure 8) is an example of one of the members of the 
cryptophycin family, which is derived from the cyanobacteria Nostoc sp.(Smith et al., 1994; 
Verma et al., 2015).  
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 Figure 7: Number of new natural products identified in 2013 from the four main phyla of 
marine algae. 
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Figure 8: Chemical structure of cryptophycin (14). 
 
Conventional or Traditional Isolation and Identification of Natural 
Products 
Traditionally, the isolation and identification of natural products is carried out using 
fractionation steps involving various separation/purification methodologies followed by 
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characterisation using conventional solution state Nuclear Magnetic Resonance (NMR) 
spectroscopy in conjunction with mass spectrometric analyses. Bench column 
chromatography such as silica, C18 and Sephadex LH-20 are commonly employed to 
fractionate crude extracts which are then typically further purified by reversed phase High 
Pressure Liquid Chromatography (RP-HPLC). This fractionation/isolation process can be 
quite a time consuming approach and can leave compounds susceptible to possible 
degradation or conversion to artifacts (Ghisalberti, 2007). It is also highly probable that 
following lengthy isolation procedures known compounds may be isolated. Once a pure 
compound is isolated it is identified using a range of 1D and 2D NMR spectroscopic 
experiments. An overview of these experiments and the approach taken to identify a range of 
natural products is outlined in Chapter 2. Isolated natural products (or secondary 
metabolites), often require further studies to deduce the complete structure and to characterise 
the compound. For instance to determine the absolute configuration, approaches including 
chemical degradation/derivatisation, circular dichroism (CD) or single crystal X-ray 
diffraction are available. For new compounds, mass spectrometry (MS), infra-red 
spectrometry (IR), ultra-violet spectrometry (UV) and specific rotation (in the case of chiral 
compounds) measurements need to be routinely carried out to undertake a complete 
characterisation.  
Dereplication and Chemical Profiling 
Chemical profiling or dereplication allows for the rapid identification of natural 
products without the need for lengthy off-line isolations and to attempt to minimise the risk 
of possible degradation. The aim is to identify the presence of known natural products as well 
as possible new compounds as rapidly as possible.  
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Dereplication generally refers to the identification of secondary metabolites in 
bioactive natural product extracts utilising a range of methodologies (Lang et al., 2008). 
Approaches in this area have involved the generation of fractions using various solid-phase 
chromatographic supports (eg. C18, Sephadex LH-20 and ion-exchange) to ascertain the 
relative polarity, size and possible charge of the bioactive fractions. More recently a HPLC 
bioactivity profiling/microtitre plate technique was reported in conjunction with capillary 
NMR (CapNMR) (Lang et al., 2008). Finally, hyphenated spectrometric or spectroscopic 
techniques such as HPLC-MS or HPLC-NMR can also be used to assist in dereplication. The 
use of these techniques is often not sufficient for actual compound identification, but can 
greatly assist with structure class confirmation. Once information such as mass, UV 
chromophore, taxonomy or the presence of any unique NMR signals can be concluded, the 
use of chemical databases (eg. MarinLit, Dictionary of Natural Products or Scifinder) to 
assist the dereplication is mandatory.  
Databases 
Each chemical database has a separate set of parameters that can be searched, but 
generally, most contain the ability to search by taxonomy, UV and MS data. The ‘MarinLit’ 
and ‘Dictionary of Naturals Products’ databases were the two databases used throughout 
these studies. Unique to the MarinLit database is the ability to search by NMR spectroscopic 
data. Dereplication of the components described in this thesis was generally achieved by 
searching a combination of the taxonomy, UV, proton/carbon NMR and MS data. In cases 
where multiple probable structures were identified, the NMR data obtained from HPLC-
NMR was further reviewed to establish which of the structures was most likely. In cases 
where no match or a possible new compound was suggested, dereplication was carried out 
using a broader search regime. This generally involved using the taxonomy and UV data, to 
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assist in determining the nature of the structure class. Further evaluation of the MS and NMR 
data would then allow for a tentative structure to be proposed.  
HPLC-MS 
As indicated earlier, chemical profiling can involve the use of hyphenated 
spectrometric or spectroscopic methodologies. High Pressure Liquid Chromatography 
coupled to Mass Spectrometry (HPLC-MS) is a widely utilised profiling technique in the area 
of natural products. In this approach components within a crude extract can be easily 
separated, which allows for the acquisition of UV spectra (through PDA detection) and for 
potential molecular ions to be identified. Ideally an instrument capable of accurate mass (4 or 
5 decimal places) is employed, which allows for the determination of molecular formulae, 
however low resolution instrumentation can also provide sufficient information to aid in 
possible compound identification. HPLC-MS is a sensitive technique making it suited to the 
area of natural product identification. However, molecular ions and molecular formulae alone 
are not always sufficient to unequivocally or tentatively identify components and additional 
data is needed, such as NMR spectroscopic data, especially in the case of structurally related 
isomers. In addition, a drawback of HPLC-MS is that it relies on the ability of compounds to 
ionise, whereby if a compound does not ionise, no molecular ion will be detected. HPLC-MS 
utilises soft ionisation techniques such as electrospray ionisation (ESI) and atmospheric 
pressure chemical ionisation (APCI). These soft ionisation techniques are perfectly suited for 
natural product analysis as it results in the observation of primarily the molecular ion and 
very few fragments, and, in this way it can easily allow for the determination of molecular 
formulae. Tandem mass spectrometry systems (MS/MS) allow for further fragmentation of 
the molecular ion and subsequent ions, yielding further information about the compound’s 
structure.  
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HPLC-NMR 
High Pressure Liquid Chromatography coupled to Nuclear Magnetic Resonance 
(HPLC-NMR) allows for the acquisition of important 1D and 2D NMR spectroscopic data 
that is vital for complete structure identification. HPLC-NMR still remains an underutilised 
technique, but it has seen the greatest application in the area of natural product identification. 
One of the limitations of HPLC-NMR when compared to HPLC-MS is the sensitivity. Recent 
advancements in probe design and suppression techniques have allowed the application of 
HPLC-NMR to become more widespread. A review outlining these advances and examples 
of the applications is provided in Chapter 3. Since the time of publication of this review in 
2011, no further advancements have been made in the HPLC-NMR hardware. However, a 
number of publications reporting on the application of HPLC-NMR have appeared. For 
instance, the application of ultrafast 2D NMR was recently demonstrated for HPLC-NMR, 
whereby 2D NMR spectra, in this case COSY NMR spectra, were recorded in two scans 
(Queiroz Junior, Queiroz, Dhooghe, Ferreira, & Giraudeau, 2012). Between 2011-2014, 
HPLC-NMR has been most commonly used to profile natural product crude extracts but it 
has also been used for degradation and conformer studies. These have included the 
monitoring of titrations (Hentschel, Holtin, Steinhauser, & Albert, 2012), conformer studies 
(Haroune, Crowson, & Campbell, 2011), identification of degradation products (Narayanam, 
Sahu, & Singh, 2013; Shah, Sahu, & Singh, 2011), and for a variety of chemical profiling 
studies of marine and terrestrial organisms (De la Cruz et al., 2012; Kang et al., 2014; 
Schmidt, Nyberg, & Staerk, 2014; M. A. Timmers, Dias, & Urban, 2012; M. Timmers & 
Urban, 2013). 
The limit of detection (LOD) of HPLC-NMR is well within the limits to easily 
identify multiple components within a natural product crude extract. In Chapter 4 the LOD 
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for a 500 MHz HPLC-NMR system equipped with a 60 µL conventional flowprobe is 
outlined for the HPLC-NMR system in the School of Applied Sciences at RMIT University 
in Melbourne, Australia. The LOD for five key 1D and 2D NMR spectroscopic experiments 
was established, using two reference compounds, including the on-flow (WET1D proton), 
stop-flow (WET1D proton), gCOSY, HSQCAD and gHMBCAD NMR experiments. Once 
established, application to a multiple component natural product crude extract was 
implemented to rapid identify the components present. There has been a steady increase of 
the application of HPLC-NMR for the identification of compounds present in multiple 
component mixtures since 2011. Between the years 2011-2014, a total of 52 HPLC-NMR 
publications appeared (Figure 9). This represents the greatest number of HPLC-NMR 
publications within a four year period since the technique was first reported in 1987 (Laude 
Jr. & Wilkins, 1987).  
 
Figure 9: Number of publications featuring HPLC-NMR between the years 2011-
2014. 
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techniques also have the ability to propose the identity of new natural products. While there 
are cases where a natural product can be completely identified on the basis of HPLC-NMR 
and HPLC-MS, in many instances this is not the case, and traditional off-line isolations 
become necessary. Off-line isolations are also necessary in order to deduce and evaluate the 
bioactive components present in a crude extract. 
Strategies adopted 
The aim of this thesis was to identify new natural products potentially displaying anti-
microbial activity, which was accomplished by two separate approaches. Firstly a 
phytochemical profiling study of each organism utilising HPLC-NMR and HPLC-MS was 
conducted. This approach allowed for the identification of the structure classes present in 
each organism, along with the identity of the major, and some minor constituents. This step 
also enabled the identification of compounds that should be prioritised for further isolation on 
the basis that they may represent new structural derivatives.  
The second approach involved the more traditional or conventional off-line isolation 
of the crude extract and in some cases, a bioassay-guided isolation approach. In this 
approach, crude extracts of the specimen were evaluated for anti-microbial activity. The 
crude extract was then fractionated using various solid-phase chromatographic supports 
(silica, C18, Sephadex LH-20) and then, in general, approximately every third fraction was 
evaluated for anti-microbial activity. Fractions of interest were subsequently purified further 
by RP-HPLC, which resulted in pure compounds being obtained. This allowed for the 
confirmation of the structures as proposed by phytochemical profiling as well as 
unequivocally deducing the structures of new compounds. Importantly this approach enabled 
evaluation of the anti-microbial activity for the isolated compounds.  
Page 17
Reported in this thesis is the phytochemical profiling and off-line isolation studies of 
thirteen marine and terrestrial organisms.  
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CHAPTER 2 
NMR Spectroscopy for the Identification of Natural Products 
Chapter 2 describes the various NMR spectroscopic experiments which are used to 
elucidate the structures of secondary metabolites or natural products. This work has been 
published as outlined below. 
Book section in book chapter publication resulting from this study: 
Brklja?a, Robert, & Urban, Sylvia. (2014). Selected Applications of NMR Spectroscopy - 
Natural Products. In J. Fisher (Ed.), Modern NMR Techniques for Synthetic Chemistry. 
Florida, USA: CRC Press. 
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 NATURAL PRODUCTS
Robert Brkljacˇa and Sylvia Urban
1.1 INTRODUCTION
For the last few centuries, natural products have played a pivotal role as a source of 
new pharmaceutical agents.1 During the period 1981 to 2010, it has been documented 
that more than 40% of new chemical drug entities released were either a natural 
product or derived from a natural product.2 While the total number of new drugs 
derived from a natural source decreased to only 12.2% in 1997, this figure soared to 
a new high of 50% in 2010.2 This trend illustrates that, despite the efforts made in the 
combinatorial chemistry area, where potential new drug entities are systematically 
synthesised, natural products continue to play an important part in the future of drug 
discovery. This is especially important as new diseases emerge and the resistance to 
drugs, such as antibiotics, escalates.3
Many areas of the natural environment, including the marine and microbial envi-
ronments, remain understudied. It is from these environments that natural product 
researchers are focussing their efforts to discover further new bioactive secondary 
metabolites possessing unique pharmacophores with pharmaceutical potential.4–6
In a natural product study, marine or terrestrial organisms are, first, solvent-extracted 
and then typically screened for potential biological activity. This can be achieved by 
screening the crude extract against a selected bioassay or, alternatively, against a 
variety of assays. If biological activity is detected, the crude extract is fractionated in 
an effort to isolate and then determine the structure of the active component(s) via a 
 bioassay-directed approach. Any bioactive compounds identified are then further evalu-
ated. The isolation and identification exercise c an t ypically t ake a  f ew s hort weeks 
or, in extreme cases, it can take years. Two important examples of anti-cancer natu-
ral products that took years to resolve include ecteinascidin 743 and taxol (Figure 1). 
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The tetrahydroisoquinoline alkaloid, ecteinascidin 743, is a potent anti-tumour nat-
ural product that was isolated from the Caribbean tunicate/ascidian Ecteinascidia 
turbinata.7 In 1970, it had been established that the crude extract derived from this 
ascidian displayed potent anti-tumour activity,8 but it was not until 1987 that the 
isolation and complete structure elucidation of the component responsible for this 
activity could be reported.7 Trabectedin (also known as ecteinascidin 743 or ET-743) 
is sold by Zeltia and Johnson and Johnson under the brand name Yondelis™. It is 
approved for use in Europe, Russia, and South Korea for the treatment of advanced 
soft tissue sarcoma. In the case of the anti-cancer natural product taxol, which was 
isolated from the Pacific yew tree Taxus brevifolia, the compound was isolated in 
its pure form in 1967, but its complete structure was not reported until 1971.9 When 
it was developed commercially by Bristol-Myers Squibb (BMS), the generic name 
was changed to paclitaxel™, and the BMS compound is sold under the trademark 
Taxol™. A newer formulation, in which paclitaxel is bound to albumin, is sold under 
the trademark Abraxane™. Taxol (paclitaxel) is used to treat a range of cancers, such 
as lung, ovarian, and breast cancers. Owing to a combination of the complexity in 
these structures, the low quantities isolated, and in the case of ET-743, the difficulty 
encountered with the isolation, it took many years and a tremendous effort to identify 
these important natural product drugs. Particularly, in the case of taxol (paclitaxel), it 
was the advances made in NMR spectroscopic techniques that enabled its structure 
to be finally elucidated.
The typical process for the isolation and identification of new bioactive 
natu-ral products in a marine or terrestrial organism is summarised in 
Figure 2. Once an organism is collected and identified, a crude extract is 
generated by solvent extraction and evaluated for bioactivity against a panel of 
biological assays (e.g. anti-microbial and anti-tumour activities). Selection of an 
organism can be either random or targeted (e.g. a plant with known 
ethnopharmacological precedence or a 
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FIGURE 1 Structure of the anti-tumour agents ecteinascidin 743 (a) and taxol (paclitaxel) (b).
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marine organism known for its chemical defense strategies). If biological activity is 
observed, the crude extract is further fractionated usually by column chromatogra-
phy. In a bioassay- guided isolation, resulting fractions are tested against the particu-
lar biological assay(s) to confirm which fraction(s) contains the active component(s) 
of interest. Once a bioactive fraction(s) has been identified, each compound present 
is further fractionated and purified using high-performance liquid chromatography 
(HPLC). When a pure compound has been obtained, the structure of the natural 
product is elucidated and characterised using a variety of methodologies. These 
include   infrared spectrometry, ultraviolet-visible (UV-VIS) spectroscopy, mass 
 spectrometry (MS), X-ray diffraction, and most importantly, nuclear magnetic reso-
nance (NMR) spectroscopy. The use of NMR spectroscopy for the structure deter-
mination of an unidentified natural product provides the greatest and most useful 
structure connectivity information. MS is used to confirm the molecular formula 
and weight. Once a natural product’s structure has been elucidated, the compound 
can then be subjected to further biological evaluation, and if necessary/feasible, a 
total synthesis can be formulated to provide larger quantities for further studies. 
These further studies would include in vivo biological activity studies and, possibly, 
the determination of the mechanism of action, particularly for new bioactive natural 
products.
Since the isolation process can be lengthy and require considerable effort, it is 
important to recognise the presence of potential new secondary metabolites at the 
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FIGURE 2 General process for the discovery of new bioactive natural products.
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earliest possible stage. The process known as ‘dereplication’ is vital to avoid the 
time-consuming process of isolating known and/or nuisance compounds. Combining 
both chemical and biological screening provides the quickest method to identify new 
lead compounds. Simple biological assays can be carried out to identify activity in 
crude extracts or fractions. These active extracts or fractions can then be chemically 
screened/profiled using techniques such as HPLC, UV-VIS spectroscopy, and NMR 
spectroscopy, or alternatively using hyphenated spectroscopic techniques such as 
HPLC-NMR or HPLC-MS.
Natural product structure elucidation studies have become increasingly easier 
over the last three to four decades due to the major advances that have occurred in 
a variety of NMR techniques. This is particularly evident when the introduction of 
higher magnetic field strengths and improved pulse sequences that became avail-
able is considered.10 There are many NMR experiments available for carrying out 
natural product structure elucidations. These can be broadly categorised into two 
main groups: the 1-D or the 2-D NMR experiments. Following an illustration of the 
utility of these two classes of experiment, we describe a high-throughput, hyphen-
ated approach, HPLC-NMR, which is proving advantageous in the search for, and 
characterisation of, new natural products.
1.2  1-D NMR EXPERIMENTS
For natural product structure elucidations, 1H and 13C are the most important nuclei, 
and several 1-D pulse sequences (some of which are discussed in the following) 
used for their observation are of fundamental importance. Together, they provide 
a detailed account of the number of protons and their associated coupling to other 
protons, the chemical environment, and an estimate of the number of carbons pres-
ent. Experiments such as the 1-D single-irradiation (or steady-state) nuclear 
Overhauser enhancement (1-D NOE) and the distortionless enhancement by 
polarisation transfer (DEPT) NMR approach play a pivotal role in natural product 
characterisation.
1.2.1  1-D NOE and 1-D TOCSY Experiments
The steady-state NOE experiment involves the selected irradiation (or 
saturation) of a proton, which then relaxes via other protons that are close in 
space.11 If the outcome of this experiment is subtracted from a control (off-
resonance) experi-ment, the resultant difference spectrum will display a peak for 
the originally sat-u ra ted  resonance ,  which  ( fo r  r e la t ive ly  low–
molecu la r -we igh t  spec ies )  wi l l  have  a  phase opposite to that for 
resonances of protons with which it shares a close spa-tial proximity. 
Typically, proton nuclei of up to 5 to 6 Å away will be detected via this 
through-space NMR experiment.12 The strength of an observed NOE is greatly 
dependent on the combination of the molecular weight of the molecule and the satu-
ration time.13 If the combination of these parameters is not optimised, no NOE will 
be observed. The 1-D NOE is favoured over the 2-D nuclear overhauser effect 
spectroscopy (NOESY) (transient NOE equivalent) for low– and medium–
molecular-weight compounds primarily due to differing time demands.
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A 1-D NOE NMR experiment was utilised to determine the relative configura-
tion of the natural product cycloelatanene A, which was isolated from the Australian 
marine red alga Laurencia elata.14 The 1H and 13C NMR experiments confirmed 
this compound to be a C16 chamigrene, and the relative configuration was 
deduced  through a  series of 1-D NOE NMR experiments.  Figure 3 illustrates the 
NOE difference spectrum for cycloelatanene A where the proton resonance at δH 
2.21 (H7a) was irradiated. This irradiation resulted in four NOE enhancements 
being observed to the proton resonances at positions 7b, 8, 12 and 15 which 
concluded that these protons were all situated on the same face of the molecule.
The 1-D NOE NMR experiment only provides information on the protons con-
nected through space. In contrast, the 1-D total correlation spectroscopy (1-D 
TOCSY) NMR experiment uses variable spin-locking times to allow for the deter-
mination of proton couplings along a compound chain.15 As the mixing time is 
changed, the polarisation energy is transferred through the bonds to other protons. 
Signals that appear with a shorter spin-locking time are closer (through-bonds) to the 
excited proton, and correspondingly, those appearing when longer spin-lock times 
are employed are further away from the selected proton. This NMR experiment is 
particularly useful for defining individual spin systems within a compound.
The natural product furospinosulin-1 was first isolated from the marine sponge 
Ircinia spinosula16 and recently re-isolated by the marine and terrestrial natural 
product (MATNAP) research group from Dactylospongia sp.17 Figure 4 shows the 
1-D TOCSY spectra obtained for furospinosulin-1 using spin-lock times of 30, 70, 
150 and 200 ms. The proton at δH 2.45 (H1) was selected, and by comparing the
peak  heights in each spectrum, it was possible to determine which protons were 
closer or further away in the covalently linked spin system.
This 1-D TOCSY NMR experiment indicated that the H2 and H3 protons were 
closest to the H1 proton and that the H18 and H3′ protons were further away in terms
of bonding from the H1 proton. The 2-D variant of the experiment provides a wealth 
of information, is not as easily interpreted as the 1-D experiment.
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FIGURE 3 1-D NOE difference NMR spectrum of cycloelatanene A, illustrating the irra-
diation of the proton resonance at δH 2.21 (H7a).
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1.2.2  DEPT and APT
The DEPT NMR experiment is a direct-detect heteronuclear experiment, in this case, 
13C detect, which provides information of the number of protons attached to the 
carbon nucleus. There are several versions of this experiment, which lead to 
slightly different data, but all of these reflect the attached-proton status of the 13C atom. 
The DEPT45 NMR experiment shows all CH (methine), CH2 (methylene), and CH3 
(methyl) carbons having the same (positive) phase.11 Comparing the DEPT45 to the 
normal-broadband, proton-decoupled 13C NMR spectrum, thus, enables quaternary 
carbons to be identified. The DEPT90 experiment is more selective and only displays 
CH (methine) carbons.11 The DEPT135 shows all CH (methine), CH2 (methylene), and 
CH3 (methyl) carbons but with phase modulation. The CH (methine) and CH3 (methyl) 
carbons appear with the same (positive) phase, and CH2 (methylene) carbons appear 
with a 180° (negative) phase shift.11 Combining a DEPT90 and DEPT135 NMR allows 
for all carbon-substitution types to be assigned. Another experiment similar to DEPT 
is the attached proton test (APT) experiment. The APT NMR experiment results in 
quaternary (C) and methylene (CH2) carbons being positive and methyl (CH3) and 
methine (CH) carbons being negative in their phasing.18 While these experiments still 
have their uses, they have been made almost redundant with the advent of the indirect-
detection heteronuclear experiments (see in the following section).
Figure 5 shows the DEPT 13C NMR spectrum as well as the APT NMR spec-
trum of the natural product furospinosulin-1. Comparison of the three different 
DEPT NMR spectra allows for each of the carbon multiplicities to be determined. 
Analysis of the APT will also allow for multiplicities to be determined; however, 
unlike in the DEPT NMR experiment, the quaternary carbons are observed.
O
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FIGURE 4 1-D TOCSY NMR spectra (spin-lock times [from top] of 30, 70, 150 and 
200 ms) of furospinosulin-1.
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1.3  2-D NMR EXPERIMENTS
In this section, we illustrate the application of 2-D NMR techniques to natural product 
characterisation. These are divided into two types. The homonuclear 2-D NMR experi-
ments typically utilised include the correlation spectroscopy (COSY), NOESY, rotating 
frame Overhauser effect spectroscopy (ROESY), and TOCSY experiments. The hetero-
nuclear 2-D NMR experiments (proton and carbon nuclei here) frequently implemented 
include the heteronuclear single quantum coherence (HSQC) and heteronuclear multiple 
quantum correlation (HMBC) NMR experiments. Most 2-D experiments come with 
non-gradient and gradient options (usually indicated by a ‘g’ in the name for the pulse 
sequence). The use of gradients typically increases the signal-to-noise as well as the qual-
ity of the spectra, and for this reason, it is very uncommon for gradient versions of the 
2-D NMR experiments not to be used.
1.3.1  Homonuclear Approaches
1.3.1.1 Correlation S pectroscopy
The COSY NMR experiment provides information on which protons are immedi-
ate (bonding) neighbours, allowing for the spin systems of the natural product to 
(a)
(b)
(c)
(d)
O
Furospinosulin-1
140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
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140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
FIGURE 5 DEPT 45 (a), DEPT 90 (b), DEPT 135 (c) and APT (d) NMR spectra of 
furospinosulin-1, displaying selective carbon multiplicities.
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be determined.13 While coupling constants and splitting patterns observed in the 
1-D 1H NMR spectrum can be used to determine the number and geometric rela-
tionship of neighbouring protons, in complex systems, sometimes, this cannot be 
achieved. In these situations, 2-D COSY and related experiments are useful. The 
double-quantum– filtered COSY (DQFCOSY) NMR experiment, like the COSY 
NMR experiment, provides cross-peaks, indicating proton–proton coupling. 
However, unlike the COSY NMR experiment, the DQFCOSY is able to eliminate 
any peaks that do not have a double-quantum transition (i.e. singlets); this phase-
sensitive spectrum has higher resolution and clearer-looking spectra, but the longer 
pulse sequence and quantum filter employed results in a loss of sensitivity.19
To illustrate the ability of the DQFCOSY to simplify and improve resolution, the 
natural product furospinosulin-1 was subjected to a gCOSY and a gDQFCOSY experi-
ment. Figure 6 shows an expansion of the gCOSY and gDQFCOSY NMR experi-
ments. It can be seen that the gCOSY NMR spectrum has regions where clear contours 
cannot be easily distinguished as well as the presence of long-range couplings. The 
gDQFCOSY NMR spectrum shows better resolution and a clearer-looking spectrum. 
In this NMR experiment, the long-range gCOSY correlations are not present.
1.3.1.2 NOESY and ROESY
The 2-D NOESY experiment provides the same type of information as the 1-D NOE 
spectrum  except that all  through-space  connectivities  within  a molecule   can be 
explored  in  a single   experiment.   Once again,   proton–proton   through-space 
relationships up to a distance of approximately 5 to 6 Å will be detected.
The compound 2,5,6-trimethoxy-9-phenyl-1H-phenalen-1-one has been previ-
ously reported as being synthetically derived from a natural product.20,21 We have 
recently isolated this compound for the first t ime, a rising as a naturally occurring 
pigment from the Australian plant Haemodorum sp.22 In the structure elucidation of 
this natural product, the point of attachment of the aromatic ring to either position 
7 or 9 needed to be confirmed. The NOESY spectrum shown in Figure 7 clearly 
revealed a cross-peak between the aromatic proton at position 7 (δH 8.50) and the
methoxy protons at position 6 (δH 4.10), demonstrating that the aromatic moiety must
be attached at position 9. In this way, the NOESY spectrum could unequivocally 
confirm the structure of the natural pigment.
Just as the single-irradiation 1-D NOE NMR experiment requires the combina-
tion of the molecular weight and mixing time to be optimised to observe an NOE, the 
same criteria applies to the 2-D NOESY experiment. For intermediate-sized com-
pounds or those that do not show strong NOESY correlations, the ROESY experi-
ment is appropriate.15,23 While the ROESY NMR experiment may provide more 
information for intermediate-sized molecules compared to NOESY, the ROESY 
experiment is susceptible to also showing COSY- and TOCSY-type correlations, 
which adds complexity to the spectrum.11
1.3.2  Heteronuclear Approaches
1.3.2.1 HSQC and HMBC
Earlier heteronuclear 2-D NMR experiments (pre-1990s) utilised the X nucleus, in 
this case, the carbon, as the observation frequency. These experiments were known 
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as the ‘heteronuclear shift correlation’ (HETCOR) and ‘correlation through long-
range coupling’ (COLOC) approaches. The sensitivity of these experiments was dic-
tated by that of the X nucleus and, thus, were not high. Subsequently, experiments 
have been implemented that employ the proton as the observation nucleus and car-
bon as the indirectly detected nucleus, therefore substantially increasing the sensitiv-
ity of these experiments. Thus, the indirect-detect equivalent of the HETCOR is the 
heteronuclear multiple quantum correlation (HMQC) NMR experiment, although 
the single-quantum equivalent (HSQC) is more frequently employed and the indirect 
equivalent of COLOC is the HMBC. These indirect-detection experiments are much 
more time efficient, and this is an imperative in the field of natural products, where 
frequently low to sub-milligram quantities are typically isolated.
In the past, assigning each proton to a specific carbon was almost exclusively done on 
the basis of the chemical shifts, and as such, sometimes, assignments were interchange-
able or incorrectly applied. The HSQC NMR experiment has removed this ambiguity 
and determines which protons are directly attached to which carbon.18 The most basic 
HSQC NMR experiment will only correlate protons and carbons that are bonded to one 
another, and therefore, quaternary carbons do not appear in a HSQC NMR experiment. 
There are variants of the HSQC NMR experiment that offer spectra of improved quality 
with increased information. For example, the use of gradients along with adiabatic pulse 
versions during experiments offers increased sensitivity.24–26 There is also a version of 
the HSQC that provides carbon multiplicity information. In this experiment, methylene 
(CH2) multiplicities are displayed in the negative phase, and methine/methyl (CH/CH3) 
multiplicities are displayed in the positive phase.11
While a COSY NMR experiment allows for the spin systems to be determined, 
the HMBC NMR experiment is the most important of the NMR experiments for 
natural product structure determination as it allows for the carbon skeleton of a natu-
ral product to be pieced together. This is achieved by formulating structure frag-
ments on the basis of all the NMR (both 1-D and 2-D) information gathered and then 
forming connections of these structure fragments via through-bond connectivities 
observed in the HMBC NMR experiment. While the HSQC NMR experiment dis-
plays direct one-bond proton to carbon connectivities, the HMBC NMR experiment 
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provides proton to carbon connectivity usually up to two to three bonds removed27 
(in aromatic systems, four-bond correlations are also encountered). Unlike the HSQC 
NMR experiment, quaternary carbons are observed in the HMBC NMR experiment, 
thereby providing vital structure connectivity information.
The gradient heteronuclear single quantum coherence adiabatic (gHSQCAD) 
and gradient heteronuclear multiple-bond correlation adiabatic (gHMBCAD) 
NMR spectra of haemoxiphidone, a pigment isolated from the Australian plant 
Haemodorum simulans, are illustrated in Figure 8.28 All the correlations observed 
in the gHSQCAD NMR spectrum were in the positive phase, indicating that the 
multiplicities of the carbons were either CH (methines) or CH3 (methyls).
In the structure elucidation of this pigment, it was uncertain whether the aromatic 
moiety was attached at position 7 or 9 of the compound. Analysis of the HMBC 
NMR spectrum supported a position-9 attachment, which was also confirmed by 
1-D NOE NMR experiments.28
1.3.2.2 Coupled HSQC
In many natural products, it is common for proton signals to overlap, particularly, 
signals for those protons having complex splitting patterns. Some compounds require 
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the splitting patterns of protons to be clearly observed so that the structures may be 
deduced. The splitting patterns of overlapping protons may be observed by editing 
the standard HSQC experiment. The limiting factor is that the overlapping protons 
must be coupled to different carbons that do not overlap. In this variant of the HSQC 
NMR experiment, two parameters are changed. First, the number of data points 
collected in F2 (the acquisition dimension) is increased for greater resolution in the 
proton dimension. The second parameter that is changed is that the 13C decoupling is 
turned off. This means that each proton signal will now be split by its H–C coupling 
constant. By extracting the 1-D traces from the 2-D HSQC, the splitting patterns of 
the overlapping protons may now be observed.29,30
This particular problem was encountered in the structure of elatenyne, which was 
isolated from the Australian red alga Laurencia elata.14,31 The two protons at the 
ring junction (positions 9 and 10) were overlapped. It was vital to obtain the splitting 
pattern and coupling constant of these overlapped ring junction protons to propose 
a relative configuration for elatenyne. Figure 9 shows the region of the 1H NMR 
spectrum for the overlapped protons at positions 9 and 10 (δH 3.86). Here, no split-
ting/coupling information about the overlapped protons could be deduced.
Figure 10 shows the edited gHSQCAD spectrum and extracted 1-D traces for the 
overlapped protons; the splitting pattern and coupling for the overlapped protons could 
be clearly observed. Each proton is split by their H–C coupling, and it is not uncommon 
for one mirrored splitting pattern to be clearer than the other. The splitting patterns were 
able to be deduced as a doublet of triplets and the coupling constant was measured, 
confirming that the two ring junction protons were in an axial–equatorial arrangement.31
1.3.2.3 CIGAR-HMBC
In rare instances, the HMBC NMR experiment will not be suited to particular com-
pounds. The HMBC experiment uses fixed coupling constants to detect carbons cor-
relating up to two to three bonds away. If expected correlations are not observed, the 
constant time inverse-detection gradient accordion rescaled (CIGAR)-HMBC may 
provide a better solution. The CIGAR-HMBC experiment is less sensitive than the 
Br
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FIGURE 9 Expansion of the 1H NMR spectrum (500 MHz, C6D6) of elatenyne.
Page 38
Modern NMR Techniques for Synthetic Chemistry
HMBC experiment; however, the CIGAR-HMBC uses variable coupling constants.32 
This experiment, therefore, provides a better opportunity to observe correlations fur-
ther than three bonds away to detect situations where small coupling constants exist 
or instances where there might be a large range of coupling constants, as in the case 
of nitrogen-containing compounds.
1.3.2.4 HSQC-NOESY
In the previously discussed 2-D NOESY NMR experiment, one disadvantage is that, 
if two (or more) protons have the same chemical shift, it is difficult to distinguish 
which proton is, in fact, being detected. The band-selective HSQC-NOESY NMR 
experiment utilises both the NOESY and HSQC pulse sequences and can, therefore, 
be used to overcome the issues of overlapping proton chemical shifts. 
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For example, if a proton at δH 3.50 shows an NOE to a proton at δH 6.70 with an
associated carbon chemical shift at δC 126.7 ppm, a cross-peak between δH 3.50
and δC 126.7 ppm will be observed. If another proton also co-occurs at δH 6.70 but
with an associated carbon chemical shift at δC 130.5 ppm, this distinction would be
evident in a band-selective HSQC-NOESY experiment.
1.3.2.5 Excitation-Sculptured Indirect-Detection Experiment
The HMBC experiment provides information about protons coupled to carbons two to 
three bonds away. However, this experiment does not provide any information about 
the magnitude of these coupling constants. The excitation-sculptured indirect-detection 
experiment (EXIDE) is similar to the HMBC in that it shows proton-to-carbon coupling 
two to three bonds away but, unlike the HMBC, also displays the coupling constants.33 
This experiment displays a 2-D NMR spectrum similar to the HMBC, but each correla-
tion appears as a doublet in the F1 dimension. By measuring the distance between each 
doublet and dividing by the J scaling factor, the coupling constants can be determined. 
To illustrate the ability of the EXSIDE experiment to determine nJ C–H coupling 
constants, Figure 11 compares the results obtained in both the gHMBCAD and 
EXSIDE experiments for furospinosulin-1. In the gHMBCAD experiment, three dis-
tinct correlations can be observed for the proton at δH 7.21; however, no information
about the coupling to the carbons can be deduced. The EXSIDE version still shows 
not only these three distinct correlations, but also the splitting of each carbon signal. 
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By measuring the distance between each split carbon and dividing by the J factor, 
the coupling constants of these carbons were determined to be 6, 16 and 3 Hz.
1.4  HYPHENATION: HPLC-NMR
One of the more recent advancements and application of NMR spectroscopy has been 
the hyphenation to other separation and detection methodologies traditionally used 
separately in natural product isolation and characterisation. An example of such is 
the coupling of NMR to an HPLC system to yield the hyphenated spectroscopic tech-
nique known as ‘HPLC-NMR’. This technique was developed in the 1970s;10 however, 
it has only recently taken over as a robust and powerful tool for chemical profiling, 
 dereplication, and structure elucidation. Principally, the drawback for the hyphen-
ated spectroscopic technique included the initial high costs and the lack of sensitivity. 
Developments in probe design, solvent suppression, loop collection, cold probes, column 
trapping, capillary NMR, and microcoils have allowed it to become the powerful tech-
nique that it is today and is now finding extensive use in the field of natural products.34
HPLC-NMR operates in two main modes: on-flow and stop-flow.34 On-flow mode 
utilises continuous 1H NMR data acquisition for all components as they elute from 
the HPLC column and, for this reason, is a far less sensitive mode of operation. The 
on-flow mode is, therefore, useful in providing quick general structure class informa-
tion that can be used to search various databases.
The more useful, stop-flow mode (Figure 12), allows for any one particular 
component to be trapped in the NMR flow cell at a time. By trapping one compo-
nent, extended acquisitions are now possible, allowing for 2-D NMR experiments 
to be carried out.10,34 This increase in sensitivity is particularly important in natural 
FID
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HPLC pump
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Photo-diode array
detector
Single-component
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with
flow cell
Waste or
collection
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FIGURE 12 Schematic of stop-flow operation of HPLC-NMR.
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product identification. In general, complete 2-D NMR data can be obtained for major 
components in crude extracts/enriched fractions, whereas usually, only 1H NMR and 
COSY NMR data can be obtained for the minor components in the typical overnight 
time frame used to conduct conventional NMR experiments.
Other variants of HPLC-NMR utilise solid-phase extraction (SPE) columns to 
pre-concentrate analytes before NMR analysis to increase the signal-to-noise and 
experiment capability.33 Loop collection allows for analytes to be separately col-
lected and then either flushed into the flow cell one at a time or transferred into 
conventional NMR tubes for off-line analysis. Cold probes (or cryo probes) and 
microcoils have also allowed for increased sensitivity and, therefore, the NMR 
detection of smaller quantities of analytes.34
HPLC-NMR can be further extended to include MS to yield HPLC-NMR-MS. This 
technique has two possible set-ups, namely ‘parallel’ and ‘series’.34 In a parallel set-up, 
a splitter is placed after the column and a small amount of the analyte is directed to the 
mass spectrometer, with the majority directed to the NMR spectrometer. In the series 
configuration, the mass spectrometer is placed after the NMR spectrometer. The latter 
set-up can sometimes be at a disadvantage since peaks can broaden and retention times 
can change by the time that the analytes reach the mass spectrometer.
1.4.1  A       pplication to Organism Profiling and Structure Elucidation
We have conducted various studies utilising HPLC-NMR to chemically profile both 
marine and terrestrial natural product extracts and enriched fractions.14,35–41 Only 
recently, HPLC-NMR has been utilised to chemically profile t he Australian b rown 
alga Sargassum paradoxum.42 The crude dichloromethane extract of the alga was 
analysed, and a number of constituents were detected. The major constituent was 
identified u sing t he s top-flow HPLC-NMR mo de. Th is major co nstituent wa s pr es-
ent in sufficient a b u ndance to  a l l ow fo r  c o m plete 2 - D  c h a racterisation in c luding 
gCOSY, gHSQCAD, and gHMBCAD analysis. The results obtained from the stow-
flow HPLC-NMR analysis allowed the major constituent t o b e i dentified as  is osar-
gahydroquinoic acid.41 The double bond geometry of this compound was secured by 
application of the 1-D NOE NMR experiment. The Wet1D (used to solvent 
suppress), gCOSY, gHSQCAD, and gHMBCAD NMR spectra are provided in 
Figures 13 to 16, respectively. This represents the first instance of a HMBC-NMR 
spectrum being  obtained  in the stop-flow H P LC-NMR  mode  on  a  system 
equipped with a 60 μL flow cell. T he ability to obtain a  H MBC N MR spectrum 
relies on the amount of analyte present, and the limitation is the ability to dissolve 
the fraction in a minimal amount of solvent. The mass limitation in HPLC-NMR 
analyses often remains a restriction for the technique since a reasonable signal-to-
noise ratio for  the compound must be achieved. However, as demonstrated by this 
example, it is possible to obtain HMBC data for main constituents in crude extracts 
without the need for pre-concentration, SPE cartridges, loop storage, or cold probes. 
In the gHSQCAD NMR spectrum (Figure 15) of isosargahydroquinoic acid 
obtained by stop-flow HPLC-NMR, the proton resonances between δH 3.00 and
δH 4.50 ppm were attached to carbons that appeared in the negative phase (indicat-
ing methylene [CH2] multiplicities) with all other carbon resonances appearing in the 
positive phase (indicating methine [CH] or methyl [CH3] multiplicities).
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FIGURE 14 gCOSY NMR spectrum of isosargahydroquinoic acid (500 MHz, 75% CH3CN/D2O).
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FIGURE 13 Wet 1-D HPLC-NMR spectrum of isosargahydroquinoic acid (500 
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The importance of the application of HPLC-NMR was illustrated through two 
separate studies conducted by our research group. These included the investigation 
of two southern Australian red algae, namely Laurencia filiformis36 and Plocamium 
angustum.35 In both cases, new unstable natural products (Figure 17) were able to 
be identified by application of H PLC-NMR. A ny a ttempted off-line i solation a nd 
characterisation of these two natural products could not be achieved, owing to their 
rapid degradation. HPLC-NMR analyses of the crude extracts of these two algae 
successfully established the structures in situ.
The unstable nature of natural products is a frequently encountered issue that is 
brought about by exposure to light, heat, or air oxidation, among other scenarios. 
The use of HPLC-NMR in such instances is invaluable in securing their structure.
1.5  SUMMARY
The use of NMR in natural product structure elucidation has continued to evolve. 
From its humble beginnings in 1-D proton and carbon spectra to the advanced meth-
ods such as 2-D experiments and hyphenated spectroscopic techniques, NMR has 
played a large and important role in the natural product field. Continuing efforts and 
progress in NMR spectroscopy with regard to new and improved pulse sequences, 
faster and more sensitive hardware, easier access to higher field strengths, and smaller 
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FIGURE 16 gHMBCAD NMR spectrum of isosargahydroquinoic acid (500 MHz, 75% CH3CN/D2O).
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FIGURE 17 Structures of two new natural products (a, Isoallolaurenterol [Laurencia 
filiformis] and b, Isoplocamenone [Plocamium angustum]), both of which are unstable and, 
hence, could only be elucidated in situ.
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sample volumes will play an important role in natural product structure determination, 
allowing for the elucidation of ever-decreasing quantities. This is of vital importance 
in the field of natural product drug discovery where structure determination of sub-
milligram quantities is now possible. The application of NMR spectroscopy in the 
hyphenated spectroscopic techniques such as HPLC-NMR will continue to evolve as 
more applications of the technique emerge, illustrating its strength and importance in 
chemical profiling/de-replication and in the rapid identification of natural products.
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CHAPTER 3 
HPLC-NMR for Chemical Profiling 
 
Chapter 3 provides a review of the HPLC-NMR literature and details the recent 
advancements and applications of the technique. This work has been published as outlined 
below. 
 
Journal publication resulting from this review: 
Brkljača, Robert, & Urban, Sylvia. (2011). Recent Advancements in HPLC-NMR and 
Applications for Natural Product Profiling and Identification. Journal of Liquid 
Chromatography & Related Technologies, 34(12), 1063-1076.  
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RECENT ADVANCEMENTS IN HPLC-NMR AND APPLICATIONS
FOR NATURAL PRODUCT PROFILING AND IDENTIFICATION
Robert Brkljacˇa and Sylvia Urban
School of Applied Sciences, Health Innovations Research Institute (HIRi) RMIT
University, Melbourne, Victoria, Australia
& This review provides a summary of the recent advances in high pressure liquid chromato-
graphy (HPLC) coupled to nuclear magnetic resonance (NMR) spectroscopy. Significant improve-
ments have included the miniaturization of NMR components as well as the use of cryogenically
cooled probes. Further hyphenated applications such as HPLC-SPE-NMR, column trapping and
HPLC-NMR-MS are also discussed. Finally, an overview of the application of these methodologies
to the profiling and dereplication of natural products is provided.
Keywords advances, HPLC-NMR, hyphenated spectroscopy, natural products
INTRODUCTION
High pressure liquid chromatography (HPLC) coupled to nuclear
magnetic resonance (NMR) spectroscopy (HPLC-NMR) was developed in
1978[1] but has taken many years to evolve and become a more routine
method for analysis. The initial draw-back for the hyphenated technique
included the initial high costs and the lack of sensitivity.[1] Over the years,
developments in probe design and suppression techniques have enabled
it to evolve into an effective method for principle component mixture
analysis.[1]
HPLC-NMR has various modes of operation, the two primary being
on-flow and stop-flow, respectively.[2] On-flow HPLC-NMR acquires solely
1H NMR data and, as such, is most suitable for rapid identification of prin-
ciple components. Stop-flow HPLC-NMR allows for longer acquisitions to
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be carried out on any one or more selected components, thereby resulting
in improved spectra and the ability to also acquire 2D NMR data.[2] Other
HPLC-NMR modes such as time-slicing and loop collection are also becom-
ing more commonly employed.[3] Unfortunately, the lack of sensitivity
remains somewhat of a drawback for the technique, with the limit of de-
tection depending on a number of factors such as the magnetic field
strength, the volume of the flow probe being used, and the mode of the
experiment.[4] However, in 2003 it was reported that for a 500 molecular
weight analyte at a 1H observation frequency of 600MHz, the limit of detec-
tion was 100 ng for stop-flow and loop storage modes.[5] This is a vast
improvement in the detection limit of HPLC-NMR as compared to analyses
conducted in the 1990s, which required anywhere between 150–500ng.[1]
On-flow analyses rely heavily on sensitivity because analytes have short resi-
dence times in the NMR spectrometer. Providing that reasonable amounts
of material are injected, stop-flow and loop collection make it possible for
2D NMR data such as COSY, TOCSY, and HSQC NMR spectra to be
acquired. In spite of this, analyses such as natural product profiling require
an improved detection limit and, therefore, efforts were focused on
increasing the sensitivity of the technique.
This review discusses the more recent advancements in HPLC-NMR and
how they have enhanced the sensitivity of the technique, enabling it to
become a successful method for multicomponent analysis. The review also
includes application of the various HPLC-NMR and related techniques to
natural product analysis and identification.
MICROCOIL HPLC-NMR AND CAPILLARY NMR (CapNMR)
Undoubtedly the development of microcoil HPLC-NMR and capillary
NMR (CapNMR) technologies have had a large impact on HPLC-NMR.
Typically, NMR flow probes have volumes ranging from 40–120 mL.[6] With
the emergence of microcoil and CapNMR, which utilize active volumes of
2.5–5 mL,[7] the sensitivity of the technique dramatically increased. Both
probes took advantage of reducing the flow cell diameter and the size of
the receiver coils. By reducing the size of the cell and receiver coils, an
increase in sensitivity resulted[7] with a 5-fold increase in sensitivity being
typically observed.[8] The probes use a solenoid microcoil design[9] com-
pared to the traditional Helmholtz design that is achieved by wrapping a
receiver coil directly around a capillary flow cell,[7] with the cell and coil
being placed in a magnetic susceptible fluid to reduce magnetic field inho-
mogeneities.[7] The use of the solenoid receiver coils also allowed for
the flow cell to be orientated horizontally in the NMR spectrometer. By
R. Brkljacˇa and S. Urban
Page 50
utilizing a horizontal orientation, a stronger coupling to the sample is
observed that results in an increased sensitivity.[7] Another advantage of
the microcoil and CapNMR probes is in their ease of shimming, brought
about from the smaller sample volumes and the coil design.[7] In a similar
fashion to conventional HPLC-NMR, microcoil HPLC-NMR can be run
using different modes of operation such as on-flow and stop-flow.[9]
Microcoil HPLC-NMR (Figure 1) is most suited for on-line HPLC-NMR
analyses where components are separated and analyzed in a conventional
HPLC-NMR system using either on-flow, stop-flow, or time slicing. CapNMR
is used in off-line analyses whereby it is possible to inject single components
or mixtures that have been previously isolated or fractionated. This can be
achieved by either manually collecting the components and injecting them
into the NMR spectrometer or alternatively by automatically injecting com-
ponents that have been previously collected into a microtitre plate
(Figure 1).[10]
The CapNMR technique allows for the use of nondeuterated solvents
in the off-line HPLC separation. This is attractive in that it reduces the
analysis cost and it also allows for a wider range of solvents to be used.
Previously isolated components are then redissolved in deuterated sol-
vents and injected into the CapNMR flow probe. The advantage with
this methodology is that very small amounts of deuterated solvents
(approximately 6mL) are needed.[11] Using the CapNMR technique,
1H NMR spectra can be obtained in minutes for samples in the
2–30 mg range.[11]
FIGURE 1 Flow chart variations of microcoil HPLC-NMR and CapNMR analyses.
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CRYOGENICALLY COOLED PROBES
Noise observed in NMR spectra is created primarily by the receiver coils[12]
and a way to increase the signal-to-noise (S=N) ratio is to decrease the observed
noise. This noise can be reduced by cryogenically cooling the receiver coils[13]
and other components such as the preamplifiers.[12] The coils are cooled in a
bath of liquid helium or with a stream of helium gas to a temperature of
15–30K.[13] The S=N ratios typically increase by a factor of 4[12] compared
to the same samples acquired with coils maintained at room temperature.
Combining cryoprobe technology with microcoil technology has increased
the sensitivity and detection limit of the technique by over 20 fold.[14]
HPLC-SPE-NMR AND COLUMN TRAPPING
In recent years Solid Phase Extraction (SPE) has been included into the
HPLC-NMR (Bruker NMR) set-up in an attempt to increase the amount of
analyte in the flow cell. The SPE cartridge is placed after the HPLC separ-
ation and the technique allows for NMR data to be obtained for increased
amounts of sample.[15] Moreover, it allows for the use of non-deuterated
solvents in the HPLC separation[16] thereby reducing the cost for analysis
dramatically and allowing for a wider range of solvents and higher gradi-
ents to be used in the separation.[16] The SPE cartridges are kept in a nitro-
gen environment to avoid the risk of oxidation and a stream of nitrogen is
used to dry the sample prior to washing the analyte off the cartridge.[12]
Repeated injections of the sample are made and the analyte of interest is
collected on the SPE cartridge.[12] Once sufficient quantities are collected,
the cartridge is washed with a deuterated solvent which is then injected
directly into the NMR flow cell (refer to Figure 2).[12]
FIGURE 2 Schematic of HPLC-SPE-NMR (Bruker NMR) setup.
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In this methodology it is important to ensure the analyte is eluted in a
sharp band to maximize the amount of the analyte in the active volume of
the flow cell.[16] One final advantage of this set-up is it that because a deu-
terated solvent is used in the analysis, suppression is generally unnecessary
during the NMR acquisition.[12]
A similar and parallel technique to HPLC-SPE-NMR is the use of auto-
mated column trapping. Unlike the SPE technique, this utilizes a C18 guard
column to trap the analyte and is used for VarianHPLC-NMR systems.[17] The
HPLC-NMR is set up to automatically collect the analyte on the guard column
and once collected, the system automatically back flushes the analyte as a
sharp band into the flow probe.[17] By placing a C18 guard column after
the HPLC it is possible for the analyte to be collected and preconcentrated
before it enters the flow probe.[17] Using this technique, an increase in the
S=N ratio of 14 fold was obtained[17] and the advantage lies in the fact that
it is a faster than the SPEmethod described earlier as no drying of the samples
or column washing is required. Both techniques provide a robust way to
increase the amount of analyte and produce a higher quality NMR spectrum.
The HPLC-SPE-NMR technique can be extended to include mass spec-
trometry (MS), creating the hyphenated system HPLC-SPE-NMR-MS. The
HPLC-SPE-NMR-MS technique diverts the eluant from the HPLC column
to both the MS and SPE cartridge, which is split in a ratio of 95%=5% to
the SPE cartridge and MS, respectively.[18] Once the eluant has been
diverted to both the MS and SPE cartridge, the technique follows the same
principles as the HPLC-SPE-NMR technique.
HPLC-NMR-MS
HPLC-NMR provides invaluable spectroscopic data (UV profiles and
NMR spectra), which is crucial in identifying compounds. Unfortunately,
in many instances, NMR data alone (in conjunction with the UV data
obtained from the HPLC) is insufficient to completely identify a com-
pound, especially for new chemical entities. Further information such as
mass spectrometry (MS) can assist further in compound identification.
Previously MS had to be conducted off-line and separately from the
HPLC-NMR process. However, in recent years, successful hyphenation of
HPLC-NMR-MS has been achieved whereby all of the NMR and MS data
is obtained in a single acquisition.[19] The HPLC-NMR-MS hyphenation
technique utilizes a splitter to divert the eluant from the HPLC column
to both the NMR flow probe and to the MS [2] and this set-up is known
as a parallel configuration (Figure 3).[20]
Owing to the vast differences in the sensitivities of MS and NMR, the
splitter is set-up to divert considerably higher amounts of the analyte to
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the NMR than the MS. Using a splitting ratio of 20:1 allows for the MS to
operate at optimal conditions and for sufficient amounts of the analyte
to be detected by the NMR spectrometer.[20]
HPLC-NMR-MS can also be run in the series configuration (Figure 3)
whereby the splitter and MS are placed after the NMR spectrometer.[20]
This set up has the advantage of being a simpler system which can be easily
disconnected to allow for separate NMR and MS analyses to be conduc-
ted.[20] The disadvantage of the series configuration in HPLC-NMR-MS is
that it introduces the opportunity for the peaks to disperse or for the reten-
tion times of the peaks to drift as they reach the MS.[20] Despite which con-
figuration is employed, HPLC-NMR-MS is unquestionably a powerful and
valuable technique for both rapid compound identification=profiling and
for complex mixture analysis.
NATURAL PRODUCT APPLICATIONS
The application of HPLC-NMR to assist in natural product profiling
and identification has been attracting more interest in recent years, parti-
cularly in the analysis of marine natural products.[21–23] As a result of the
advancements made in HPLC-NMR, many publications have appeared in
the literature, which have taken advantage of these improvements. A brief
overview of some of these more recent analyses is provided in the following
sections.
FIGURE 3 Schematic of HPLC-NMR-MS showing parallel (A) and series (B) configurations.
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On-Flow and Stop Flow HPLC-NMR Analyses
In2009,on-flowandstop-flowHPLC-NMR,utilizinga60mL(active volume)
flow probe, was used to profile the crude extract of a southern Australian
marine alga, Laurencia filiformis. This resulted in the identification of two
new compounds, cycloisoallolaurinterol (1) and isoallolaurinterol (2), together
with the ability to monitor on-line chemical conversions (Figures 4 and 5).[23]
FIGURE 4 Chemical structures of cycloisoallolaurinterol (1) and isoallolaurinterol (2).
FIGURE 5 2D-HPLC-NMR contour plot with extracted WET-1D 1H NMR of isoallolaurinterol (2).
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This application of HPLC-NMR was also able to demonstrate the impor-
tance of using the technique to identify unstable, inter-converting second-
ary metabolites.
Other studies conducted by the same research group have focused on
rapidly profiling the crude extract of a southern Australian marine sponge,
Dactylospongia sp.[22] and an Australian marine alga, Plocamium mertensii.[21]
The study of the marine red alga, Plocamium mertensii resulted in the partial
identification of several polyhalogented monoterpenes (3)–(6) using both
on-flow and stop-flow HPLC-NMR (Figures 6 and 7). Subsequent off-line
characterization studies also led to a number of chemical shift
re-assignment for (5).[21] Time-slicing was also employed in the HPLC-
NMR analysis to resolve the two closely eluting secondary metabolites (5)
and (6).[21]
These analyses were able to demonstrate successful natural product
profiling using crude extracts for the HPLC-NMR analyses, whereas others
have demonstrated the use of enriched fractions in their HPLC-NMR
studies.[24]
FIGURE 6 Chemical structures of compounds identified from Plocamium mertensii.
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Microcoil HPLC-NMR Analyses
In 2005, a 1.5mL (active volume) microcoil flow probe was employed to
identify three compounds in a rosemary extract using the stop-flow
mode.[25] The retention times and UV data of the three compounds was suf-
ficient for identification, but NMR data was also acquired to further confirm
their identities.[25] In 2004, another study dealt with the application of
the microcoil HPLC-NMR technique for the separation of six tocopherol
homologues (7)–(12) from a standard solution mixture (Figure 8). These
compounds were subsequently identified using a microcoil flow probe with
an active volume of 1.5mL using on-flow and stop-flow modes.[26]
FIGURE 7 2D-HPLC-NMR contour plot of compounds (3)–(6) from Plocamium mertensii.
FIGURE 8 Chemical structures of the six tocopherol derivatives identified.
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CapNMR Analyses
In 2005, CapNMR was successful in identifying thirteen new
steroids from fireflies such as compound (13) (Figure 9).[27] Using this
methodology, 2D NMR data could be acquired for each fraction of
interest.[27]
CapNMR has also been used successfully to identify new halichondrin
derivatives from a New Zealand marine sponge, Lissodendoryx sp.[28] This
particular sponge had previously been investigated, but as a result of the
improvements in NMR sensitivity (acquisition of the CapNMR probe), the
sponge extract was re-examined. This resulted in four new halichondrin
derivatives (14)–(17) being identified which displayed different structural
features to halichondrin B (18) on the left-hand side of the compound
(Figure 10).[28]
FIGURE 9 Chemical structure of one of the steroids identified from fireflies.
FIGURE 10 Chemical structures of halichondrin B (18) and the new halichondrin derivatives (14–17).
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HPLC-SPE-NMR Analyses
In 2007 HPLC-SPE-NMR was applied for the rapid identification of the
major constituents in the plant Hubertia sp., including three new quinic
acids (19), (20), and (21) (Figure 11).[15]
Also in 2007, it was demonstrated that the HPLC-SPE-NMR technique
was able to identify and determine structures of compounds comprising
<0.5% of the extract.[29]
A 2008 study, which focused on the metabolism of a synthesized com-
pound, was able to successfully demonstrate the use of a HPLC-SPE-
NMR-MS system. New compounds formed after metabolism were identified
using the HPLC-SPE-NMR-MS set-up.[30]
Column Trapping HPLC-NMR Analyses
In 2006 the use of a HPLC-NMR system with automated column trap-
ping was demonstrated.[17] A mixture of three nonsteroidal anti-
inflammatory drugs were separated and preconcentrated on a C18 guard
column prior to injection into the NMR flow probe.[17] It was reported that
the automated column trapping technique yielded gains of up to 14-fold in
the sensitivity of the analytes.[17]
HPLC-NMR-MS Analyses
In 2008, a parallel HPLC-NMR-MS system was utilized to identify active
metabolites in Fischerella ambigua, a strain of cyanobacteria.[10] A bioactive
FIGURE 11 Chemical structures of the three new quinic acids (19–21) identified from the plant
Hubertia sp.
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extract was fractionated using silica gel chromatography which yielded a
bioactive fraction showing anti-bacterial activity against Myobacterium
tuberculosis.[10] The bioactive fraction was then separated on a HPLC col-
umn and the eluant split between the MS and a microtitre plate fraction
collector. The fractions in the microtitre plate were evaporated and then
resuspended in deuterated NMR solvent and sequentially injected into
the flow probe.[10] Once the MS and NMR data were obtained, both sets
of data were compared and correlated to identify the metabolites in the
Cyanobacteria.[10] Several known compounds were identified as well as
one unknown compound, which was later identified after a scaled-up
growth and re-extraction of the organism.[10,31,32]
CONCLUSION
The incorporation of the advancements in HPLC-NMR have enabled
the methodology to become a robust and powerful technique for rapidly
profiling and dereplicating mixtures such as natural product extracts and
enriched fractions. It is now possible to determine chemical structures from
much smaller quantities and this, in turn, has resulted in the identification
of a number of new compounds. The recent advancements have also
reduced analysis time, allowing for faster throughput of samples.
HPLC-NMR is an especially relevant methodology to employ in the study
of unstable or light sensitive compounds. A search conducted in the
Scifinder database clearly indicates that the number of publications utiliz-
ing HPLC-NMR and closely related hyphenated spectroscopic techniques,
as discussed in this review, have steadily increased since its development
and implementation. A review of the application of HPLC-NMR methodol-
ogies tends to suggest that interest peaked in approximately 2003, but has
not shown any signs of abating. It is expected that further future advance-
ments in the hyphenated technique will also have a large impact on the
ability to employ the methodology even more successfully, with further
improvements to the limits of detection anticipated.
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CHAPTER 4 
Limit of Detection in HPLC-NMR 
 
Chapter 4 describes the limit of detection (LOD) of HPLC-NMR, as applied to a 500 
MHz NMR spectrometer, equipped solely with a 60 ?L flow cell. The LOD was established 
for five key NMR experiments and the results have been published as outlined below. 
Appendix A contains supplementary information relevant to this study.  
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a b  s  t  r  a c t
In  the  pursuit  of  new  natural  products,  the  demand  to rapidly  identify  compounds  present, in  ever
decreasing  amounts,  in  complex  crude  extracts  has become  a limiting  factor. Despite improvements
in  HPLC–NMR  hardware  and  pulse  sequences,  no extensive  limit  of  detection  (LOD)  investigations  have
been  reported  for the  acquisition  of  2D  NMR  spectroscopic  experiments  acquired  through  HPLC–NMR.  In
this  study  the LOD  for five  key 1D  and  2D  NMR  spectroscopic experiments  have  been  established,  using
two  reference  compounds,  including  the  on-flow  (WET  1D  proton), stop-flow  (WET1D proton),  gCOSY,
HSQCAD  and gHMBCAD  NMR  experiments.  The LOD for all of the  NMR  experiments were within the  range
of  700  ng  to  1 mg for the  set  of  fixed  experimental  parameters  implemented. For  principle components  in
a  complex  multi-component  mixture,  this would  allow  for in  situ  compound  identification.  HPLC–NMR
analysis  was employed  to investigate  the principle  components  present in  a  marine brown alga  crude
extract,  Cystophora  subfarcinata.
Crown  Copyright  ©  2014 Published by  Elsevier  B.V.  All  rights reserved.
1. Introduction
HPLC–NMR remains an underutilised technique particularly in
the identification of natural products. The technique was  devel-
oped in the 1970s [1] but has only recently become a more routine
method for analysis. Developments in suppression methodologies
and probe design have largely overcome the initial drawbacks of
the  insensitivity that is  so widely attributed to the instrumen-
tal technique [1,2]. HPLC–NMR is  now becoming recognised as
being pivotal for the on-line identification of natural products [3],
particularly those that are unstable and in its  ability to resolve
closely eluting compounds. While HPLC–MS offers increased sen-
sitivity and is frequently employed for structure identification, for
unknown compounds with isobaric masses, HPLC–NMR is  the only
method that provides structural information such as the ability to
differentiate between structural isomers such as compounds with
varying substitution patterns.
There  are two primary modes of operation for HPLC–NMR.
These include the on-flow and stop-flow HPLC–NMR method-
ologies respectively [4]. Rapid identification of general structure
class(es) for principle components is  frequently possible in the
∗ Corresponding author. Tel.: +61 3  9925 3376; fax: +61 3  9925 3747.
E-mail address: sylvia.urban@rmit.edu.au (S. Urban).
on-flow mode [1,2]. Unlike on-flow HPLC–NMR, which acquires
continuous 1H NMR  data as the sample is separated, in the stop-
flow HPLC–NMR mode the HPLC pumps are paused to allow for the
analysis of a single component in the NMR  flow cell for an indef-
inite period. This allows for extended NMR  acquisition times to
be implemented and therefore results in improved signal to noise
(S/N) NMR  spectra as well as permitting 2D NMR experiments to
be acquired [4].
The  sensitivity of HPLC–NMR is  influenced by  the magnetic field
strength, the volume of the flow probe being used and the mode of
the  HPLC–NMR experiment [5]. In 2002, a  limit of detection (LOD)
of 100 ng  was reported for a  600 MHz  system using either the stop-
flow or loop storage modes for proton observations for a  compound
of molecular weight of 500 g/mol [6]. While a  range of NMR  exper-
iments including 1H, COSY, NOESY, ROESY, HSQC and HMBC NMR
experiments have been carried out using various HPLC–NMR sys-
tems, no  LOD has been reported for these experiments [2]. In the
case of HMBC NMR  spectra, these experiments have been acquired
on HPLC–NMR systems, equipped with cold probes, microcoils or
after pre-concentration steps [2]. A study recently conducted by
the  Marine and Terrestrial Natural Product (MATNAP) research
group has resulted in the first acquisition of a  gHMBCAD NMR  spec-
trum, acquired on a 500 MHz  HPLC–NMR system solely equipped
with a  60 L flow cell (active volume) without the use of any pre-
concentration or cold probes [7]. We  have also reported several
http://dx.doi.org/10.1016/j.chroma.2014.11.074
0021-9673/Crown Copyright © 2014 Published by Elsevier B.V. All rights reserved.
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(1) methylparaben (2) rhodamine B
OCH3O
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CO2H
NEt2Et2N
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Fig. 1. Structures of the reference compounds employed for the determination of
the LOD for the 1D and 2DNMR spectroscopic experiments acquired viaHPLC–NMR.
instanceswhereHPLC–NMRhasbeen successful in identifyingnew,
unstable compounds that could not be isolated by conventional
off-line approaches [2,7–9].
The current study established the LOD for various common 1D
and 2D NMR experiments using two reference compounds (Fig. 1),
and found that the LOD was well within the range that is typically
observed for components occurring within natural product crude
extracts.
2. Materials and methods
2.1. Instrumentation
The HPLC–NMR analyses were carried out on a 500MHz Agilent
DD2 NMR spectrometer equipped with a Varian 1H [13C] pulsed
field gradient flow probe with a 60L active volume flow cell cou-
pled to a Varian Prostar 210 solvent delivery system, a Prostar 430
Autosampler and a Prostar 335 PDA detector. The HPLC–NMR anal-
yses were carried out using a CORBA communication and operated
withVnmrJ software. The2H resonance observed from theD2Owas
used to obtain field-frequency lock. The resonances from the HOD
and the methyl of the acetonitrile were suppressed using the WET
solvent suppression experiment [10]. The residual HOD resonance
of D2O was referenced to 4.64ppm. Indirectly detected 13C NMR
shifts were referenced to the unified TMS scale with a frequency
ratio of 25.15 [11]. For both on-flow and stop-flow HPLC–NMR
modes 50L injections of the two reference compounds (methyl-
paraben and rhodamine B) were injected onto an Agilent Eclipse
Plus C18 (150×4.6) 5mHPLC columnusing a solvent composition
of 50% CH3CN/D2O at a flow rate of 0.8mL/min.1
2.2. Reference compounds and solvents
Speciality solvents were used for the HPLC–NMR analyses
to minimise the need for solvent suppression. Reversed phase
HPLC–NMR was carried out using a CH3CN/D2O HPLC solvent sys-
tem. Acetonitrile (HPLC–NMR grade) was purchased from Fluka
Analytical, which had been purified (glass distilled) to ensure only
trace amounts of proprionitrile were present. D2O (99.9%) was
purchased from Cambridge Isotope Laboratories, Inc. To deter-
mine the LOD for the various NMR experiments conducted via
HPLC–NMR, two reference compounds were selected that would
1 It is important to note that this particular HPLC–NMR system utilises solely D2O
and CH3CN as mobile phase solvents. The use of methanol as an eluent is found to
irreversibly stick to the HPLC tubing and flow cell, and is therefore is not recom-
mended for HPLC–NMR use. In addition samples must be dissolved in either D2O or
HPLC–NMR grade CH3CN or a combination of the two solvents for similar reasons.
readily dissolve in CH3CN andD2O. One of the standard compounds
selected was of low molecular weight, namely methylparaben
(152.15g/mol) (Ajax) and the other compound was of a medium to
highmolecularweight, namely rhodamine B (479.01g/mol) (Gurr).
These compounds were selected as they were readily available,
highly soluble in acetonitrile, display a variety of chemical shift
environments andmultiplicities/coupling constants, together with
the fact that they represent the typical range of molecular weights
frequently encountered in smallmolecule natural product isolation
and identification studies.
2.3. Preparation of reference compound solutions for HPLC–NMR
LOD studies
Standards of themethylparaben reference compoundwere pre-
pared so that thesewould yield injected amounts of 1000, 500, 200,
50, 25, 15, 10, 5, 2.5, 1, 0.7 and 0.5g per 50L injection respec-
tively. Based on the S/N observed in the NMR spectra obtained for
the methylparaben reference compound, the rhodamine B refer-
ence compound standardswere increased since a highermolecular
weight compoundwould require a greater amount to be injected to
achieve a reasonable S/N. Therefore rhodamine B was prepared so
that injected amounts of 1000, 500, 250, 100 and 50g per 50L
injection respectively were achieved.
2.4. NMR pulse sequences
The NMR pulse sequences used for this study included the
on-flow WET 1D and in the stop-flow mode the WET1D, gCOSY,
HSQCAD and gHMBCAD NMR experiments. All NMR experiments
were carried out at 25 ◦C and utilised the standard experimen-
tal parameters supplied by the VnmrJ software unless otherwise
stated. During the WET suppression, decoupling of the 13C satel-
lites was enabled. In the on-flow WET1D NMR experiment, WET
suppression was utilised followed by acquisition of four scans (and
two steady state scans) for each subsequent spectrum. The stop-
flow WET1D NMR experiment utilised suppression sequences for
both the CH3CN and HDO resonances (suppression at 2.82 and
4.64ppm respectively, andwas acquired for 64 scans (ns) for a total
acquisition time of 3min 12 s (fn =32,768, at = 1.81939, np=32,960,
lb =0.5). Each of the twodimensionalNMRexperiments utilised the
WET solvent suppression pulse sequence prior to acquisition. The
gCOSY NMR experiment was acquired for four scans (ns) and 256
increments (ni), for a total acquisition timeof 20min59 s (fn =4096,
fn1=4096, at = 0.148378, np=2688, weighting= sqsinebell). The
HSQCAD NMR experiment utilised a delay time (d1) of 1.5 s,
and was acquired for 16 scans (ns) and 256 increments (ni),
for a total acquisition time of 4h 7min (fn =4096, fn1=2048,
at = 0.150034, np=2718, 1JHC =146Hz, weighting=Gaussian). The
gHMBCAD NMR experiment utilised a delay time (d1) of 0.8 s,
and was acquired for 64 scans (ns) and 512 increments (ni),
for a total acquisition time of 20h 50min (fn =4096, fn1=4096,
at = 0.132701, np=2404, nJHC =8Hz, weighting=Gaussian). Each of
the pulse sequences contained the WET solvent suppression pro-
cedure developed by Smallcombe et al., commonly employed on
Varian (Agilent) HPLC–NMR systems, which selectively suppresses
the residual signals of D2O and CH3CN, to substantially increase the
detection sensitivity of the analytes.
2.5. Marine brown alga specimen
The marine brown alga (Cystophora subfarcinata) was collected
at low tide on 22 January, 2006 from the Borough of Queenscliff,
near Point Lonsdale, Victoria, Australia. The alga was identified
by Dr G. Kraft (The University of Melbourne, Victoria, Australia)
and a voucher specimen designated the code number 2006-11 is
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deposited at the School of Applied Sciences (Discipline of Chem-
istry), RMIT University.
2.6. Marine alga extraction
The frozen marine alga (20.3 g, wet weight) was extracted with
3:1 methanol/dichloromethane (1 L). The crude extract was then
decanted and concentrated under reduced pressure and sequen-
tially solvent partitioned (trituated) into dichloromethane and
methanol soluble extracts respectively. HPLC–NMR and HPLC–MS
was carried out on the dichloromethane soluble extract of the
alga. The dichloromethane extract (741.9mg) was dissolved in
HPLC–NMR grade CH3CN and filtered through a 0.45 PTFE mem-
brane filter, whereby each injection (50L) represented 3520g
of the crude extract.
2.7. HPLC–NMR conditions for marine alga analysis
For both the on-flow and stop-flow HPLC–NMR analyses 50L
injections (representing 3520g) of the dichloromethane crude
extract of the alga were injected onto an Agilent Eclipse Plus C18
(150×4.6) 5m HPLC column using a solvent composition of 75%
CH3CN/D2O at a flow rate of 1.0mL/min.
2.8. HPLC–MS conditions for marine alga analysis
HRESI LC–MS was carried out on an Agilent 6540 Series Q-TOF
system (ESI operation conditions of 12 L/min N2, 325 ◦C drying gas
temperature and 3500V capillary voltage) equipped with an Agi-
lent 1260 Series LC solvent delivery module (75% CH3OH at a flow
rate of 1.0mL/min) in both the negative and positive ionisation
modes using an Agilent Eclipse Plus C18 (4.6×150) 5 HPLC col-
umn. The instrument was calibrated using the ‘Agilent Tuning Mix’
with purine as the reference compound and the Hewlett–Packard
standard HP0921.
3. Results and discussion
3.1. Limit of detection (LOD) and dynamic linearity
Several approaches exist for determining the detection limit
depending on whether the procedure is non-instrumental or
instrumental. Forhyphenatedmethods, the limit of detection (LOD)
is generally defined by the performance of the less-sensitive detec-
tor. In analytical procedures that exhibit baseline noise such as
NMR spectroscopy, determination of the S/N ratio is performed.
A S/N ratio of 3 is generally considered acceptable for estimating
the detection limit [12]. For the structural elucidation of unknown
compounds it is necessary to observe all signals in the NMR spec-
trum and so the S/N of the smallest peakmust be detected and used
for the LOD determination.
The LODwas found to vary for eachNMRexperiment conducted.
The LOD for the on-flow and stop-flow WET1D NMR experiments
was established based on a S/N of 3 for the smallest peak in the
1H NMR spectrum for the reference compound (ı 8.30ppm for
methylparaben and ı 8.41ppm for rhodamine B respectively). For
HPLC–NMR in natural product applications, the LOD would appro-
priately be the amount of a minor component necessary to obtain
an interpretable NMR spectrum, suitable for dereplication under
typical acquisition conditions. To achieve an interpretable 1H NMR
spectrum, the integration, multiplicity and coupling constants for
the signals must be easily determined.
Visual evaluation may also be used for non-instrumental or
instrumental methods as an approach for determining the LOD.
Here the detection limit is determined by the analysis of samples
with known concentrations (or in this case, the known amount
injected) of the reference compound and by establishing the min-
imum level at which the reference compound can be reliably
detected [12]. This LODapproachwas adopted for all of the 2DNMR
experiments which were acquired in the stop-flow HPLC–NMR
mode.
The LOD for the gCOSYNMRexperimentwasdefined as themin-
imumamount injected of the sample thatwould enable cross peaks
or correlations to be observed between each coupled proton. The
LOD for theHSQCADNMRexperimentwasdefined as theminimum
injectable amount required to observe all of the correlations arising
from protonated carbons. Lastly, the LOD for the gHMBCAD NMR
experimentwas defined as theminimumrequired amount injected
that would result in sufficient two and three bond proton to car-
bon correlations to be observed that would permit an unequivocal
structural elucidation of the component to be established. Together
with the LOD, the linear dynamic range for the on-flow and stop-
flow WET1D NMR experiments of the reference compounds were
recorded (Figs. 2 and 3). Linearity of the NMR S/N was observed for
the lower amounts injected of the two reference compounds. For
the 2D NMR experiments the dynamic linear range was not deter-
mined because the LOD for these experiments is based on a visual
evaluation rather than determination of the S/N.
NMR experiments for each of the two reference compounds
were evaluated beginning with the highest amount injected. NMR
experiments were re-acquired for each of the amounts injected
until the smallest peak for the two reference compounds could
no longer be observed with a S/N of 3 or until the expected 2D
correlations were no longer observed.
3.1.1. On-flow WET1D NMR analysis
The on-flow HPLC–NMR experiment estimated LOD values at
the 2.3 and 85g levels respectively for each of the two reference
compounds, methylparaben and rhodamine B. The increase in the
S/N for the smallest peak resulting for themethylparaben reference
compound from each injection corresponding to a higher amount
injected can be seen in Fig. 2. These LODs are only accurate for a
flow rate of 0.8mL/min and a block size of four scans. Changes in
the flow rate and block size would affect the LOD for the on-flow
WET1D NMR experiment. These detection limits would be easily
achieved for principle components within a natural product crude
extract.
3.1.2. Stop-flow analysis – Wet1D
The stop-flow WET1D NMR experiment was the most sensi-
tive of the NMR experiments evaluated. This was not surprising in
that this mode permits single component analysis to be achieved
by trapping the compound in the NMR flow cell for an indefinite
period, resulting in an approximately 200% increase in the sensitiv-
ity compared to the data obtained from the on-flow WET1D NMR
analysis.ALODat the700ng levelwasestimated formethylparaben
while a LOD at the 20g level was estimated for rhodamine B.
The increase in S/N for methylparaben and for rhodamine B result-
ing from higher amounts of the reference compounds injected is
evident in Fig. 3. These LODs would allow for not only principle
component, but also minor component analysis and identification
in a complex mixture. Only 64 scans were utilised in these exper-
iments so increasing the number of scans would easily allow for
lower amounts of the compounds to be detected.
3.1.3. Stop-flow analysis – gCOSY
The gCOSY NMR experiment acquired in the stop-flow
HPLC–NMR mode estimated LODs of 5 and 250g for methyl-
paraben and rhodamine B respectively. One of the drawbacks of
protonNMRspectra acquired via the stop-flowWET1DNMRexper-
iment, is that for the very low amounts injected, signals that closely
reside in the suppression regions of the D2O and CH3CN are often
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Fig. 2. (A) On-flow WET1D NMR spectra of a selection of amounts injected for methylparaben and (B) the dynamic linear range illustrating the LOD of methylparaben for
on-flow and stop-flow WET1D NMR experiments based on achieving a S/N of 3 for the smallest peak (8.30ppm).
Fig. 3. (A) Stop-flowWET1DNMR spectra of a selection of amounts injected for rhodamine B and (B) the dynamic linear range illustrating the LOD of rhodamine B for on-flow
and stop-flow WET1D NMR experiments based on achieving a S/N of 3 for the smallest peak (8.41ppm).
difficult to observe as they are inadvertently also suppressed. The
advantage of the gCOSYNMR experiment is that, as long as the pro-
ton NMR signals that reside in the suppression region are coupled,
valuable proton-to-proton coupling can still be observed andhence
protons in this region can still be identified.
3.1.4. Stop-flow analysis – HSQCAD
Only limited studies have been reported for some of the 2D het-
eronuclear NMR experiments. For instance HSQC and HMBC NMR
spectra have been published for basic HPLC–NMR systems together
with systems equipped with pre-concentration abilities such as
guard columns or SPE cartridges [8,13–15]. The LOD for methyl-
paraben and rhodamine B for the HSQCAD NMR experiment were
estimated as 50 and 500g respectively. These LOD values fall
within the range that typify components occurring within natu-
ral product crude extracts. If these LOD values are not achieved,
partial HSQCAD NMR data can still be obtained.
3.1.5. Stop-flow analysis – gHMBCAD
The last of the 2D NMR experiments evaluated was the gHMB-
CAD NMR experiment. Depending on the molecular weight as well
as the solubility of the analyte(s), gHMBCADNMR spectra acquired
through the stop-flowHPLC–NMRmodemay only be acquired suc-
cessfully for major or principle components. LOD values of 250g
and 1000g were estimated for methylparaben and rhodamine B
respectively. The LOD of rhodamine B clearly illustrates that when
higher molecular weight compounds are analysed, difficulties
may be encountered in obtaining quality gHMBCAD NMR spectra
that permit sufficient through bond correlations to be observed.
The other problem is that many compounds do not possess the
solubility that is required to analyse them via HPLC–NMR. As
the gHMBCAD NMR experiment is the definitive experiment
required to link structural fragments assembled from other NMR
experiments, the ability to acquire this experiment successfully
will be the determining factor as to whether a complete structure
(particularly a de novo structure determination) can be elucidated.
3.1.6. Summary of results
A comparison of the LOD established for the two reference
compounds (methylparaben and rhodamine B) in each of the NMR
experiments is illustrated in Figs. 2–4. As the NMR pulse sequence
becomes more complex, as in the case for the HSQCAD and gHM-
BCAD NMR experiments, the amount of compound required for
low compared to medium to high molecular weight compound
Fig. 4. LOD for 1D and 2D NMR experiments for the reference compounds
methylparaben and rhodamine B.
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Fig. 5. On-flow 2D HPLC–NMR contour plot resulting from the analysis of the dichloromethane crude extract of the marine alga, C. subfarcinata showing the detection of
components 1–8 (note: components 6 and 7 could only be detected via stop-flow HPLC–NMR analyses).
identifications becomes more apparent, whereby the latter will
require exceedinglymore amounts injected to obtain interpretable
results. Previous 2D NMR spectra acquired via various HPLC–NMR
studies have only provided LOD values for stop-flow WET1D
and gCOSY NMR experiments. This therefore represents the first
report of the LOD (for a set of fixed parameters) for the gCOSY,
HSQCAD and gHMBCAD NMR experiments acquired on a 500MHz
HPLC–NMR system equipped with a 60L active volume flow
cell. In defining the LOD an important factor that needs to be
considered is the chromatographic peak width. To obtain NMR
Table 1
NMR data (500MHz, 75% CH3CN/D2O) for 1-(2,4,6-trihydroxyphenyl)-6,9,12,15-octadecatetraen-1-one (3) and 1-(2,4,6-trihydroxyphenyl)-5,8,11,14,17-eicosapentaen-1-
one (4) obtained via stop-flow HPLC–NMR.
1-(2,4,6-Trihydroxyphenyl)-6,9,12,15-octadecatetraen-1-one (3) 1-(2,4,6-Trihydroxyphenyl)-5,8,11,14,17-eicosapentaen-1-one (4)
Position ıC,a mult. ıH (J in Hz) gCOSY gHMBCAD ıC,a mult. ıH (J in Hz) gCOSY
1 207.2, C ND
2 44.3, CH2 3.88, t (7.5) 3 1, 3, 4 ND 3.90, t (7.5) 3
3 25.1, CH2 2.48, p (7.5) 2, 4 1, 2 ND 2.53, p (7.5) 2
4 30.0, CH2 2.24, p (7.5) 3, 5 6 ND SS
5 ND 2.95, mb 129.0, CH 6.20, m
6 130.9, CH 6.20, m 5 8 129.0, CH 6.20, m 7
7 128.8, CH 6.20, m 8 8 26.1, CH2 3.66, m 6, 8
8 26.1, CH2 3.66, m 7, 9 7, 9, 10 129.0, CH 6.20, m 7
9 128.8, CH 6.20, m 8 8, 11 129.0, CH 6.20, m 10
10 128.8, CH 6.20, m 11 8, 11 26.1, CH2 3.66, m 9, 11
11 26.1, CH2 3.66, m 10, 12 9, 10, 12, 13 129.0, CH 6.20, m 10
12 128.8, CH 6.20, m 11 11, 14 129.0, CH 6.20, m 13
13 128.8, CH 6.20, m 14 11, 14 26.1, CH2 3.66, m 12, 14
14 26.1, CH2 3.66, m 13, 15 12, 13, 15 129.0, CH 6.20, m 13
15 128.8, CH 6.20, m 14 14 129.0, CH 6.20, m 16
16 132.7, CH 6.20, m 14 26.1, CH2 3.66, m 15, 17
17 21.1, CH2 SS 129.0, CH 6.20, m 16
18 14.5, CH3 1.77, t (8.0) 16, 17 129.0, CH 6.20, m
19 ND SS
20 ND 1.77, t (8.0)
1′ 105.1, C ND
2′ 164.9, C* ND
3′ 95.6, CH 6.70, s 1′ , 2′ , 5′ 95.8, CH 6.71, s
4′ ND* ND
5′ 95.6, CH 6.70, s 1′ , 3′ , 6′ 95.8, CH 6.71, s
6′ 164.9, C* ND
1′-OH ND ND
4′-OH ND ND
6′-OH ND ND
Referenced to D2O (ıH 4.64ppm).
SS, signal suppressed.
ND, not detected.
* Signals interchangeable.
a Carbon assignments based on HSQCAD and gHMBCAD NMR experiments
b Proton chemical shift based on correlation observed in gCOSY NMR experiment
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Fig. 6. Structures of the previously reported phloroglucinols (components 1 and 2) identified based on the HPLC–NMR and HPLC–MS analyses of the dichloromethane crude
extract of the marine alga, C. subfarcinata.
spectra with the necessary S/N of 3, it is important that the chro-
matographic peaks eluting from the HPLC are containedwithin the
active volume of the HPLC–NMR flow cell. The compromise to this
scenario is that in HPLC–NMR analyses it is often a requirement
to overload the HPLC column in an effort to achieve a higher
injectable amount and therefore have a better chance to detect the
component, particularly in the acquisition of the heteronuclear 2D
NMR experiments. However, at the lower amounts injected chro-
matographic peak shape is generally not an issue as components
tend to typically show a sharp peak shape.
The LOD for methylparaben and rhodamine B analyses con-
cluded that it is possible to carry out complete on-line 1D and 2D
NMR acquisition for structure identification. The intention was to
then extend the LOD HPLC–NMR study to the analysis of a multi-
component mixture (i.e. a natural product extract).
3.2. LOD case study: stop-flow HPLC–NMR analysis of a natural
product crude extract and secondary metabolite identification
A natural product crude extract was selected as a case study
following the LOD study. The crude extract of the marine brown
alga (C. subfarcinata) was analysed by HPLC–NMR and HPLC–MS
in an attempt to ascertain the ability of HPLC–NMR in combination
withHPLC–MS to completely characterise and identify components
in situ within a multi-component mixture. HPLC–NMR was imple-
mented in an effort to rapidly establish the nature of the structure
class(es) and to attempt to identity of the components present in
the dichloromethane crude extract of the marine alga, C. subfarci-
nata. A combination of on-flow and stop-flow HPLC–NMR analyses
detected the presence of eight components (Fig. 5) of which two
could be rapidly identified. Analysis of the extracted stop-flow
WET1D NMR spectra suggested that almost all of the compounds
were structurally related with characteristic proton NMR signals
in the aromatic and olefinic regions, together with various upfield
proton NMR signals. By direct comparison of the S/N for each of
the compounds it could be concluded that component 1 repre-
sented the main constituent of the dichloromethane crude extract
of the marine alga. Component 1 was completely characterised
by 1D and 2D NMR experiments acquired through the stop-flow
HPLC–NMRmode. This illustrated that the established LODs for the
selectedNMRexperiments acquiredvia stop-flowHPLC–NMRwere
achievable within a multi-component mixture using the fixed set
of experimental parameters.
Dereplication and identification of component 1 was achieved
using the MarinLit database using the molecular weight (obtained
by high resolution HPLC–MS), taxonomy of the alga, several of
the distinct carbon NMR signals and analysis of both the 1D and
2D NMR data. This suggested the identity of component 1 to be
a previously reported phloroglucinol (3) (Fig. 6) [16]. The stop-
flow HPLC–NMR WET 1D proton NMR spectrum of component 1
supported this structure with the presence of two distinct pro-
ton signals in the downfield region of the spectrum at ıH 6.70 and
6.20 respectively, a triplet methyl (ıH 1.77, t, J=8.0Hz, H-18) and
various other upfield signals. Due to the suppression of the acetoni-
trile signal, no signals were observed in the 2.65–3.00ppm region
of the spectrum. However analysis of the gCOSY NMR spectrum
showed the presence of a correlation within the HDO suppression
region, thereby confirming the presence of a proton signal at ıH
2.95. A set of methylene protons at ıH 3.88 and 2.48 (H-2 and H-
3 respectively) showed HMBC NMR correlations to a carbon at ıC
207.2 (C-1), confirming the position of the carbonyl group. Com-
plete analysis of the 1D and 2D NMR data obtained via stop-flow
HPLC–NMR (Table 1), along with the observed UV chromophore
at 285nm, which supported the presence of a phloroglucinol
moiety [17], allowed the complete structure of component 1 to
be deduced as the previously described phloroglucinol, 1-(2,4,6-
trihydroxyphenyl)-6,9,12,15-octadecatetraen-1-one (3) [18].
Stop-flow HPLC–NMR analysis of component 2 allowed for
the acquisition of a WET1D proton NMR spectrum, gCOSY and
partial HSQCAD NMR data (Table 1). This data alone was not
sufficient to completely identify component 2, however searches
conducted in the MarinLit database using the taxonomy, UV data,
molecular mass, and key carbon NMR chemical shifts, permitted
dereplication. Component 2 could be identified as the previously
reported phloroglucinol 1-(2,4,6-trihydroxyphenyl)-5,8,11,14,17-
eicosapentaen-1-one (4) (Fig. 6) [19].On thebasis of theHPLC–NMR
and HPLC–MS studies conducted on the remaining components
(3–8) in the crude extract of C. subfarcinata, in consultation with
theMarinLit database, thesemost likely representednewstructural
variants of the phloroglucinal structure class. However, insuffi-
cient structural information was obtained via HPLC–NMR since
these components were present in much lower amounts in the
crude extract. In summary the extracted UV profiles for each of the
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components, the stop-flow WET1D NMR spectra and the use of
the MarinLit database were able to conclude two distinct struc-
ture classes (phloroglucinols and a meroditerpenoid). An estimate
of the amounts of the two main components present in the crude
extract was proposed. Component 1 was present at approximately
0.8–1.0mg since complete 2D NMR data was easily achieved in
the stop-flow HPLC–NMR mode within the fixed time restrictions
and parameters. Component 2 was present at less than 0.5mg as
complete 2D NMR data could not be obtained within the fixed
parameter set. The LODsof theHSQCADandgHMBCADNMRexper-
iments require that approximately 0.5–1.0mg of a component be
present for sufficient correlations to be observed in these two NMR
experiments.
4. Conclusions
The LOD for various 1D and 2D NMR experiments acquired via
on-flow and stop-flow HPLC–NMR has been extensively reported
for the first time. This was achieved using a low and a medium
to high molecular weight reference compound with fixed NMR
experimental acquisition times, on a 500MHz HPLC–NMR system
equippedwith a 60L active volumeflowcell. The LODHPLC–NMR
study was extended to include the analysis of a complex natural
product crude extract (representing a multi-component mixture)
which, providing that there is sufficient solubility inwater and ace-
tonitrile, enables rapid on-line structure elucidation to be achieved.
To improve the LOD of HPLC–NMR on this system higher capacity
columns could be considered.
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 PART B – Terrestrial 
Organisms 
 
The chapters that make up this section (Chapters 5-7) of the thesis highlight the 
investigations conducted on two Australian plants from the Haemodoraceae family and one 
fungus. The studies conducted include application of phytochemical profiling (HPLC & 
HPLC-MS) to rapidly dereplicate the structure classes and the identity of the compounds 
present in the crude extracts of these organisms. This was conducted in conjunction with the 
use of traditional off-line isolation methodologies in order to explore the nature of the 
bioactive secondary metabolites present. This section of the thesis describes the identification 
of a total of ten new and twenty previously reported secondary metabolites and is comprised 
of three journal publications as listed below: 
1. Brkljača, Robert, White, Jonathan M., & Urban, Sylvia. (2015). 
Phytochemical Investigation of the Constituents Derived from the 
Australian Plant Macropidia fuliginosa. Journal of Natural Products, 
78(7), 1600-1608.  
 
2. Brkljača, Robert, & Urban, Sylvia. (2015). HPLC-NMR & HPLC-MS 
profiling and bioassay-guided identification of secondary metabolites 
from the Australian plant Haemodorum spicatum. Journal of Natural 
Products, 78(7), 1486-1494.  
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3. Brkljača, Robert, & Urban, Sylvia. (2015). Rapid Dereplication and 
Identification of the Bioactive Constituents from the Fungus, 
Leucocoprinus birnbaumii. Natural Product Communications, 10(1), 
95-98. 
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CHAPTER 5 
Constituents from the Australian Plant Macropidia fuliginosa 
 
 
Kingdom: Plantae 
Phylum: Charophyta 
Class: Equisetopsida 
Order: Commelinales 
Family: Haemodoraceae 
Genus: Macropidia 
Species: fuliginosa 
 
Purchased from Garden World Nursery 
(Braeside, Victoria, Australia) in October 
2012 and also from the Kuranga Native 
Nursery (Mount Evelyn, Victoria, 
Australia) in January 2011 and again in 
November 2012. 
 
Chapter 5 details the isolation of various new and known compounds from the flowers 
and bulbs of Macropidia fuliginosa. This work has been published in the Journal of Natural 
Products. Appendix B contains supplementary information relevant to this study.  
 
Journal publication resulting from this study: 
Brkljača, Robert, White, Jonathan M., & Urban, Sylvia. (2015). Phytochemical investigation 
of the constituents derived from the Australian plant Macropidia fuliginosa. Journal of 
Natural Products, 78(7), 1600-1608.  
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2476 V, Melbourne, Victoria 3001, Australia
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ABSTRACT: A phytochemical study of the flowers and bulbs
derived from the Australian plant Macropidia fuliginosa,
involving hyphenated spectroscopic methodologies (HPLC-
NMR and HPLC-MS), together with conventional isolation
strategies, resulted in the identification of 16 constituents (1, 2,
4−17) representative of six different structural classes. Six new
compounds (12−17) were identified from the bulbs of the
plant. The isolated compounds were assessed for antimicrobial
activity, and compound 8 was found to be more potent against
P. aeruginosa than ampicillin.
Plants commonly known as kangaroo paw comprise anumber of species belonging to two genera of the family
Hemodoraceae, which are endemic to the southwest corner of
Western Australia. There are 11 different species of kangaroo
paw, 10 of which belong to the Anigozanthos genus and one to
the Macropidia genus.1 Various species of the Anigozanthos
genus have been studied and have yielded a range of secondary
metabolites including phenylphenalenones, dimeric phenyl-
phenalenones, resveratrol analogues, and oxabenzochryse-
nones.2−7 By contrast, Macropidia f uliginosa, commonly
known as black kangaroo paw, which is classified separately
from the other kangaroo paw species, has not been extensively
studied. The flowers of M. fuliginosa have been reported to
produce the two oxabenzochrysenones hemofluorones A (1)
and B (2).8 Initially hemofluorone B was reported to have the
structure as depicted by 3,8 but this was subsequently revised to
2.3 Other plants belonging to the family Hemodoraceae, such
as Hemodorum simulans and Xiphidium caeruleum, also produce
oxabenzochrysenones as well as phenylphenalenones,9,10 which
are typical secondary metabolites of many of the species derived
from this family.
As part of our continuing efforts to study the chemical
diversity of Australian plants, we recently conducted
phytochemical studies of two different Hemodorum species,
one of which is used for the treatment of dysentery.10,11
Motivated by the limited studies that have been conducted on
M. fuliginosa, together with our interest in the constituents
derived from the Hemodoraceae family of plants, specimens of
M. fuliginosa were purchased and subjected to a phytochemical
study. Investigation of the flowers and bulbs of M. fuliginosa
yielded six new (12−17) and 10 known compounds (1, 2, 4−
11). The structures of three of these compounds (14, 16, and
17) were defined by single-crystal X-ray diffraction in
combination with detailed spectroscopic methods, while the
complete 2D NMR spectroscopic characterization of 1, 6, and
11 is reported herein for the first time.
■ RESULTS AND DISCUSSION
The flowers and bulbs of M. fuliginosa were separately extracted
with 3:1 MeOH/CH2Cl2, and the solvent was evaporated
under reduced pressure and sequentially solvent-partitioned
(triturated) into CH2Cl2- and MeOH-soluble fractions,
respectively. The crude CH2Cl2 extract of the flowers was
found to be more active than the MeOH crude extract and was
selected for phytochemical profiling. While both the CH2Cl2-
and MeOH-soluble fractions of the bulbs displayed antimicro-
bial activity, only the CH2Cl2 extract was subjected to an on-
line phytochemical profiling study. This selection was made on
the basis of preliminary analytical HPLC and 1H NMR
analyses, which indicated the presence of more secondary
metabolites in the CH2Cl2 crude extract. The CH2Cl2 crude
extract showed better separation of the secondary metabolites
present. Both the CH2Cl2 and MeOH crude extracts derived
from the bulbs of M. fulginosa were subjected to an off-line
phytochemical investigation.
On-line Phytochemical Profiling (HPLC-NMR and
HPLC-MS). The CH2Cl2 extracts of the bulbs and flowers
were subjected to HPLC-NMR and HPLC-MS chemical
profiling with a total of 10 peaks detected (see Supporting
Received: February 16, 2015
Article
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Information). While the CH2Cl2 crude extract of the bulbs
displayed reasonable solubility in MeCN and D2O, the CH2Cl2
crude extract of the flowers did not. This meant that HPLC-
NMR data could not be obtained for the crude extract derived
from the flowers and that dereplication of the constituents
present in this extract relied solely on the interpretation of the
HPLC-MS and UV spectroscopic data. The process known as
dereplication aims to rapidly deduce the chemical classes or
compounds present in a crude extract and involves the use of
chemical databases such as the Dictionary of Natural Products,
MarinLit, or SciFinder. These databases can be utilized to
search characteristic UV, MS, and NMR data.
HPLC-MS of the CH2Cl2 crude extract of the flowers
showed the presence of four compounds, each displaying
unique UV absorbance maxima. The molecular formula of the
compound eluting at tR = 2.45 min was determined as
C27H30O16 [observed m/z at 609.1453 [M − H]− (calcd for
C27H29O16: m/z 609.1456)], and the compound displayed UV
absorbance maxima above 350 nm. A search conducted in the
Dictionary of Natural Products using the molecular formula
and consideration of the UV absorbance maxima allowed the
tentative identification of the compound eluting at tR = 2.45 min
as rutin (4). Similar analyses of the data and literature searches
conducted for the compounds eluting at tR = 3.74 and 4.44 min
resulted in these constituents being tentatively identified as
hemofluorones A (1) and B (2), respectively. The fourth
compound eluting at tR = 15.05 min could not be identified, but
based on the characteristic UV absorbance at 368 nm it was
concluded to be a flavonoid,12,13 a common chemical class of
the Hemodoraceae.14
The HPLC-NMR and HPLC-MS of the CH2Cl2 crude
extract derived from the bulbs displayed the presence of six
compounds, of which three (tR = 4.11, 12.35, and 19.18 min)
were identified as the known compounds 5−7, respectively,
based on a dereplication strategy involving the use of the
Dictionary of Natural Products to search the molecular
formulas and characteristic UV absorbance maxima in
combination with the taxonomy of the plant. The WET1D
1H NMR spectrum and extracted UV profile of the two
compounds eluting at tR = 3.28 min (coeluting peaks) showed
close similarity to 5, suggesting these compounds were
structural analogues containing a formyl (δH 10.25, s) and a
methoxy (δH 4.18, s) moiety. The WET1D NMR spectrum of
the compound eluting at tR = 11.31 min suggested an
unsubstituted phenylphenalenone; however the extracted UV
profile was not in agreement, displaying an absorbance below
400 nm. Phenylphenalenones typically display an absorbance at
450 nm,2 suggesting that the compound eluting at tR = 11.31
min was of a closely related structural class.
Off-line Phytochemical Isolation. The off-line isolation
and fractionation of the crude extracts derived from the flowers
and bulbs of M. fulginosa yielded a total of 16 compounds (1, 2,
4−17). The identities of the four compounds (tR = 3.28, 11.31,
and 15.05 min) dereplicated in the on-line chemical profiling
approach were subsequently confirmed as 12, 13, 14, and 8,
respectively. In total the off-line phytochemical isolation
approach resulted in the identification of seven known
secondary metabolites from the flowers (1, 2, 4, 8−11) and
three from the bulbs (5−7), and their NMR and MS data were
in accordance with literature values.2−5,8,15−18
Fuliginosins A (12) and B (13) were isolated as brown oils
from the bulbs of M. fuliginosa. Comparison of the 1H NMR
spectra of 12 and 13 supported the fact that these compounds
were structural analogues and that they were closely related to
anigopreissin A (5) except that the resonances for the trans-
phenylvinyl system in anigopreissin A (5) were absent in both
12 and 13. The 1H NMR spectrum of fuliginosin A (12)
showed the presence of a formyl moiety (δH 9.91, s) which
showed key gHMBCAD NMR correlations to the adjacent
aromatic ring (C-5 and C-7, respectively), confirming its
attachment to position C-6. Complete analyses of the 1D and
2D NMR data (Table 1) allowed for 12 to be identified as the
new benzofuran 3-(3,5-dihydroxyphenyl)-4-hydroxy-2-(4-
hydroxyphenyl)benzofuran-6-carbaldehyde and given the trivial
name fuliginosin A. Inspection of the 1H and HSQCAD NMR
spectra of fuliginosin B (13) indicated the presence of two
methoxy moieties (δH 3.23, s, (6H); δC 52.9) as well as a
characteristic deshielded methine [δH 5.36, s, (1H); δC 103.1].
Key gHMBCAD NMR correlations indicated that these
methoxy moieties and the deshielded methine were attached
to an aromatic ring. Specifically, the deshielded methine proton
showed correlations to the carbons at positions C-5 and C-7
together with correlations to the two methoxy moieties, which
confirmed the attachment of this structural unit to C-6.
Analyses of the 1D and 2D NMR data (Table 1) allowed for 13
to be identified as the new benzofuran 5-[6-dimethoxymethyl-
4-hydroxy-2-(4-hydroxyphenyl)benzofuran-3-yl]benzene-1,3-
diol and given the trivial name fuliginosin B. Fuliginosin B (13)
is the dimethyl acetal of fuliginosin A (12), and it was suspected
that 13 could be an artifact produced from 12 as a result of the
extraction with MeOH. An attempt to convert fuliginosin A
(12) to fuliginosin B (13), whereby the former was stored in
MeOH as well as in a mixture of 3:1 MeOH/CH2Cl2, showed
no conversion after a period of approximately 1 week. This
Journal of Natural Products Article
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suggested that fuliginosin B (13) may be a natural product, but
the possibility of it being an artifact cannot be excluded.
Fuliginosone (14) was isolated as bright yellow needles. The
1H NMR spectrum showed the presence of eight discrete
aromatic/olefinic signals (δH 8.30 (1H), 8.29 (1H), 8.15 (1H),
7.87 (1H), 7.85 (1H), 7.72 (2H), 7.55 (2H), and 7.52 (1H),
respectively). Inspection of the UV spectrum of 14 showed an
absorbance at 323 nm, which is not consistent with a
phenylphenalenone skeleton (typically >400 nm).2 In addition
the 13C NMR spectrum showed the presence of two diagnostic
carbonyl signals (δC 187.7 and 186.9), which also was not in
accordance with typical phenylphenalenones.9,10,19 HRESIMS
Table 1. 1H and 13C NMR Data (500 MHz, DMSO-d6) for Fuliginosins A (12) and B (13)
fuliginosin A (12) fuliginosin B (13)
position δC, mult δH (J in Hz) gCOSY gHMBCAD δC,
a mult δH (J in Hz) gCOSY gHMBCAD
2 152.9, C 149.8, C
3 116.1, C 115.8, C
3a 116.1, C 118.3, C
4 152.8, C 154.9, Cd
5 107.3, CH 7.07, s 1′, 3a,c 4,c 6, 7 107.2, CH 6.63, s 1′, 3a, 7, 7a
6 124.0, C ND
7 106.2, CH 7.61, s 1′, 5, 6, 7a 100.9, CH 6.98, s 1′, 3a, 4b,c 5
7a 154.5, C 152.3, Cd
1′ 192.6, CH 9.91, s 7, 5 103.1, CH 5.36, s 7, 5, 2a′-OCH3, 2b′-OCH3
1″ 120.9, C 121.7, C
2″ 128.7, CH 7.35, d (9.0) 3″ 2, 4″, 6″ 128.4, CH 7.27, d (8.5) 3″ 2, 4″
3″ 116.0, CH 6.73, d (9.0) 2″ 1″, 4″, 5″ 115.9, CH 6.69, d (8.5) 2″ 1″, 4″
4″ 158.7, C 158.2, C
5″ 116.0, CH 6.73, d (9.0) 6″ 1″, 3″, 4″ 115.9, CH 6.69, d (8.5) 6″ 1″, 4″
6″ 128.7, CH 7.35, d (9.0) 5″ 2, 2″, 4″ 128.4, CH 7.27, d (8.5) 5″ 2, 4″
1‴ 133.9, C ND
2‴ 109.0, CH 6.22, d (2.0) 3, 3‴, 4‴, 6‴ 109.1, CH 6.20, d (2.0) 4‴ 3, 3‴, 4‴, 5‴,c 6‴
3‴ 158.5, C 158.6, C
4‴ 102.4, CH 6.20, dd (2.0, 2.0) 2‴, 3‴, 5‴, 6‴ 102.3, CH 6.16, dd (2.0, 2.0) 2‴, 6‴ 2‴, 3‴, 5‴, 6 ‴
5‴ 158.5, C 158.6, C
6‴ 109.0, CH 6.22, d (2.0) 3, 2‴, 4‴, 5‴ 109.1, CH 6.20, d (2.0) 4‴ 3, 2‴, 3‴,c 4‴, 5‴
4-OH NDb NDb
4″-OH NDb NDb
3‴-OH NDb NDb
5‴-OH NDb NDb
2a′-OCH3 52.9, CH3 3.23, s 1′
2b′-OCH3 52.9, CH3 3.23, s 1′
aCarbon assignments based on HSQCAD and gHMBCAD NMR experiments. bSignal not detected. cIndicates weak or long-range signal. dSignals
interchangeable.
Figure 1. Single-crystal X-ray diffraction structures (ORTEP) of fuliginosone (14), fuliginol (16), and 3-chlorofuliginol (17).
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revealed the molecular formula of 14 to be C18H10O2 (observed
m/z at 259.0752 [M + H]+ (calcd for C18H11O2: m/z
259.0759). The presence of 18 carbons, as compared to
phenylphenalenones, which typically contain 19 carbons, also
supported a deviation to that structure class. It was proposed
that 14 contained a “dione” moiety in a five-membered ring,
rather than containing a “dione” moiety in a six-membered ring.
This would account for the reduction in the number of carbons
that is typically observed in the phenylphenalenones. A pendant
aromatic ring substituted at C-3 or C-5 was established by
analysis of the NMR data. Predicted carbon chemical shifts for
the two possible structures were compared using Advanced
Chemistry Development (ACD) laboratories and ChemDraw
software.20,21 Substitution of the pendant aromatic ring at C-3
showed carbon chemical shits of δC 126 and 138 for C-4 and C-
5, respectively. The alternative C-5-substituted structure
showed carbon chemical shifts of δC 122 and 130 for C-3
and C-4, respectively. Two of the predicted carbon chemicals
shifts (δC 138 and 130) differ significantly, and on the basis of a
comparison of the observed and calculated carbon chemical
shifts, the pendant aromatic ring was placed at C-3. A single-
crystal X-ray diffraction (Figure 1) study of 14 enabled the
structure to be unequivocally deduced as 3-phenylacenaph-
thylene-1,2-dione and given the trivial name fuliginosone.
Analyses of the 1D and 2D NMR data (Table 2) also supported
the structure of fuliginosone (14).
Fuliginone (15) was isolated as a brown solid. The UV
spectrum showed a diagnostic absorbance at 430 nm,
confirming a phenylphenalenone-type structure.2 Two spin
systems were evident from H-4 to H-6 and from H-7 to H-9 on
the basis of gCOSY and gHMBCAD NMR data. An aromatic
proton (δH 7.17) and a pendant aromatic ring could be located
at either C-2 or C-3, respectively. Key NOE enhancements
were observed between H-4 (δH 7.72) and the proton at δH
7.17. This secured the position of the aromatic proton (δH
7.17) at C-3 and, therefore, the aromatic ring at C-2. Thus, the
structure of compound 15 was defined as 2-phenyl-1H-
phenalen-1-one. A literature review indicated that this
compound was obtained as a synthetic analogue;22 however
the UV and NMR data provided in that study do not support
this structure. All reported phenylphenalenones display a
diagnostic UV absorbance between 430 and 450 nm;2,5,9,10,19
however, the product obtained in the synthetic study showed
an absorbance at 403 nm.22 Second, several NMR signals were
not observed in the synthetic compound reported, in particular
the proton signal at δH 7.17 and the carbon signals at δC 149.5
and 113.8.22 Thus, this represents the first isolation and
characterization of compound 15, and it was given the trivial
name fuliginone.
Fuliginol (16) was isolated as a brown solid, and analysis of
the UV spectrum revealed an absorption at 463 nm, which was
supportive of a phenylphenalenone.2 The 1H and 13C NMR
spectra indicated the presence of a methoxy moiety (δH 3.10
(3H); δC 61.5), and the IR spectrum supported the presence of
a hydroxy group (3369 cm−1). The molecular formula was
obtained via ESIMS and deduced as C20H14O4 (observed m/z
at 317.0814 [M − H]− (calcd for C20H13O4: m/z 317.0814).
This indicated the presence of two hydroxy groups. Analysis of
the gHMBCAD NMR data for H-4 revealed correlations to two
deshielded oxygenated tertiary carbons (δC 142.8 and 147.8).
The methoxy moiety (δH 3.10) also showed an HMBC
correlation to the carbon at δC 142.8, indicating that the
methoxy moiety was at C-6. Comparison of the NMR data with
those of structurally related phenylphenalenones showed that
the C-6 methoxy resonances are deshielded (approximately at
δH 4.00) compared to their C-5 counterparts (approximately at
δH 3.00) due to the shielding effect of the aromatic ring.
19 The
assignment of the methoxy group at C-6 allowed for
subsequent assignment of the C-5 and C-6 chemical shifts at
δC 147.8 and 142.8 ppm, respectively. A single-crystal X-ray
diffraction study (Figure 1) provided the unequivocal
identification for 16 as 2,5-dihydroxy-6-methoxy-7-phenyl-1H-
phenalen-1-one, and it was given the trivial name fuliginol
(Table 4).
Fuliginol (16) was isolated as a pure compound prior to the
crystallization process, and NMR, UV, and IR data were
acquired on the single compound. During the process of
crystallization and in the single-crystal X-ray diffraction study
the presence of a cocrystal occurring with 16 (in a ratio of
approximately 1:1) was noted. This cocrystal (Figure 1), a
chlorinated derivative of 16, was identified as 3-chloro-2,5-
dihydroxy-6-methoxy-7-phenyl-1H-phenalen-1-one (17) and
given the trivial name 3-chlorofuliginol. It is believed that the
CHCl3 used during the IR analysis was responsible for the
introduction of the chlorine substituent. Upon completion of
the X-ray analysis, the crystals were resuspended in the same
batch of CHCl3 in an attempt to convert all of 16 to 17;
however after 4 weeks the two compounds remained present in
a ratio of approximately 1:1. HPLC purification was attempted
on the mixture; however, 16 and 17 were inseparable.
Complete 1D and 2D NMR, together with MS analysis, were
done on the mixture (Table 4). While fuliginol (16) was
isolated from the bulbs of the plant, 3-chlorofuliginol (17) may
represent an artifact of the isolation process.
The absolute configuration of rutin (4) was established by
comparison of the specific rotation with an authentic standard.
The absolute configurations of compounds 8 and 11 remain
Table 2. 1H and 13C NMR Data (500 MHz, CDCl3) of
Fuliginosone (14)
position δC, mult δH (J in Hz) gCOSY gHMBCAD
1 187.7, C
2 186.9, C
2a 130.1, C
3 136.4, C
4 131.1, CH 7.87, d (8.5) 5 2,b 2a, 3, 5a
5 132.6, CHa 8.30, d (8.5) 4 2a,b 4,b 5a, 8b,
1′b
5a 123.9, C
6 132.5, CHa 8.29, d (8.0) 7 5, 5a, 7,b 8, 8b
7 128.0, CH 7.85, ddd (8.0, 7.0,
1.0)
6, 8 5a, 8a
8 122.3, CH 8.15, dd (7.0, 1.0) 7 1, 6, 7,b 8b
8a 128.1, C
8b 146.9, C
1′ 139.8, C
2′ 128.5, CH 7.55, m 3′ 3, 6′
3′ 129.7, CH 7.72, ddd (8.0, 8.0,
1.5)
2′ 1′, 2′, 4′
4′ 129.2, CH 7.52, m 3′, 5′
5′ 129.7, CH 7.72, ddd (8.0, 8.0,
1.5)
6′ 1′, 4′, 6′
6′ 128.5, CH 7.55, m 5′ 3, 2′
aSignals interchangeable. bIndicates weak or long-range correlation.
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unassigned. Insufficient quantities of these compounds
precluded a specific rotation from being obtained.
Biological Activity Studies. Of the compounds isolated
from M. fulginosa, rutin (4) possesses a range of properties
including antioxidant,23,24 antihypertensive,25 and antiviral26
activities, while anigopreissin A (5) has been reported to
prevent wrinkles that are caused by muscular contractions.27
Anigorufone (7) inhibits the growth of the casual agent of
Panama’s disease,28 antifungal activity against Mycosphaerella
f ijiensis,29,30 and activities as a nematostatic and nematocidal
compound.31 Methyl trans-p-coumarate (9) displays antimela-
nogenic,32 antiadipogenic,33 anti-inflammatory,34 and antiox-
idant activities,16 along with α-glucosidase inhibitory effects.16
Methyl cis-p-coumarate (10) has been reported as an antiradical
compound.35 Isosalipurposide (11) shows a range of activity
including cytotoxicity against CaCo-236 and L929 cells37 and
antileishmanial,38 anticarcinogenic,39 and anticancer activities.40
Antimicrobial evaluation of the crude extracts and the
isolated compounds was carried out against five bacteria and
one fungus. Crude extracts and mixtures were tested at 50, 25,
or 1 mg/mL, while pure compounds, together with a
commercially available antibiotic and antifungal agent, were
tested between 1639 and 5230 μM (Table 5). Compared to the
antibiotic ampicillin, the isolated compounds were less active;
however compound 8 was more potent against Pseudomonas
aeruginosa than ampicillin. In recent years concern has grown
around P. aeruginosa with regard to its prevalence and
multidrug resistance;41 thus the identification of possible drug
leads against this bacteria is important.
Thus, on-line phytochemical profiling studies conducted via
HPLC-NMR and HPLC-MS were successful in dereplicating
the structures of several known compounds, as well as
identifying the presence of new compounds in the crude
extract of the bulbs of M. fulginosa. This approach, in
combination with the off-line phytochemical isolation, led to
the identification of a total of 16 compounds representative of
six different structure classes, including the identification of six
new compounds (12−17). The isolated compounds were
evaluated for antimicrobial activity, with only one compound
(8) showing promising activity.
Table 3. 1H and 13C NMR Data (500 MHz, CDCl3) of
Fuliginone (15)
position δC,
a mult δH (J in Hz) gCOSY gHMBCAD 1D NOE
1 180.5, C
2 149.5, C
3 113.8, CH 7.17, s 1, 2, 4, 9b 4, 2′, 6′
3a 128.4, C
4 130.5, CH 7.72, d (7.5) 5 3, 6, 9b 3
5 127.2, CH 7.59, dd (7.5,
8.0)
4, 6 3a, 6a
6 129.8, CH 7.94, d (8.0) 5 4, 7, 9b 5, 7
6a 132.0, C
7 136.6, CH 8.28, d (7.5) 8 6, 9, 9b 6, 8
8 126.8, CH 7.81, t (7.5) 7, 9 6a, 9a
9 131.1, CH 8.74, d (7.5) 8 1, 7, 9b
9a 127.5, C
9b 124.4, C
1′ 142.9, C
2′ 128.1, CH 7.49, m 3′ 1′, 6′
3′ 127.8, CH 7.39, m 2′ 4′, 5′
4′ 127.3, CH 7.44, m 3′, 5′
5′ 127.8, CH 7.39, m 6′ 3′, 4′
6′ 128.1, CH 7.49, m 5′ 1′, 2′
aCarbon assignments based on HSQCAD and gHMBCAD NMR
experiments.
Table 4. 1H and 13C NMR Data (500 MHz, CDCl3) for Fuliginol (16) and 3-Chlorofuliginol (17)
fuliginol (16) 3-chlorofuliginol (17)
position δC, mult δH (J in Hz) gCOSY gHMBCAD δC, mult δH (J in Hz) gCOSY gHMBCAD
1 180.4, C 178.2, C
2 148.8, C 146.1, C
3 114.0, CH 7.07, s 1, 2, 4, 9b 121.3, Cb
3a 127.6, C 124.4, Cb
4 122.0, CH 7.49, s 3, 3a, 5, 6, 9b 120.7, CH 8.10, s 3, 3a, 5, 6, 9b
5 147.8, C 147.9, C
6 142.8, C 143.7, C
6a 127.0, C 127.7, C
7 145.7, C 146.2, C
8 131.1, CH 7.63, d (7.5) 9 6a, 7, 9, 9a, 1′ 131.1, CH 7.65, d (7.5) 9 6a, 1′
9 128.4, CH 8.61, d (7.5) 8 1, 7, 8, 9a, 9b 129.0, CH 8.62, d (7.5) 8 1, 7, 9b
9a 124.9, C 125.9, C
9b 121.2, C 120.7, C
1′ 141.7, C 141.6, C
2′ 129.5, CH 7.50, m 3′ 7, 1′, 3′, 4′ 129.3, CH 7.50, m 3′ 3′, 4′
3′ 127.3, CH 7.44, m 2′ 1′, 2′, 4′, 5′ 127.3, CH 7.45, m 2′ 1′, 2′
4′ 127.3, CH 7.44, m 2′, 3′, 5′, 6′ 127.3, CH 7.45, m 2′, 6′
5′ 127.3, CH 7.44, m 6′ 1′, 3′, 4′, 6′ 127.3, CH 7.45, m 6′ 1′, 6′
6′ 129.5, CH 7.50, m 5′ 7, 1′, 4′, 5′ 129.3, CH 7.50, m 5′ 4′, 5′
2-OH NDa NDa
5-OH NDa NDa
6-OCH3 61.5, CH3 3.10, s 6 61.6, CH3 3.14, s 6
aSignal not detected. bSignals interchangeable.
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■ EXPERIMENTAL SECTION
General Experimental Procedures. All organic solvents used
were analytical reagent (AR or GR), UV spectroscopic, or HPLC
grade with Milli-Q water also being used. Optical rotations were
carried out using a 1.5 mL cell on a Rudolph Research Analytical
Autopol IV automatic polarimeter, set to the Na 589 nm wavelength.
UV/vis spectra were recorded on an Agilent Cary 60 spectropho-
tometer, using EtOH. FTIR spectra were recorded as a film using
NaCl disks on a PerkinElmer Spectrum One FTIR spectrometer.
Uncorrected melting points were recorded on a Gallenkamp melting
point apparatus. 1H (500 MHz), 13C (125 MHz), and 1D NOE
spectra were acquired in CDCl3 and DMSO-d6 on a 500 MHz Agilent
DD2 NMR spectrometer with referencing to solvent signals (δH 7.26;
δC 77.0 and δH 2.50; δC 39.5 ppm, respectively). Two-dimensional
NMR experiments recorded included gradient correlation spectrosco-
py (gCOSY), heteronuclear single-quantum correlation spectroscopy
with adiabatic pulses (HSQCAD), and gradient heteronuclear
multiple-bond spectroscopy with adiabatic pulses (gHMBCAD). Silica
gel flash chromatography was carried out using Davisil LC35 Å silica
gel (40−60 mesh) with a 20% stepwise solvent elution from 100%
petroleum ether (60−80 °C) to 100% CH2Cl2 to 100% EtOAc and
finally to 100% MeOH. C18 vacuum liquid chromatography (VLC)
was carried out on silica gel 60 RP-18 (40−63 μm) using a 20%
stepwise solvent elution from 100% H2O to 100% MeOH, and, finally,
to 100% CH2Cl2 or a 20% stepwise elution from 30% CH3CN/H2O to
90% CH3CN/H2O and a final elution of 100% CH3CN. ESI mass
spectra were obtained on a Micromass Platform II mass spectrometer
equipped with an LC-10AD Shimadzu solvent delivery module (50%
CH3CN/H2O at a flow rate of 0.2 mL/min) in both the positive and
negative ionization modes using cone voltages between 20 and 30 V.
HRESIMS was carried out on an Agilent 6200 Series TOF system
(ESI operation conditions of 8 L/min N2, 325 °C drying gas
temperature, and 3500 V capillary voltage) equipped with an Agilent
1200 Series LC solvent delivery module (100% MeOH at a flow rate
of 0.3 mL/min) in either the positive or negative ionization modes.
The instrument was calibrated using the “Agilent Tuning Mix” with
purine as the reference compound and the Hewlett−Packard standard
HP0921. HRMS was also carried out on a Waters Xevo QTof mass
spectrometer, with an atmospheric solids analysis probe (ASAP)
source (probe temperature set to 300 °C; source temperature set to 80
°C; sampling cone voltage of 20.0 V). Accurate mass was obtained by
lockmass using leucine enkephalin as the reference compound. All
analytical HPLC analyses and method development were performed
on a Dionex P680 solvent delivery system equipped with a PDA100
UV detector (operated using Chromeleon software). Analytical HPLC
analyses were carried out using either a gradient method (0−2 min
10% CH3CN/H2O; 14−24 min 75% CH3CN/H2O; 26−30 min 100%
CH3CN; and 32−40 min 10% CH3CN/H2O or 0−3.5 min 30%
CH3CN/H2O; 8.5−40 min 50% CH3CN/H2O) or an isocratic
method (either 70, 50, 45, 40, 30, or 25% CH3CN/H2O) on an
Alltech Alltima HP C18 (250 × 4.6) 5 μm column at a flow rate of 1.0
mL/min. Semipreparative HPLC was carried out on a Varian Prostar
210 solvent delivery system equipped with a Prostar 335 PDA detector
(operated using Star Workstation software) using either a gradient
method (0−2 min 10% CH3CN/H2O; 14−24 min 75% CH3CN/
H2O; 26−30 min 100% CH3CN; and 32−40 min 10% CH3CN/H2O
or 0−3.5 min 30% CH3CN/H2O; 8.5−40 min 50% CH3CN/H2O) or
an isocratic method (either 70, 50, 45, 40, 30, or 25% CH3CN/H2O)
using an Alltech Alltima C18 (250 × 10) 5 μm column at a flow rate of
3.5 mL/min.
Single-Crystal X-ray Diffraction. Crystals of fuliginosone (14),
fuliginol (16), and 3-chlorofuliginol (17) were obtained by dissolving
the compounds in CH2Cl2 and allowing the solvent to evaporate at
room temperature. Crystallographic diffraction data were collected
with an Oxford SuperNova diffractometer using Cu radiation (k =
1.541 84 A). Data were reduced using the CrysalisPRO software. The
temperature of the data collection was maintained at 130 K, using an
Oxford Cryostream cooling device. The structure was solved by direct
methods and difference Fourier synthesis and was refined on F2
(SHELXL-97).42 A thermal ellipsoid plot was generated using the
program ORTEP-343 integrated within the WINGX program suite.44
Biological Evaluation. For the biological evaluation procedure,
refer to Brkljacǎ and Urban.45
Table 5. Antimicrobial Activity of the Crude Extracts and Pure Compounds Obtained from M. fuliginosa, Together with
Commercial Standard Antibiotic and Antifungal Compounds, Showing Zones of Inhibition (mm)
microorganism
concentration
E. colia ATCC
25922
S. aureusb
ATCC 25923
S. aureus MRSAc
344/2-32
P. aeruginosad
ATCC 27853
S. pyogenese
345/1
C. albicansf
ATCC 10231
CH2Cl2 extract of flowers 25 mg/mL ND
g 1 NDg 3 1 NDg
MeOH extract of flowers 50 mg/mL NDg NDg NDg NDg NDg NDg
CH2Cl2 extract of bulbs 50 mg/mL ND
g 1 NDg 2 3 1
MeOH extract of bulbs 50 mg/mL NDg 1 2 1 4 1
mixture of hemofluorones A (1)
and B (2)
1 mg/mL NDg NDg NDg 1 NDg NDg
rutin (4) 1639 μM NDg NDg NDg NDg NDg NDg
anigopreissin A (5) 2211 μM NDg 2 NDg NDg 1 NDg
2-phenylnaphthalic anhydride (6) 3649 μM NDg NDg NDg 2 NDg NDg
anigorufone (7) 3675 μM NDg NDg NDg NDg NDg NDg
compound 8 1724 μM 1 NDg NDg 10 1 NDg
mixture of compounds 9 and 10 1 mg/mL NDg 1 NDg NDg 1 NDg
isosalipurposide (11) 3030 μM NDg NDg NDg 2 NDg NDg
fuliginosin A (12) 2762 μM NDg 1 NDg NDg 1 NDg
fuliginosin B (13) 2450 μM NDg NDg NDg NDg NDg NDg
fuliginosone (14) 3875 μM NDg 2 NDg 1 NDg NDg
fuliginone (15) 3905 μM NDg NDg NDg NDg 2 NDg
mixture of fuliginol (16) and 3-
chlorofuliginol (17)
1 mg/mL NDg NDg NDg NDg 3 NDg
ampicillin (antibiotic) 2862 μM NDg 15 3 2 20 NTh
carbendazim (antifungal) 5230 μM NTh NTh NTh NTh NTh NDg
aEscherichia coli. bStaphylococcus aureus. cMethicillin-resistant Staphylococcus aureus. dPseudomonas aeruginosa. eStreptococcus pyogenes. fCandida
albicans. gIndicates no zone of inhibition detected. hIndicates not tested.
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Plant Material. Several specimens of the plant (M. fuliginosa) were
purchased from Kuranga Native Nursery (Mount Evelyn, Victoria,
Australia) and from Gardenworld Nursery (Braeside, Victoria,
Australia) in January 2011, October 2012, and November 2012. The
bulbs of the plants purchased in 2011 and 2012 were used in this
study, while the flowers were harvested from the plants purchased in
2012. The bulbs and flowers were separated and then stored at −80 °C
until extraction. Voucher specimens were designated with the code
numbers 2011-01a (bulbs), 2011-02a (bulbs), 2012-01a (bulbs), and
2012_05a (flowers), respectively, and are deposited in the School of
Applied Sciences (Discipline of Applied Chemistry), RMIT University.
Phytochemical Profiling. Chemical profiling was carried out on
the CH2Cl2-soluble extracts of the bulbs and flowers using HPLC-
NMR and HPLC-MS methodologies. Details of these analyses are
provided in the General ExpErimental Procedures section and in
Brkljacǎ and Urban.45 The CH2Cl2 extract of the bulbs (157.9 mg) was
dissolved in HPLC-NMR grade CH3CN (1580 μL) and filtered
through a 0.45 PTFE membrane filter (Grace Davison Discovery
Sciences) for HPLC-NMR analysis. Owing to the poor solubility of
the CH2Cl2 crude extract of the flowers in CH3CN, no HPLC-NMR
was conducted. HPLC-MS analyses were carried out on the CH2Cl2
crude extracts of both the bulbs and flowers.
Extraction and Isolation of Flowers. The flowers of the plant
(31 g, wet weight) were extracted with 3:1 MeOH/CH2Cl2 (2 L). The
crude extract was decanted and concentrated under reduced pressure
and sequentially solvent partitioned (triturated) into CH2Cl2- and
MeOH-soluble extracts, respectively. A portion of the MeOH extract
of the flowers (200 mg) was subjected to Sephadex LH-20 column
chromatography (100% MeOH) to yield seven fractions. The fourth
fraction was subjected to RP-HPLC (using a gradient of 0−3.5 min
30% CH3CN/H2O; 8.5−40 min 50% CH3CN/H2O) to yield
isosalipurposide (11) (0.7 mg, 0.01%). Another portion of the
MeOH extract of the flowers (244 mg) was subjected to Sephadex
LH-20 column chromatography (100% MeOH) to yield six fractions.
The fourth fraction yielded a mixture (13.6 mg, 0.2%) of
hemofluorones A (1) and B (2). The second fraction was subjected
to RP-HPLC (25% CH3CN/H2O) to yield rutin (4) (4.6 mg, 0.08%).
The third fraction was subjected to reversed-phase HPLC (30%
CH3CN/H2O) to yield the p-hydroxycinnamate of salipurposide (8)
(0.4 mg, 0.007%), a mixture of methyl trans- and cis-p-coumarate (9
and 10) (0.1 mg, 0.002%), and isosalipurposide (11) (0.1 mg,
0.002%). Another portion of the MeOH extract (83.4 mg) was
subjected to C18 VLC (20% stepwise elution from 30% CH3CN/H2O
to 90% CH3CN/H2O and finally to 100% CH3CN) to yield 11
fractions. The first fraction (50% CH3CN/H2O) was subjected to
Sephadex LH-20 column chromatography (100% MeOH) to yield
rutin (4) (6.4 mg, 0.1%). The second VLC fraction (50% CH3CN/
H2O) was subjected to Sephadex LH-20 column chromatography
(100% MeOH) to yield 11 fractions. Fractions 5−8 were combined to
yield the p-hydroxycinnamate of salipurposide (8) (2.1 mg, 0.04%).
The percentage yields are reported on the basis of the dry mass of the
flowers extracted.
Extraction and Isolation of Bulbs. The bulbs of the plant (77 g,
wet weight) were extracted with 3:1 MeOH/CH2Cl2 (2 L). The crude
extract was decanted and concentrated under reduced pressure and
sequentially solvent partitioned (triturated) into CH2Cl2- and MeOH-
soluble extracts, respectively. The CH2Cl2 extract was subjected to
flash silica gel column chromatography (20% stepwise elution from
petroleum ether (60−80 °C) to CH2Cl2 to EtOAc and, finally, to
MeOH). The 100% CH2Cl2 fraction yielded anigorufone (7) (35.8
mg, 0.05%). The 80% CH2Cl2/EtOAc fraction (first eluting band) was
subjected to RP-HPLC (70% CH3CN/H2O) to yield 2-phenyl-
naphthalic anhydride (6) (0.8 mg, 0.001%), anigorufone (7) (6.0 mg,
0.009%), and fuliginosone (14) (1.6 mg, 0.002%). The 80% CH2Cl2/
EtOAc fraction (second eluting band) was subjected to Sephadex LH-
20 column chromatography (100% MeOH) to yield four fractions.
The third fraction was subjected to reversed-phase HPLC (70%
CH3CN/H2O) to yield anigorufone (7) (4.5 mg, 0.007%),
fuliginosone (14) (1.5 mg, 0.002%), 2-phenyl-1H-phenalen-1-one
(15) (1.9 mg, 0.003%), and fuliginol (16) (6.5 mg, 0.01%). A portion
of the MeOH extract (150 mg) was subjected to RP-HPLC (50%
CH3CN/H2O) to yield anigopreissin A (5) (12.2 mg, 0.02%) and
fuliginosin A (12) (4.0 mg, 0.006%). Another portion of the MeOH
extract (220 mg) was subjected to C18 VLC (20% stepwise elution
from H2O to MeOH and finally to CH2Cl2) to yield 10 fractions. The
20% H2O/MeOH fraction was subjected to reversed-phase HPLC
(50% CH3CN/H2O) to yield anigopreissin A (5) (17.1 mg, 0.03%)
and fuliginosin A (12) (5.6 mg, 0.008%). One of the fractions from the
HPLC purification was further subjected to RP-HPLC (50% CH3CN/
H2O) to yield fuliginosin A (12) (0.6 mg, 0.001%) and fuliginosin B
(13) (0.7 mg, 0.001%). The percentage yields are reported on the
basis of the dry mass of the bulbs extracted.
On-line (HPLC-NMR and HPLC-MS) Characterization of
Compounds. Compounds Derived from the Flowers of M.
fulginosa. Hemofluorone A (5,8,9-trihydroxy-1H-naphtho[2,1,8-
mna]xanthen-1-one) (1): tR = 3.74 min; UV (extracted from PDA)
(30% CH3CN/D2O) λmax 572 nm; HPLC-MS m/z 317.0453 (calcd
for C19H9O5, 317.0450).
Hemofluorone B (5,8,9-trihydroxy-3H-naphtho[2,1,8-mna]xanthen-
3-one) (2): tR = 4.44 min; UV (extracted from PDA) (30% CH3CN/
D2O) λmax 551 nm; HPLC-MS m/z 317.0453 (calcd for C19H9O5,
317.0450).
Rutin (4): tR = 2.45 min; UV (extracted from PDA) (30% CH3CN/
D2O) λmax 353 nm; HPLC-MS m/z 609.1453 (calcd for C27H29O16,
609.1456).
p-Hydroxycinnamate of salipurposide (8): tR = 15.05 min; UV
(extracted from PDA) (30% CH3CN/D2O) λmax 317, 368 nm; HPLC-
MS m/z 579.1503 (calcd for C30H27O12, 579.1503).
Compounds Derived from the Bulbs of M. f ulginosa.
Anigopreissin A (5-[4-hydroxy-2-(4-hydroxyphenyl)-6-{(1E)-2-(4-
hydroxyphenyl)ethenyl}-3-benzofuranyl]-1,3-benzenediol) (5): tR =
4.11 min; UV (extracted from PDA) (50% CH3CN/D2O) λmax 263,
303, 355 nm; HPLC-NMR WET1D NMR (500 MHz, 50% CH3CN/
D2O) obtained from stop-flow HPLC-NMR mode δ 7.82 (2H, d, J =
9.0 Hz, H-2a/H-6a*), 7.77 (2H, d, J = 9.0 Hz, H-3a/H-5a*), 7.59
(1H, d, J = 1.0 Hz, H-10b°), 7.52 (1H, d, J = 16.0 Hz, H-7b∧), 7.42
(1H, d, J = 16.0 Hz, H-8b∧), 7.22 (2H, d, J = 8.0 Hz, H-2b/H-6b#),
7.20 (1H, s, H-12a), 7.15 (2H, d, J = 8.0 Hz, H-3b/H-5b#), 6.83 (1H,
d, J = 1.0 Hz, H-14b°), 6.78 (2H, s, H-10a/H-14a), *#∧°signals
interchangeable; HPLC-MS m/z 451.1189 (calcd for C28H19O6,
451.1182).
2-Phenylnaphthalic anhydride (6): tR = 12.35 min; UV (extracted
from PDA) (50% CH3CN/D2O) λmax 240, 323 nm; HPLC-NMR
WET1D NMR (500 MHz, 50% CH3CN/D2O) obtained from stop-
flow HPLC-NMR mode δ 8.80 (2H, d, J = 8.5 Hz, H-4/H-5#), 8.52
(1H, d, J = 8.0 Hz, H-7#), 8.29 (1H, dd, J = 8.0, 8.5 Hz, H-6), 8.27
(1H, d, J = 8.5 Hz, H-3), 8.10 (2H, d, J = 7.5 Hz, H-2′/H-6′), 7.94
(2H, m, H-3′/H-5′), 7.92 (1H, m, H-4′), #signals interchangeable;
HPLC-NMR 13C NMR (125 MHz, 50% CH3CN/D2O) obtained
from stop-flow HPLC-NMR mode δ 134.0 (CH, C-4/C-5#), 131.6
(CH, C-3), 130.4 (CH, C-2′/C6′), 129.8 (CH, C-4′), 129.2 (CH, C-
3′/C-5′), 129.1 (CH, C-6), 123.1 (CH, C-7#), #signals interchange-
able; HPLC-MS m/z 275.0700 (calcd for C18H11O3, 275.0708).
Anigorufone (2-hydroxy-9-phenyl-1H-phenalen-1-one) (7): tR =
19.18 min; UV (extracted from PDA) (50% CH3CN/D2O) λmax 410
nm; HPLC-NMR WET1D NMR (500 MHz, 50% CH3CN/D2O)
obtained from stop-flow HPLC-NMR mode δ 8.73 (1H, d, J = 8.0 Hz,
H-7#), 8.44 (1H, d, J = 8.0 Hz, H-4*), 8.22 (1H, d, J = 7.0 Hz, H-6*),
8.06 (1H, dd, J = 7.0, 8.0 Hz, H-5), 7.97 (1H, d, J = 8.0 Hz, H-8#),
7.84 (2H, m, H-3′/H-5′), 7.82 (1H, m, H-4′), 7.75 (2H, d, J = 7.5 Hz,
H-2′/H-6′), 7.59 (1H, s, H-3), *#signals interchangeable; HPLC-
NMR 13C NMR (125 MHz, 50% CH3CN/D2O) obtained from stop-
flow HPLC-NMR mode δ 136.5 (CH, C-7#), 132.0 (CH, C-8#), 131.8
(CH, C-6*), 130.8 (CH, C-4*), 129.1 (CH, C-3′/C-5′), 128.5 (CH,
C-2′/C-6′), 128.2 (CH, C-4′), 128.0 (CH, C-5), 114.7 (CH, C-3),
*#signals interchangeable; HPLC-MS m/z 271.0765 (calcd for
C19H11O2, 271.0759).
Fuliginosin A [3-(3,5-dihydroxyphenyl)-4-hydroxy-2-(4-
hydroxyphenyl)benzofuran-6-carbaldehyde] (12) and B [5-(6-
(dimethoxymethyl)-4-hydroxy-2-(4-hydroxyphenyl)benzofuran-3-
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yl)benzene-1,3-diol] (13): tR = 3.28 min; UV (extracted from PDA)
(50% CH3CN/D2O) λmax 238, 268, 322, 362 nm; HPLC-NMR
WET1D NMR (500 MHz, 50% CH3CN/D2O) obtained from stop-
flow HPLC-NMR mode δ 10.25 (s), 8.01 (s), 7.82 (d, J = 8.5 Hz),
7.79 (s), 7.51 (s), 7.17 (d, J = 8.5 Hz), 7.02 (s), 6.77 (s), 6.74 (s), 4.18
(s), 4.15 (s).
Fuliginosone (3-phenylacenaphthylene-1,2-dione) (14): tR =
11.31 min; UV (extracted from PDA) (50% CH3CN/D2O) λmax
240, 345 nm; HPLC-NMR WET1D NMR (500 MHz, 50% CH3CN/
D2O) obtained from stop-flow HPLC-NMR mode δ 9.02 (1H, d, J =
8.0 Hz, H-4*), 8.88 (1H, d, J = 8.0 Hz, H-5*), 8.83 (1H, d, J = 8.0 Hz,
H-6*), 8.29 (1H, dd, J = 8.0, 8.0 Hz, H-7), 8.07 (1H, d, J = 8.0 Hz, H-
8*), 7.80−7.96 (5H, m, H-2′/H-3′/H-4′/H-5′/H-6′), *signals
interchangeable; HPLC-MS m/z 259.0766 (calcd for C18H9O2,
259.0759).
Off-line Characterization of Compounds. Hemofluorone A
(5,8,9-trihydroxy-1H-naphtho[2,1,8-mna]xanthen-1-one) (1): pur-
ple, amorphous solid; all off-line NMR and MS data were identical to
literature data;8 13C NMR (125 MHz, DMSO-d6) δ 181.8 (C, C-1),
158.1 (C, C-6a), 148.1 (C, C-9#), 146.6 (C, C-8#), 141.6 (C, C-5*),
140.0 (C, C-5a*), 139.3 (CH, C-3), 135.5 (C, C-10b), 131.4 (CH, C-
12), 126.9 (CH, C-2), 124.5 (C, C-12a), 122.6 (CH, C-4), 121.8 (C,
C-3a), 121.5 (C, C-12b), 118.3 (C, C-12c), 113.6 (CH, C-11), 107.0
(C, C-10a), 105.4 (CH, C-10), 102.5 (CH, C-7), *#signals
interchangable.
Hemofluorone B (5,8,9-trihydroxy-3H-naphtho[2,1,8-mna]-
xanthen-3-one) (2): purple, amorphous solid; all off-line NMR and
MS data were identical to literature data.3,8
Rutin: brown oil; all off-line NMR, MS, and specific rotation data
were identical to literature data17 and compared to an authentic
standard of rutin.
Anigopreissin A (5-[4-hydroxy-2-(4-hydroxyphenyl)-6-{(1E)-2-(4-
hydroxyphenyl)ethenyl}-3-benzofuranyl]-1,3-benzenediol) (5):
brown oil; all off-line NMR and MS data were identical to literature
data.4
2-Phenylnaphthalic anhydride (6): yellow, amorphous solid; all
off-line UV and MS data were identical to literature data;2 1H NMR
(500 MHz, CDCl3) δ 8.71 (1H, dd, J = 7.5, 1.5 Hz, H-7), 8.34 (1H, dd
(J = 8.5, 1.5 Hz, H-5), 8.29 (1H, d, J = 8.5 Hz, H-4), 7.85 (1H, dd, J =
8.5, 7.5 Hz, H-6), 7.69 (1H, d, J = 8.5 Hz, H-3), 7.42−7.57* (5H, m,
H-2′, H-3′, H-4′, H-5′, H-6′); 13C NMR (125 MHz, CDCl3) δ 161.0
(C, C-9), 150.2 (C, C-2), 140.3 (C, C-1′), 135.4 (CH, C-5), 134.2
(CH, C-4), 133.7 (CH, C-7), 131.8 (CH, C-3), 131.2 (C, C-4a), 131.1
(C, C-8a), 128.2−128.4* (CH, C-2′, C-3′, C-4′, C-5′, C-6′), 127.1
(CH, C-6), 119.2 (C, C-8), 115.5 (C, C-1), ND (C, C-10), * indicates
signals overlapped.
Anigorufone (2-hydroxy-9-phenyl-1H-phenalen-1-one) (7): or-
ange, amorphous soild; all off-line NMR and MS data were identical to
literature data.5
p-Hydroxycinnamate of salipurposide (2,3-dihydro-7-hydroxy-2-
(4-hydroxyphenyl)-5-{[6-O-[3-(4-hydroxyphenyl)-1-oxo-2-propen-1-
yl]-β-D-glucopyranosyl]oxy}-4H-1-benzopyran-4-one) (8): light
brown, amorphous solid; all off-line NMR and MS data were identical
to literature data.18
Mixture of methyl trans-p-coumarate (9) and methyl cis-p-
coumarate (10): amorphous, brown solid; trans to cis ratio was
1:0.17, respectively; all off-line NMR and MS data were identical to
literature data.16,46,47
Isosalipurposide (11): yellow, amorphous solid; all off-line NMR
and MS data were identical to literature data;15 1H NMR (500 MHz,
CD3OD) δ 8.05 (1H, d, J = 15.5 Hz, H-8), 7.65 (1H, d, J = 15.5 Hz,
H-7), 7.61 (2H, d, J = 9.0 Hz, H-2/H-6), 6.83 (2H, d, J = 9.0 Hz, H-3/
H-5), 6.17 (1H, brs, H-14*), 5.95 (1H, brs, H-12*), 5.15 (1H, d, J =
7.0 Hz, H-16), 3.92 (1H, d, J = 12.0 Hz, H-21a), 3.75 (1H, dd, J = 4.5,
12.0 Hz, H-21b), 3.55 (1H, m, H-17), 3.52 (1H, m, H-19#), 3.48 (1H,
m, H-20), 3.46 (1H, m, H-18#), *#signals interchangeable; 13C NMR
(125 MHz, CD3OD) δ 192.9 (C, C-9), 160.5 (C, C-13), 159.7 (C, C-
4), 142.3 (CH, C-7), 130.4 (CH, C-2/C-6), 127.1 (C, C-1), 124.8
(CH, C8), 115.5 (CH, C-3/C-5), 105.6 (C, C-10), 100.4 (CH, C-16),
97.6 (CH, C-12*), 95.1 (CH, C14*), 73.6 (CH, C-17), 77.2 (CH, C-
19#/C-20), 69.7 (CH, C-18#), 60.9 (CH2, C-21), ND (C-11/C-15),
*#signals interchangeable.
Fuliginosin A [3-(3,5-dihydroxyphenyl)-4-hydroxy-2-(4-
hydroxyphenyl)benzofuran-6-carbaldehyde] (12): dark yellow oil;
UV (EtOH) λmax (log ε) 285 (3.75), 324 (3.77), 367 (3.79) nm; IR
νmax 3208, 2926, 1682, 1607, 1515, 1443, 1397, 1324, 1276 cm
−1; 1H
NMR (500 MHz, DMSO-d6) see Table 1;
13C NMR (125 MHz,
DMSO-d6) see Table 1; HRESIMS m/z 361.0715 (calcd for
C21H13O6, 361.0712).
Fuliginosin B [5-(6-(dimethoxymethyl)-4-hydroxy-2-(4-
hydroxyphenyl)benzofuran-3-yl)benzene-1,3-diol] (13): brown oil;
UV (EtOH) λmax (log ε) 303 (3.08), 313 (4.08), 369 (3.53) nm; IR
νmax 3419, 2923, 2131, 1645 cm
−1; 1H NMR (500 MHz, DMSO-d6)
see Table 1; 13C NMR (125 MHz, DMSO-d6) see Table 1; HRESIMS
m/z 407.1138 (calcd for C23H19O7, 407.1131).
Fuliginosone (3-phenylacenaphthylene-1,2-dione) (14): bright
yellow needles (CH2Cl2); mp 217−222 °C; C18H10O2, M = 258.26,
T = 130.0(2) K, λ = 1.5418 Å, orthorhombic, space group Pbca, a =
8.4671(4) Å, b = 7.3151(4) Å, c = 39.179(2) Å, V = 2426.7(2) Å3, Z =
8, Dc = 1.414 Mg/m
3 μ(Cu Kα) 0.736 mm−1, F(000) = 1072, crystal
size 0.27 × 0.07 × 0.02 mm, 6910 reflections measured, 2188
independent reflections (Rint = 0.052), the final R was 0.0493 [I >
2σ(I)] and wR(F2) was 0.1255 (all data). Crystallographic data for 14
have been deposited at the Cambridge Crystallographic Data Centre
(CCDC 1044045), 12 Union Road, Cambridge, CB2 1EZ, UK (www.
ccdc.cam.ac.uk/data_request/cif); UV (EtOH) λmax (log ε) 244
(4.43), 324 (3.76) nm; IR νmax 1719, 1590 cm
−1; 1H NMR (500
MHz, CDCl3) see Table 2;
13C NMR (125 MHz, CDCl3) see Table 2;
HRESIMS m/z 259.0752 (calcd for C18H11O2, 259.0759).
Fuliginone (2-phenyl-1H-phenalen-1-one) (15): brown, amor-
phous solid; UV (EtOH) λmax (log ε) 333 (3.63), 368 (3.65), 431
(3.59) nm; IR νmax 3350, 2925, 2854, 1622, 1574, 1510, 1491, 1409,
1274, 1214 cm−1; 1H NMR (500 MHz, CDCl3) see Table 3;
13C
NMR (125 MHz, CDCl3) see Table 3; HRASAPMS m/z 257.0856
(calcd for C19H13O, 257.0966).
Fuliginol (2,5-dihydroxy-6-methoxy-7-phenyl-1H-phenalen-1-
one) (16): cocrystal with 3-chlorofuliginol, orange needles (CHCl3);
did not melt below 360 °C; 0.57(C20H12ClO4) 0.43(C20H14O4), M =
337.79, T = 130.0(2) K, λ = 1.5418 Å, triclinic, space group P1 ̅, a =
7.1864(15) Å, b = 10.074(2) Å, c = 10.803(3) Å, α = 89.17(2)°, β =
77.53(2)°, γ = 82.260(18)°, V = 756.6(3) Å3, Z = 2, Dc = 1.483 Mg/
m3, μ(Cu Kα) 1.732 mm−1, F(000) = 350, crystal size 0.14 × 0.04 ×
0.02 mm, 3885 reflections measured, 2213 independent reflections
(Rint = 0.057), the final R was 0.0704 [I > 2σ(I)] and wR(F
2) was
0.200 (all data). Crystallographic data for 16 and 17 have been
deposited at the Cambridge Crystallographic Data Centre (CCDC
1044044), 12 Union Road, Cambridge, CB2 1EZ, UK (www.ccdc.cam.
ac.uk/data_request/cif); UV (EtOH) λmax (log ε) 275 (4.10), 375
(3.91), 463 (3.54) nm; IR νmax 3369, 1618, 1569, 1393, 1215 cm
−1; 1H
NMR (500 MHz, CDCl3) see Table 4;
13C NMR (125 MHz, CDCl3)
see Table 4; HRESIMS m/z 317.0814 (calcd for C20H13O4, 317.0814).
3-Chlorofuliginol (3-chloro-2,5-dihydroxy-6-methoxy-7-phenyl-
1H-phenalen-1-one) (17): cocrystal data (see fuliginol (16)); 1H
NMR (500 MHz, CDCl3) see Table 4;
13C NMR (125 MHz, CDCl3)
see Table 4; HRESIMS m/z 351.0427 (calcd for C20H12
35ClO4,
351.0424).
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CHAPTER 6 
Chemical Profiling and Isolation of Secondary Metabolites from 
Haemodorum spicatum 
 
Kingdom: Plantae 
Phylum: Charophyta 
Class: Equisetopsida 
Order: Commelinales 
Family: Haemodoraceae 
Genus: Haemodorum 
Species: spicatum 
 
Collected from the Arrowsmith River 
Region, Eneabba, Western Australia, 
Australia in October 2010.  
 
Chapter 6 outlines the phytochemical profiling and bioassay guided isolation of the 
constituents from the bubs of the Australian plant Haemodorum spicatum. This work has 
been published in the Journal of Natural Products. Appendix C contains supplementary 
information relevant to this study.  
 
Journal publication resulting from this study: 
Brkljača, Robert, & Urban, Sylvia. (2015). Chemical Profiling/HPLC-NMR and HPLC-MS 
profiling and bioassay-guided identification of secondary metabolites from the Australian 
plant Haemodorum spicatum. Journal of Natural Products, 78(7), 1486-1494.  
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Haemodorum spicatum
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ABSTRACT: Phytochemical dereplication was undertaken on
the bioactive crude CH2Cl2 extract of the bulbs of the
Australian plant Haemodorum spicatum employing HPLC-
NMR and HPLC-MS methodologies. Subsequent bioassay-
guided isolation resulted in the identification of two new
phenylphenalenones [haemoxiphidone (8) and haemodoronol
(17)] and two new chromenes [haemodordione (13) and
haemodordiol (16)], together with seven previously described
compounds. Antimicrobial testing showed that the compounds
displayed selective antibacterial activity. Most noteworthy were
the activities displayed by several of the compounds against
multi-drug-resistant Pseudomonas aeruginosa.
The Haemodorum genus (Haemodoraceae family) consistsof 20 different species.1 Various studies have reported that
the Haemodoraceae family contains chemotaxonomic markers
made up of three distinct secondary metabolite structural
classes including the phenylphenalenones, the oxabenzochry-
senones, and the chromenes.2−4 Altogether, 30 phenyl-
phenalenones have been reported from the family Haemodor-
aceae, including four from the Haemodorum genus, of which 15
possess a 9-substituted aromatic moiety, while the others
display a 4-, 6-, or 7-substituted aromatic ring.2−24 Phenyl-
phenalenones containing sugar moieties appear to favor the 7-
substituted aromatic position. Only six oxabenzochrysenones
have been reported from the family Haemodoraceae, half of
which occur in the Haemodorum genus, and, unlike the
phenylphenalenones, the oxabenzochrysenones contain no
terminal aromatic ring.2,3,7,11,15,19,25−29 The final structural
class associated with the family Haemodoraceae is the
chromenes, which can contain either one or two carbonyl
functional groups in the lower right ring system. Twenty-three
chromenes have been reported from the family Haemodor-
aceae, of which five occur within the genus Haemodo-
rum.2,3,5−11,18,19,26,30,31 All but one of the chromenes have a
7-substituted aromatic ring.
Biosynthetically, the phenylphenalenones are derived from a
diarylheptanoid intermediate formed from phenylalanine and
tyrosine.14,32−36 The chromenes are produced by the same
diarylheptanoid intermediate pathway, but this most likely
undergoes oxidative rearrangement and decarboxylation to
incorporate the additional oxygen into the ring system.37 No in-
depth studies have been conducted to conclude the
biosynthetic pathway of the oxabenzochrysenones. However,
two reports have suggested that oxidative cyclization may be
involved in converting phenylphenalenones to oxabenzochry-
senones.27,28
As part of continuing efforts to study the chemical diversity
and ethnopharmacology of Australian plants, particularly of the
family Haemodoraceae, the chemistry of Haemodorum spicatum
R. Br. was investigated. Of significance is the fact that the bulbs
of H. spicatum are reported to have been used as a traditional
medicine by the Australian Aborigines to treat dysentery.38 The
present investigation on the bulbs of H. spicatum has yielded
two new [(haemoxiphidone (8) and haemodoronol (17)] and
two previously reported phenylphenalenones (2 and 15), four
known oxabenzochrysenones (1, 5, 11, and 12), and two new
[haemodordione (13) and haemodordiol (16)] chromenes as
well as a reported (3) chromene. For three (2, 5, and 11) of the
known compounds identified, this represents their first
occurrence as natural products. The complete 2D NMR
spectroscopic characterization of 2, 5, and 11 is also reported
herein for the first time. All isolated compounds were evaluated
for their selective antibacterial activity.
■ RESULTS AND DISCUSSION
The bulbs and stems of H. spicatum were extracted with 3:1
MeOH/CH2Cl2, evaporated under reduced pressure, and then
sequentially and exhaustively solvent partitioned into CH2Cl2-
and MeOH-soluble fractions, respectively. Antimicrobial testing
was carried out on both the CH2Cl2- and MeOH-soluble crude
Received: November 12, 2014
Article
pubs.acs.org/jnp
Published XXXX by the American Chemical
Society
Page 84
extracts of the bulbs and the aerial parts of the plant. It was
found that the CH2Cl2-soluble extract of the bulbs displayed
significant antibacterial activity. On the basis of the observed
activity along with the known ethnopharmacology associated
with the crude extract derived from the bulbs, the CH2Cl2
crude extract was prioritized for further chemical investigation.
Dereplication of the secondary metabolites present in the
bioactive CH2Cl2 crude extract was achieved using HPLC-
NMR and HPLC-MS in combination with the use of selected
databases. Nine peaks (peaks A−I in Figure 1) were detected
by HPLC-NMR and HPLC-MS. Analysis of the HPLC-NMR
data showed the presence of characteristic proton NMR signals
that suggested the presence of aromatic and methoxy moieties,
and further examination of the UV profiles obtained (as
detected by PDA) confirmed the presence of three distinct
chemical classes. These were the phenylphenalenones (λ >400
nm),18 oxabenzochrysenones (λ >500 nm),27 and chromenes
(λ <400 nm),2 which are all known to occur within the family
Haemodoraceae.2,3
An important requirement for HPLC-NMR analysis is that
the sample to be analyzed is at least moderately soluble in
acetonitrile. It is important to note that this particular HPLC-
NMR system utilizes only D2O and CH3CN as mobile-phase
solvents. MeOH as a solvent for elution is found to stick
irreversibly to the HPLC tubing and flow cell and therefore is
not recommended for HPLC-NMR use. In addition, samples
must be dissolved in either D2O or HPLC-NMR grade CH3CN
or a combination of the two solvents for similar reasons. The
CH2Cl2 crude extract of the bulbs of H. spicatum displayed poor
solubility in acetonitrile. In terms of HPLC-NMR chemical
profiling this meant that only WET1D (stop-flow proton
NMR) and gCOSY NMR spectra could be obtained for the
compounds present, given the small amounts that could be
loaded onto the HPLC column. These two NMR experiments
alone are not sufficient for an unequivocal structure
identification; however by adopting the use of chemical
databases such as the Dictionary of Natural Products (www.
dnp.chemnetbase.com) and SciFinder (https://scifinder.cas.
org), dereplication may assist in concluding the structure
classes present and often the most likely identity for some of
the compounds detected. During HPLC-MS analysis it was
noted that some of the compounds (11 and 12) displayed an
inability to ionize or would only ionize on the low-resolution
Figure 1. Stop-flow Wet1D proton NMR spectra (500 MHz, 50% CH3CN/D2O, suppression of HDO and CH3CN at δH 4.64 and 2.38 ppm,
respectively) of peaks A−I resulting from analysis of the CH2Cl2 crude extract of H. spicatum.
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instrument ion source (3). In these instances, the chemical
profiling/dereplication identification process was hindered.
Peaks A, G, and H (Figure 1) were dereplicated and
identified based on examination of the WET1D (stop-flow
proton NMR), gCOSY NMR, the molecular mass obtained
from either low- or high-resolution HPLC-ESIMS together
with the extracted UV profile/spectrum (obtained from PDA
detection). On the basis of these analyses and data, the most
likely structure was deduced for these three peaks. Peak A was
proposed to be the known oxabenzochrysenone 5-hydroxy-2-
methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (1), peak G
was proposed to be the previously reported phenylphenalenone
2,5,6-trimethoxy-9-phenyl-1H-phenalen-1-one (2), and peak H
was suggested to be the previously described chromene 5,6-
dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione
(3).
Peak B closely eluted with peak A (Figure 1), which
displayed a characteristic UV chromophore at 540 nm,
consistent with an oxabenzochrysenone-type structure.27 A
SciFinder (https://scifinder.cas.org) database search using the
HPLC-NMR and UV (which supported a oxabenzochrysenone
structure) data was refined using the molecular ion (m/z
287.0705 [M + H]+) observed in the high-resolution HPLC-
MS analysis. This resulted in two possible structures being
proposed for peak B, namely, 2-hydroxy-1H-naphtho[2,1,8-
mna]xanthen-1-one (4) and 5-hydroxy-1H-naphtho[2,1,8-
mna]xanthen-1-one (5). It was not possible to establish
which isomer could be attributed to peak B based on the
WET1D (stop-flow proton NMR) and gCOSY NMR data
alone.
Peaks C and E (Figure 1) could not be identified, but
analysis of their UV profiles confirmed an oxabenzochrysenone-
type structure for both.
Peaks D and F (Figure 1) displayed UV chromophores at
460 and 438 nm, respectively, consistent with those observed
for phenylphenalenones.18 Both peaks also displayed isobaric
molecular ions at m/z 333.1123 [M + H]+. Unlike peak F,
which showed only two large aromatic multiplets (δH 7.78, m;
7.75, m), peak D exhibited various resolved signals (δH 8.81, d,
J = 8.5 Hz; 7.92, d, J = 8.5 Hz; 7.71, d, J = 7.5 Hz; 7.43, s). The
mass of peaks D and F (332 Da) and the family
Haemodoraceae were used to search the Dictionary of Natural
Products (www.dnp.chemnetbase.com) database. Four possible
phenylphenalenone structures were suggested, including 5-
hydroxy-2,5-dimethoxy-7-phenylphenalen-1-one (6), 6-hy-
droxy-2,5-dimethoxy-7-phenylphenalen-1-one (7), 5-hydroxy-
2,5-dimethoxy-9-phenylphenalen-1-one (8), and 6-hydroxy-2,5-
dimethoxy-9-phenylphenalen-1-one (9). Of these possibilities,
compound 8 represents a new phenylphenalenone. On the
basis of literature precedence, which shows that 9-substituted
phenylphenalenones tend to be favored, either compound 8 or
9 would be the most likely structure for peak D.
The identify of peak F, which displayed only two large
aromatic multiplets, was not represented by any of the
structures as depicted for compounds 6−9. Peak F was
therefore concluded to represent an unidentified phenyl-
phenalenone, warranting further off-line isolation and identi-
fication.
A characteristic UV profile (345 and 388 nm) was observed
for peak I (Figure 1). Typically chromenes display one
absorbance at <400 nm, but, in this case, peak I showed two
distinct absorbances of <400 nm, suggesting an analogue of the
chromene skeleton.2 In reviewing compounds that have been
reported from the family Haemodoraceae, a structural analogue
(10) of the chromene structure was noted.2 Chromenes
isolated from the Haemodoraceae family typically contain one
Chart 1
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or two carbonyl groups in the lower ring system. While
compound 10 contains two carbonyl groups, these are now
located in two separate aromatic ring systems. It is expected
that such a structural analogue would give rise to two slightly
different UV absorbances. The two observed UV absorbances
for peak I were not in agreement with those reported for
compound 10 (243 and 390 nm), which suggested a possible
isomer.2 Unfortunately, no clear molecular ion was observed in
the HPLC-MS analysis, and so no conclusive structure could be
proposed for peak I.
An off-line bioassay-guided isolation approach was conducted
to determine which compounds were responsible for the
observed antibacterial activity of the crude extract of the plant,
to identify unequivocally each of the components, and to isolate
and confirm the structures of the putative new compounds
suggested by the chemical profiling methodology adopted. The
bioassay-guided isolation approach resulted in a total of 10
compounds (1, 2, 5, 8, 11−13, and 15−17) being isolated. Off-
line isolation confirmed that peaks B and D corresponded to
compounds 5 and 8, respectively. The structures for peaks C, E,
and I were found to correspond to the previously reported
oxabenzochrysenones 11 and 12 and the new chromene 13,
respectively. Compound 3 and peak F were not obtained by the
off-line bioassay-guided isolation approach. It is uncertain
whether these components degraded or if they had converted
into other compounds.
Six previously identified oxabenzochrysenone and phenyl-
phenalenone compounds (1, 2, 5, 11, 12, and 15) were
identified by comparison of their NMR spectroscopic and mass
spectrometric data to values reported in the litera-
ture.2,17,27−29,39,40
Off-line isolation and subsequent characterization of peak D
(Figure 1) confirmed this component to be the new
phenylphenalenone haemoxiphidone (8), which was isolated
as an orange solid. This particular compound was concurrently
isolated within the research group from a separate Haemodorum
species.3 Unequivocal identification of haemoxiphidone (8) was
ultimately achieved by consideration of the data obtained in
both studies. While the earlier study established a C-9
substitution for the aromatic moiety by HMBC NMR
correlations,3 the present investigation was able to assign the
point of attachment utilizing single-irradiation 1D NOE NMR
experiments. Specifically, a key NOE NMR enhancement was
observed between the proton at δH 8.32 (d, J = 8.5 Hz) and the
methoxy moiety at position H-6 (δH 4.06, s), which confirmed
that the aromatic ring is substituted at the C-9 position in
compound 8.3
Haemodordione (13) displayed characteristic UV absorban-
ces at 313 and 373 nm, which were attributed to the chromene
structure class.2 Comparison of the off-line NMR data obtained
for haemodordione (13) and compound 10 showed similarities,
although two principal differences were noted. These included
the H-3 proton in compound 10, which appeared significantly
downfield (δH 8.09) when compared to that observed for 13
(δH 6.62). In addition, the C-3 resonance was dramatically
different between 10 and 13 (δC 145.7 and 114.4, respectively),
suggesting 13 to be an isomer of 10 whereby the lactone
moiety is reversed. Further literature searches of compounds
containing the substructure present in 13 with the lactone
moiety reversed41 provided support for the structure of the
chromene 14. A comparison of the proton and carbon chemical
shifts at positions H-3 and C-3 for 13 and 14 (δH 6.62 and 5.98
and δC 114.4 and 105.9, respectively) showed a closer
agreement than the chemical shifts between 10 and 13. This
provided confirmation that in 13 the carbonyl group is located
at position C-2. The HRESIMS of 13 displayed a [M + H]+
peak at m/z 305.0809 (calcd for C19H13O4, m/z 305.0814),
consistent with 14 degrees of unsaturation and a molecular
formula of C19H12O4. Complete analysis of the NMR (Table 1)
and MS data allowed 13 to be identified as the new chromene
5-methoxy-7-phenylbenzo[de]chromene-2,6-dione, to which
was accorded the trivial name haemodordione.
Haemodordiol (16) displayed a characteristic UV absorbance
at 326 nm, which was consistent with the chromene structural
class.2 Analysis of the NMR data of haemodordiol (16) (Table
1) supported the presence of a single carbonyl group. A
characteristic proton chemical shift at δH 6.54 (s) suggested
that one of the carbonyl groups had been replaced by a methine
group. This proton displayed gHMBC NMR correlations to the
carbonyl at position C-1 (δC 163.4) as well as to a methoxy
moiety (δC 56.8, δH 3.80, s). The HRMS of haemodordiol (16)
yielded a molecular formula of C19H14O5 (observed m/z
345.0749 [M + Na]+ (calcd for C19H14O5Na, m/z 345.0739)).
This supported the fact that two hydroxy groups are retained in
this structure. On the basis of the proton coupling and splitting
observed for the remaining protons, it was proposed that the
two hydroxy groups are located at positions C-4, C-5, or C-6.
The singlet proton at δH 8.09 showed key gHMBC NMR
correlations to carbons δC 102.0 (C-3), 146.3 (C-6), and 127.0
(C-9b), enabling the hydroxy group moieties to be placed at
positions C-4 and C-5. All but one of the previously reported
chromenes display a 7-substituted terminal aromatic moiety.
The observed gHMBC NMR correlations from the proton at
position H-9 (δH 8.61, d, J = 7.0 Hz) to the carbon at position
C-1 (δC 163.4) permitted the location of substitution of the
terminal aromatic ring to be established for 16, since only a 7-
substituted terminal aromatic ring would enable such a
correlation to be observed. Analysis of the remaining NMR
and MS data allowed 16 (haemodordiol) to be proposed as the
new compound 5,6-dihydroxy-3-methoxy-7-phenyl-1H,3H-
benzo[de]isochromen-1-one. The absolute configuration of
the C-3 stereogenic center remains undefined.
Haemodoronol (17) was isolated as a brown solid. The
proton NMR and UV spectroscopic data (Table 1) of
haemodoronol (17) showed similarities to analogous data for
compounds 8 and 15, indicating the presence of a phenyl-
phenalenone skeleton. HRMS yielded a molecular ion at m/z
333.1120 [M + H]+ (calcd for C21H17O4, m/z 333.1127),
supporting a molecular formula of C21H16O4. Characteristic of
this phenylphenalenone was the presence of a considerably
deshielded 1H NMR singlet at δH 8.39 (s). This suggested a
different substitution pattern from the other phenylphenale-
nones isolated in this investigation. This proton showed key
gHMBC NMR correlations to the carbons at δC 184.8 (C-1),
148.2 (C-2), 121.3 (C-3a), and 124.2 (C-9b), indicating that it
is located on the ring containing the carbonyl moiety and
situated at position C-3.
The carbon signal at δC 148.2 was located at position C-2
and substituted with a hydroxy group. Another singlet was
observed at δH 6.16, s, which is usually positioned on the upper
aromatic moiety, typically at position H-4. However, the
significant deshielding observed for the H-3 proton (δH 8.39, s)
suggested the proton at δH 6.16 (s) to be located at either
position H-5 or H-6, rather than at position H-4. Two methoxy
moieties were also observed (δH 4.03, s and 4.08, s), and it was
rationalized that one of these is substituted at position C-4. To
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establish the locations for the terminal aromatic ring and
methoxy moieties, a NOESY NMR experiment was conducted.
The signal at δH 8.20 (d, J = 7.5 Hz, H-7) showed a NOE
enhancement to one of the methoxy signals (δH 4.03, s), which
confirmed the terminal aromatic moiety to be substituted at
position C-9 and the methoxy group at δH 4.03 to occur at
position C-6. In addition, the signal at δH 8.39 (s, H-3) showed
a NOE enhancement to the other methoxy signal (δH 4.08, s),
confirming that this second methoxy group is located at C-4.
Complete analysis of the NMR data allowed 17 (haemodor-
onol) to be identified as the new compound 2-hydroxy-4,6-
dimethoxy-9-phenyl-1H-phenalen-1-one. This compound rep-
resents a new variation of the substitution pattern seen usually
in the phenylphenalenones, where typically the methoxy
moieties occur on adjacent carbons.
Each of the new compounds identified in this study (8, 13,
16, and 17) contain methoxy substituents. A review of the
literature provides evidence that methoxy substituents present
at the C-4, C-5, and C-6 positions occur in natural product
molecules of compounds of the family Haemodoraceae, even
when solvents such as acetone are used.2 However, the same
study concluded that a methoxy group moiety at position C-3
in the chromenes may be artifactual, arising from the use of
MeOH during solvent extraction.2 This indicates that
compound 16 may be an artifact produced due to the isolation
procedure that was used.
In the bioassay-guided isolation procedure implemented, the
plant crude extracts, selected silica gel column fractions, each of
the compounds isolated (1, 2, 5, 8, 11−13 and 15−17), a
commercially available standard antibiotic (ampicillin), and an
antifungal agent (carbendazim) were assessed for antimicrobial
activity. Antimicrobial assays were conducted against five
bacteria, E. coli, S. aureus, S. aureus MRSA, P. aeruginosa, and
S. pyogenes, and a yeast, C. albicans. Crude extracts and enriched
fractions were tested at a concentration of 25 or 50 mg/mL,
while pure compounds and the standards were tested at 1 mg/
mL. Each of the isolated compounds showed selective and
varying degrees of antimicrobial activity.
Previous reports indicate that 15 showed no reportable
antialgal activity42 and that haemoxiphidone (8) displayed no
significant activity in the P388 murine lymphocytic leukemia
cytotoxicity assay.3
This represents the first instance where all three co-occurring
structure classes have been assessed for antimicrobial activity in
a single study. The 10 compounds tested showed only
antibacterial properties (against both Gram-positive and
Gram-negative bacteria), but no antifungal activity (Table 2).
For each of the compounds isolated, the greatest activity was
observed against P. aeruginosa and S. pyogenes. Three of the
compounds (2, 12, and 17) slightly inhibited the growth of the
resistant S. aureus MRSA. Of significance is that compounds 1,
5, 11, 12, 15, and 17 all inhibited the growth of P. aeruginosa in
a more potent manner than ampicillin. In recent years concern
has increased for P. aeruginosa in relation to its prevalence and
multidrug resistance.41 The importance of identifying com-
pounds that can inhibit this bacterium remains important and
highly relevant. No significant differences in activity were
observed for the phenylphenalenones and the oxabenzochry-
senones, irrespective of the substitution pattern of the aromatic
ring.
■ EXPERIMENTAL SECTION
General Experimental Procedures. All organic solvents used
were analytical reagent (AR or GR), UV spectroscopic, or HPLC
grade, with Milli-Q water also being used. UV/vis spectra were
recorded on an Agilent Cary 60 spectrophotometer, using ethanol.
FTIR spectra were recorded as a film using NaCl disks on a
PerkinElmer Spectrum One FTIR spectrometer. 1H (500 MHz), 13C
Table 2. Antimicrobial Activity of the Plant Crude Extracts and Pure Compounds Isolated from H. spicatum Together with
Commercial Standard Antibiotic and Antifungal Compounds, Showing Zones of Inhibition (mm)
microorganism
concentration
(mg/mL)
E. coli ATCC
25922
S. aureus ATCC
25923
S. aureus MRSA
344/2-32
P. aeruginosa ATCC
27853
S. pyogenes
345/1
C. albicans ATCC
10231
CH2Cl2 extract
(bulbs)
50 NDa 1 1 3 2 NDa
MeOH extract
(bulbs)
50 NDa NDa NDa NDa NDa NDa
CH2Cl2 extract
(stems)
50 NDa 3 3 NDa NDa NDa
MeOH extract
(stems)
50 NDa NDa 1 NDa 1 NDa
compound 1 1 1 NDa NDa 5 2 NDa
compound 2 1 1 NDa 1 1 1 NDa
compound 5 1 NDa NDa NDa 3 1 NDa
haemoxiphidone (8) 1 1 1 NDa 1 1 NDa
compound 11 1 NDa NDa NDa 4 2 NDa
compound 12 1 NDa 1 1 3 3 NDa
haemodordione
(13)
1 1 NDa NDa NDa NDa NDa
compound 15 1 1 NDa NDa 3 1 NDa
haemodordiol (16) 1 1 NDa NDa 1 1 NDa
haemodoronol (17) 1 1 1 1 5 1 NDa
ampicillin
(antibiotic)
1 NDa 15 3 2 20 NTb
carbendazim
(antifungal)
1 NTb NTb NTb NTb NTb NDa
aIndicates no zone of inhibition detected. bIndicates not tested.
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(125 MHz), and 1D NOE spectra were acquired in CDCl3 on a 500
MHz Agilent DD2 NMR spectrometer with referencing to solvent
signals (δ 7.26 and 77.0 ppm). Two-dimensional NMR experiments
recorded included gCOSY, HSQCAD, gHMBCAD, and NOESY
NMR experiments. Low-resolution ESI mass spectra were obtained on
a Micromass Platform II mass spectrometer equipped with an LC-
10AD Shimadzu solvent delivery module (50% CH3CN/H2O at a flow
rate of 0.2 mL/min) in both the positive and negative ionization
modes using cone voltages between 20 and 30 V. Silica gel flash
chromatography was carried out using Davisil LC35 Å silica gel (40−
60 mesh) with a 20% stepwise solvent elution from 100% petroleum
spirits (60−80 °C) to 100% CH2Cl2, to 100% EtOAc, and finally to
100% MeOH. HRMS was also analyzed using a Waters Xevo QTOF
mass spectrometer, with an atmospheric solids analysis probe (ASAP)
source (probe temperature set to 300 °C; source temperature set to 80
°C; sampling cone voltage of 20.0 V). Accurate mass was obtained by
lockmass using leucine enkephalin as the reference compound. All
analytical HPLC analyses and method development were performed
on a Dionex P680 solvent delivery system equipped with a PDA100
UV detector (operated using “Chromeleon” software). Analytical
HPLC analysis was carried out using either a gradient method of 0−2
min 10% CH3CN/H2O; 14−24 min 75% CH3CN/H2O; 26−30 min
100% CH3CN; and 32−40 min 10% CH3CN/H2O or else an isocratic
method (either 70% or 60% CH3CN/H2O) on an Alltech Alltima HP
C18 (250 × 4.6) 5 μm column at a flow rate of 1.0 mL/min.
Semipreparative HPLC was carried out on a Varian Prostar 210
solvent delivery system equipped with a Prostar 335 PDA detector
(operated using “Star Workstation” software) using an isocratic
method (either 70% or 60% CH3CN/H2O) and an Alltech Alltima C18
(250 × 10) 5 μm column at a flow rate of 3.5 mL/min.
Biological Evaluation. Crude extracts, enriched fractions,
compounds isolated from the bulbs, and the commercially available
standard antibiotic (ampicillin, Sigma-Aldrich (Castle Hill, NSW,
Australia)) and antifungal (carbendazim, Sigma-Aldrich (Castle Hill,
NSW, Australia)) compounds were evaluated against six micro-
organisms (five bacteria and one fungus) at concentrations of 50, 25,
or 1 mg/mL. Each microorganism was prepared by creating a 0.5
McFarlane solution suspension. Lawn cultures were prepared on either
Mueller-Hinton or brain heart infusion agar (BHIA) (used for S.
pyogenes). Then, 20 μL of the crude extracts, enriched fractions, pure
compounds, or the standard compounds (ampicillin and carbendazim)
were pipetted onto 6 mm diameter filter paper disks, and their solvents
evaporated. These disks were then placed onto the prepared lawn
cultures and incubated at 37 °C overnight. Active antimicrobial
samples displayed a zone of inhibition outside the disk, which was
measured in millimeters as the radius of inhibition for each bacterium/
fungus. The six test organisms used were Eschericha coli (ATCC
25922), Staphylococcus aureus (ATCC 25923), Staphylococcus aureus
MRSA (344/2-32), Pseudomonas aeruginosa (ATCC 27853) Strepto-
coccus pyogenes (345/1), and Candida albicans (ATCC 10231).
Plant Material. The plant (H. spicatum) was collected in October
2010 from the Arrowsmith River Region, close to the Western Flora
Caravan Park, near Eneabba in Western Australia. The plant was
collected and identified by Mr Allan Tinker (plant license SW008335).
Voucher specimens designated with the codes 2010-20a (bulbs) and
2010-20b (aerial parts), respectively, were deposited at the School of
Applied Sciences (Discipline of Applied Chemistry), RMIT University.
In this study, only the bulbs (2010-20a) of H. spicatum were
investigated.
Chemical Profiling. Chemical profiling was carried out on the
CH2Cl2-soluble extract of the bulbs of H. spicatum employing HPLC-
NMR and HPLC-MS techniques. HPLC-NMR was carried out on a
500 MHz Agilent DD2 NMR spectrometer equipped with a Varian
1H[13C] pulsed field gradient flow probe with a 60 μL active volume
flow cell coupled to a Varian Prostar 210 solvent delivery system, a
Prostar 430 autosampler, and a Prostar 335 PDA detector. HPLC-
NMR analysis was carried out using CORBA communication and
operated with VnmrJ software. The 2H resonance observed from the
D2O was used to obtain field-frequency lock. The signals from the
HOD and the methyl of the acetonitrile were suppressed using the
WET solvent suppression experiment.43 The residual HOD signal of
D2O was referenced to 4.64 ppm. For both the on-flow and stop-flow
HPLC-NMR modes, 50 μL injections (approximately 2500 μg) of the
CH2Cl2 extract were injected onto an Agilent Zorbax Eclipse Plus C18
(150 × 4.6) 5 μm column using a solvent composition of 50%
CH3CN/D2O at a flow rate of 0.8 mL/min. In the stop-flow HPLC-
NMR mode, WET1D and gCOSY NMR experiments were acquired.
HRESIMS was carried out on an Agilent 6200 Series TOF system
(ESI operation conditions of 8 L/min N2, 325 °C drying gas
temperature, and 3500 V capillary voltage) equipped with an Agilent
1200 Series LC solvent delivery module (100% CH3OH at a flow rate
of 0.3 mL/min) in either the positive or negative ionization modes.
The instrument was calibrated using the “Agilent Tuning Mix” with
purine as the reference compound and the Hewlett−Packard standard
HP0921. High-resolution electrospray liquid chromatography mass
spectrometry (LC-HRESIMS) was carried out on the same system and
conditions using an Agilent Zorbax Eclipse Plus C18 (150 × 4.6) 5 μm
column using a solvent composition of 50% CH3CN/H2O at a flow
rate of 0.8 mL/min. Low-resolution electrospray liquid chromatog-
raphy mass spectrometry (LC-LRESIMS) was carried out on an
Applied Biosystems MDS Sciex Q Trap LC/MS/MS system (3500 V
capillary voltage) equipped with an Agilent 1200 Series LC solvent
delivery module using a solvent composition of 50% CH3CN/H2O at
a flow rate of 0.2 mL/min using an Agilent Zorbax Eclipse Plus C18
(150 × 2.1) 5 μm column. Formic acid and ammonium acetate buffers
were also evaluated during LC-MS analysis. However, no improve-
ment in ionization of the molecular ions was observed; therefore no
buffers were utilized. The CH2Cl2-soluble extract (123.6 mg) was
dissolved in HPLC-NMR grade CH3CN (2500 μL) and filtered
through a 0.45 PTFE membrane filter (Grace Davison Discovery
Sciences).
Extraction and Isolation. The stems of the H. spicatum (252.5 g,
wet weight) were extracted with 3:1 MeOH/CH2Cl2 (2 L). The crude
extract was then decanted and concentrated under reduced pressure
and finally sequentially solvent partitioned (triturated) into CH2Cl2-
and MeOH-soluble extracts, respectively. The bulbs of H. spicatum
(121.6 g, wet weight) were extracted with 3:1 MeOH/CH2Cl2 (2 L).
The crude extract was then decanted and concentrated under reduced
pressure and sequentially triturated exhaustively into CH2Cl2- and
MeOH-soluble extracts, respectively. The CH2Cl2 extract was
subjected to flash silica gel column chromatography (20% stepwise
elution from petroleum spirits (60−80 °C) to CH2Cl2 to EtOAc, and
finally to MeOH). The first of the 60% CH2Cl2/EtOAc silica gel
column fractions collected was subjected to reversed-phase HPLC
(70% CH3CN/H2O) to yield 2,5,6-trimethoxy-9-phenyl-1H-phenalen-
1-one (2) (9.8 mg, 0.033%), haemodordione (13) (1.0 mg, 0.003%),
2,6-dimethoxy-9-phenyl-1H-phenalen-1-one (15) (0.7 mg, 0.002%),
and haemodordiol (16) (0.9 mg, 0.003%). The second of the 60%
CH2Cl2/EtOAc silica gel column fractions collected was further
purified by reversed-phase HPLC (70% CH3CN/H2O) to yield
haemoxiphidone (8) (0.9 mg, 0.003%). The 20% CH2Cl2/EtOAc to
80% EtOAc/MeOH silica gel fractions were combined and subjected
to reversed-phase HPLC (60% CH3CN/H2O) to yield 5-hydroxy-2-
methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (1) (0.9 mg, 0.003%),
5-hydroxy-1H-naphtho[2,1,8-mna]xanthen-1-one (5) (0.7 mg,
0.002%), 2,5-dimethoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (11)
(0.4 mg, 0.001%), 5-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one
(12) (0.6 mg, 0.002%), and haemodoronol (17) (1.3 mg, 0.004%).
The percentage yields are reported on the basis of the dry mass of the
bulbs extracted.
Online (HPLC-NMR and HPLC-MS) Characterization of Com-
pounds. 5-Hydroxy-2-methoxy-1H-naphtho[2,1,8-mna]xanthen-1-
one (1): UV (50% CH3CN/D2O) λmax 540 nm; HPLC-MS m/z
317.0809 (calcd for C20H13O4, 317.0814).
2,5,6-Trimethoxy-9-phenyl-1H-phenalen-1-one (2): UV (50%
CH3CN/D2O) λmax 464 nm; HPLC-NMR WET 1D NMR (500
MHz, 50% CH3CN/D2O) obtained from stop-flow HPLC-NMR
mode δ 8.88 (1H, d, J = 8.5 Hz, H-7*), 8.15 (1H, s, H-4#), 7.93 (1H,
d, J = 8.5 Hz, H-8*), 7.80 (3H, m, H-3′/H-4′/H-5′), 7.71 (2H, d, J =
7.0 Hz, H-2′/H-6′), 7.50 (1H, s, H-3#), 4.41 (3H, s, OCH3-2^), 4.39
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(3H, s, OCH3-5
̂^), 4.20 (3H, s, OCH3-6
^) (*#^signals interchange-
able); HPLC-MS m/z 347.1277 (calcd for C22H19O4, 347.1283).
5,6-Dimethoxy-7-phenyl-1H,3H-naphtho[1,8-cd]pyran-1,3-dione
(3): UV (50% CH3CN/D2O) λmax 360 nm; HPLC-NMR WET 1D
NMR (500 MHz, 50% CH3CN/D2O) obtained from stop-flow
HPLC-NMR mode δ 8.77 (1H, d, J = 8.5 Hz, H-8*), 8.43 (1H, s, H-
4), 8.19 (1H, d, J = 8.5, H-9*), 8.06 (2H, d, J = 7.0 Hz, H-2′/H-6),
7.90 (3H, m, H-3′/H-4′/H-5′), 4.53 (3H, s, OCH3-5#), 4.44 (3H, s,
OCH3-6
#) (*#signals interchangeable); HPLC-MS m/z 357 [M +
Na]+.
5-Hydroxy-1H-naphtho[2,1,8-mna]xanthen-1-one (5): UV (50%
CH3CN/D2O) λmax 540 nm; HPLC-MS m/z 287.0705 (calcd for
C29H10O3, 287.0708).
Haemoxiphidone (5-hydroxy-2,6-dimethoxy-9-phenyl-1H-phe-
nalen-1-one) (8): UV (50% CH3CN/D2O) λmax 460 nm; HPLC-
NMR WET 1D NMR (500 MHz, 50% CH3CN/D2O) obtained from
stop-flow HPLC-NMR mode δ 8.81 (1H, d, J = 8.5 Hz, H-8), 7.93
(1H, s, H-3*), 7.92 (1H, d, J = 8.5 Hz, H-7), 7.80 (3H, m, H-3′/H-4′/
H-5′), 7.71 (2H, d, J = 7.5 Hz, H-2′/H-6′), 7.43 (1H, s, H-4*), 4.36
(3H, s, OCH3-2
#), 4.18 (3H, s, OCH3-6
#), ND (OH-5) (*#signals
interchangable); HPLC-MS m/z 333.1123 (calcd for C21H17O4,
333.1127).
2,5-Dimethoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (11): UV
(50% CH3CN/D2O) λmax 535 nm; HPLC-NMR WET 1D NMR (500
MHz, 50% CH3CN/D2O) obtained from stop-flow HPLC-NMR
mode δ 8.94 (d, J = 8.0 Hz), 8.56 (d, J = 7.0 Hz), 7.89 (d, J = 8.0 Hz),
7.72−7.83 (m), 6.84 (s), 3.98 (s).
5-Methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (12): UV
(50% CH3CN/D2O) λmax 510 nm; HPLC-NMR WET 1D NMR
(500 MHz, 50% CH3CN/D2O) obtained from stop-flow HPLC-NMR
mode δ 8.91 (d, J = 8.0 Hz), 8.35 (s), 7.99 (d, J = 8.0 Hz), 7.67−7.84
(m), 7.33 (s), 4.23 (s).
Off-line Characterization of Compounds: 5-Hydroxy-2-methoxy-
1H-naphtho[2,1,8-mna]xanthen-1-one (1): purple solid; the UV,
NMR spectroscopic and mass spectrometric data were identical to
those reported in the literature.2
2,5,6-Trimethoxy-9-phenyl-1H-phenalen-1-one (2): orange solid;
the UV, NMR spectroscopic and mass spectrometric data were
identical to those reported in the literature;17 1H NMR (500 MHz,
CDCl3) δ 8.50 (1H, d, J = 8.5 Hz, H-7), 7.58 (1H, d, J = 8.5 Hz, H-8),
7.46 (1H, s, H-4), 7.44 (2H, m, H-3′, H-5′), 7.39 (1H, m, H-4′), 7.36
(2H, m, H-2′, H-6′), 6.80 (1H, s, H-3), 4.10 (3H, s, OCH3-6), 4.08
(3H, s, OCH3-5), 3.88 (3H, s, OCH3-2);
13C NMR (500 MHz,
CDCl3) δ 179.9 (s, C-1), 153.1 (s, C-2), 148.7 (s, C-5), 146.7 (s, C-9),
144.4 (s, C-6), 142.8 (s, C-1′), 131.6 (d, C-8), 128.2 (d, C-3′, C-5′),
128.1 (d, C-7), 127.9 (d, C-2′, C-6′), 127.7 (s, C-9a), 127.0 (d, C-4′),
125.6 (s, C-6a), 125.2 (s, C-9b), 121.1 (s, C-3a), 118.1 (d, C-4), 111.1
(d, C-3), 62.0 (q, OCH3-6), 57.0 (q, OCH3-5), 55.5 (q, OCH3-2);
ESIMS m/z 347 [M + H]+.
5-Hydroxy-1H-naphtho[2,1,8-mna]xanthen-1-one (5): purple
solid; the UV, NMR spectroscopic and mass spectrometric data
were identical to those reported in the literature;29 1H NMR (500
MHz, d6-DMSO) δ 8.46 (1H, d, J = 8.0 Hz, H-12), 8.41 (1H, d, J = 8.0
Hz, H-10), 8.34 (1H, d, J = 8.0 Hz, H-11), 8.03 (1H, d, J = 10.0 Hz,
H-3), 7.87 (1H, s, H-4), 7.63 (1H, dd, J = 7.0, 8.0 Hz, H-8), 7.51 (1H,
d, J = 8.0 Hz, H-7), 7.41 (1H, dd, J = 7.0, 8.0 Hz, H-9), 6.69 (1H, d, J
= 10.0 Hz, H-2); 13C NMR (500 MHz, d6-DMSO) δ 183.2 (s, C-1),
151.8 (s, C-6a), 141.1 (d, C-3), 140.3 (s, C-5*) 132.7 (d, C-8, C-10b),
129.9 (d, C-12), 127.6 (s, C-12a), 127.2 (d, C-2), 125.2 (d, C-9),
124.9 (d, C-10), 124.6 (d, C-4), 121.1 (s, C-12b), 120.4 (s, C-12c),
120.1 (s, C-3a), 119.3 (s, C-10a), 118.2 (d, C-7), 116.8 (d, C-11), ND
(s, C-5a*) (*signals interchangeable); ESIMS m/z 285 [M − H]−.
Haemoxiphidone (5-hydroxy-2,6-dimethoxy-9-phenyl-1H-phe-
nalen-1-one) (8): orange solid; UV (EtOH) λmax (log ε) 275 (4.10),
375 (3.70), 468 (3.48) nm; IR νmax 3246, 2928, 2854, 1730, 1627,
1556, 1466, 1359, 1212 cm−1; 1H NMR (500 MHz, CDCl3) and
13C
NMR (125 MHz, CDCl3) see ref 3; ESIMS m/z 333 [M + H]
+;
HRESIMS m/z 333.1125 (calcd for C21H17O4, 333.1127).
2,5-Dimethoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (11): pur-
ple solid; the UV, NMR spectroscopic and mass spectrometric data
were identical to those reported in the literature;28 1H NMR (500
MHz, CDCl3) δ 8.89 (1H, d, J = 8.0 Hz, H-12), 8.22 (1H, d, J = 8.5
Hz, H-10), 8.14 (1H, d, J = 8.0 Hz, H-11), 7.72 (1H, s, H-4), 7.57
(2H, m, H-7, H-8), 7.39 (1H, m, H-9), 7.12 (1H, s, H-3), 4.18 (3H, s,
OCH3-5), 4.02 (3H, s, OCH3-2);
13C NMR (500 MHz, d6-CDCl3) δ
178.1 (s, C-1), 153.2 (s, C-2), 151.9 (s, C-6a), 142.3 (s, C-5), 139.9 (s,
C-5a) 133.8 (s, C-10b), 132.2 (d, C-12), 131.8 (d, C-8),127.5 (s, C-
12c), 124.7 (d, C-9), 123.8 (d, C-10), 119.7 (s, C-10a), 118.5 (s, C-
12b), 118.1 (d, C-3, C-7), 117.7 (d, C-4), 115.5 (d, C-11), 57.4 (q,
OCH3-5), 55.9 (q, OCH3-2), ND (s, C-12a*) (*signals interchange-
able); ESIMS m/z 331 [M + H]+.
5-Methoxy-1H-naphtho[2,1,8-mna]xanthen-1-one (12): purple
solid; the UV, NMR spectroscopic and mass spectrometric data
were identical to those reported in the literature.27,39
Haemodordione (5-methoxy-7-phenylbenzo[de]chromene-2,6-
dione) (13): orange solid; UV (EtOH) λmax (log ε) 255 (3.83), 313
(3.51), 373 (3.41) nm; IR νmax 2925, 2854, 1724, 1670, 1626, 1598,
1465, 1279, 1197, 1139 cm−1; 1H NMR (500 MHz, CDCl3) and
13C
NMR (125 MHz, CDCl3), see Table 1; ESIMS m/z 305 [M + H]
+,
327 [M + Na]+; HRESIMS m/z 305.0809 (calcd for C19H13O4,
305.0814).
2,6-Dimethoxy-9-phenyl-1H-phenalen-1-one (15): orange solid;
the UV, NMR spectroscopic and mass spectrometric data were
identical to those reported in the literature.40
Haemodordiol (5,6-dihydroxy-3-methoxy-7-phenyl-1H,3H-
benzo[de]isochromen-1-one) (16): purple solid; [α]22D +16 (c
0.00025, CHCl3); UV (EtOH) λmax (log ε) 261 (5.74), 326 (5.20)
nm; IR νmax 3419, 2925, 2854, 1730, 1634, 1460 cm
−1; 1H NMR (500
MHz, CDCl3) and
13C NMR (125 MHz, CDCl3) see Table 1;
HRASAPMS m/z 345.0749 (calcd for C19H14O5Na, 345.0739).
Haemodoronol (2-hydroxy-4,6-dimethoxy-9-phenyl-1H-phena-
len-1-one) (17): brown solid; UV (EtOH) λmax (log ε) 275 (4.69),
295, (4.77), 400 (4.16), 519 (4.38) nm; IR νmax 3368, 2925, 2853,
1736, 1615, 1582, 1492, 1464, 1403, 1375, 1337, 1305, 1267 cm−1; 1H
NMR (500 MHz, CDCl3) and
13C NMR (125 MHz, CDCl3) see
Table 1; ESIMS m/z 333 [M + H]+; HRESIMS m/z 333.1120 (calcd
for C21H17O4, 333.1127).
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CHAPTER 7 
Secondary Metabolites of the fungus Leucocoprinus 
birnbaumii 
 
 
Kingdom: Fungi 
Phylum: Basidiomycota 
Class: Agaricomycetes 
Order: Agaricales 
Family: Agaricaceae 
Genus: Leucocoprinus 
Species: birnbaumii 
 
Collected from Eltham, Victoria, Australia 
in January 2006.  
 
Chapter 7 describes the compounds identified from the terrestrial fungus 
Leucocoprinus birnbaumii. This work has been published, the details of which are outlined 
below. 
 
Journal publication resulting from this study: 
Brkljača, Robert, & Urban, Sylvia. (2015). Rapid Dereplication and Identification of the 
Bioactive Constituents from the Fungus, Leucocoprinus birnbaumii. Natural Product 
Communications, 10(1), 95-98. 
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A series of fatty acids were rapidly dereplicated and partially identified from the flowerpot fungus, Leucocoprinus birnbaumii using HPLC-NMR and  
HPLC-MS. Subsequent off-line isolation unequivocally established the structures, and anti-microbial testing concluded that the fatty acids displayed moderate 
but selective anti-microbial activity. This represents the first report of these compounds occurring in this particular terrestrial fungus.  
Keywords:  Leucocoprinus birnbaumii, HPLC-NMR, Fungus, Biological Activity, Dereplication, Fatty Acids. 
The bright yellow fungus, Leucocoprinus birnbaumii (Agaricaceae), 
is a species of gilled mushroom. It is also known as the “flowerpot 
parasol and the plantpot dapperling” as it is commonly found 
growing in flowerpots and greenhouses [1]. The fungus has been 
reported to be poisonous, and ingestion can cause symptoms such as 
vomiting, nausea and diarrhea [2]. As yet, there has been no 
reported biological activity study conducted on either the crude 
extract or any of the compounds previously reported from the 
fungus. One of the first studies of L. birnbaumii established the 
content of crude protein, amino acids, sugars and minerals present 
in the fungus [3]. A second and more in depth study, reported on the 
isolation and identification of the two hydroxyindole pigments, 
birnbaumin A (1) and B (2), which are responsible for the bright 
yellow color associated with the fungus [4].  
Figure 1: Structures of the pigments identified from L. birnbaumii. 
As part of the continuing bioactive natural product discovery 
activities of the Marine and Terrestrial Natural Product (MATNAP) 
research group at RMIT University, a sample of L. birnbaumii that 
was found growing in a flowerpot was harvested and subjected to a 
chemical investigation. In this study we report the first biological 
activity evaluation of the crude extract and for three of the 
compounds isolated from the fungus. 
Initial analysis 
The dichloromethane crude extract of the fungus displayed no anti-
microbial activity while the methanol crude extract showed only 
minimal anti-microbial activity against Streptococcus pyogenes. 
Based on subsequent proton NMR and analytical HPLC analyses, 
only the dichloromethane extract showed the presence of 
compounds that warranted further investigation. Despite this, C18 
Vacuum Liquid Chromatography (VLC) was carried out on the 
methanol crude extract in an effort to deduce if this extract could be 
deconvoluted and whether it warranted further chemical 
investigation. Subsequent analysis of the resulting C18 fractions 
concluded that birnbaumin A (1) and B (2), which have 
characteristic UV chromophores at ?max 322 and 356 nm
respectively, could not be detected in any of the fractions on the 
basis of the HPLC contour plot obtained via PDA. Only very polar 
compounds present in minor quantities were observed and so only 
the dichloromethane crude extract was further investigated. No 
previous studies have focused on evaluating the secondary 
metabolites present in the dichloromethane extract of this fungus.  
Phytochemical profiling 
The dichloromethane crude extract was subjected to phytochemical 
profiling and dereplication using HPLC-NMR and HPLC-MS. A 
total of three components were detected, and comparison of the on-
flow HPLC-NMR proton NMR data indicated that these differed 
vastly to the data reported for birnbaumin A (1) and B (2) [4], 
immediately indicating the presence of a different structural class. 
Analysis of the WET1D proton NMR spectra (extracted from 
the on-flow  HPLC-NMR experiment)  for each of the components, 
Dr Sylvia Urban leads the Marine and Terrestrial Natural Product (MATNAP) research group at RMIT University. She was 
awarded the Gerald Blunden Award for the best research article for 2011 in Natural Product Communications, was the 
recipient of the Ronald Riseborough prize in chemistry, and has also been awarded the American Society of Pharmacognosy 
Research Starter Grant for a project entitled “Investigation into the Chemistry and Biological Activity of the Orange-Rot 
Fungus, Pycnoporus cinnabarinus”. Dr Urban has been researching in the field of natural products chemistry for in excess of 
20 years. Her interests include marine and terrestrial natural products chemistry; isolation and structural characterization; 
NMR spectroscopy and analytical separation and profiling methodologies for natural product discovery. 
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clearly showed that they were structurally related. The presence of 
olefinic signals and signals in the upfield region of the spectra 
suggested the presence of alkenes, such as those observed in fatty 
acids. This was further supported by the UV profile observed for 
these components which indicated very little conjugation since no 
UV chromophores were observed above 212 nm. Due to the small 
quantity of the dichloromethane crude extract available, only one 
stop flow HPLC-NMR experiment was conducted, which allowed 
for a WET1D proton NMR spectrum and gCOSY NMR data to be 
obtained for component 1. 
Analysis of the WET1D proton NMR spectrum of component 1 
showed the presence of four olefinic protons (?H 6.77, m, 4H). In 
addition, an observed molecular ion of m/z 279.2338 [M-H]- was 
observed for this component for which a molecular formula of 
C18H32O2 could be deduced. This particular formula has three 
degrees of unsaturation, two of which are confirmed by the 
presence of the four olefinic protons, thereby confirming the 
presence of two double bonds, and the remaining degree of 
unsaturation is due to the presence of a carbonyl bond which is 
typically present as a carboxylic acid in fatty acids. However, the 
position of the two double bonds could not be unequivocally placed. 
In this way component 1 could only be partially identified as a 
variant of octadecadienoic acid with unspecified double bond 
placement. Component 2 exhibited the same characteristic UV and 
NMR features as component 1. The HPLC-MS showed the presence 
of a molecular ion at m/z 281.2493 [M-H]-, which is two mass units 
higher than for component 1. This is attributed to the loss of one of 
the double bonds. As in the case of component 1, the double bond 
positions in component 2 could not be unequivocally located. This 
allowed component 2 to be partially identified as a variant of 
octadecenoic acid with unspecified double bond placement. Lastly, 
component 3 also showed the characteristic features of a fatty acid. 
However, the extracted WET1D proton NMR spectrum also 
showed the presence of a methoxy moiety (?H 5.03, s, 3H). 
Component 3 did not ionize in either positive or negative ESI 
modes during the HPLC-MS analyses due to methylation of the 
carboxylic acid preventing ionization from occurring. Based on the 
two previously identified components and on biosynthetic grounds, 
it was assumed that component 3 contained the same number of 
carbons in the alkene side chain. Integration of the extracted 
WET1D proton NMR spectrum, and comparison of the methoxy 
and olefinic resonances, supported the presence of four olefinic 
protons (?H 6.77, m, 4H) and, therefore, two double bonds. On this
basis, component 3 was partially identified as a variant of methyl 
octadecadienoate with unspecified double bond placement. 
Off-line isolation of fatty acids 
In an attempt to unambiguously identify the fatty acids present in L. 
birnbaumii, and to possibly identify the presence of any other minor 
compounds, an off-line isolation was implemented. The 
dichloromethane crude extract was subjected to reversed phase 
HPLC and the HPLC chromatogram showed the presence of the 
same three components as those observed in the off-line study. 
These components were separated and collected based on their 
retention time and peak height/area using an automatic fraction 
collector. 
Component 1 was isolated as yellow oil. The proton NMR spectrum 
showed the presence of four olefinic protons (?H 5.36, m, 4H),
along with five methylene functionalities (?H 2.78, dd, J = 6.5, 7.0
Hz; 2.35, t, J = 8.0 Hz; 2.05, dt, J = 6.5, 7.0 Hz; 1.64, p, J = 8.0 Hz; 
and 1.33, m) and one methyl group (?H 0.90, t, J = 7.0 Hz, 3H). The
carbon NMR spectrum showed the presence of an ester functional 
group (?C 179.7),  four olefinic carbons (?C 130.2, 130.0,  128.0 and
Figure 2: Identity and possible structures of components 1, 2 and 3, with expected fragments 
resulting from the ozonolysis with reductive and oxidative workups.
127.8) and various methylene and methyl carbons. Complete 
analysis of the 2D NMR spectroscopic data obtained (gCOSY, 
HSQCAD and gHMBCAD) allowed for the overall structure to be 
determined as a fatty acid. However, despite the ability to obtain 
comprehensive 2D NMR data, the position of the double bonds 
could not be unequivocally placed due to the overlapped nature of 
the proton and carbon NMR chemical shifts. In order to determine 
the position of the double bonds, a chemical derivatization would be 
necessary.  
It is well established that the location of olefinic bonds in fatty acids 
can be secured by ozonolysis and mass spectrometry whereby 
fragments are converted either into aldehydes, ketones or acids, 
depending on the subsequent work up used [5, 6]. Ozonolysis of 
component 1 was carried out with a reductive workup. In this 
reaction, dimethyl sulfide was used as the reducing agent, which 
results in the production of aldehydes [7, 8]. Subsequent mass 
spectrometric analysis of the fragment showed a molecular ion at 
m/z 171 [M-H]- for the ozonoid aldehyde product. Analysis of the 
gCOSY and gHMBCAD NMR data supported five possible 
positions for the location of the double bonds. 
Comparing the mass of each of the aldehydes produced that could 
result from the five possible structures with the actual observed 
mass, allowed the position of the double bonds to be secured. The 
position of the two double bonds was, therefore, established as 
commencing at position 9, as the resulting fragment would yield an 
observed ion at m/z 171.0 [M-H]- (Figure 2). Therefore, component 
1 was identified as the previously reported fatty acid octadeca-9,12-
dienoic acid, also known as linoleic acid (3) [9].  
Component 2 was identified in a similar manner. Initial analysis of 
the proton NMR spectrum showed that there were only two olefinic 
protons (?H 5.36, m, 2H). A reductive workup of the ozonolysis
reaction, followed by mass spectrometric analysis of the fragment 
indicated the presence of a molecular ion at m/z 171.0 (Figure 2). 
Considering all possible structures, component 2 was identified as 
the previously reported fatty acid octadec-9-enoic acid, also known 
as oleic acid (6) [9].  
Lastly, component 3 did not ionize in either positive or negative 
ESI-MS modes, but a molecular ion was observed at m/z 294, which 
was obtained via GC-MS analysis. Component 3 also had very 
similar proton and carbon NMR data to the other two components, 
but contained a methoxy moiety (?H 3.67, s; ?C 51.5). Ozonolysis
was also carried out on component 3 using a reductive workup, but 
this was unsuccessful. Instead, an oxidative workup of the 
ozonolysis reaction using Jones’ reagent was implemented, and this 
was successful. Unlike the reductive workup, oxidative workups 
produce acids [7, 8]. Mass spectrometry carried out after ozonolysis 
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showed the presence of a molecular ion at m/z 201, which 
confirmed that the double bonds were also located at position 9 
(Figure 2). The identity of this compound was concluded to be the 
methyl ester of the fatty acid octadeca-9,12-dienoic acid methyl 
ester, also known as methyl linoleate (8) [9]. 
Most naturally occurring fatty acids possess a cis or Z double bond 
geometry [10, 11]. On biosynthetic grounds this was concluded to 
also be the case for the fatty acids identified in this study  
Biological evaluation of the three fatty acids (3, 6 and 8) was 
carried out against six microorganisms (Escherichia coli, 
Staphylococcus aureus, S. aureus MRSA, Streptococcus pyogenes, 
Pseudomonas aeruginosa and Candida albicans). Each of the three 
fatty acids (3, 6 and 8) showed moderate anti-bacterial activity with 
some selectivity and the fatty acids were able to inhibit the growth 
of both Gram-positive and Gram-negative bacteria. The observed 
activity (measured as a zone of inhibition) against the six organisms 
tested for each of the three fatty acids (3, 6 and 8), which were 
tested at a concentration of 1 mg/mL, is given in Table 1. The 
observed activity for the three acids is in agreement with that 
previously reported, with fatty acids known to display various 
antibacterial activity [12-16].  
Table 1: Anti-microbial activity (reported as measured zones of inhibition in mm) of 
the isolated fatty acids. 
Compound Linoleic acid (3) Oleic acid 
(6) 
Methyl linoleate (8) 
Microorganism 
E. coli ND ND ND 
S. aureus 1 ND 1 
MRSA ND ND ND 
P. aeruginosa ND 3 2 
S. pyogenes 3 ND 1 
C. albicans ND ND ND 
ND Indicates no zone of inhibition was detected 
Experimental 
General experimental procedures: All organic solvents used were 
analytical reagent (AR or GR), UV spectroscopic, or HPLC grades 
with milli-Q water also being used. 1H (500 MHz) and 13C (125 
MHz) NMR spectra were acquired in CDCl3 on a 500 MHz Agilent 
DD2 NMR spectrometer with referencing to solvent signals (? 7.26
and 77.0 ppm). Two-dimensional NMR experiments recorded 
included gCOSY, HSQCAD, and gHMBCAD experiments. ESI 
mass spectra were obtained on a Micromass Platform II mass 
spectrometer equipped with a LC-10AD Shimadzu solvent delivery 
module (50% CH3CN/H2O at a flow rate of 0.2 mL/min) in both the 
positive and negative ionization modes using cone voltages between 
20 and 30 V. GCMS was carried out on a Varian CP-3800 gas 
chromatograph equipped with a Varian CP-8410 autoinjector and 
Varian Saturn 2200 GC/MS/MS detector. The injector port 
temperature was set to 280°C; the column oven was set to 150°C 
and was ramped at a rate of 5°C/min to 225°C, which was held for 8 
min. The carrier gas flow rate was 1.0 mL/min. HPLC-NMR was 
carried out on a 500 MHz Agilent DD2 NMR spectrometer 
equipped with a Varian 1H[13C] pulsed field gradient flow probe 
with a 60 ?L active volume flow cell coupled to a Varian Prostar
210 solvent delivery system, a Prostar 430 Autosampler and a 
Prostar 335 PDA detector. THE HPLC-NMR analyses were carried 
out using the CORBA communication and operated with VnmrJ 
software. The 2H resonance observed from the D2O was used to 
obtain field-frequency lock. The resonances from the HOD and the 
methyl of the acetonitrile were suppressed using the WET solvent 
suppression experiment [17]. The residual HOD resonance of D2O 
was referenced to 4.79 ppm. For both on-flow and stop-flow HPLC-
NMR analyses, 50 ?L (2,500 µg) of the dichloromethane extract
was injected onto an Agilent Eclipse Plus C18 (150 x 4.6) 5 µ HPLC 
column using a solvent composition of 90% CH3CN/D2O at a flow 
rate of 1 mL/min. In the stop-flow HPLC-NMR mode WET1D and 
gCOSY NMR experiments were acquired. HRESILCMS was 
carried out on an Agilent 6540 Series Q-TOF system (ESI operation 
conditions of 12 L/min N2, 325°C drying gas temperature and 3500 
V capillary voltage) equipped with an Agilent 1260 Series LC 
solvent delivery module (90% CH3OH at a flow rate of 1.0 mL/min) 
in negative and positive ionization modes using an Agilent Eclipse 
Plus C18 (4.6 x 150) 5µ HPLC column. The instrument was 
calibrated using the ‘Agilent Tuning Mix’ using purine as the 
reference compound and the Hewlett–Packard standard HP0921. 
Analytical HPLC analyses were carried out using either a gradient 
HPLC method 0–2 min 10% CH3CN/H2O; 14–24 min 75% 
CH3CN/H2O; 26–30 min 100% CH3CN and 32– 40 min 10% 
CH3CN/H2O or an isocratic HPLC method (90% CH3CN/H2O) on 
an Alltech Alltima HP C18 (250 x 4.6) 5 µ column at a flow rate of 
1.0 mL/min. Semi-preparative HPLC was carried out on a Dionex 
P680 (solvent delivery module) equipped with a Dionex UVD340U 
PDA detector and a Foxy Jr. automated fraction collector. An 
isocratic HPLC method (90% CH3CN/H2O) was employed using a 
Phenomenex Luna (2) 100 Å C18 250 x 10 mm (5 µm) HPLC 
column. The automatic fraction collector was programmed to 
collect the 3 fatty acids based on their retention times (12.89, 18.81 
and 26.02 min, respectively) and a peak threshold value at a flow 
rate of 3.5 mL/min. Vacuum flash chromatography (VLC) was 
carried out using C18 on the methanol crude extract of the fungus. 
The VLC separation began with a solvent system comprised of 
100% H2O which, in 20% stepwise increments, made its way 
through to MeOH and finally DCM. 
Biological evaluation: Crude extracts of the fungus 
(dichloromethane and methanol extract) were evaluated against 6 
micro-organisms (5 bacteria and one test fungi) at concentrations of 
25 and 50 mg/mL respectively. Pure compounds were tested at a 
concentration of 1 mg/mL. Each micro-organism was prepared by 
creating a 0.5 McFarlane solution suspension. Lawn cultures were 
prepared on either Mueller-Hinton or Brain Heart Infusion Agar 
(BHIA) (used for the S. pyogenes). Then 20 µL of the crude extracts 
or pure compounds were pipetted onto 6 mm diameter filter paper 
disks and their solvents evaporated. These disks were then placed 
onto the prepared lawn cultures and incubated at 37°C overnight. 
Active anti-microbial samples displayed a zone of inhibition outside 
the disk, which was measured in mm as the radius of inhibition for 
each bacteria/fungi. The 6 test organisms were Eschericha coli 
(ATCC 25922), Staphylococcus aureus (ATCC 25923), S. aureus 
MRSA (344/2-32), Pseudomonas aeruginosa (ATCC 27853) 
Streptococcus pyogenes (345/1) and Candida albicans (ATCC 
10231). 
Terrestrial fungus material: The bright yellow fungus (L. 
birnbaumii) was collected on 29 January, 2006 in Eltham North, 
Victoria, Australia by Dr S. Urban. The fungus was growing in a 
pot alongside a palm. The fungus was identified by Prof A. Lawrie 
(School of Applied Sciences, Discipline of Biotechnology and 
Biological Sciences, RMIT University). A voucher specimen 
(designated the code number 2006_15) is deposited at the School of 
Applied Sciences (Discipline of Applied Chemistry), RMIT 
University. 
Chemical profiling: Chemical profiling was carried out on the 
dichloromethane soluble extract of the fungus employing HPLC-
NMR and HPLC-MS methodologies. Details of these analyses are 
provided in the Experimental Details section. The dichloromethane 
extract (29.5 mg) was dissolved in HPLC-NMR grade CH3CN (590 
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?L) and filtered through a 0.45 PTFE membrane filter (Grace
Davison Discovery Sciences). 
Extraction and solation: The fungus (8.5 g, wet weight) was 
extracted with 3:1 methanol/dichloromethane (1 L). The crude 
extract was then decanted and concentrated under reduced pressure 
and sequentially solvent partitioned (triturated) into 
dichloromethane and methanol soluble extracts, respectively. The 
dichloromethane crude extract was subjected to reversed phase 
HPLC (90% CH3CN/H2O) to yield linoleic acid (3) (17.8 mg, 
0.40%), oleic acid (6) (6.9 mg, 0.15%) and methyl linoleate (8) (4.4 
mg, 0.10%), respectively. The percentage yields are reported on the 
basis of the dry mass of the fungus extracted.  
Ozonolysis: (Reductive workup) - Linoleic acid (3) (8.0 mg) and 
oleic acid (6) (3.0 mg) were individually dissolved in 25 mL of 
dichloromethane. The samples were then placed into an acetone/dry 
ice bath and ozone bubbled though at a rate of 19 mg/L for 5 min. 
The ozonides were quenched with dimethyl sulfide and then 40 mL 
of water was added. The ozonolysis products were extracted by 
washing with dichloromethane (3 x 50 mL) and subsequently 
analyzed by LRESIMS. 
(Oxidative workup) - Methyl linoleate (8) (2.0 mg) was subjected to 
the same ozonolysis conditions as described above, with the 
exception that the ozonide was quenched using Jones’ reagent. The 
extraction of the product was also carried out as specified above.  
On-line (HPLC-NMR & HPLC-MS) characterization of 
compounds:  
Component 1 (variant of octadecadienoic acid with unspecified 
double bond positions).  
1H NMR (500 MHz, 90% CH3CN/D2O) (Stop-flow mode): 6.77
(4H, m), 4.20 (2H, dd, J = 6.5, 7.0 Hz), 3.66 (m), 2.96 (2H, m), 2.71 
(16H, m), 2.30 (3H, m). 
HPLC-HR-ESI-MS (negative mode): m/z at 279.2338 [M-H]- 
(calcd. for C18H31O2: m/z 279.2324).  
Component 2 (variant of octadecenoic acid with unspecified 
doubled bond position).  
1H NMR (500 MHz, 90% CH3CN/D2O) (On-flow mode): 6.77 (2H,
m), 3.67 (2H, m), 2.96 (4H, m), 2.69 (22H, m), 2.30 (3H, m). 
HPLC-HR-ESI-MS (negative mode): m/z at 281.2493 [M-H]- 
(calcd. for C18H33O2: m/z 281.2481).  
Component 3 (variant of methyl octadecadienoate with 
unspecified double bond positions).  
1H NMR (500 MHz, 90% CH3CN/D2O) (On-flow mode): 6.77 (4H,
m), 5.03 (3H, s), 4.20 (2H, m), 3.70 (2H, m), 2.98 (2H, m), 2.71 
(m), 2.30 (3H, m). 
LRESIMS: no molecular ion observed in either positive or negative 
ionization modes. 
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 PART C – Marine Organisms 
 
The chapters that encompass this section of the thesis (Chapters 8-11) include studies 
conducted on various marine algae derived from the Phaeophyta (eight species) and 
Rhodophyta (2 species) phyla. The application of phytochemical profiling (HPLC-NMR & 
HPLC-MS) to rapidly dereplicate and identify the structure classes and the identities of the 
compounds present in a variety of algae is presented. In total this section of the thesis 
describes the identification of thirteen new and twenty two previously reported secondary 
metabolites. The acquisition of a gHMBCAD NMR experiment without the use of pre-
concentration, cold probes or microcoils is also documented for the first time. Finally the 
application of NMR (nOe experiments) and circular dichroism (CD) spectroscopy were 
implemented to either deduce or propose the relative and absolute configuration for some of 
the compounds identified from these marine organisms. 
This section of the thesis is comprised of four journal publications as detailed below: 
1. Brkljača, Robert, Gӧker, Emrehan S., & Urban, Sylvia. (2015). Dereplication 
and Chemotaxonomical Studies of Marine Algae of the Ochrophyta and Rhodophyta 
Phyla. Marine Drugs, 13(5), 2714-2731.  
 
2. Brkljača, Robert, & Urban, Sylvia. (2015). Chemical Profiling (HPLC-NMR 
& HPLC-MS), Isolation and Identification of Bioactive Meroditerpenoids from the 
Southern Australian Marine Brown Alga Sargassum paradoxum. Marine Drugs, 
13(1), 102-127. 
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3. Brkljača, Robert, & Urban, Sylvia. (2015). HPLC-NMR and HPLC-MS 
investigation of antimicrobial constituents in Cystophora monilifera and Cystophora 
subfarcinata. Phytochemistry, 117, 200-208.  
 
4. Brkljača, Robert, & Urban, Sylvia. (2013). Relative Configuration of the 
Marine Natural Product Elatenyne using NMR Spectroscopic and Chemical 
Derivatization Methodologies. Natural Product Communications, 8(6), 729-732. 
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CHAPTER 8 
Dereplication and Chemotaxonomical Profiling of Seven Marine 
Algae by HPLC-NMR & HPLC-MS. 
 
Chapter 8 describes the rapid dereplication of sixteen compounds from six marine 
algae from the Phaeophyceae and one from the Rhodophyceae phyla, which was achieved by 
HPLC-NMR and HPLC-MS. This work has been published (see details as given below). 
Appendix D contains supplementary information relevant to the study. 
 
Brkljača, Robert, Gӧker, Emrehan S., & Urban, Sylvia. (2015). Dereplication and 
Chemotaxonomical Studies of Marine Algae of the Ochrophyta and Rhodophyta Phyla. 
Marine Drugs, 13(5), 2714-2731. 
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Abstract: Dereplication and chemotaxonomic studies of six marine algae of the Ochrophyta 
and one of the Rhodophyta phyla resulted in the detection of 22 separate compounds. All 16 
secondary metabolites, including four new compounds (16–19), could be rapidly 
dereplicated using HPLC-NMR and HPLC-MS methodologies in conjunction with the 
MarinLit database. This study highlights the advantages of using NMR data (acquired via 
HPLC-NMR) for database searching and for the overall dereplication of natural products. 
Keywords: ochrophyta; rhodophyta; dereplication; profiling; algae; HPLC-NMR; HPLC-MS 
1. Introduction
The Ochrophyta phylum contains in excess of 1800 species [1]. Recently, 17 new compounds, mostly
terpenoids, were reported from the Ochrophyta phylum [2]. In contrast, marine algae belonging to the 
Rhodophyta phylum, are represented by over 6500 species [1] and produce a large number of 
halogenated secondary metabolites [3]. For example, nine new compounds were recently reported from 
the Rhodophyta phylum, a majority representative of bromophenols [2]. 
The intention of this study was to select a range of marine algae and conduct a dereplication/ 
chemotaxonomical investigation as a means to rapidly differentiate the secondary metabolites present 
across different genera and between species of the same genera. For instance, marine algae of the 
Ochrophyta phylum such as Cystophora retroflexa have been reported to produce carotenoids, 
OPEN ACCESS
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phlorethols and fucophlorethols [4–6] while Cystophora subfarcinata is known to produce tocotrienols 
and phloroglucinols [7]. The remaining Ochrophyta phylum genera and species investigated included, 
Sargassum decipiens, Sargassum vestitum, Sargassum cf. fallax, and Halopteris pseudospicata and 
importantly these have not had any marine secondary metabolites reported. However, the Sargassum 
genus is known to produce meroditerpenoid, tocotrienol and terpenoid type compounds [8]. The only 
marine alga of the Rhodophyta phylum studied was of the Laurencia genus which is known to produce 
very different secondary metabolites from the marine brown algae [9–12]. 
In this study, we examined six specimens of marine brown algae belonging to the Ochrophyta phylum 
(Sargassum cf. fallax, Sargassum decipiens (R.Brown ex Turner) J.Agardh, Sargassum vestitum 
(R.Brown ex Turner) C.Agardh, Cystophora retroflexa (Labillardière) J.Agardh, Cystophora subfarcinata 
(Mertens) J.Agardh and Halopteris pseudospicata Sauvageau) and one marine red alga from the 
Rhodophyta phylum (Laurencia sp.), all of which were collected from Port Phillip Bay, Victoria, 
Australia. These marine algae were selected for phytochemical evaluation on the basis of three criteria, 
but in all three instances the intention was to rapidly dereplicate the secondary metabolites present and 
to avoid lengthy isolations. The marine algae were either selected on the basis of the observed biological 
activity of the crude extracts, or due to the fact that no previous secondary metabolites had been described 
from the species of marine alga. The final motivation for the selection was based upon the fact that our 
research group has previously conducted studies on other closely related Sargassum, Cystophora  
and Laurencia species and so the intention was to compare the secondary metabolites in closely 
related species.  
Herein, we report the chemical profiling/dereplication conducted using HPLC-NMR and HPLC-MS 
leading to the identification of seven different structure classes. In total, 22 compounds were detected in 
the dichloromethane crude extracts of the marine algae studied, of which 16 could be dereplicated. 
2. Results and Discussion
The frozen marine algae were extracted with 3:1 methanol/dichloromethane, evaporated under
reduced pressure and sequentially solvent partitioned (triturated) into dichloromethane and methanol 
soluble fractions, respectively. The dichloromethane and methanol crude extracts were initially analysed 
by off-line analytical HPLC and 1H-NMR analyses and this established that the majority of the secondary 
metabolites were present in the dichloromethane crude extracts. Based on this, only the dichloromethane 
extracts were further examined by chemical profiling methodologies (HPLC-NMR & HPLC-MS). 
2.1. Chemical Profiling (HPLC-NMR & HPLC-MS) 
The dichloromethane crude extracts were subjected to both HPLC-NMR and HPLC-MS chemical 
profiling and a total of 22 compounds were detected from the seven separate marine algae. Identical 
HPLC-NMR and HPLC-MS conditions were employed to probe the dichloromethane crude extracts of 
each alga to allow for comparison between each genera and/or species. Analysis of the stop-flow 
WET1D proton NMR spectra and extracted UV profiles for each of the compounds concluded the 
presence of seven distinct chemical structure classes including phenolic acids, phenols, resorcinols, 
phloroglucinols, xanthophylls, tocotrienols and C15 halogenated acetogenins, which are known to occur 
in these genera or species of algae [6–8,13–17]. 
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Twelve known (1–5, 11–15, 20 and 21) and four new (16–19) compounds (Figure 1) were 
dereplicated from the dichloromethane crude extracts of the algae. Compounds were dereplicated by 
analysis of the HPLC-NMR acquired data (WET1D and various combinations of gCOSY, HSQCAD, 
and gHMBCAD), high resolution HPLC-MS data, and use of the MarinLit database by searching 
parameters such as the taxonomy (usually genus), UV, MS and NMR data. While some structure classes 
are unique to certain genera or species, some can be present across various genera or species of algae 
(Table 1). For instance, in this study, phloroglucinols were detected in S. cf. fallax, C. subfarcinata and 
C. retroflexa while tocotrienols were exclusive to S. cf. fallax. The xanthophylls, which are known to 
occur in many marine brown algae [8,18], were found in high abundance in S. vestitum and 
H. pseudospicata. The specimen of S. decipiens was concluded to produce phenolic acids, phenols, and 
resorcinols while the specimen of Laurencia sp. could be deduced as containing C15 halogenated 
acetogenins. Table 2 summarises each of the components detected in the seven marine algae studied 
together with the search criteria used to dereplicate the structures present in the dichloromethane crude 
extracts. The amount of compound present in each of the crude extracts was estimated on the basis of 
the limit of detection (LOD) methodology recently reported for our HPLC-NMR system [19]. In this 
study, the LOD for five key NMR experiments was established for a given set of parameters. These 
LODs and the parameters utilized were reviewed, and on this basis, the approximate amount of each 
compound present in the crude extract for each of the HPLC-NMR analyses undertaken was estimated 
(see Table 2). In HPLC-NMR analyses, it is imperative to supress signals arising from the HPLC solvents 
(HDO signal arising from D2O and the CH3CN peak) in order to maximise signal intensity and obtain 
better quality NMR spectra. Unfortunately, during this process NMR signals of the compound of interest 
which occur within this suppression region are also inadvertently suppressed. 
Table 1. Chemotaxonomic comparison of the seven marine algae studied and the chemical 
classes present in each.  
Alga Chemical Class(es) Present Compounds Present *
C. subfarcinata Phloroglucinols 18, 19 
C. retroflexa Phloroglucinols 11-13, 16, 18, 20, 21 
S. cf. fallax Phlroglucinols, tocotrienols 12, 14, 15, 17, 20, 21 
S. decipiens Phenols, phenolic acids, resorcinols 1–4 
S. vestitum Xanthophylls 5 
H. pseudospicata Xanthophylls 5 
Laurencia sp. Polyhalogenated C15 acetogenins - 
* Retention times for compounds present are provided in Table 2.
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Figure 1. Compounds and range of structure classes as dereplicated by HPLC-NMR and 
HPLC-MS in conjunction with the MarinLit database. 
2.2. Identification of Phenols, Phenolic Acids and Resorcinols 
The specimen of S. decipiens was concluded to contain compounds 1–4, which represent three 
different structure classes (phenols, phenolic acids and resorcinols). While the phenols and phenolic 
acids displayed similar UV absorbances (300 nm), the resorcinol exhibited unique UV absorbances 
(276 and 281 nm). The compound eluting at Rt = 3.55 min was dereplicated from the MarinLit database 
using the molecular formula and UV absorbances as search parameters. This yielded four possible 
compounds, but analysis of the NMR data obtained from HPLC-NMR supported only one of these 
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structures. In this way, the compound eluting at Rt = 3.55 min could be identified as 6-tridecylsalicylic 
acid (1) which had been previously reported from the marine brown alga Caulocystis cephalornithos [20]. 
The remaining compounds eluting at Rt = 2.29, 2.44 and 7.87 min did not yield any matches in the 
MarinLit database when using various combinations of UV, mass and molecular formulae, and, when 
only UV data was searched this resulted in far too many possible structure classes. On the basis of the 
WET1D NMR spectra and UV profiles of the remaining three compounds (Rt = 2.29, 2.44 and 7.87 min) 
it could be concluded that they were closely related to 6-tridecylsalicylic acid (1). The marine brown 
alga C. cephalornithos, which is known to produce 6-tridecylsalicylic acid (1), also produces a variety 
of structurally related analogues [20,21]. Comparison of the data obtained from HPLC-NMR and 
HPLC-MS to the data for the compounds reported from C. cephalornithos, allowed for the compounds 
eluting at Rt = 2.29, 2.44 and 7.87 min to be identified as undecylsalicylic acid (2), 3-undecylphenol (3) 
and 5-undecylresorcinol (4) respectively. It is important to point out that these compounds do not appear 
separately in the MarinLit database and care must be taken in such dereplication exercises. This is the 
first study conducted on S. decipiens and compounds 1–4 have not been reported from the Sargassum 
genus. This highlights the importance of profiling different genera and species as a means of extending 
knowledge on marine biodiversity. The HPLC-NMR and HPLC-MS data of the compounds identified 
were consistent with the data reported previously [20–23]. 
2.3. Identification of Xanthophylls 
The dichloromethane crude extracts of S. vestitum and H. pseudospicata were found to contain an 
abundance of xanthophylls. The main compound in the dichloromethane crude extract of each of these 
two algae (compound eluting at Rt = 14.53 min) was identified as all-trans-fucoxanthin (5), the main 
pigment found in marine brown algae. This pigment was identified using the MarinLit database by 
searching the molecular formula obtained by high resolution HPLC-MS, which yielded only one 
structure. The UV profile, WET1D, gCOSY and HSQCAD NMR spectra of 5 were found to be in 
agreement with the structure of all-trans-fucoxanthin [24,25] A ROESYAD NMR experiment conducted 
in stop-flow HPLC-NMR mode confirmed that the configuration for all of the double bonds was trans 
(Figure 2). 
Figure 2. key ROESYAD correlations confirming the all trans configuration in 
all-trans-fucoxanthin (5). 
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A further two structurally related compounds eluting at Rt = 26.71 and 30.27 min were also detected 
in the dichloromethane crude extract of both S. vestitum and H. pseudospicata, but in much lower 
quantities. Identification was not possible due to the insufficient quantities present to obtain HPLC-NMR 
data, and due to the fact that the compounds did not ionize in either positive or negative ESI high 
resolution HPLC-MS. However, these compounds could be deduced to be two xanthophyll structural 
analogues based upon comparison of their UV profiles to all-trans-fucoxanthin (5) (Figure 3). This is 
the first report of all-trans-fucoxanthin (5) and other xanthophylls occurring in the Halopteris genus [8]. 
Figure 3. UV profiles (obtained from HPLC-NMR) of the three related xanthophylls 
present in the dichloromethane crude extracts of H. pseudospicata and S. vestitum showing 
their similarity. 
2.4. Identification of Halogenated C15 Acetogenins 
Profiling of a specimen of Laurencia sp. yielded three compounds (eluting at Rt = 5.00, 6.05 and 
6.70 min), which displayed similar WET1D NMR spectra (Figure 4) confirming that they were 
structurally related. WET1D and gCOSY NMR data were obtained for the compounds eluting at 
Rt = 5.00 and 6.70 min, while WET1D, gCOSY, HSQCAD and gHMBCAD NMR data was obtained 
for the compound eluting at Rt = 6.05 min. 
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Figure 4. WET1D NMR spectra (75% CH3CN/D2O, 500 MHz) of compounds eluting at 
Rt = 5.00, 6.05 and 6.70 min from the dichloromethane crude extract of Laurencia sp. 
Based upon the HPLC-NMR WET1D spectra (Figure 4), it was clear that the compounds eluting at 
Rt = 5.00 and 6.70 min were structural analogues, whereas the compound eluting at Rt = 6.05 min was a 
closely related structural derivative. A MarinLit search was conducted for the compound eluting at 
Rt = 5.00 min using the genus, UV and the presence of a single triplet methyl in the WET1D proton 
NMR spectrum obtained from stop-flow HPLC-NMR. This yielded nine possible structures including 
five polyhalogenated C15 acetogenins (6–10) (Figure 1). The WET1D NMR data for the compound 
eluting at Rt = 5.00 min supported the presence of olefinic protons (δ 6.93, dt, J = 7.5, 10.0 Hz; 6.69, t, 
J = 8.0 Hz; 6.46, d, J = 10.0 Hz), and the presence of halogens was deduced based on the presence of 
several deshielded methines (δ 5.30, s; 4.90, m; 4.84, s; 4.76, s; 4.35, s). Unfortunately, due to 
suppression of the methine signals in the D2O suppression region, it was not possible to confirm the total 
number of halogens present. Furthermore, the compound eluting at Rt = 5.00 min did not ionize in either 
positive or negative ESI high resolution HPLC-MS, making it impossible to determine a molecular 
formula. It could only be proposed that the compounds eluting at Rt = 5.00 min and Rt = 6.70 min are of 
the polyhalogenated C15 acetogenin structure class, but the exact nature of the ring size could not 
be concluded. 
The WET1D NMR spectrum for the compound eluting at Rt = 6.05 min showed slight differences 
suggesting it was a structural variant, further supported by the UV profile (220, 237 nm for the 
compounds eluting at Rt = 5.00 and 6.70 min), which also differed, and the absence of any absorbances 
in the UV profile suggested very little conjugation (220, 240 and 255 nm). Only partial HSQCAD and 
gHMBCAD NMR data could be obtained for this component and this hindered the ability to dereplicate 
the compound. Similar to the compounds eluting at Rt = 5.00 and 6.70 min, the compound eluting at 
Rt = 6.05 min did not ionize in ether positive or negative ESI high resolution HPLC-MS. Various 
searches conducted of the MarinLit database using different combinations of data (taxonomy, UV and 
NMR) did not aid in dereplicating a general structure class, and so the compound eluting at Rt = 6.05 min 
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remains unidentified. Off-line isolation would be necessary to unequivocally deduce the structures of 
these three compounds. 
2.5. Identification of Phloroglucinols and Tocotrienols 
The dichloromethane crude extracts of S. cf. fallax, C. subfarcinata and C. retroflexa yielded a total 
of eleven phloroglucinols (11–14, 16–21) and one tocotrienol (15). These two structure classes display 
similar UV absorbances, with the phloroglucinols typically displaying an absorbance at 285 nm and the 
tocotrienols at 300 nm, however, differences are observed in the WET1D NMR spectra. This represents 
the first instance of phloroglucinols and tocotrienols being reported from C. retroflexa and S. cf. fallax. 
The known phloroglucinols (11–14) and tocotrienol (15) were all dereplicated with use of the MarinLit 
database utilising the search parameters as indicated in Table 2, and by comparison of the NMR data 
obtained by HPLC-NMR. One of the phloroglucinols (compound eluting at Rt = 23.16 min) could not 
be identified due to insufficient quantities present to permit sufficient HPLC-NMR data acquisition and 
also due to there being no observed molecular ion in the high resolution HPLC-MS. However, based on 
the similarities of the UV absorbances and WET1D NMR data to 11, it was concluded to represent a 
phloroglucinol containing an alcohol substituent in the terpene side chain. δ-tocotrienol (15) did not 
ionize in the high resolution HPLC-MS analysis, but a search of the MarinLit database together with 
consideration of the WET1D NMR data, resulted in δ-tocotrienol (15) being identified. The HPLC-NMR 
and HPLC-MS data of the known compounds was consistent with the data previously reported [26–29]. 
As well as compounds 11–15, a series of new phloroglucinols were also determined. A MarinLit 
search conducted on these phloroglucinols using combinations of taxonomy, UV, molecular formulae 
and NMR data did not result in any confirmed structures, supporting the fact that these represented 
new phloroglucinols. 
High resolution HPLC-MS yielded a molecular formula of C24H34O5 for 16 (observed 401.2337 
[M − H]−, calcd. for C24H33O5, 401.2328) and stop-flow HPLC-NMR enabled for WET1D proton, 
gCOSY, HSQCAD and gHMBCAD NMR data to be obtained (Table 3). Three double bonds were 
concluded to be present based on the degrees of unsaturation and inspection of the WET1D NMR 
spectrum (δH 7.30, 1H; 6.80, 1H; 6.48, 1H; 6.32, 1H; 6.28, 1H; 6.23, 1H). A diagnostic methine at δH 
4.96 was observed which suggested the presence of an alcohol substituent, together with a diagnostic 
methylene at δH 3.89, which is typical of the methylene group attached adjacent to the ketone 
functionality. The gCOSY and gHMBCAD NMR data was able to secure the spin system from this 
diagnostic methylene (δH 3.89, H-2) to the first olefinic proton (δH 6.32, H-6). Further interpretation of 
the gCOSY NMR data secured the spin system from H-6 (δH 6.32) to H-14 (δH 3.00). The proton at 
position H-14 lies on the edge of the suppression region of the acetonitrile signal, which prevented any 
gCOSY NMR correlations from the proton being observed. Fortunately, in the gHMBCAD NMR 
spectrum, key correlations were observed from this methylene which allowed for the carbon at position 
C-15 to be assigned (δC 29.9). The terminal methyl group (δH 1.72, H-18) displayed a key gHMBCAD 
NMR correlation to the carbon at position C-16 (δC 32.0), confirming its assignment. The protons at 
positions H-5, H-15 and H-16 could not be assigned as these signals resided in the acetonitrile 
suppression region. The configuration of the double bonds was established by consideration of the NMR 
coupling constants and on biosynthetic grounds. Compound 16 represents a structure analogue of the 
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known phloroglucinol 11, which is known to have a 6Z configuration [28].The co-occurrence of 11 and 
16 led to the conclusion that their double bond configuration about position 6/7 would be the same when 
considering their biosynthesis. As such, the structure for 16 was proposed as 9-hydroxy-1-(2,4,6-
trihydroxyphenyl)octadeca-6Z,10E,12Z-trien-1-one, attributed the trivial name retroflexanone (16). The 
configuration of the single stereogenic center at position C-9 remains undefined. 
Table 3. NMR data (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at δH 
4.64 and 2.82 ppm, respectively) for retroflexanone (16) obtained via stop-flow HPLC-NMR. 
Retroflexanone (16) 
Position δH (J in Hz) δC a, Type gCOSY gHMBCAD 
1 207.2, s
2 3.89, t (7.0) 44.2, t 3 1, 3, 4
3 2.48, p (7.0) 25.1, t 2, 4 1, 2, 4, 5 
4 2.23, m 29.9, t 3 2, 3, 5, 6 
5 SS 27.8, t
6 6.32, m 132.6, d 7 
7 6.23, m 126.2, d 6, 8 
8 3.12, m 35.8, t 7 w, 9 6, 7, 9 
9 4.96, dt (6.5, 7.0) 72.6, d 8, 10 11 
10 6.48, dd (7.0, 15.0) 136.6, d 9, 11 12 
11 7.30, dd (15.0, 11.0) 126.4, d 10, 12 
12 6.80, t (11.0) 128.8, d 11, 13 w
13 6.28, m 133.3, d 12, 14 
14 3.00, m b ND 12, 13, 15 
15 SS 29.9, t
16 SS 32.0, t
17 2.13, m 23.0, t 18 16 
18 1.72, t (6.5) 14.3, q 17 16, 17 
1′ 105.2, s
2′ 165.0, s *
3′ 6.72, s 95.7, d 1′, 2′, 5′ 
4′ ND *
5′ 6.72, s 95.7, d 1′, 3′, 6′ 
6′ 165.0, s *
2′-OH ND
4′-OH ND
6′-OH ND
a carbon assignments based on HSQCAD and gHMBCAD NMR experiments; b signal assigned based on 
correlations in gCoSY experiment; * signals for C-2′ and C-6′are interchangeable with C4′; w indicates weak 
or long range correlation; SS Signal suppressed; ND Not Detected. 
Based upon the molecular formula of the phloroglucinols eluting at Rt = 13.65, 22.96 and 33.40 min, 
the number of double bonds present in each compound could be concluded. Unfortunately, NMR and 
MS data alone is not sufficient to determine the placement of the double bond within the structures. This 
meant that only tentative structures could be proposed, which are represented as 17–19, respectively. To 
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establish the position of the double bonds in the terpene side chain, off-line approaches such as chemical 
derivatization or degradation are required. The double bonds were assigned on the basis that olefinic 
protons that correspond to a cis geometry appear as a narrow multiplet in the proton NMR spectrum [28] 
which was also observed for the known compounds (12–14) during this study. 
Phloroglucinols 20 and 21 (compounds eluting at Rt = 20.15 and 15.50 min) do not appear in the 
MarinLit database, however, a recent study conducted by the research group describes the first report of 
these phloroglucinols occurring in C. monilifera and C. subfarcinata [13]. 
2.6. Anti-Microbial Activity 
The crude extracts of S. cf. fallax, S. vestitum, C. subfarcinata, H. pseudospicata and C. retroflexa 
were assessed for their anti-microbial activity against six bacteria and three fungi (Table 4). The crude 
extracts of the algae showed varying selectivity and activity across the micro-organisms tested, with 
S. vestitum, C. subfarcinata and C. retroflexa showing the most promising activity. The crude extracts 
of the two marine algae specimens containing the xanthophylls (S. vestitum and H. pseudospicata) 
displayed different biological activity suggesting that the active component(s) was unlikely to be the 
xanthophylls but other chemical component(s). However, all-trans-fucoxanthin (5) has been reported to 
display anti-inflammatory, anti-oxidant and anti-tumor activity [30–33]. The crude extracts of S. cf. fallax, 
C. subfarcinata, C. retroflexa all showed similar anti-microbial activities which can potentially be 
attributed to the presence of the phloroglucinols. Phloroglucinols have been demonstrated to possess 
various anti-microbial activities [34–36]. The crude extracts of S. decipiens and Laurencia sp. were not 
evaluated for their biological activity. 
3. Experimental Section
3.1. Marine Alga Material 
S. cf. fallax was collected at low tide on January 3, 2003 from St Paul’s Beach, Sorrento, Port Phillip 
Bay, Victoria, Australia. C. subfarcinata, S. vestitum and H. pseudospicata were collected at low tide on 
January 22, 2006 from the Borough of Queenscliff (near Point Lonsdale), Port Phillip Bay, Victoria, 
Australia. Laurencia sp., S. decipiens and C. retroflexa were collected by SCUBA on 21 April 2010 
from Governor Reef (near Indented Head), Port Phillip Bay, Victoria, Australia. The marine algae were 
identified by Dr. Gerald Kraft (The University of Melbourne) and voucher specimens (designated the 
code numbers 2003-06, 2006-11, 2006-12, 2006-13, 2010-04, 2010-08 and 2010-09, respectively) are 
deposited at the School of Applied Sciences (Discipline of Applied Chemistry), RMIT University, 
Melbourne, Australia. 
3.2. Extraction 
Each of the frozen marine algae were extracted with 3:1 methanol/dichloromethane (1 L). The crude 
extracts were then decanted and concentrated under reduced pressure and sequentially solvent 
partitioned (triturated) into dichloromethane and methanol soluble extracts, respectively. 
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3.3. Biological Evaluation 
For details on the biological evaluation of the dichloromethane and methanol crude extracts of 
C. retroflexa please refer to [37]. The 3:1 MeOH/DCM crude extracts of S. cf. fallax, C. subfarcinata,  
S. vestitum and H. pseudospicata were assessed for anti-microbial activity at the University of 
Canterbury, Christchurch, New Zealand. A standardized inoculum was prepared by transferring a loop 
of bacterial/fungal cells, from a freshly grown stock slant culture, into a 10 mL vial of sterile water. This 
was vortexed and compared to a 5% BaCl2 in water standard to standardize the cell density. This gave a 
cell density of 108 colony-forming units per millilitre. Ten millilitres of the standardized inoculum was 
then added to 100 mL of Mueller Hinton or potato dextrose agar (at between 40 and 50 °C) and mixed 
by swirling, giving a final cell density of 107 colony forming units per millilitre. Five millilitres of this 
was poured into sterile 85 mm petri dishes. The suspensions were allowed to cool and solidify on a level 
surface to give a “lawn” of bacteria/fungi over the dish. The crude extract was pipetted onto 6 millimeter 
diameter filter paper disks and the solvent evaporated. These disks were then placed onto the prepared 
seeded agar dishes (with appropriate solvent and positive controls) and incubated. Active anti-microbial 
samples displayed a zone of inhibition outside the disk, which was measured in mm as the radius of 
inhibition for each bacteria/fungi. The six organisms were Eschericha coli (ATCC 25922), Bacillus 
subtilis (ATCC 19659) and Pseudomonas aeruginosa (ATCC27853) for the bacteria and, Candida 
albicans (ATCC 14053), Trichophyton mentagrophytes (ATCC 28185) and Cladosporium resinae for 
the fungi. 
3.4. Chemical Profiling 
Chemical profiling was carried out on the dichloromethane soluble extracts of the marine algae 
employing HPLC-NMR and HPLC-MS methodologies. The dichloromethane extracts were dissolved 
in HPLC-NMR grade CH3CN and filtered through a 0.45 PTFE membrane filter (Grace Davison 
Discovery Sciences, Columbia, MD, USA). S. decipiens: 109.1 mg dissolved in 1090 μL (5005 μg per 
HPLC-NMR injection); C. retroflexa: 185.6 mg dissolved in 2230 μL (4161 μg per HPLC-NMR injection); 
S. cf. fallax: 166.5 mg dissolved in 1665 μL (5000 μg per HPLC-NMR injection); S. vestitum: 342.8 mg 
dissolved in 3430 μL (4997 μg per HPLC-NMR injection); H. pseudospicata: 61.6 mg dissolved in 
615 μL (5008 μg per HPLC-NMR injection); Laurencia sp.: 216.2 mg dissolved in 2160 μL  
(5005 μg per HPLC-NMR injection); C. subfarcinata: 741.9 mg dissolved in 7420 μL (4999 μg per 
HPLC-NMR injection). 
3.5. HPLC-NMR & HPLC-MS Conditions 
For details of the HPLC-NMR conditions please refer to [37]. For both on-flow and stop-flow 
HPLC-NMR modes, 50 μL injections of the dichloromethane extracts were injected onto an Agilent 
Eclipse Plus C18 (150 × 4.6) 5 μ column using a solvent composition of 75% CH3CN/D2O at a flow rate 
of 1 mL/min. During HPLC-NMR analyses, the HDO and CH3CN signals are suppressed at 4.64 and 
2.82 ppm, respectively. In the stop-flow HPLC-NMR mode, WET1D, gCOSY, HSQCAD and 
gHMBCAD NMR experiments were acquired. HRESILCMS was carried out on an Agilent 6540 Series 
TOF system in either the positive or negative ionization mode (ESI operation conditions of 12 L/min 
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N2, 325 °C drying gas temperature, and 3500 V capillary voltage) equipped with an Agilent 1260 Infinity 
Binary Pump, Agilent 1290 Infinity Autosampler and Agilent 1260 DAD detector (Agilent, Santa Clara, 
CA, USA). The instrument was calibrated using the “Agilent Tuning Mix” with purine as the reference 
compound and the Hewlett-Packard standard HP0921. The separations were carried out using an Agilent 
Eclipse Plus C18 (4.6 × 150) 5 μ column using a solvent composition of 75% CH3CN/H2O at a flow rate 
of 1 mL/min. 
3.6. On-Line (HPLC-NMR & HPLC-MS) Partial Characterization of Compounds 
1-(2,4,6-trihydroxyphenyl)-hexadecadien-1-one (unknown double bond positions) (17): HPLC-NMR 
WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 4.64 and 
2.82 ppm, respectively) obtained from stop-flow mode δ 6.71 (2H, s, H-3′/H-5′), 6.22 (4H, m, CHCH), 
3.89 (2H, t, J = 8.0, H-2), 3.62 (2H, m, CHCH2CH), 2.11 (m, CH2)*, 1.77 (3H, t, J = 8.0 ; HRESILCMS; 
m/z 359.2226 (calcd for C22H31O4, 359.2222). 
1-(2,4,6-trihydroxyphenyl)-octadecadien-1-one (unknown double bond positions) (18): HPLC-NMR 
WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 4.64 and 
2.82 ppm, respectively) obtained from stop-flow mode δ 6.70 (2H, s, H-3’/H-5’), 6.20 (4H, m, CHCH), 
3.87 (2H, t, J = 7.5, H-2), 3.61 (2H, dd, J = 6.0, 7 Hz, CHCH2CH), 2.46 (2H, m, H-3), 2.11 (m, CH2)*, 1.71 
(3H, t, J = 7.0 ; HRESILCMS; m/z 387.2539 (calcd for C24H35O4, 387.2535). 
1-(2,6-dihydroxy-4-methoxyphenyl)-octadecatrien-1-one (unknown double bond positions) (19): 
HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 4.64 
and 2.82 ppm, respectively) obtained from stop-flow mode δ 6.82 (2H, s, H-3’/H-5’), 6.21 (6H, m, 
CHCH), 3.91 (2H, t, J = 7.0, H-2), 3.66 (4H, m, CHCH2CH), 2.49 (2H, m, H-3), 2.25 (2H, m, H-4), 2.10, 
(m, CH2)*, 1.70 (3H, t, J = 6.5 ; HRESILCMS; m/z 399.2539 (calcd for C25H35O4, 399.2535). 
Please refer to the supplementary information file containing UV profiles, HPLC-NMR data 
including tabulated NMR data and the high resolution HPLC-MS chromatograms for all remaining 
compounds (these are listed in order of retention time). 
4. Conclusions
This study has demonstrated the importance and ability of HPLC-NMR in conjunction with high
resolution HPLC-MS and databases such as MarinLit to rapidly dereplicate the identity of secondary 
metabolites from a range of marine algae. The chemical diversity between, and within, marine algae 
genera was highlighted (See Tables 1 and 2). The phloroglucinols (11–14, 16–21) are an example of 
compounds that can be found occurring across different species of the same genus (Cystophora), while 
the xanthophylls (15) provide an example of compounds that can extend over different genera 
(Halopteris and Sargassum). The application of HPLC-NMR to investigate either genera or species of 
marine algae which were previously not studied (S. decipiens, S. vestitum, S. cf. fallax, and H. pseudospicata) 
and to rapidly identify structure classes present, without the need for traditional and lengthy isolation 
procedures is noteworthy. Finally, this study also highlights the advantage of using HPLC-NMR over 
HPLC-MS data for dereplication, especially when compounds do not easily ionize during HPLC-MS 
analyses. In such cases, crucial NMR data, which can be acquired via HPLC-NMR, provides important 
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structural features and connectivity, which can enable a compound to be dereplicated. Unlike HPLC-MS, 
HPLC-NMR also allows for the differentiation of structural isomers. 
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CHAPTER 9 
Chemical Profiling and Isolation Studies of the Marine Brown 
Alga Sargassum paradoxum 
 
 
Kingdom: Chromista 
Phylum: Ochrophyta 
Class: Phaeophyceae 
Order: Fucales 
Family: Sargassaceae 
Genus: Sargassum 
Species: paradoxum 
 
Collected by SCUBA from Governor Reef, near 
indented Heads at a depth of 3 m from Port Phillip 
Bay, Victoria, Australia in April 2010.  
 
Chapter 9 describes the chemical profiling and isolation methodologies adopted in the 
identification of the constituents present in the crude extract of the marine brown alga 
Sargassum paradoxum. The results of this study have been published as outlined below. 
Supplementary information relevant to the study is provided in Appendix E.  
 
Journal publication resulting from this study: 
Brkljača, Robert, & Urban, Sylvia. (2015). Chemical Profiling (HPLC-NMR & HPLC-MS), 
Isolation and Identification of Bioactive Meroditerpenoids from the Southern Australian 
Marine Brown Alga Sargassum paradoxum. Marine Drugs, 13(1), 102-127. 
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Sargassum paradoxum, resulted in the isolation and identification of four new (5, 9, 10, 
and 15) and nine previously reported (1, 2, 6–8, and 11–14) bioactive meroditerpenoids. 
HPLC-NMR and HPLC-MS were central to the identification of a new unstable 
compound, sargahydroquinal (9), and pivotal in the deconvolution of eight (1, 2, 5–7, and 
10–12) other meroditerpenoids. In particular, the complete characterization and 
identification of the two main constituents (1 and 2) in the crude dichloromethane extract 
was achieved using stop-flow HPLC-NMR and HPLC-MS. This study resulted in the first 
acquisition of gHMBCAD NMR spectra in the stop-flow HPLC-NMR mode for a system 
solely equipped with a 60 μL HPLC-NMR flow cell without the use of a cold probe, 
microcoil, or any pre-concentration. 
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1. Introduction
Terpenoids and phenolic compounds represent the largest group of secondary metabolites reported 
from marine brown algae [1]. Marine brown algae belonging to the Sargassum genus (Sargassaceae, 
Fucales) number in excess of 300 species [2] located throughout most regions of the world [3,4], and are 
known to produce secondary metabolites such as meroterpenoids [1,5]. Meroditerpenoids are metabolites 
of mixed biogenesis containing terpenoid and non-terpenoid derived fragments. Meroditerpenoids 
derived from algae of the genus Sargassum are comprised of a polyprenyl chain attached to either a 
p-benzoquinone or hydroquinone moiety [6–8]. Variations of the meroditerpenoid structures occur 
mainly in the terpene side chain and include the addition of exocyclic double bonds, carboxylic acids, 
alcohols, or aldehyde functional groups [1,7,9]. Meroditerpenoids have been reported to display a 
range of biological activities including antibacterial, antioxidant, and antitumor activities [6,7,10–12]. 
We recently examined a specimen of the marine brown alga Sargassum paradoxum (R. Brown ex 
Turner) Hooker and Harvey, collected from Port Phillip Bay, Victoria, Australia. This alga was 
selected for chemical investigation on the basis of the crude extract antimicrobial activity and that no 
previous chemistry had been reported from this particular Sargassum species [1,13]. Previous studies 
conducted by our research group on another closely related Sargassum species (S. fallax) resulted in 
the isolation of three new meroditerpenoids [7]. This also provided the motivation for studying this 
Sargassum species in that a comparison of the two species could potentially allow for chemotaxonomic 
markers to be identified. Herein we report the chemical profiling study conducted using HPLC-NMR 
and HPLC-MS together with the bioassay-guided isolation and structure determination of one new 
meroditerpenoid with a hydroquinone moiety paradoxhydroquinone (5) and two new meroditerpenoids 
possessing a p-benzoquinone moiety, paradoxquinol (10) and paradoxquinone (15). A new unstable 
meroditerpenoid, sargahydroquinal (9), was identified on the basis of the HPLC-NMR and HPLC-MS 
studies conducted. Revisions in the proton and/or carbon NMR chemical shift assignments for three of 
the meroditerpenoids (1, 2, and 13) have also been documented. In all, 14 meroditerpenoids (Figure 1) 
were detected in the crude extract of S. paradoxum and, of these, 13 could be identified using a 
combination of on-line (HPLC-NMR and HPLC-MS) and off-line (conventional isolation and 
structure elucidation) methodologies. 
2. Results and Discussion
The frozen marine alga was extracted with 3:1 methanol/dichloromethane, evaporated under 
reduced pressure, and sequentially solvent partitioned (triturated) into dichloromethane- and 
methanol-soluble fractions, respectively. While both the dichloromethane- and methanol-soluble 
fractions displayed some antimicrobial activity, the dichloromethane extract was slightly more selective 
in its activity (Section 2.3). 1H NMR and analytical HPLC analyses indicated that the dichloromethane 
extract contained a series of structurally related compounds. On the basis of these observations, only 
the dichloromethane extract was further examined. 
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Figure 1. Structures of meroditerpenoids. 
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2.1. Chemical Profiling (HPLC-NMR & HPLC-MS) 
The dichloromethane extract was subjected to both HPLC-NMR and HPLC-MS chemical profiling 
and a total of 10 peaks (A–J) were detected (Figure 2). Analysis of the stop-flow WET1D proton NMR 
spectra showed the presence of characteristic proton NMR signals in the aromatic and olefinic regions, 
together with various upfield proton NMR signals (Figure 2). Examination of the UV profile extracted 
for each of the peaks detected by PDA showed the presence of two distinct UV chromophores at 
λmax 255 and 290 nm, typical of p-benzoquinones and hydroquinones that are known to occur in this 
genera of algae [1,13]. 
Figure 2. Stop-flow Wet1D proton NMR spectra (500 MHz, 75% CH3CN/D2O, 
suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) of peaks A–J 
resulting from analysis of the dichloromethane crude extract of S. paradoxum. 
The two main peaks that were present in the dichloromethane crude extract of S. paradoxum (peaks 
A and B in Figure 2) were completely identified and characterized by HPLC-NMR and HPLC-MS. 
Both compounds displayed a UV maxima at 290 nm, supporting the presence of a hydroquinone 
moiety [14]. 
The HPLC-NMR stop-flow WET1D proton NMR spectrum of peak A (Figure 2) showed two 
meta-coupled protons at δH 7.22 and 7.25, indicating the presence of an aromatic moiety displaying an 
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AB splitting pattern as well as deshielded proton signals at δH 4.95, 4.88, and 4.87. Complete analysis 
of the 1D and 2D NMR data (Table 1) obtained via stop-flow HPLC-NMR, and the high resolution 
ESI MS obtained for this peak via HPLC-MS analysis (m/z 427.2846 [M − H]−), allowed for the structure 
to be unequivocally elucidated as the previously described meroditerpenoid fallahydroquinone (1) [7]. 
The HPLC-NMR stop-flow WET1D proton NMR spectrum of peak B (Figure 2) supported the 
presence of a meta-coupled aromatic AB system (δH 7.23 and 7.26). Also present was a deshielded 
olefinic proton resonance (δH 6.69). The gHMBCAD NMR spectrum obtained in the stop-flow 
HPLC-NMR mode showed a signal at δC 170.9 ppm, confirming a carboxylic acid functional group 
(Table 1). Complete analysis of the 1D and 2D NMR data obtained via stop-flow HPLC-NMR and the 
high-resolution ESI MS obtained via HPLC-MS (m/z 425.2694 [M − H]−) suggested the previously 
described meroditerpenoid sargahydroquinoic acid (2) [8]. While a direct comparison of the proton 
NMR chemical shifts obtained via stop-flow HPLC-NMR to the NMR data reported in the literature is 
impeded by the expected chemical shifts differences that occur for spectra acquired using off-line 
conventional deuterated NMR solvents compared to HPLC-NMR solvents, the majority of the proton 
NMR signals for this compound varied from the literature data by a consistent factor. However, the 
proton chemical shift for position H-10′ (δH 6.69) differed to that reported for sargahydroquinoic acid 
(2) (δH 6.02) [8]. To confirm the 10′/11′ double bond configuration, single irradiation nOe NMR 
experiments were carried out whilst in the stop-flow HPLC-NMR mode. The proton at δH 6.69 was 
irradiated and a key nOe enhancement observed to the methylene protons at δH 3.02 (H-12′). This 
provided confirmation that peak B (Figure 2) has a 10′Z double bond configuration, which corresponds 
to the structure assigned to sargahydroquinoic acid. Further confirmation of the 10′Z double bond 
configuration came from comparison to the meroditerpenoids chabrolohydroxybenzaquinone A (3) and 
C (4), which were isolated as co-occurring double bond isomers from the soft coral Nephthea charoli [15]. 
These compounds show that there is a characteristic difference in the carbon chemical shift of the 
C-12’ methylene (δC 26.7 ppm and 34.5 ppm for the 10′E and 10′Z isomers, respectively) [15]. This γ 
effect is particularly valuable for distinguishing E and Z isomers of trisubstitued alkenes. Since the 
carbon for the C-12′ methylene in (2) displayed a carbon chemical shift at δC 35.3, this provided 
further confirmation for the 10′Z configuration. 
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The HPLC-NMR stop-flow WET1D proton NMR spectra of peaks C and D resembled that of peak 
A [fallahydroquinone (1)] (Figure 2), both of which eluted closely. Upon closer examination, it was 
evident that peak D was a meroditerpenoid that contained one alcohol functional group, due to the 
presence of a deshielded methylene proton at δH 4.84. Examination of the high resolution-ESI 
MS obtained via HPLC-MS for peaks C and D indicated that these were isobaric and that they 
both possessed a UV maxima at 290 nm, supportive of a hydroquinone moiety [14]. On the basis 
of the mass difference and the proton NMR differences it was proposed that peak D contained 
a terminal alcohol moiety but, unlike fallahydroquinone (1), did not contain a secondary alcohol 
functional group; this led to peak D being identified as the previously reported compound 
2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol 
(6) [16]. This represents the first report of 6 occurring as a natural product. Due to suppression of the 
HDO peak, no deshielded proton resonances could be observed for peak C; however, in consideration 
of the slight elution time difference, and the identical molecular masses, it was suspected that peak C 
contained an oxymethine group. While in stop-flow HPLC-NMR, the closely eluting compounds 
showed diffusion, and the oxymethine signal at δH 4.84 could clearly be distinguished via on-flow 
HPLC-NMR as being present in peak D and absent in peak C (see Supplementary Information file). 
The structure of peak C was proposed to be the new meroditerpenoid 2-[12-hydroxy-3,7,11, 
15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol, attributed the trivial name 
paradoxhydroquinone (5). Although subsequent off-line isolation of peaks C and D afforded an 
inseparable mixture, identification of these peaks was possible via the chemical profiling approach 
since individual WET1D proton and gCOSY NMR data could be obtained separately for each peak. 
This highlights an important feature of HPLC-NMR: typically co-eluting secondary metabolites that are 
difficult to obtain separately by conventional off-line isolation approaches can be obtained as separate 
entities via stop-flow HPLC-NMR. 
Peak E was determined to be the previously described meroditerpenoid fallaquinone (7) [7], based 
on the observed UV maxima, together with the stop-flow WET1D proton NMR spectrum and the 
high-resolution ESI MS obtained via HPLC-MS, which showed the presence of an ion at m/z 
425.2694 [M − H]−. 
On the basis of the HPLC-NMR stop-flow WET1D proton NMR spectrum of peak F and the UV 
profile (λmax 290 nm), this compound also possessed a hydroquinone moiety [14]. The high-resolution 
ESI MS ion m/z of 409.2745 [M − H]− obtained via HPLC-MS suggested a molecular formula of 
C27H38O3. The stop-flow WET1D proton NMR spectrum showed a distinct proton signal at δH 10.07, 
s, confirming the presence of an aldehyde moiety. The MarinLit database indicated that sargaquinal 
(8), which possesses a p-benzoquinone moiety and an aldehyde functional group, had been previously 
reported from the Sargassum genus [17]. Peak F was proposed as being the new meroditerpenoid 
(possessing a hydroquinone moiety), attributed the name sargahydroquinal (9). During subsequent 
off-line bioassay-guided isolation, sargahydroquinal (9) oxidized into sargaquinal (8) before any 
off-line data could be obtained. Owing to the low abundance of sargahydroquinal (9) in the crude 
dichloromethane extract, only the stop-flow WET1D proton NMR and gCOSY data were obtained in 
the HPLC-NMR mode for sargahydroquinal (9) and are provided in Table 2. By comparison of the 
off-line data for sargaquinal (8) to peak F, the structure of sargahydroquinal (9) could be established. 
The configuration of the double bonds for sargaquinal (8) have been reported as 2′E, 6′E, and 10′E [17]. 
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A bsNOESY NMR experiment carried out for sargaquinal (8) revealed nOe enhancements between the 
olefinic protons at positions H-2′ and H-6′ to the methylene protons at positions H-4′ and H-8′, along 
with the olefinic proton at position H-10′ showing a nOe enhancement to the aldehyde proton at 
position H-20′. On biosynthetic grounds, the same configuration was attributed to the double bonds in 
sargahydroquinal (9). 
Table 2. NMR data (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 
4.64 and 2.82 ppm, respectively) for sargahydroquinal (9) obtained via stop-flow HPLC-NMR. 
Sargahydroquinal (9) 
Position δH (J in Hz) gCOSY 
1 
2 
3 7.23, d (2.5) 
4 
5 7.25, d (2.5) 
6 
7 2.94, s 
1′ 4.05, d (7.5) 2′, 18′ 
2′ 6.10, t (7.5) 1′ 
3′ 
4′ 2.70-3.00, m 
5′ 2.96, m 6′ 
6′ 6.00, t (7.0) 5′ 
7′ 
8′ 2.98, m 9′ 
9′ 3.26, dt (7.0, 8.0) 8′, 10′ 
10′ 7.37, t (7.0) 9′ 
11′ 
12′ 2.70-3.00, m 
13′ 2.70-3.00, m 
14′ 5.92, t (7.0) 16′ 
15′ 
16′ 2.37, s 14′ 
17′ 2.48, s 
18′ 2.52, s 1′, 2′ 
19′ 2.35, s 
20′ 10.07, s 
1-OH ND a 
4-OH ND a 
a Signal not detected. 
The UV profile (λmax 255 nm) observed for peak G in the HPLC-NMR and HPLC-MS analyses 
confirmed a p-benzoquinone moiety [14]. The HPLC-NMR stop-flow WET1D proton NMR spectrum 
of peak G showed close resemblance to fallaquinone (7), except that an aromatic proton NMR 
resonance was absent. Comparison of the mass of peak G to fallaquinone (7), observed from ESI MS 
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obtained via HPLC-MS analysis, showed a difference of 14 mass units, indicating that one of the 
aromatic proton signals had been replaced by a methyl substituent. The structure of peak G was 
therefore proposed to be the new meroditerpenoid 5-[12R-hydroxy-11-(hydroxymethyl)-3,7, 
15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-2,3-dimethyl-1,4-benzoquinone, attributed the trivial 
name paradoxquinol (10). 
Peak I showed close similarities to sargahydroquinoic acid (2) and was identified as the previously 
reported sargahydroquinoic acid (11) [7,17], the benzoquinone counter part of 2. 
Peak J possessed a p-benzoquinone moiety from the UV chromophore at 263 nm [14]. Analysis of 
the HPLC-NMR stop-flow WET1D NMR data showed close resemblance to 6. On the basis of the 
molecular ion deduced from the high-resolution ESI MS (409.2742 [M − H]−) obtained via HPLC-MS, 
in consultation with a SciFinder search, peak J was identified as previously described meroditerpenoid 
2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzoquinone 
(12) [16,17]. Although subsequent off-line isolation afforded 12 and 15 as an inseparable mixture, 
identification of these compounds was possible via the chemical profiling approach since individual 
WET1D and gCOSY NMR data could be obtained separately for 12, which could then be related back 
to the mixture. 
2.2. Off-Line Bioassay-Guided Isolation 
Following the chemical profiling (HPLC-NMR and HPLC-MS) conducted on the dichloromethane 
crude extract, a bioassay-guided isolation approach was undertaken to deduce the nature of the 
bioactive constituent(s) responsible for the crude extract bioactivity. The off-line isolation also allowed 
for any further identification and characterization of the meroditerpenoids concluded on the basis of 
the chemical profiling analysis as well as identifying any additional minor constituents not detected 
by HPLC-NMR. 
A portion of the dichloromethane extract was fractionated by silica gel flash chromatography and 
selected fractions were evaluated for antimicrobial activity. Fractions for further purification were 
selected based on the observed antimicrobial activity, analysis of the 1H NMR spectra, and the 
analytical HPLC chromatograms. Purification was conducted using reversed phase HPLC resulting in 
the isolation of 12 meroditerpenoids, eight (1, 2, 5–7, and 10–12) of which were previously detected 
by HPLC-NMR and HPLC-MS analyses, and four of which were additional meroditerpenoids (8 and 
13–15) that were not observed in the chemical profiling. Nine known meroditerpenoids (1, 2, 6–8, and 
11–14) were isolated and identified by direct comparison of their NMR spectroscopic and mass 
spectrometry data with that reported in the literature [7,8,16–19]. The off-line study also confirmed the 
structures of 1, 2, 5–7, and 9–12 as deduced by HPLC-NMR and HPLC-MS. 
Fallahydroquinone (1) was isolated as an unstable yellow oil. Analysis of the 2D NMR data showed 
that the carbon NMR chemical shifts for positions C-2 and C-6, reported as occurring at δC 125.4 and 
127.8, respectively, should be reassigned to δC 127.8 (C-2) and δC 125.4 (C-6), respectively. In 
addition, the proton NMR signals for the position H-4′ and H-8′ protons reported at δH 2.01 and 2.08, 
respectively, should also be reversed. The specific rotations of the previously reported 
meroditerpenoids fallahydroquinone (1) and fallaquinone (7) were compared to literature values [7]. 
While the specific rotation for fallahydroquinone (1) was comparable in sign and magnitude, the 
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specific rotation of fallaquinone (7) differed to that reported. The purity of fallaquinone (7) in this 
study was higher than that obtained in the original isolation. It was concluded that the impurities 
present were sufficient to cause the specific rotation to vary in sign and magnitude. The accuracy of 
the specific rotations was considered given the low quantities isolated. The relevant compounds 
isolated in this study were of high purity, and did not display small specific rotations. That both the 
specific rotation of both fallahydroquinone (1) and fallaquinone (7) are of the same sign and magnitude 
is consistent with the fact that the former oxidizes to the latter with retention of configuration. 
Sargahydroquinoic acid (2) was isolated as an unstable oil. Analysis of the 2D NMR data showed 
that the carbon NMR chemical shifts for positions C-9′ and C-13′, reported as occurring at δC 27.8 and 
28.3, respectively, should be reassigned to δC 28.3 (C-9′) and δC 27.8 (C-13′), respectively. 
Comparison of the 2D NMR data of sargaquinone (13) with the literature data indicated 
discrepancies with some of the carbon NMR chemical shift assignments. The carbon NMR chemical 
shifts for positions C-3, C-5, C-3′, and C-15′ were either incorrectly assigned or not assigned. These 
carbon NMR chemical shifts have been unequivocally established as occurring at δC 132.3, 133.2, 
140.0 and 131.3, respectively. 
Sargahydroquinal (9) and one other unidentified peak (peak H) (Figure 2) degraded during the off-line 
isolation, which meant that it was not possible to conduct a complete 2D NMR or antimicrobial 
activity evaluation on these constituents. 
Paradoxhydroquinone (5) was isolated off-line as an inseparable mixture with 2-[11-(hydroxymethyl)-3, 
7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol (6) in a ratio of approximately 
3:5. While complete 2D NMR characterization was conducted on the mixture, these components were 
obtained as separate entities via stop-flow HPLC-NMR. By analysis of the data obtained from both 
chemical profiling and off-line isolation, the compounds could be identified. In the first instance, the 
previously reported compound 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-
yl]-6-methyl-1,4-benzenediol (6) could be confirmed [16]. The comparison of the aromatic proton 
signals of 5 with those of the known meroditerpenoids isolated supported the presence of a 
hydroquinone moiety. The structure of 5 as proposed by chemical profiling was confirmed by analysis 
of the gHMBCAD NMR spectrum, which indicated that the proton signal at δH 3.97 (H-12′) showed 
correlations with the carbons at δC 126.2 (C-10′), 120.2 (C-14′), and 11.7 (C-20′) (Table 3). The 
oxymethine group was concluded to be located at position 12′ on the basis of the HMBC NMR 
correlation observed from the singlet methyl group at position H-20′ (δH 1.61, s) to the carbon at δC 
77.3 (C-12′), which is directly coupled to the signal at δH 3.97. The compound was identified as the 
new meroditerpenoid 2-[12-hydroxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzenediol, and attributed the trivial name paradoxhydroquinone (5). Unfortunately, 5 and 6 
oxidized to 15 and 12 before any NOESY NMR experiments could be carried out. Therefore a 
bsNOESY NMR experiment was carried out on 15 and 12, respectively, and the results related back to 
5 and 6. On biosynthetic grounds, the configuration of the double bonds was therefore confirmed as 
2′E, 6′E, and 10′E for 5, and 2′E, 6′E, and 10′Z for 6. 
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Table 3. 1H and 13C NMR data (500 MHz, CDCl3) data for paradoxhydroquinone (5). 
Paradoxhydroquinone (5) 
Position δC a, Type δH (J in Hz) gCOSY gHMBCAD 
1 146.4, C 
2 127.6, C 
3 114.0, CH 6.46, d (2.5) 5, 1′ 1, 4, 5, 1′ 
4 149.0, C 
5 115.5, CH 6.50, d (2.5) 3, 7 1, 3, 4, 7 
6 125.5, C 
7 16.0, CH3 2.18, s 5 1, 5, 6 
8 
1′ 30.0, CH2 3.28, d (7.0) 3, 2′, 4′w, 18′w 1, 2, 3, 2′, 3′ 
2′ 122.0, CH 5.26, t (7.0) 1′, 4′, 18′ 1′, 4′, 18′ 
3′ 138.1, C 
4′ 39.5, CH2 2.08, m 1′w 5′, 18′ 
5′ 26.1, CH2 2.13, m 4′, 7′ 
6′ 124.4, CH 5.09, m 4′, 5′, 19′ 
7′ 135.1, C 
8′ 39.2, CH2 2.01, m 6′, 7′, 9′, 19′ 
9′ 26.1, CH2 2.10, m 8′ 7′, 10′, 11′ 
10′ 126.2, CH 5.37, t (6.5) 9′, 20′ 12′, 20′ 
11′ 136.6, C 
12′ 77.3, CH 3.97, dd (6.0,7.0) 13a′, 13b′ 10′, 14′, 20′ 
13a′ 34.2, CH2 2.20, m 12′, 16′, 17′ 
13b′ 2.28, ddd (7.0, 8.0, 14.0) 12′, 16′, 17′ 12′, 14′, 15′ 
14′ 120.2, CH 5.09, m 16′, 17′ 
15′ 134.7, C 
16′ 18.0, CH3 1.63, s 14′ 14′, 15′, 17′ 
17′ 25.9, CH3 1.72, s 13b′, 14′ 14′, 15′, 16′ 
18′ 16.2, CH3 1.75, s 1′, 2′ 2′, 3′, 4′ 
19′ 16.1, CH3 1.59, s 5′, 6′ 7′, 8′ 
20′ 11.7, CH3 1.61, s 10′ 10′, 11′, 12′ 
1-OH ND b 
4-OH ND b 
12′-OH ND b 
a Carbon NMR assignments made on the basis of gHSQCAD and gHMBCAD NMR experiments. b Signal 
not detected. 
Paradoxquinol (10), unlike many of the previously isolated meroditerpenoids, which show the 
presence of an AB aromatic system, only displayed a single aromatic proton NMR signal at δ 6.46, s (H-3), 
suggesting further substitution of the p-benzoquinone ring. The gHMBCAD NMR spectrum confirmed 
the structure of 10 as proposed by chemical profiling. The two deshielded methyl groups [δH 2.03 (s, H-7) 
and 2.00 (s, H-8)] showed correlations to carbons at δC 140.6 (C-5), 141.5 (C-6), and 187.7 (C-1), and 
δ 140.6 (C-5), 141.5 (C-6), and 187.9 (C-4), respectively (Table 4). Further analysis of the HMBC 
NMR data confirmed the position of attachment for the terminal and the secondary alcohol moieties as 
positions 20′ and 12′, respectively, and confirmed 10 as the new meroditerpenoid 5-[12R-hydroxy-11-
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(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-2,3-dimethyl-1,4-benzoquinone, 
attributed the trivial name paradoxquinol (10). A single irradiation nOe NMR experiment confirmed 
the configuration of the double bond at position C-10′ as 10′E (irradiation of H-10′ showed a key 
enhancement to H-12′). Although this represents the first occurrence in a marine alga of a 
meroditerpenoid containing the position 8 methyl, this biosynthetic feature has been reported in 
terrestrial natural products [20,21]. It is suggested that the biosynthetic pathway of 10 is reminiscent to 
that of γ-tocotrienol (16). 
Paradoxquinone (15) was isolated off-line as an inseparable mixture with 2-[11-(hydroxymethyl)-3, 
7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzoquinone (12) in a ratio of 
approximately 3:5. While complete NMR characterization was conducted on the mixture, the latter of 
these was identified as a separate entity via stop-flow HPLC-NMR. By analysis of the data obtained 
from both chemical profiling and off-line isolation, the latter of these compounds could be identified as 
the known meroditerpenoid 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-
6-methyl-1,4-benzoquinone (12). This compound had previously been reported as a derivative of a 
natural product; however, this represents the first report of its natural occurrence [17]. The 1H NMR 
spectrum of paradoxquinone (15) was similar to that of paradoxhydroquinone (5). Minor differences 
were observed for the aromatic protons (6.46, bs and 6.54, bs) and the terminal methyl group at position 
H-7 (δH 2.05, s) (Table 4). Complete analysis of the 2D NMR spectra resulted in the compound being 
identified as the new meroditerpenoid 2-[12-hydroxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-
1-yl]-6-methyl-1,4-benzoquinone, attributed the trivial name paradoxquinone (15). For compound 12, 
nOe enhancements were observed from each of the olefinic protons at positions H-2′, H-6′, and H-10′ 
to the methylene protons at H-4′, H-8′, and H-12′. For compound 15, nOe enhancements were 
observed from the olefinic protons at positions H-2′ and H-6′ to the methylene protons at H-4′ and 
H-8′, together with an enhancement from the olefinic proton at H-10′ to the oxymethine proton at 
H-12′. The configuration of the double bonds was therefore confirmed as 2′E, 6′E, and 10′E for 15, and 
2′E, 6′E, and 10′Z for 12. 
The chirality of secondary allylic alcohols can be elucidated via the exciton chirality method 
(usually by preparation of a benzoate derivative) or by NMR spectroscopy of the diastereoisomeric 
Mosher or modified Mosher esters [22–25]. In the former methodology, the absolute configuration of 
acyclic secondary alcohols have been assigned by interpretation of the Cotton effects observed at two 
wavelength regions (~220 and ~240–260 nm, respectively) [22,24]. 
The CD spectra of fallahydroquinone (1), fallaquinone (7), and paradoxquinol (10) were 
recorded and Cotton effects observed in the circular dichroism spectra noted. The CD spectra of 
fallahydroquinone (1), fallaquinone (7), and paradoxquinol (10) all showed the presence of positive 
Cotton effects at 260, 247, and 245 nm, respectively, of Δε +2.0, +2.3, and +2.4 as well as at 224, 220, 
and 220 nm of Δε +1.8, +1.0, and +6.4, respectively. On the basis of the similarities in the CD spectra, 
these compounds were concluded to have the same (undefined) absolute configuration. Subsequent to 
these analyses, fallahydroquinone (1), fallaquinone (7), and paradoxquinol (10) completely degraded, 
which precluded any further attempts to address the absolute configuration by conversion to the 
corresponding Mosher esters. 
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The compounds isolated from S. paradoxum in this study also occur in many other Sargassum 
species. However, two of the compounds—fallahydroquinone (1) and fallaquinone (7)—have only 
been reported from one other Sargassum species (S. fallax) [7]. On this basis, it is proposed that the 
presence of these two compounds could potentially be used as chemotaxonomic biomarkers for 
S. paradoxum and S. fallax. 
2.3. Antimicrobial Studies 
Fallahydroquinone (1) and fallaquinone (7) have been previously reported to display slight 
antitumor activity [7]. Sargahydroquinoic acid (2) and sargaquinoic acid (11) display similar 
antitumor [7,26] and peroxynitrite-scavenging activity [27], as well as antiplasmodial activity against 
malaria parasites [28]. Sargahydroquinoic acid (2) also shows insecticidal activity [29], selective 
vasodilatation effects [30], the ability to stimulate adipocyte differentiation [31], and radical 
scavenging activity [6]. Sargaquinoic acid (11) shows weak antimicrobial activity [7], the ability to 
promote neurite outgrowth [32], the ability to induce cell apoptosis [33], antioxidant activity [34], and 
cholinesterase inhibition activity [35]. Sargaquinal (8) displays antiplasmodial activity against malaria 
parasites [28]. A range of activities have been reported for sargaquinone (13) including radical 
scavenging [36], anti-inflammatory activity [37], activity against P-388 cells [7,38], and ichthyotoxicity 
to certain species of fish [39]. Antileishmanial activity has been reported for 9-(6-hydroxy-2,8-dimethyl-
2H-1-benzopyran-2-yl)-6-methyl-2-(4-methyl-3-penten-1-yl)-2,6-nonadienal (14) [19]. 
Antimicrobial evaluation of the crude extracts, selected silica column fractions, and the isolated 
meroditerpenoids was carried out against five bacteria and one fungus. Eleven of the isolated 
meroditerpenoids (1–2, 5–7, 9–13, and 15), together with a commercially available antibiotic and 
antifungal agent, were tested at 1 mg/mL, with all displaying varying degrees of zones of inhibition in 
the antimicrobial assays (Table 5). Compared to the antibiotic ampicillin, the isolated compounds were 
far less potent against S. aureus and S. pyogenes. However, compounds 2, 7, 8, and 13 were more 
potent against P. aeruginosa than ampicillin. In recent years, concern has grown around P. aeruginosa 
with regards to its prevalence and multidrug resistance [40]; therefore, the importance of identifying 
possible drug leads against these bacteria remains highly relevant. There was no difference in activity 
between compounds with the hydroquinone or the p-benzoquinone moieties. The activity observed for 
sargaquinone (13), the simplest of the meroditerpenoids isolated, suggests that the unsubstituted 
meroditerpenoid skeleton is responsible for the activity against P. aeruginosa. The addition of an 
alcohol group at position 12′ or 20′ (1, 5, 6, 12, and 15) appears to reduce the activity against 
P. aeruginosa, but increases the activity against S. pyogenes. Finally, incorporation of a carboxylic 
acid at position C-20′ (2 and 11) gives rise to activity against S. aureus and S. aureus MRSA. 
3. Experimental Section
3.1. General Experimental Procedures 
All organic solvents used were analytical reagent (AR or GR), UV spectroscopic, or HPLC grades 
with milli-Q water also being used. Optical rotations were carried out using a 1.5-mL cell on a 
Rudolph Research Analytical Autopol IV automatic polarimeter, set to the Na 589 nm wavelength. 
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UV/VIS spectra were recorded on an Agilent CARY 60 spectrophotometer, using ethanol. CD spectra 
were obtained on a Jasco 815 Circular Dichroism spectrometer in ethanol. FTIR spectra were recorded 
as a film using a NaCl disk on a Perkin-Elmer Spectrum One FTIR spectrometer. 1H (500 MHz), 13C 
(125 MHz), and 1D nOe spectra were acquired in CDCl3 on a 500 MHz Agilent DD2 NMR 
spectrometer with referencing to solvent signals (δ 7.26 and 77.0 ppm). Two-dimensional NMR 
experiments recorded included gradient correlation spectroscopy (gCOSY), heteronuclear single-quantum 
correlation spectroscopy with adiabatic pulses (HSQCAD), gradient heteronuclear multiple-bond 
spectroscopy with adiabatic pulses (gHMBCAD), and band selective 2D nuclear overhauser 
enhancement spectroscopy (bsNOESY) experiments. ESI mass spectra were obtained on a Micromass 
Platform II mass spectrometer equipped with a LC-10AD Shimadzu solvent delivery module (50% 
CH3CN/H2O at a flow rate of 0.2 mL/min) in both the positive and negative ionization modes using 
cone voltages between 20 and 30 V. Silica gel flash chromatography was carried out using Davisil 
LC35Å silica gel (40–60 mesh) with a 20% stepwise solvent elution from 100% petroleum spirits 
(60–80 °C) to 100% dichloromethane to 100% ethyl acetate and finally to 100% methanol. HPLC-NMR 
was carried out on a 500 MHz Agilent DD2 NMR spectrometer equipped with a Varian 1H[13C] pulsed 
field gradient flow probe with a 60-μL active volume flow cell coupled to a Varian Prostar 210 solvent 
delivery system, a Prostar 430 Autosampler, and a Prostar 335 PDA detector. The HPLC-NMR 
analyses were carried out using CORBA communication and operated with VnmrJ software. The 2H 
resonance observed from the D2O was used to obtain a field-frequency lock. The resonances from the 
HOD and the methyl of the acetonitrile were suppressed using the water enhanced through transverse 
gradients (WET) solvent suppression experiment [41]. The residual HOD resonance of D2O was 
referenced to 4.64 ppm. For both on-flow and stop-flow HPLC-NMR modes, 50-μL injections 
(4995 µg) of the dichloromethane extract were injected onto an Agilent Eclipse Plus C18 (150 × 4.6) 
5-µ column using a solvent composition of 75% CH3CN/D2O at a flow rate of 1 mL/min. In the 
stop-flow HPLC-NMR mode WET1D, gCOSY, HSQCAD, gHMBCAD, and 1D nOe NMR 
experiments were acquired. HRESIMS was carried out on an Agilent 6200 Series TOF system (ESI 
operation conditions of 8 L/min N2, 325 °C drying gas temperature, and 3500 V capillary voltage) 
equipped with an Agilent 1200 Series LC solvent delivery module (100% CH3OH at a flow rate of 
0.3 mL/min) in either the positive or negative ionization modes. The instrument was calibrated using 
the “Agilent Tuning Mix” with purine as the reference compound and the Hewlett–Packard standard 
HP0921. HRESILCMS was carried out on the same system and conditions using an Agilent Eclipse 
Plus C18 (4.6 × 150) 5-µ column using a solvent composition of 75% CH3CN/H2O at a flow rate of 
1 mL/min. All analytical HPLC analyses and method development were performed on a Dionex P680 
solvent delivery system equipped with a PDA100 UV detector (operated using “Chromeleon” 
software). Analytical HPLC analyses were carried out using either a gradient method 0–2 min 10% 
CH3CN/H2O; 14–24 min 75% CH3CN/H2O; 26–30 min 100% CH3CN; and 32–40 min 10% CH3CN/H2O 
or an isocratic method (either 100%, 95%, 90%, or 85% CH3CN/H2O) on an Alltech Alltima HP C18 
(250 × 4.6) 5-µ column at a flow rate of 1.0 mL/min. Semi-preparative HPLC was carried out on a 
Varian Prostar 210 solvent delivery system equipped with a Prostar 335 PDA detector (operated using 
“Star Workstation” software) using an isocratic method (either 100%, 95%, 90%, or 85% 
CH3CN/H2O) and an Alltech Alltima C18 (250 × 10) 5-µ column at a flow rate of 3.5 mL/min. 
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3.2. Biological Evaluation 
Crude extracts, enriched fractions, and compounds isolated from the marine alga, together with the 
standard antibiotic (ampicillin, Sigma-Aldrich, Castle Hill, Australia) and antifungal (carbendazim, 
Sigma-Aldrich, Castle Hill, Australia) compounds, were evaluated against six microorganisms (five 
bacteria and one fungus) at concentrations of 50, 25, or 1 mg/mL (see Table 5). Each microorganism 
was prepared by creating a 0.5 McFarlane solution suspension. Lawn cultures were prepared on either 
Mueller–Hinton or Brain Heart Infusion Agar (BHIA) (used for S. pyogenes). Then 20 µL of the crude 
extracts, enriched fractions, pure compounds or the standard compounds (ampicillin and carbendazim) 
were pipetted onto 6 mm diameter filter paper disks and their solvents evaporated. These disks were 
then placed onto the prepared lawn cultures and incubated at 37 °C overnight. Active antimicrobial 
samples displayed a zone of inhibition outside the disk, which was measured in mm as the radius of 
inhibition for each bacteria/fungi. The five test bacteria were Eschericha coli (ATCC 25922), 
Staphylococcus aureus (ATCC 25923), Staphylococcus aureus MRSA (344/2-32), Pseudomonas 
aeruginosa (ATCC 27853), and Streptococcus pyogenes (345/1). The test fungus was Candida 
albicans (ATCC 10231). 
3.3. Marine Alga Material 
The marine brown alga was collected by SCUBA at a depth of 3 m on 21 April 2010 from 
Governor Reef near Indented Head, Port Phillip Bay, Victoria, Australia and then stored at −80 °C. 
The alga was identified as Sargassum paradoxum (R. Brown ex Turner) Hooker and Harvey by Dr. 
Gerald Kraft (Honorary Principal Fellow), Faculty of Science, School of Botany, The University of 
Melbourne, Australia. A voucher specimen (designated the code number 2010–12) is deposited at the 
School of Applied Sciences (Discipline of Applied Chemistry), RMIT University. 
3.4. Chemical Profiling 
Chemical profiling was carried out on the dichloromethane soluble extract of the alga employing 
HPLC-NMR and HPLC-MS methodologies. Details of these analyses are provided in Section 3.1. The 
dichloromethane extract (77 mg) was dissolved in HPLC-NMR grade CH3CN (771 μL) and filtered 
through a 0.45 PTFE membrane filter (Grace Davison Discovery Sciences). 
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3.5. Extraction and Isolation 
The frozen marine alga (88 g, wet weight) was extracted with 3:1 methanol/dichloromethane (2 L). 
The crude extract was then decanted and concentrated under reduced pressure and sequentially solvent 
partitioned (triturated) into dichloromethane- and methanol-soluble extracts, respectively. 
Approximately 450 mg of the dichloromethane extract was subjected to flash silica gel column 
chromatography (20% stepwise elution from petroleum spirits (60–80 °C) to dichloromethane to ethyl 
acetate and finally to methanol). The 40% petroleum spirits/dichloromethane silica gel column fraction 
was subjected to reversed phase HPLC (100% CH3CN) to yield sargaquinone (13) (2.5 mg, 0.02%). 
The 80% dichloromethane/ethyl acetate silica gel fraction was subjected to reversed-phase HPLC 
(95% CH3CN/H2O) to yield paradoxquinone (15) and 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2, 
6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzoquinone (12) as an inseparable mixture (6.0 mg, 
0.04%), and sargaquinal (8) (3.0 mg, 0.02%). The 40% dichloromethane/ethyl acetate to 60% 
dichloromethane/ethyl acetate silica gel column fractions were combined and subjected to Sephadex 
LH-20 size exclusion column chromatography using 100% methanol. The third fraction resulting from 
this analysis was subjected to reversed phase HPLC (85% CH3CN/H2O) to yield fallaquinone (7) 
(1.3 mg, 0.01%) and paradoxquinol (10) (0.2 mg, 0.001%). The remaining half of the dichloromethane 
extract was purified separately using reversed-phase HPLC (90% CH3CN/H2O) to yield 
fallahydroquinone (1) (7.3 mg, 0.05%), sargahydroquinoic acid (2) (17.6 mg, 0.11%), 
paradoxhydroquinone (5) and 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-
yl]-6-methyl-1,4-benzenediol (6) as an inseparable mixture (6.5 mg, 0.04%), sargaquinoic acid (11) 
(13.1 mg, 0.08%), and 9-(6-hydroxy-2,8-dimethyl-2H-1-benzopyran-2-yl)-6-methyl-2-(4-methyl-3-
penten-1-yl)-2,6-nonadienal (14) (0.4 mg, 0.005%). The percentage yields are reported on the basis of 
the dry mass of the alga extracted (refer to the supporting information for details of the 
bioassay-guided isolation scheme adopted). 
3.6. On-Line (HPLC-NMR & HPLC-MS) Characterization of Compounds 
2-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzenediol (fallahydroquinone) (1): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, 
suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow 
mode (see Table 1); HRESILCMS m/z 427.2846 (calcd for C27H39O4, 427.2849). 
12-(2,5-Dihydroxy-3-methylphenyl)-6,10-dimethyl-2-(4-methyl-3-penten-1-yl)-(2Z,6E,10E)-2,6,10-
dodecatrienoic acid (sargahydroquinoic acid) (2): HPLC-NMR WET1D NMR (500 MHz, 75% 
CH3CN/D2O, suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm respectively) obtained from 
stop-flow mode (see Table 1); HRESILCMS m/z 425.2694 (calcd for C27H37O4, 425.2692). 
2-[12-Hydroxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol 
(paradoxhydroquinone) (5): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of 
HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow mode δ 7.26 (1H, 
d, J = 3.0, H-5), 7.22 (1H, d, J = 3.0, H-3), 6.11 (1H, t, J = 7.0, H-2′), 6.06 (1H, t, J = 7.0, H-10′), 5.96 (2H, 
m, H-6′/H-14′), 4.06 (2H, d, J = 7.0, H-1′), 3.30 (1H, dd, J = 7.0, 7.0, H-12′), 2.95–3.04 (m), 2.96 (3H, 
s, H-7), 2.94 (2H, m, H-5′/H-13′*), 2.53 (3H, s, H-18′), 2.49 (3H, s, H-17′), 2.42 (3H, s, H-16′), 2.41 (3H, s, 
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H-20′*), 2.37 (3H, s, H-19′*), ND (1-OH, 4-OH, 12′-OH) *signals interchangeable; HRESILCMS 
m/z 411.2899 (calcd for C27H39O3, 411.2899). 
2-[11-(Hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol 
(6): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t 
δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow mode δ 7.25 (1H, d, J = 3.0, H-5), 7.22 
(1H, d, J = 3.0, H-3), 6.10 (1H, t, J = 7.0, H-2′), 6.06 (1H, t, J = 7.5, H-10′), 5.95 (2H, m, H-6′/H-14′), 
4.84 (2H, s, H-20′), 4.05 (2H, d, J = 7.0, H-1′), 2.95–3.04 (m), 2.97 (3H, s, H-7), 2.95 (2H, m, H-9′), 
2.93 (2H, m, H-5′/H-13′*), 2.52 (3H, s, H-18′), 2.48 (3H, s, H-17′), 2.41 (6H, s, H-16′/H19′) ND (1-OH, 
4-OH, 20′-OH) *signals interchangeable; HRESILCMS m/z 411.2899 (calcd for C27H39O3, 411.2899). 
5-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzoquinone (fallaquinone) (7): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, 
suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow 
mode δ 7.42 (1H, bs, H-5), 7.28 (1H, bs, H-3), 6.30 (1H, t, J = 7.5, H-10′), 6.00 (1H, t, J = 7.0, H-2′), 
5.95 (1H, t, J = 6.5, H-6′), 5.91 (1H, t, J = 6.5, H-14′), 4.95 (1H, d, J = 12.0, H-20a′), 4.89 (1H, d, 
J = 12.5, H-20b′), 4.87 (1H, dd, J = 6.0, 7.0, H-12′), 3.93 (2H, d, J = 7.0, H-1′), 2.95–3.10 (m), 3.08 (2H, 
m, H-13′), 3.03 (2H, m, H-9′), 2.96 (2H, m, H-5′), 2.50 (3H, s, H-17′), 2.46 (3H, s, H-18′), 2.42 (6H, s, 
H-16′/H-19′) ND (12′-OH, 20′-OH); HRESILCMS m/z 425.2694 (calcd for C27H37O4, 425.2692). 
6,10-dimethyl-12-(5-methyl-3,6-dihydroxy-1,4-cyclohexadien-1-yl)-2-(4-methyl-3-pentenyl)-(2E, 
6E,10E)-2,6,10-dodecatrienal (sargahydroquinal) (9): UV (75% CH3CN/D2O) λmax 238, 292; 
HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 
4.64 and 2.82 ppm, respectively) obtained from stop-flow mode (see Table 2); HRESILCMS m/z 
409.2745 (calcd for C27H37O3, 409.2743). 
5-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-2,3-dimethyl-1, 
4-benzoquinone (paradoxquinol) (10): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, 
suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow 
mode δ 7.27 (1H, s, H-3), 6.29 (1H, t, J = 7.0, H-10′), 5.99 (1H, m, H-2′), 5.92 (2H, m, H-6′/H-14′), 
4.95 (1H, d, J = 12.0, H-20a′), 4.88 (1H, d, J = 13.0, H-20b′), 4.87 (1H, dd, J = 6.0, 7.5, H-12′), 3.92 
(2H, d, J = 7.5, H-1′), 2.95-3.10 (m), 2.49 (3H, s, H-18′), 2.45 (3H, s, H-17′), 2.41 (6H, s, H-16′/H-19′) ND 
(12′-OH, 20′-OH); HRESILCMS m/z 439.2850 (calcd for C28H39O4, 439.2849). 
6,10-Dimethyl-12-(5-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-2-(4-methyl-3-pentenyl)-(2Z,6E, 
10E)-2,6,10-dodecatrienoic acid (sargaquinoic acid) (11): HPLC-NMR WET1D NMR (500 MHz, 
75% CH3CN/D2O, suppression of HDO and CH3CN at t δH 4.64 and 2.82 ppm, respectively) obtained 
from stop-flow mode δ 7.42 (1H, d, J = 1.5, H-5), 7.28 (1H, d, J = 1.5, H-3), 6.69 (1H, t, J = 7.5, 
H-10′), 6.00 (1H, t, J = 7.0, H-2′), 5.95 (1H, t, J = 6.5, H-6′), 5.91 (1H, t, J = 6.5, H-14′), 3.93 (2H, d, 
J = 7.0, H1′), 3.31 (2H, dt, J = 7.5, 8.0, H-9′), 3.02 (2H, m, H-12′), 2.95–3.10 (m), 2.97 (2H, m, H-5′), 
2.49 (3H, s, H-17′), 2.46 (3H, s, H-18′), 2.41 (3H, s, H-19′), 2.40 (3H, s, H-16′) ND (20′-OH); 
HRESILCMS m/z 423.2542 (calcd for C27H35O4, 423.2536). 
2-[11-(Hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzoquinone 
(12): HPLC-NMR WET1D NMR (500 MHz, 75% CH3CN/D2O, suppression of HDO and CH3CN at 
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t δH 4.64 and 2.82 ppm, respectively) obtained from stop-flow mode δ 7.41 (1H, bs, H-5), 7.27 (1H, bs, 
H-3), 6.05 (1H, t, J = 7.5, H-10′), 6.00 (1H, t, J = 7.5, H-2′), 5.94 (2H, m, H-6′/H-14′), 4.84 (2H, s, 
H-20′), 3.93 (2H, d, J = 7.5, H1′), 2.95–3.10 (m), 2.49 (3H, s, H-17′), 2.46 (3H, s, H-18′), 2.41 (6H, s, 
H-16′/H-19′) ND (20′-OH); HRESILCMS m/z 409.2742 (calcd for C27H37O3, 409.2743). 
3.7. Off-Line Characterization of Compounds 
(2′E,6′E,10′Z)-2-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-
yl]-6-methyl-1,4-benzenediol (fallahydroquinone) (1): unstable yellow oil; [α] 25
𝐷
 +45.1 (c 0.035, 
CHCl3); CD (EtOH) λmax (Δε) 202 (+6.1), 221 (+1.6), 224 (1.8), 243 (−0.2), 260 (+2.0), 275 (+0.5), 
290 (+0.6); UV (EtOH) λmax (log ε) 252 (3.60), 288 (3.58); IR νmax 3391, 2925, 2855, 1652, 1607, 
1470, 1381, 1197, 1037 cm−1. All off-line NMR spectroscopic and mass spectrometric data were 
identical to those reported in the literature; however, some carbon and proton NMR chemical shift 
reassignments have been made [7]. 
(2′E,6′E,10′Z)-12-(2,5-Dihydroxy-3-methylphenyl)-6,10-dimethyl-2-(4-methyl-3-penten-1-yl)-2,6,10-
dodecatrienoic acid (sargahydroquinoic acid) (2): yellow oil which darkened with time. All off-line 
NMR spectroscopic and mass spectrometric data were identical to those reported in the literature [7,8]. 
(2′E,6′E,10′Z)-2-[12-Hydroxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzenediol (paradoxhydroquinone) (5): dark yellow oil; 1H and 13C NMR (500 MHz, CDCl3) (see 
Table 3); ESIMS m/z 411 [M − H]−; HRESIMS m/z 411.2898 (calcd for C27H39O3, 411.2899). 
(2′E,6′E,10′Z)-2-[11-(Hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzenediol (6): dark yellow oil. All off-line NMR spectroscopic and mass spectrometric data were 
identical to those reported in the literature [16]. Acquisition of the 1D and 2D NMR data has resulted 
in the first complete assignment of this compound and is provided in the supporting information. 
(2′E,6′E,10′Z)-5-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-
6-methyl-1,4-benzoquinone (fallaquinone) (7): unstable yellow oil which darkened with time; 
[α] 25
𝐷
 +31.4 (c 0.065, CHCl3); CD (EtOH) λmax (Δε) 206 (+1.8), 220 (+1.0), 238 (+2.1), 247 (+2.3), 262 
(+1.6), 270 (+1.9), 286 (+0.1), 294 (+0.3); UV (EtOH) λmax (log ε) 254 (4.10); IR νmax 3392, 2924, 
2855, 1652, 1614, 1510, 1436, 1378, 1295, 1195, 1156 cm−1. All off-line NMR spectroscopic and 
mass spectrometric data were identical to those reported in the literature [7]. 
(2′E,6′E,10′Z)-6,10-Dimethyl-12-(5-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-2-(4-methyl-3-
pentenyl)-2,6,10-dodecatrienal (sargaquinal) (8): yellow oil which darkened with time; 1H NMR 
(500 MHz, CDCl3) δ 9.34 (1H, s, H-20′), 6.54 (1H, bs, H-5), 6.45 (1H, bs, H-3), 6.43 (1H, t, J = 7.5, 
H-10′), 5.15 (2H, t, J = 7.5, H-2′, H-6′), 5.09 (1H, m, H-14′), 3.12 (2H, d, J = 7.5, H1′), 2.45 (2H, dt, 
J = 7.0, 7.5, H-9′), 2.26 (2H, t, J = 7.5 Hz, H-12′), 2.17 (2H, m, H-8′), 2.14 (2H, m, H-5′), 2.07 (2H, m, 
H-4′), 2.06 (3H, s, H-7), 2.03 (2H, m, H-13′), 1.66 (3H, s, H-16′), 1.63 (3H, s, H-18′), 1.62 (3H, s, 
H-19′), 1.57 (3H, s, H-17′); 13C NMR (125 MHz, CDCl3) δ 195.2 (CH, C-20′), 188.0 (C, C-1, C-4), 
155.0 (CH, C-10′), 148.4 (C, C-2), 146.0 (C, C-6), 143.2 (C, C-11′), 139.7 (C, C-3′), 133.9 (C, C-7′), 133.2 
(CH, C-5), 132.4 (C, C-15′), 132.2 (CH, C-3), 125.1 (CH, C-6′), 123.6 (CH, C-14′), 118.2 (CH, C-2′), 
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39.5 (CH2, C-4′), 38.3 (CH2, C-8′), 27.5 (CH2, C-1′), 27.4 (CH2, C-9′), 27.0 (CH2, C-13′), 26.4 (CH2, 
C-5′), 25.7 (CH3, C-16′), 24.3 (CH2, C-12′), 17.7 (CH3, C-17′), 16.0 (CH3, C-7, C-18′, C-19′). 
(2′E,6′E,10′Z)-5-[12S-Hydroxy-11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-
2,3-dimethyl-1,4-benzoquinone (paradoxquinol) (10): unstable yellow oil which darkened with time; 
[α] 25
𝐷
 +48.5 (c 0.0125, CHCl3); CD (EtOH) λmax (Δε) 218 (+6.2), 220 (+6.4), 235 (−4.2), 245 (+2.4), 
255 (+1.2); UV (EtOH) λmax (log ε) 232 (4.17), 254 (4.32); IR νmax 3401, 2924, 2853, 1652, 1511, 
1456, 1249 cm−1; 1H and 13C NMR (500 MHz, CDCl3) (see Table 4); ESIMS m/z 439 [M − H]−; 
HRESIMS m/z 439.2850 (calcd for C28H39O4, 439.2849). 
(2′E,6′E,10′Z)-6,10-Dimethyl-12-(5-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-2-(4-methyl-3-
pentenyl)-2,6,10-dodecatrienoic acid (sargaquinoic acid) (11): yellow oil which darkened with time. 
All off-line NMR spectroscopic and mass spectrometric data were identical to those reported in the 
literature [7,17]. 
(2′E,6′E,10′Z)-2-[11-(Hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-
1,4-benzoquinone (12): dark yellow oil. All off-line NMR spectroscopic and mass spectrometric data 
were identical to those reported in the literature [16,17]. Acquisition of the 1D and 2D NMR data has 
resulted in the first complete assignment of this compound and is provided in the supporting information. 
(2′E,6′E,10′Z)-2-Methyl-6-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl)-1,4-benzoquinone 
(sargaquinone) (13): dark yellow oil. All off-line NMR spectroscopic and mass spectrometric data 
were identical to those reported in the literature; however, some carbon NMR chemical shift 
reassignments have been made [18]. 
(3′E,7′Z)-9-(6-Hydroxy-2,8-dimethyl-2H-1-benzopyran-2-yl)-6-methyl-2-(4-methyl-3-penten-1-yl)-2, 
6-nonadienal (14): dark yellow oil; UV (90% CH3CN/H2O) λmax 232, 273s, 334; IR νmax 3351, 2961, 
2925, 2853, 2718, 1725, 1684, 1640, 1610, 1508, 1456, 1376, 1250 cm−1. All off-line NMR spectroscopic 
and mass spectrometric data were identical to those reported in the literature [19]. 
(2′E,6′E,10′Z)-2-[12-Hydroxy-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzoquinone (paradoxquinone) (15): yellow oil which darkened with time; 1H and 13C NMR 
(500 MHz, CDCl3) (see Table 4); ESIMS m/z 409 [M − H]−; HRESIMS m/z 409.2755 (calcd for 
C27H37O3, 409.2743). 
4. Conclusions
The study of the marine brown alga S. paradoxum successfully implemented the use of HPLC-NMR 
and HPLC-MS, in combination with the use of databases, to rapidly dereplicate, identify, and deduce 
the structures of nine meroditerpenoids (1, 2, 5–7, and 9–12). In particular, chemical profiling was an 
invaluable tool for the on-line identification of sargahydroquinal (9), which rapidly degraded when an 
off-line bioassay-guided isolation was employed, as well as for the meroditerpenoids 5, 6, and 12, 
which could be resolved and identified as individual components via stop-flow HPLC-NMR. This 
study reports, for the first time, the complete 1D and 2D NMR characterization and identification of 
two known (1 and 2) natural products via stop-flow HPLC-NMR and HPLC-MS. The bioassay-guided 
isolation approach confirmed the identity of the compounds responsible for the dichloromethane crude 
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extract antimicrobial activity. Subsequent biological evaluation of the isolated meroditerpenoids 
indicated that there were no significant differences in antimicrobial activity for 11 of the 
meroditerpenoids isolated. Off-line bioassay-guided isolation also permitted the first complete NMR 
characterization of 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1, 
4-benzenediol (6) and 2-[11-(hydroxymethyl)-3,7,15-trimethyl-2,6,10,14-hexadecatetraen-1-yl]-6-
methyl-1,4-benzoquinone (12) to be carried out. It is proposed that the presence of fallahydroquinone (1) 
and fallaquinone (7) could be used as potential chemotaxonomic markers for both S. paradoxum and 
S. fallax, which have only been reported from these two species of Sargassum. 
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CHAPTER 10 
Dereplication and Structural Identification Studies of Marine Algae 
of the Genus Cystophora 
 
 
Kingdom: Chromista, Phylum: Ochrophyta, Class: Phaeophyceae, Order: Fucales, Family: 
Sargassaceae 
Genus: Cystophora 
Species: monilifera 
 
 
Genus: Cystophora 
Species: subfarcinata 
 
Chapter 10 describes the dereplication and structural identification studies of two 
marine algae of the Cystophora genus. This work has been published in Phytochemistry. 
Appendix F contains supplementary information relevant to this study.  
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Brkljača, Robert, & Urban, Sylvia. (2015). HPLC-NMR and HPLC-MS investigation of 
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The crude dichloromethane extracts of the marine brown algae Cystophora monilifera and Cystophora
subfarcinata were subjected to phytochemical profiling. This enabled the structures of both new and
known phloroglucinols to be dereplicated and proposed using HPLC–NMR and HPLC–MS. Subsequent
isolation confirmed the presence of four new and eight previously reported compounds. Five of the
isolated phloroglucinols displayed selective antimicrobial activity.
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Marine brown algae of the Cystophora genus are comprised of
28 known species (Guiry and Guiry, 2015) and phytochemical
studies have been carried out on approximately 14 of these species
(MarinLit Database, 2015). Brown algae are known to produce
phlorotannins or phloroglucinols which display various biological
properties including antioxidant, anticancer, antidiabetic, anti-
inflammatory and antimicrobial activities (Ryu and Kim, 2013).
Only recently, seven new phloroglucinol and phlorotannins were
reported which display a variety of biological activities including
radical scavenging activity and antioxidant activities (Blunt et al.,
2014). Of these compounds one was identified as a potential
antidiabetic lead compound (Blunt et al., 2014).
To date, two separate reports have described the chemistry of
Cystophora monilifera and Cystophora subfarcinata respectively.
These include the discovery of two new phloroglucinols
(Kazlauskas et al., 1981) from C. monilifera and a phloroglucinol
and a tocotrienol (Laird et al., 2010) from C. subfarcinata, respec-
tively. As part of our on-going efforts to evaluate the chemistry
and biological activity of southern Australian marine algae, we
examined the crude extracts of the marine brown algae C. monilif-
era J. Agardh and C. subfarcinata (Mertens) J. Agardh. These studies
were motivated by the fact that these species of Cystophora havenot been extensively studied. This resulted in the identification
of four new (8, 9, 11 and 12) and six known phloroglucinols (1–
6) together with two previously described tocotrienols (7 and
10). Compounds 4–9 and 11 were present in both of the crude
extracts of the marine algae specimens studied.2. Results and discussion
The marine algae (C. monilifera and C. subfarcinata) were
extracted with 3:1 methanol/dichloromethane, evaporated under
reduced pressure, and sequentially solvent partitioned (triturated)
into dichloromethane and methanol soluble fractions respectively.
The dichloromethane crude extract of C. monilifera displayed
greater antimicrobial activity than the corresponding methanol
extract, and so was selected for further analysis. The 3:1 metha-
nol/dichloromethane extract of C. subfarcinata displayed selective
antimicrobial activity, however it was not further established
which of the dichloromethane or methanol crude extracts dis-
played greater activity. Subsequent off-line analytical HPLC and
1H NMR analyses on the dichloromethane and methanol extracts
of C. subfarcinata indicated that the dichloromethane extract con-
tained a greater diversity and range of compounds. Since the
antimicrobial activity of the dichloromethane extract of C. monilif-
era was greater, this was also presumed to be the case for the
dichloromethane crude extract of C. subfarcinata and on this basis
was selected for phytochemical evaluation.
R. Brkljacˇa, S. Urban / Phytochemistry 117 (2015) 200–2082.1. Chemical profiling (HPLC–NMR & HPLC–MS)
Dereplication of the components present in the dichloro-
methane crude extracts of C. monilifera and C. subfarcinata was
achieved using HPLC–NMR & HPLC–MS in conjunction with data-
base searching. Examination of the UV profiles extracted (see
Supporting file) for each of the components (Fig. 1) detected by
PDA showed the presence of a distinct UV chromophore at
280 nm supporting the presence of phloroglucinols (Scott, 1964)
and another chromophore at 300 nm supporting the presence of
tocotrienols (MarinLit Database, 2015). Both of these structural
classes are known to occur within the Cystophora genus (MarinLit
Database, 2015). The dichloromethane crude extract of C. monilif-
era and C. subfarcinata showed the presence of seven peaks (A–G)
and six peaks (D–F, H–J) respectively (Fig. 1). This represented a
total of ten different compounds (peaks A–J) being detected, three
of which were found to co-occur in the dichloromethane crude
extracts of the two algae (peaks D–F).
Seven of the peaks (A–E, I and J) (Fig. 1) present in the dichlor-
omethane crude extracts of C. monilifera and C. subfarcinata
could be identified as the previously reported phloroglucinols
9-hydroxy-1-(2,4,6-trihydroxyphenyl)-6Z,10E,12Z,15Z-octadecate-
traen-1-one (1) (Kazlauskas et al., 1981), 15-hydroxy-1-(2,4,
6-trihydroxyphenyl)-5Z,8Z,11Z,13E,17Z-eicosapentaen-1-one (2)
(Amico et al., 1982), 9-hydroxy-1-(2,6-dihydroxy-4-methoxyphe-
nyl)-6Z,10Z,12Z,15Z-octadecatetraen-1-one (3) (Kazlauskas et al.,
1981), 1-(2,4,6-trihydroxyphenyl)-6Z,9Z,12Z,15Z-octadecatetraen-
1-one (4) (Kazlauskas et al., 1981), 1-(2,4,6-trihydroxyphenyl)-
5Z,8Z,11Z,14Z,17Z-eicosapentaen-1-one (5) (Amico et al., 1981),Fig. 1. (A) On-flow HPLC–NMR 2D contour plot (500 MHz, 70% CH3CN/D2O) of the dichlor
(500 MHz, 75% CH3CN/D2O) of the dichloromethane crude extract of C. subfarcinata
components (D–F) occurring in both crude dichloromethane extracts.
Page 141-(2,6-dihydroxy-4-methoxyphenyl)-6Z,9Z,12Z,15Z-octadecate-
traen-1-one (6) (Gregson et al., 1977), and d-tocotrienol (7)
(Ohnmacht et al., 2008) respectively (Fig. 2). The identities of these
peaks could be dereplicated based on examination of a combina-
tion of the NMR spectra obtained via stop-flow HPLC–NMR
(WET1D proton, gCOSY, gHSQCAD, gHMBCAD NMR data), the
molecular formula identified from the high-resolution HPLC–MS
data, the UV absorbances and taxonomy, in conjunction with the
use of the MarinLit or SciFinder databases. In addition to these
known compounds, three new phloroglucinols (peaks F, G and H)
were likely based on the unique masses established by high-
resolution HPLC–MS and the proton NMR data obtained via
HPLC–NMR, which did not correspond to any of the known
phloroglucinols.
In the dichloromethane crude extract of C. monilifera, peaks F
and G co-eluted, which made it difficult to interpret the NMR data.
However, in the dichloromethane crude extract of C. subfarcinata,
peak F (compound 8) was also present, and importantly, it did
not co-elute with any other secondary metabolite. High resolution
HPLC–MS yielded a molecular formula of C24H34O4 for 8 (observed
385.2384 [MH], calcd for C24H33O4, 385.2384). Stop-flow HPLC–
NMR enabled for WET1D proton, gCOSY, 1D TOCSY and partial
HSQCAD NMR data to be obtained. A diagnostic methylene at dH
3.90 was observed which corresponds to the methylene adjacent
to the ketone functionality. The gCOSY NMR data was able to
secure the spin system and connectivity from this methylene at
position H-2 through to H-4. The proton at H-4 (dH 2.26, pentet)
did not show any gCOSY NMR correlations, however the multiplic-
ity of this signal indicated the presence of an additional methyleneomethane crude extract of C. monilifera and (B) On-flow HPLC–NMR 2D contour plot
illustrating the presence of ten different chemical components (A–J) and three
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Fig. 2. Structures of the phloroglucinols and tocotrienols identified in C. monilifera and C. subfarcinata.
R. Brkljacˇa, S. Urban / Phytochemistry 117 (2015) 200–208group at position 5. To confirm the connectivity from H-4, a 1D
TOCSY was acquired whereby excitation of the proton at H-2
showed a transfer of magnetization to H-3 and H-4, and four other
protons. A transfer of magnetization to dH 2.99 was observed,
which corresponds to the methylene at position H-5. This particu-
lar signal occurs close to the suppression region of the acetonitrile
signal, which explains why a correlation between H-4 and H-5 was
not observed in the gCOSY NMR spectrum obtained via HPLC–
NMR. The proton at H-2 also showed a transfer of magnetization
to the olefinic protons at dH 6.20, confirming the double bond
placement at C-6/C-7. Lastly, a transfer of magnetization was
observed to another methylene at dH 3.66 which was assigned to
position H-8. The HSQCAD NMR spectrum indicated that the
methylene at dH 3.66 was associated with a carbon at dC 26.2,
which is diagnostic of a methylene located between two double
bonds, as in the case of the phloroglucinols (Amico et al., 1981,
1982; Blackman et al., 1988; Gerwick and Fenical, 1982; Gregson
et al., 1977; Kazlauskas et al., 1981), and that each of the three
double bonds in 8 are separated by one methylene group. These
features allowed the structure for 8 to be proposed as 1-(2,4,6-tri-
hydroxyphenyl)-octadeca-6Z,9Z,12Z-trien-1-one, attributed the
trivial name moniliferanone A. No structure could be proposed
for peak G due to the limited NMR data that could be obtained
via HPLC–NMR, but based on the similarity of the NMR and mass
spectrometric data, it was known to represent a structural isomer.
Similarly, peak H displayed characteristic phloroglucinol signals
(dH 6.72, s, (2H); 6.27–6.20, m (8H); 3.90, t, (2H); 3.67, m (6H)) in
the on-flow HPLC–NMR analysis and stop-flow HPLC–NMR
allowed for the acquisition of WET1D proton and gCOSY NMR data.
Analysis of the gCOSY NMR spectrum allowed for the spin systemPage between H-2 and H-5 to be secured. Analysis of the high resolution
HPLC–MS of 9 yielded the molecular formula C26H36O4 (observed
411.2540 [MH], calcd for C26H35O4, 411.2541) which supported
nine degrees of unsaturation, four of which were attributed to the
olefinic bonds (dH 6.27 (1H), 6.21 (8H)) in the side chain and
the remaining five due to the aromatic ring. Examination of the
gCOSY NMR data indicated that the first double bond was located
at C-5/C-6, and the diagnostic methylene at dH 3.67 confirmed that
each of the four double bonds was separated by a single methylene
group. This allowed for the identity of 9 to be proposed as 1-(2,4,6-
trihydroxyphenyl)-eicosa-5Z,8Z,11Z,14Z-tetraen-1-one, attributed
the trivial name moniliferanone B.
2.2. Off-line isolation of C. monilifera and C. subfarcinata
dichloromethane crude extract secondary metabolites
An off-line isolation approach was carried out on the dichloro-
methane crude extracts of C. monilifera and C. subfarcinata to estab-
lish which compounds were responsible for the antimicrobial
activity and to confirm the structures of the suspected new
phloroglucinols identified by phytochemical profiling. This yielded
eleven compounds (1, 2, 4–12) of which compounds 1, 2, 4–12
were isolated from C. monilifera and compounds 4–9 and 11 were
isolated from C. subfarcinata.
Of the eleven compounds isolated in the off-line isolation study,
seven have been previously reported (1, 2, 4–7, and 10) while four
are new (8, 9, 11 and 12). Compound 3 was not isolated in the off-
line studies. In addition five of the previously reported phloroglu-
cinols (1, 2, 4–6) have been completely characterized by 2D NMR
for the first time, which resulted in carbon chemical shift149
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shift revisions are reported for 2.
All of the off-line NMR and MS data for the known compounds 1
(Kazlauskas et al., 1981), 2 (Amico et al., 1982), 4 (Kazlauskas et al.,
1981), 5 (Gerwick and Fenical, 1982), 6 (Gregson et al., 1977), 7
(Ohnmacht et al., 2008), and 10 (Ohnmacht et al., 2008) was in
accordance with that reported in the literature.
Analysis of the 1D and 2D NMR data of compound 2 led to a car-
bon chemical shift revision. Previously, the carbons at positions
C-3 and C-4 had been reported as dC 27.0 and 24.8 respectively
(Amico et al., 1982), but these carbon assignments have now been
revised and should be reversed.
Moniliferanone A (8) corresponding to peak F in the chemical
profiling, was obtained from C. monilifera and C. subfarcinata. The
structure as proposed for 8 by chemical profiling was confirmed
by off-line analysis (Table 1) and the position of the double bonds
was confirmed by correlations observed in the gHMBC NMR spec-
trum. Moniliferanone A (8) was obtained in an inseparable mixture
with moniliferanone C (11), however identification was possible
because the HPLC–NMR data could be obtained separately for
moniliferanone A (8) from the crude extract of C. subfarcinata since
it did not co-occur as a mixture with 11.
Moniliferanone B (9), corresponding to peak H in the
chemical profiling, was isolated as an oil from C. monilifera and
C. subfarcinata. The structure proposed for 9 by chemical profiling
was confirmed by the off-line analysis (Table 1).
Moniliferanone C (11), corresponding to peak G from the photo-
chemical profiling (Fig. 1), was isolated as an oil in a mixture with
moniliferanone A (8) from C. monilifera (in a ratio of approximately
0.45–1) and C. subfarcinata (in a ratio of 0.25–1). Identification of
moniliferanone C (11) within the mixture was made possible since
HPLC–NMR provided the ability to resolve and therefore assign the
signals belonging solely to moniliferanone A (8). The triplet methylTable 1
NMR data (500 MHz, CDCl3) for moniliferanone A (8) and B (9).
Position Moniliferanone A (8)
dC
a
, type dH (J in Hz) gCOSY gHMBC
1 205.9, C
2 43.8, CH2 3.11, t (7.5) 3 1, 3, 4
3 24.4, CH2 1.72, m 2, 4 4
4 29.5, CH2 1.46, m 3, 5 3, 6
5 27.2, CH2 2.12, dt (7.5, 7.5) 4, 6 3, 4, 6, 7
6 130.0, CH 5.41, m 5
7 128.0, CH 5.37, m 8 8, 9
8 25.6, CH2 2.82, m 7, 9 7, 9
9 128.1, CH 5.37, m 8 8, 10, 11
10 128.1, CH 5.37, m 11 8, 9, 11
11 25.6, CH2 2.82, m 10, 12 10
12 127.7, CH 5.37, m 11 11
13 130.5, CH 5.39, m
14 27.2, CH2 2.06, dt (7.5, 7.5) 13, 15 12, 13, 15,
15 29.5, CH2 1.34, m 14 13, 14
16 31.5, CH2 1.29, m
17 22.6, CH2 1.30, m 18 16
18 14.1, CH3 0.89, t (7.0) 17 16, 17
19
20
10 104.8, C
20 161.0, C
30 95.5, CH 5.90, bs 10 , 40 , 50
40 163.4, C
50 95.5, CH 5.90, bs 10 , 30 , 40
60 161.0, C
20-OH 13.47, bs
40-OH 13.49, bs
60-OH 13.47, bs
a Carbon assignment based on gHSQCAD and gHMBC NMR experiments.
b Indicates signal not detected.
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chain terminating with an ethyl group, as in the case of compounds
1, 2, 4–6 (Amico et al., 1982; Gerwick and Fenical, 1982;
Kazlauskas et al., 1981; Wisespongpand and Kuniyoshi, 2003).
Subsequent interpretation of the gHMBC NMR spectrum of 11 indi-
cated that the triplet methyl (dH 0.98) displayed correlations to two
carbons, dC 132.0 and 20.6 (C-16 and C-17 respectively). The
deshielded methylene (dH 2.82; dC 25.6) is diagnostic of a methy-
lene between two double bonds, confirming that the double bonds
are sequential in their placement. The positions of the remaining
double bonds were confirmed to occur at C-9/10, C-12/13 and C-
15/16. Complete analysis of the NMR data allowed the compound
to be deduced as 1-(2,4,6-trihydroxyphenyl)-octadeca-9Z,12Z,15Z-
trien-1-one (11), which has been attributed the trivial namemonil-
iferanone B. During the phytochemical profiling of C. monilifera,
moniliferanone A (8) was detected with moniliferanone C (11) in
a ratio of 1–0.50. This relative ratio is consistent with the ratio
obtained for the mixture of 8 and 11 when isolated off-line.
However, in the phytochemical profiling C. subfarcinata, monilifer-
anone A (8) was detected with moniliferanone C (11) in a ratio of
1–0.07. This supported the fact that 11was essentially absent from
the crude extract of C. subfarcinata. The ratios suggest that in the
time it took to extract and analyze the C. monilifera crude extract
by HPLC–NMR, moniliferanone A (8) and C (11) had sufficient time
to form an equilibrium mixture. However, in the case of C. subfar-
cinata, the relative proportions of moniliferanone A (8) and C (11)
changed dramatically between the time it took to complete the
chemical profiling by HPLC–NMR and the off-line isolation. For this
reason it is suspected that moniliferanone C (11) may represent an
artifact arising from a double bond migration.
Moniliferanone D (12) was isolated from C. monilifera and C.
subfarcinata as an oil. A molecular formula of C22H32O4 was deter-
mined by HRESIMS (359.2221 [MH] (calcd for C22H31O4,Moniliferanone B (9)
dC
a
, type dH (J in Hz) gCOSY gHMBC
205.9, C
43.6, CH2 3.13, t (7.5) 3 1, 3
24.8, CH2 1.78, m 2, 4 1, 2, 4, 5
27.2, CH2 2.18, dt (7.0, 7.0) 3, 5 2, 3, 5, 6
130.0, CH 5.44, m 4
128.2, CH 5.37, m 7 7
25.9, CH2 2.83, m 6, 8 8, 9
128.6, CH 5.37, m 7 7, 10
128.6, CH 5.37, m 10 7, 10
25.9, CH2 2.83, m 9, 11 8, 9, 11, 12
128.6, CH 5.37, m 10 10, 13
128.6, CH 5.37, m 13 10, 13
25.9, CH2 2.83, m 12, 14 11, 12
16 128.1, CH 5.37, m 13 13
130.8, CH 5.40, m 16
27.5, CH2 2.05, dt (7.0, 7.0) 15, 17 14, 15, 17
29.6, CH2 1.34, m 16
31.8, CH2 1.27, m
22.9, CH2 1.29, m 20 18
14.3, CH3 0.89, t (6.5) 19 18, 19
105.0, C
NDb
95.7, CH 5.91, s 10
NDb
95.7, CH 5.91, s 10
NDb
12.00, bs
12.00, bs
12.00, bs
0
Table 2
NMR data (500 MHz, CDCl3) for moniliferanone C (11) and moniliferanone D (12).
Position Moniliferanone C (11) Moniliferanone D (12)
dC
a
, type dH (J in Hz) gCOSY gHMBC dCa, type dH (J in Hz) gCOSY gHMBC
1 205.9, C 206.0, C
2 43.8, CH2 3.09, t (7.5) 1.72 1, 3, 4 43.8, CH2 3.13, t (7.5) 3 1, 3
3 24.4, CH2 1.72, m 3.11, 1.46 4 24.5, CH2 1.73, m 2, 4
4 29.5, CH2 1.48, m 1.72, 1.36 3 29.5, CH2 1.45, tt (7.0, 8.0) 3, 5
5 29.4, CH2 1.36, m 27.2, CH2 2.12, dt (7.0, 7.5) 4, 6 3, 4, 6, 7
6 29.4, CH2 1.36, m 130.2, CH 5.39, m 5
7 29.4, CH2 1.36, m 6 128.2, CH 5.36, m
8 27.2, CH2 2.12, dt (7.5, 7.5) 5.41, 1.46 7, 9, 10 25.6, CH2 2.79, dd (6.0, 7.5) 7 7, 10
9 130.0, CH 5.41, m 2.12 128.2, CH 5.36, m
10 128.1, CH 5.37, m 2.82 11, 12 130.2, CH 5.39, m 11
11 25.6, CH2 2.82, m 5.37 10, 12, 13 27.2, CH2 2.04, dt (6.5, 7.0) 10, 12 9, 10, 12
12 128.1, CH 5.37, m 2.82 10, 11, 13, 14 29.4, CH2 1.29, m 11
13 128.1, CH 5.37, m 2.82 11, 12, 14, 15 29.4, CH2 1.29, m
14 25.6, CH2 2.82, m 5.37 12, 13, 15 31.6, CH2 1.26, m
15 128.1, CH 5.37, m 2.82 13, 14 22.6, CH2 1.29, m 16 14
16 132.0, CH 5.40, m 2.09 14.1, CH3 0.87, m 15 14, 15
17 20.6, CH2 2.09, m 0.98, 5.40
18 14.3, CH3 0.98, t (7.5) 2.09 16, 17
10 104.8, C NDb
20 161.0, C NDb
30 95.5, CH 5.90, bs 10 , 40 , 50 95.4, CH 5.92, bs
40 163.4, C NDb
50 95.5, CH 5.90, bs 10 , 30 , 40 95.4, CH 5.92, bs
60 161.0, C NDb
20-OH 13.47, bs NDb
40-OH 13.49, bs NDb
60-OH 13.47, bs NDb
a Carbon assignment based on gHSQCAD and gHMBC NMR experiments.
b Indicates signal not detected.
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that only two double bonds (dH 5.39, 5.36; 4H) were present. The
side chain for moniferanone D (12) was also shorter than that
observed for moniliferanone C (11), consisting of a total of 16 car-
bons. Analysis of the gCOSY NMR correlations was vital in position-
ing the double bonds. The spin system from H-2 to H-6 could be
secured and allowed placement of the double bonds at positions
C-6/7 and C-9/10 respectively. Complete analysis of the NMR data
(Table 2) allowed for the identity to be deduced as 1-(2,4,6-trihy-
droxyphenyl)-hexadeca-6Z,9Z-tetraen-1-one (12), attributed the
trivial name moniliferanone D.
The configuration of the double bonds for each of the com-
pounds isolated was determined by comparison to literature data,
if available, and by consideration of 1H NMR and IR data. The
absence of significant absorptions between 800 and 900 cm1 in
the IR spectrum, is supportive of a Z double bond configuration
(Gerwick and Fenical, 1982). In addition Z double bond geometries
show a narrow multiplet for the chemical shift corresponding to
the olefinic proton signals (Kazlauskas et al., 1981). Also methyle-
nes adjacent to the double bonds display carbon chemical shifts in
the region dC 25–26 ppm, which is typical of methylenes shielded
by two cis-double bonds (Amico et al., 1982). The E double bond
geometries were concluded on the basis of 1H NMR coupling con-
stants. The absolute configuration of the secondary alcohol in 1 and
2 remains undefined, since these compounds underwent rapid
degradation and no specific rotations could be obtained prior to
their decomposition. The absolute configuration of the secondary
alcohol compound 3, which was not isolated by the off-line
approach, also remains unassigned. All naturally occurring toco-
trienols reported to date display an R configuration at the stere-
ogenic centre at position 2 (Drotleff and Ternes, 1999, 2001). On
this basis the absolute configuration of the single stereogenic cen-
tre in d-tocotrienol (7) and c-tocotrienol (10) was concluded to
most likely be R, and the measured specific rotation of d-to-
cotrienol (7) was in agreement with that reported in the literaturePage (Couladouros et al., 2007). This would represent the first report of
R-c-tocotrienol (10) being isolated from a marine source.2.3. Biological activity studies
All eleven of the compounds isolated in the off-line phytochem-
ical profiling of C. monilifera and C. subfarcinata were assessed for
antimicrobial activity against nine organisms. The isolated com-
pounds (1, 2, 4–12), together with a commercially available
antibacterial and antifungal agent, were tested at 1 mg/mL and
all displayed varying degrees of zones of inhibition in the antimi-
crobial assays (Table 3).
Biological activities have been previously reported for 2, 4 and
6, which have been shown to inhibit the growth of Bacillus subtilis
and Staphylococcus aureus (Gerwick and Fenical, 1982;
Wisespongpand and Kuniyoshi, 2003). R-d-Tocotrienol (7) and R-
c-tocotrienol (10) display broad biological activities including the
ability to induce cell cycle arrest and apoptosis in various cells such
as adipocytes, colon carcinoma, pancreatic cancer and lung cancer
(Hodul et al., 2013; Ji et al., 2011; Wu et al., 2013; Zhang et al.,
2013).
Five of the phloroglucinols (1, 4, 6, 9 and 12) isolated displayed
selective antibacterial properties, against both gram positive and
gram negative bacteria. Four of the compounds (1, 4, 9 and 12) only
showed activity against Streptococcus pyogenes, which is responsi-
ble for various ear, eye and sinus infections, along with septic
arthritis (Ryan and Ray, 2010). Compound 6 inhibited the growth
of both gram positive and gram negative bacteria, such as S. aureus
and Pseudomonas aeruginosa. Interest in obtaining drug leads to
target P. aeruginosa has increased because of the prevalence and
multidrug resistance this micro-organism has shown (Master
et al., 2011). All of the active phloroglucinols (1, 4, 6, 9 and 12)
were noticeably less active than a commercially available antibac-
terial agent (ampicillin).151
Table 3
Antimicrobial activity of the crude extracts and pure compounds obtained from C. monilifera and C. subfarcinata, together with commercial standard antibacterial and antifungal
compounds, showing zones of inhibition (mm).
Microorganism E. coli
ATCC
25922
S. aureus
ATCC
25923
S. aureus
MRSA
344/2-32
P. aeruginosa
ATCC
27853
S. pyogenes
345/1
B. subtilis
ATCC
19659
C. albicans
ATCC
10231
or 14053*
T. mentagrophytes
ATCC 28185
C. resinae
Concentration
(mg/mL)
Dichloromethane extract
of C. monilifera
50 NDa 1 2 NDa 6 NTb NDa NTb NTb
Methanol extract of C. monilifera 50 NDa NDa NDa NDa NDa NTb NDa NTb NTb
3:1 MeOH/DCM extract of
C. subfarcinata
50 NDa NTb NTb 1 NTb NDa NDa* 3 NDa
Compound 1 1 NDa NDa NDa NDa 1 NTb NDa NTb NTb
Compound 2 1 NDa NDa NDa NDa NDa NTb NDa NTb NTb
Compound 4 1 NDa NDa NDa NDa 1 NTb NDa NTb NTb
Compound 5 1 NDa NDa NDa NDa NDa NTb NDa NTb NTb
Compound 6 1 NDa 1 NDa 1 NDa NTb NDa NTb NTb
R-d-Tocotrienol (7) 1 NDa NDa NDa NDa NDa NTb NDa NTb NTb
Mixture of moniliferanone
A (8) and C (11)
1 NDa NDa NDa NDa NDa NTb NDa NTb NTb
Moniliferanone B (9) 1 NDa NDa NDa NDa 1 NTb NDa NTb NTb
R-c-Tocotrienol (10) 1 NDa NDa NDa NDa NDa NTb NDa NTb NTb
Moniliferanone D (12) 1 NDa NDa NDa NDa 1 NTb NDa NTb NTb
Ampicillin (antibacterial) 1 NDa 15 3 2 20 NTb NTb NTb NTb
Carbendazim (antifungal) 1 NTb NTb NTb NTb NTb NTb NDa NTb NTb
a Indicates no zone of inhibition detected.
b Indicates not tested.
* Indicates tested against ATCC 14053.
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Phytochemical profiling and dereplication employing HPLC–
NMR and HPLC–MS methodologies was successful in identifying
six known (1–6) phloroglucinols along with one known tocotrienol
(7), and three suspected new (8, 9 and 11) phloroglucinols.
Subsequent off-line isolation yielded five phloroglucinols (1, 4, 6,
9, and 12) displaying slight but selective antibacterial activity.
4. Experimental section
4.1. General experimental procedures
For details on the general experimental procedures please refer
to (Brkljaca and Urban, 2015). For both on-flow and stop-flow
HPLC–NMR modes 50 lL injections of C. monilifera and C. subfarci-
nata (4971 and 4999 lg, respectively) of the dichloromethane
extracts were injected onto an Agilent Eclipse Plus C18
(150  4.6) 5 l column using a solvent composition of 70% or
75% CH3CN/D2O (C. monilifera and C. subfarcinata, respectively) at
a flow rate of 1 mL/min. In the stop-flow HPLC–NMR mode
WET1D, gCOSY, HSQCAD, gHMBCAD and 1D TOCSY NMR experi-
ments were acquired. HRESILCMS was carried out using an
Agilent Eclipse Plus C18 (4.6  150) 5 l column using a solvent
composition of 70% or 75% CH3CN/H2O (C. monilifera and C. subfar-
cinata, respectively) at a flow rate of 1 mL/min. Analytical HPLC
analyses were carried out using either a gradient method 0–
2 min 10% CH3CN/H2O; 14–24 min 75% CH3CN/H2O; 26–30 min
100% CH3CN and 32–40 min 10% CH3CN/H2O or an isocratic
method (either 100%, 90% or 80% CH3CN/H2O) on an Alltech
Alltima HP C18 (250  4.6) 5 l column at a flow rate of
1.0 mL/min. Semi-preparative HPLC analysis were carried out
using an isocratic method (either 100%, 90%, 85% or 80%
CH3CN/H2O) and an Alltech Alltima C18 (250  10) 5 l column at
a flow rate of 3.5 or 4.0 mL/min.
4.2. Biological evaluation
For details on the biological evaluation please refer to
(Brkljaca and Urban, 2015). The crude extract of C. subfarcinataPage 15was also assessed for antimicrobial activity at the University of
Canterbury, Christchurch, New Zealand. A standardized inoculum
was prepared by transferring a loop of bacterial/fungal cells, from
a freshly grown stock slant culture, into a 10 mL vial of sterile
water. This was vortexed and compared to a 5% BaCl2 in water
standard to standardize the cell density. This gave a cell density
of 108 colony-forming units per mL. Ten milliliters of the stan-
dardized inoculum was then added to 100 mL of Mueller
Hinton or potato dextrose agar (at between 40 and 50 C) and
mixed by swirling, giving a final cell density of 107 colony form-
ing units per mL. Five milliliters of this was poured into sterile
85 mm petri dishes. The suspensions were allowed to cool and
solidify on a level surface to give a ‘lawn’ of bacteria/fungi over
the dish (for further information see www.clsi.org). The crude
extract was pipetted onto 6 mm diameter filter paper disks and
the solvent evaporated. This disks were then placed onto the pre-
pared seeded agar dishes (with appropriate solvent and positive
controls) and incubated. Active antimicrobial samples displayed
a zone of inhibition outside the disk, which was measured in
mm as the radius of inhibition for each bacteria/fungi. The six
organisms were Escherichia coli (ATCC 25922), B. subtilis (ATCC
19659) and P. aeruginosa (ATCC27853) for the bacteria and,
Candida albicans (ATCC 14053), Trichophyton mentagrophytes
(ATCC 28185) and Cladosporium resinae for the fungi. Since the
completion of these studies the University of Canterbury has
phased out these antimicrobial assays.4.3. Alga material
C. monilifera was collected via SCUBA on 21 April, 2010 from
Governor Reef (near indented head), Port Phillip Bay, Victoria,
Australia. C. subfarcinata was collected by hand intertidally on 22
January, 2006 from the Borough of Queenscliffe (near Point
Lonsdale), Port Phillip Bay, Victoria, Australia. The algae were iden-
tified by Dr. Gerry Kraft (The University of Melbourne) and voucher
specimens (designated the code number 2010–14 and 2006–11,
respectively) are deposited at the School of Applied Sciences
(Discipline of Applied Chemistry), RMIT University.2
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Chemical profiling was carried out on the dichloromethane sol-
uble extracts of the algae employing HPLC–NMR and HPLC–MS.
Details of these analyses are provided in the general experimental
procedures section and (Brkljaca and Urban, 2015). The dichloro-
methane extracts of C. monilifera and C. subfarcinata (170.0 and
741.9 mg, respectively) were dissolved in HPLC–NMR grade
CH3CN (1710 and 7420 lL, respectively) and filtered through a
0.45 PTFE membrane filter (Grace Davison Discovery Sciences).4.5. Extraction and isolation of C. monilifera
C. monilifera (58 g, wet weight) was extracted with 3:1 metha-
nol/dichloromethane (2 L). The crude extract was then decanted
and concentrated under reduced pressure and sequentially sol-
vent partitioned (triturated) into dichloromethane and methanol
soluble extracts respectively. The dichloromethane extract was
subjected to flash silica gel column chromatography (20% step-
wise elution from petroleum spirits (60–80 C) to dichloro-
methane to ethyl acetate and finally to methanol). The 100%
dichloromethane and 80% dichloromethane (first fraction) silica
gel column fraction were further purified by reversed phase
HPLC (100% CH3CN) to yield R-d-tocotrienol (7) (3.0 mg, 0.03%)
and R-c-tocotrienol (10) (2.1 mg, 0.02%). The 80% dichloro-
methane (second fraction) silica gel column fraction was further
fractionated by Sephadex LH-20 chromatography (100% metha-
nol) to yield 6 fractions. The second fraction was further purified
using reversed phase HPLC (90% CH3CN) to yield 1 (1.6 mg,
0.01%) and 2 (1.3 mg, 0.01%). The third fraction from the
Sephadex LH-20 column was further fractionated by VLC C18 col-
umn chromatography (20% stepwise elution from water to
methanol and finally to dichloromethane) to yield 12 fractions.
The 100% methanol and 80% methanol fractions were combined.
The combined fraction was subjected to reversed phase HPLC
(90% CH3CN) in which the compounds eluting between 0 and
14 min were collected into one flask and the compounds eluting
from 14 to 40 min were collected into another flask. The com-
pounds which eluted between 0 and 14 min were subjected to
reversed phase HPLC purification (90% CH3CN) to yield 4
(2.7 mg, 0.03%) and 5 (1.4 mg, 0.01%). The compounds eluting
between 14 and 40 min were subjected to further purification
by reversed phase HPLC (90% CH3CN) to yield 3 compounds;
moniliferanone D (12) (0.6 mg, 0.002%) and a mixture of monilif-
eranone A and C (8 and 11) (2.6 mg, 0.02%). One of the peaks
from the reversed phase HPLC purification of 14–40 min was fur-
ther purified by reversed phase HPLC (80% CH3CN) to yield 6
(0.3 mg, 0.003%) and moniliferanone B (9) (0.7 mg, 0.01%). The
percentage yields are reported on the basis of the dry mass of
the alga extracted.4.6. Extraction and isolation of C. subfarcinata
C. subfarcinata (20 g, wet weight) was extracted with 3:1
methanol/dichloromethane (2 L). The crude extract was then dec-
anted and concentrated under reduced pressure and sequentially
solvent partitioned (triturated) into dichloromethane and metha-
nol soluble extracts respectively. The dichloromethane extract
was subjected to reversed phase HPLC (85% CH3CN) to yield 4
(18.4 mg, 0.2%), 5 (5.3 mg, 0.06%), a mixture of 6 and monilifera-
none B (9) (6.8 mg, 0.08%), R-d-tocotrienol (7) (14.9 mg, 0.2%) and
a mixture of moniliferanone A and C (8 and 11) (7.5 mg, 0.09%).
The percentage yields are reported on the basis of the dry mass
of the alga extracted.Page 4.7. On-line (HPLC–NMR & HPLC–MS) characterization of compounds
9-Hydroxy-1-(2,4,6-trihydroxyphenyl)-6Z,10E,12Z,15Z-octade-
catetraen-1-one (1): HPLC–NMR WET 1D NMR (500 MHz, 70%
CH3CN/D2O) obtained from stop-flow mode d 7.21 (1H, dd,
J = 11.0, 15.0, H-11), 6.67 (1H, t, J = 11.0 Hz, H-12), 6.59 (2H, s, H-
30, H-50), 6.38 (1H, dd, J = 6.5, 15.0 Hz, H-10), 6.18 (1H, m, H-6),
6.18–6.10 (2H, m, H-15, H-16), 6.10 (2H, m, H-7, H-13), 4.84 (1H,
dt, J = 6.5, 7.0 Hz, H-9), 3.76 (2H, t, J = 7.0 Hz, H-2), 3.62 (2H, q,
J = 7.5 Hz, H-14), 2.99 (2H, m, H-8), 2.34 (2H, p, J = 7.0 Hz, H-3),
2.10 (2H, p, J = 7.0 Hz, H-4), 1.66 (3H, t, J = 7.5 Hz, H-18); HPLC–
NMR 13C NMR (125 MHz, 70% CH3CN/D2O) obtained from a HSQC
experiment in stop-flow mode d 207.4 (C, C-1), 165.0 (C, C-20, C-
40, C-60), 137.2 (CH, C-10), 133.1 (CH, C-16), 132.8 (CH, C-6),
131.1 (CH, C-13), 128.9 (CH, C-12), 127.5 (CH, C-15), 126.2 (CH,
C-7), 126.1 (CH, C-11), 105.2 (C, C-10), 95.7 (CH, C-30, C-50), 72.7
(CH, C-9), 44.3 (CH2, C-2), 35.8 (CH2, C-8), 29.9 (CH2, C-4), 27.8
(CH2, C-5), 26.5 (CH2, C-14), 25.1 (CH2, C-3), 21.1 (CH2, C-17),
14.6 (CH3, C-18); HRESILCMS m/z 399.2177 (calcd for C24H31O5,
399.2177).
15-Hydroxy-1-(2,4,6-trihydroxyphenyl)-5Z,8Z,11Z,13E,17Z-
eicosapentaen-1-one (2): HPLC–NMRWET 1D NMR (500 MHz, 70%
CH3CN/D2O) obtained from stop-flow mode d 7.17 (1H, dd, J = 11.0,
14.5 H-13), 6.67 (1H, dd, J = 11.0, 11.0 Hz, H-12), 6.35 (1H, dd,
J = 6.0, 14.5 Hz, H-14), 6.25–6.05 (6H, m, H-5, H-6, H-8, H-9,
H-17, H-18), 6.15 (1H, m, H-11), 4.83 (1H, dt, J = 6.0, 7.5 Hz,
H-15), 3.76 (2H, t, J = 7.5 Hz, H-2), 2.88 (2H, m, H-10), 2.35 (2H,
p, J = 7.5 Hz, H-3), 2.11 (2H, m, H-4), 2.01 (2H, m, H-19), 1.59
(3H, t, J = 6.5 Hz, H-20); HRESILCMS m/z 425.2334 (calcd for
C26H33O5, 425.2333).
9-Hydroxy-1-(2,6-dihydroxy-4-methoxyphenyl)-6Z,10Z,12Z,
15Z-octadecatetraen-1-one (3): HPLC–NMR WET 1D NMR
(500 MHz, 70% CH3CN/D2O) obtained from stop-flow mode d 7.25
(1H, dd, J = 11.5, 15.0, H-11), 6.70 (1H, t, J = 10.5 Hz, H-12), 6.59
(2H, s, H-30, H-50), 6.24–6.05 (6H, m, H-6, H-7, H-10, H-13, H-15,
H-16), 4.39 (1H, dt, J = 6.5, 8.0 Hz, H-9), 3.93 (3H, s, H-40-OCH3),
3.75 (2H, t, J = 7.5 Hz, H-2), 3.63 (2H, dd, J = 7.0, 8.0 Hz, H-14),
2.99 (2H, m, H-8), 2.34 (2H, m, H-3), 2.10 (2H, m, H-4), 1.66 (3H,
t, J = 7.5 Hz, H-18); HRESILCMS m/z 413.2333 (calcd for C25H33O5,
413.2333).
1-(2,4,6-Trihydroxyphenyl)-6Z,9Z,12Z,15Z-octadecatetraen-1-
one (4): HPLC–NMR WET 1D NMR (500 MHz, 70% CH3CN/D2O)
obtained from stop-flow mode d 6.60 (2H, s, H-30, H-50), 6.10 (8H,
m, H-6, H-7, H-9, H-10, H-15, H-16), 3.77 (2H, t, J = 7.5 Hz, H-2),
3.55 (6H, m, H-8, H-11, H-14), 2.83 (2H, m, H-5), 2.37 (2H, p,
J = 7.5 Hz, H-3), 2.13 (2H, p, J = 7.5 Hz, H-4), 1.66 (3H, t, J = 7.5 Hz,
H-18); HRESILCMS m/z 383.2222 (calcd for C24H31O4, 383.2228).
1-(2,4,6-Trihydroxyphenyl)-5Z,8Z,11Z,14Z,17Z-eicosapentaen-
1-one (5): HPLC–NMR WET 1D NMR (500 MHz, 70% CH3CN/D2O)
obtained from stop-flow mode d 6.59 (2H, s, H-30, H-50), 6.08
(10H, m, H-5, H-6, H-8, H-9, H-11, H-12, H-14, H-15, H-17,
H-18), 3.77 (2H, t, J = 7.0 Hz, H-2), 3.53 (8H, m, H-7, H-10, H-13,
H-16), 2.41 (4H, m, H-3, H-4), 1.65 (3H, t, J = 8.0 Hz, H-20);
HRESILCMS m/z 409.2385 (calcd for C26H33O4, 409.2384).
1-(2,6-Dihydroxy-4-methoxyphenyl)-6Z,9Z,12Z,15Z-octade-
catetraen-1-one (6): HPLC–NMR WET 1D NMR (500 MHz, 75%
CH3CN/D2O) obtained from stop-flow mode d 6.82 (2H, s, H-30, H-
50), 6.20 (8H, m, H-6, H-7, H-9, H-10, H-12, H-13, H-15, H-16),
3.90 (2H, t, J = 7.0 Hz, H-2), 3.66 (6H, m, H-8, H-11, H-14), 2.49
(2H, p, J = 7.0 Hz, H-3), 2.25 (2H, p, J = 7.0 Hz, H-4), 2.11 (2H, m,
H-17), 1.77 (3H, t, J = 7.5 Hz, H-18); HRESILCMS m/z 397.2381
(calcd for C25H33O4, 397.2384).
R-d-Tocotrienol (7): HPLC–NMR WET 1D NMR (500 MHz, 75%
CH3CN/D2O) obtained from stop-flow mode d 7.28 (1H, s, H-7),
7.20 (1H, s, H-5), 5.97 (1H, t, J = 7.0 Hz, H-30), 5.92 (2H, m, H-70,
H-110), 3.51 (2H, t, J = 7.0 Hz, H-4), 3.38 (4H, m, H-50, H-90), 2.95153
1 Specific rotation in the literature is small. Trace amounts of contaminants/impu-
rities present can affect the overall value.
R. Brkljacˇa, S. Urban / Phytochemistry 117 (2015) 200–208(6H, m, H-20, H-60, H-100), 2.60 (2H, m, H-3), 2.49 (3H, s, 12b0-CH3),
2.42 (3H, s, 80-CH3⁄), 2.41 (3H, s, 40-CH3), 2.40 (3H, s, 12a0-CH3⁄), 2.08
(3H, s, 2-CH3). *Signals interchangeable.
1-(2,4,6-Trihydroxyphenyl)-octadeca-6Z,9Z,12Z-trien-1-one
(8): HPLC–NMR WET 1D NMR (500 MHz, 70% CH3CN/D2O)
obtained from stop-flow mode d 6.73 (2H, s, H-30, H-50), 6.20 (6H,
m, H-6, H-7, H-9, H-10, H-12, H-13), 3.90 (2H, t, J = 7.5 Hz, H-2),
3.66 (4H, m, H-8, H-11), 2.99 (2H, m, H-5), 2.50 (2H, p, J = 7.5 Hz,
H-3), 2.26 (2H, p, J = 7.5 Hz, H-4), 2.18 (4H, m, H-15, H-16), 2.13
(2H, m, H-17), 1.72 (3H, t, J = 7.0 Hz, H-18); HPLC–NMR 13C NMR
(125 MHz, 75% CH3CN/D2O) obtained from a HSQC experiment in
stop-flow mode d 128.8 (CH, C-6, C-7, C-9, C-10, C-12, C-13), 95.7
(CH, C-30, C-50), 26.2 (CH2, C-8, C-11); HRESILCMS m/z 385.2384
(calcd for C24H33O4, 385.2384).
1-(2,4,6-Trihydroxyphenyl)-eicosa-5Z,8Z,11Z,14Z-tetraen-1-
one (moniliferanone B) (9): HPLC–NMR WET 1D NMR (500 MHz,
75% CH3CN/D2O) obtained from stop-flow mode d 6.72 (2H, s,
H-30, H-50), 6.21 (8H, m, H-5, H-6, H-8, H-9, H-11, H-12, H-14,
H-15), 3.90 (2H, t, J = 7.0 Hz, H-2), 3.67 (6H, m, H-7, H-10, H-13),
2.98 (2H, m, H-4), 2.55 (2H, p, J = 7.0 Hz, H-3), 2.17 (4H, m, H-17,
H-18), 2.13 (2H, m, H-19), 1.71 (3H, t, J = 6.5 Hz, H-20);
HRESILCMS m/z 411.2540 (calcd for C26H35O4, 411.2541).
4.8. Off-line characterization of compounds
9-Hydroxy-1-(2,4,6-trihydroxyphenyl)-6Z,10E,12Z,15Z-octade-
catetraen-1-one (1): unstable pale yellow oil; All off-line NMR
spectroscopic and mass spectrometric data was identical to that
reported in the literature (Kazlauskas et al., 1981). 13C NMR
(125 MHz, CDCl3) obtained from HSQC and HMBC NMR experi-
ments d 135.1 (CH, C-10), 133.6 (CH, C-6), 132.5 (CH, C-16),
131.0 (CH, C-13), 127.7 (CH, C-12), 126.4 (CH, C-15), 125.9 (CH,
C-11), 124.5 (CH, C-7), 94.5 (CH, C-30, C-50), 72.4 (CH, C-9), 43.4
(CH2, C-2), 35.2 (CH2, C-8), 29.2 (CH2, C-4), 26.8 (CH2, C-5), 26.0
(CH2, C-14), 24.5 (CH2, C-3), 20.6 (CH2, C-17), 14.3 (CH3, C-18).
15-Hydroxy-1-(2,4,6-trihydroxyphenyl)-5Z,8Z,11Z,13E,17Z-
eicosapentaen-1-one (2): unstable pale yellow oil; All off-line NMR
spectroscopic and mass spectrometric data was identical to that
reported in the literature (Amico et al., 1982). 13C NMR
(125 MHz, CDCl3) obtained from HSQC and HMBC NMR experi-
ments d 206.0 (C, C-1), 134.6 (CH, C-14), 133.5 (CH, C-11), 132.6
(CH, C-18), 131.8 (CH, C-6⁄), 129.7 (CH, C-5), 128.2 (CH, C-8⁄),
127.5 (CH, C-12), 126.4 (CH, C-9), 126.3 (CH, C-13), 124.4 (CH-C-
17), 95.4 (CH, C-30, C-50), 72.6 (CH, C-15), 43.8 (CH2, C-2), 35.1
(CH2, C-16), 27.5 (CH2, C-4), 26.0 (CH2, C-10), 25.9 (CH2, C-7),
24.7 (CH2, C-3), 20.6 (CH2, C-19), 14.3 (CH3, C-20). *Signals
interchangeable.
1-(2,4,6-Trihydroxyphenyl)-6Z,9Z,12Z,15Z-octadecatetraen-1-
one (4); unstable pale yellow oil; All off-line NMR spectroscopic
and mass spectrometric data was identical to that reported in
the literature (Kazlauskas et al., 1981). 13C NMR (125 MHz,
CDCl3) obtained from HSQC and HMBC NMR experiments d 205.9
(C, C-1), 132.1 (CH, C-16), 130.1 (CH, C-6), 128.2 (CH, C-7, C-9,
C-10, C-12, C-13), 127.1 (CH, C-15), 95.5 (CH, C-30, C-50), 43.7
(CH2, C-2), 29.5 (CH2, C-4), 27.7 (CH2, C-5), 25.6 (CH2, C-8, C-11,
C-14), 24.3 (CH2, C-3), 20.5 (CH2, C-17), 14.3 (CH3, C-18).
1-(2,4,6-Trihydroxyphenyl)-5Z,8Z,11Z,14Z,17Z-eicosapentaen-
1-one (5): unstable pale yellow oil; All off-line NMR spectroscopic
and mass spectrometric data was identical to that reported in the
literature (Gerwick and Fenical, 1982). 13C NMR (125 MHz, CDCl3)
obtained from HSQC and HMBC NMR experiments d 205.8 (C, C-1),
163.5 (C, C-20, C-40, C-60), 132.1 (CH, C-18), 129.9 (CH, C-5), 128.3
(CH, C-6, C-8, C-9, C-11, C-12, C-14, C-15), 127.0 (CH, C-17),
104.8 (C, C-10), 95.5 (CH, C-30, C-50), 43.4 (CH2, C-2), 26.9 (CH2,
C-4), 25.6 (CH2, C-7, C-10, C-13, C-16), 24.5 (CH2, C-3), 20.4
(CH2, C-19), 14.2 (CH3, C-20).Page 151-(2,6-Dihydroxy-4-methoxyphenyl)-6Z,9Z,12Z,15Z-octade-
catetraen-1-one (6); unstable pale yellow oil; All off-line NMR
spectroscopic and mass spectrometric data was identical to that
reported in the literature (Gregson et al., 1977); 13C NMR
(125 MHz, CDCl3) obtained from HSQC and HMBC NMR experi-
ments d 206.7 (C, C-1), 165.4 (C, C-40), 132.1 (CH, C-16), 130.1
(CH, C-6), 128.1 (CH, C-9, C-10, C-12, C-13), 127.9 (CH, C-7),
127.0 (CH, C-15), 105.3 (C, C-10), 93.9 (CH, C-30, C-50), 55.4 (CH3,
40-OCH3), 44.1 (CH2, C-2), 29.5 (CH2, C-4), 27.2 (CH2, C-5), 25.5
(CH2, C-8, C-11, C-14), 24.2 (CH2, C-3), 20.6 (CH2, C-17), 14.3
(CH3, C-18).
R-d-Tocotrienol (7); light yellow, unstable oil; [a]D24 +12.4 (c
0.00476, CHCl3)1; All off-line NMR spectroscopic, mass spectromet-
ric and specific rotation data was in agreement to that reported in
the literature (Couladouros et al., 2007; Ohnmacht et al., 2008).
R-c-Tocotrienol (10); light yellow, unstable oil; no specific rota-
tion could be recorded prior to decomposition. All off-line NMR
spectroscopic and mass spectrometric data was identical to that
reported in the literature (Ohnmacht et al., 2008).
Mixture of 1-(2,4,6-trihydroxyphenyl)-octadeca-6Z,9Z,12Z-
trien-1- (moniliferanone A) (8) and 1-(2,4,6-trihydroxyphenyl)-
octadeca-9Z,12Z,15Z-trien-1-one (moniliferanone C) (11): isolated
in a ratio of 1–0.45, respectively in C. monilifera and in a ratio of
1–0.25, respectively in C. subfarcinata; unstable oil, which dark-
ened over time; UV (EtOH) kmax(loge) 229 (3.85), 289 (3.99); IR
vmax 3290, 3012, 2927, 2856, 1635, 1521, 1456, 1394, 1251 cm1;
1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see
Tables 1 and 2; ESIMS m/z 385 [MH]; HRESIMS m/z 385.2385
(calcd for C24H33O4, 385.2384).
1-(2,4,6-Trihydroxyphenyl)-eicosa-5Z,8Z,11Z,14Z-tetraen-1-
one (moniliferanone B) (9): unstable oil, which darkened over
time; UV (EtOH) kmax(loge) 228 (3.98), 290 (3.96); IR vmax 3283,
3012, 2956, 2926, 2855, 1622, 1513, 1456, 1261 cm1; 1H NMR
(500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 1;
ESIMS m/z 411 [MH]; HRESIMS m/z 411.2536 (calcd for
C26H35O4, 411.2541).
1-(2,4,6-Trihydroxyphenyl)-hexadeca-6Z,9Z-tetraen-1-one
(moniliferanone D) (12): unstable oil, which darkened over time;
UV (EtOH) kmax(loge) 226 (3.37), 289 (3.36); IR vmax 3351, 3010,
2926, 2855, 1711, 1626, 1457, 1257 cm1; 1H NMR (500 MHz,
CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 2; ESIMS m/z
359 [MH]; HRESIMS m/z 359.2221 (calcd for C22H31O4,
359.2228).
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CHAPTER 11 
Relative Configuration Studies of the Marine Natural Product 
Elatenyne 
 
 
 
Kingdom: Plantae 
Phylum: Rhodophyta 
Class: Florideophyceae 
Order: Ceramiales 
Family: Rhodomelaceae 
Genus: Laurencia 
Species: elata 
 
Collected at low tide at St. Paul’s Beach, 
Sorrento, Port Phillip Bay, Victoria, 
Australia in January 2003. 
 
Chapter 11 details the chemical derivatisation and relative configuration studies 
carried out on elatenyne, a marine natural product isolated from Laurencia elata. This work 
has been published as outlined below. 
 
Journal publication resulting from this study: 
Brklja?a, Robert, & Urban, Sylvia. (2013). Relative Configuration of the Marine Natural 
Product Elatenyne using NMR Spectroscopic and Chemical Derivatization Methodologies. 
Natural Product Communications, 8(6), 729-732. 
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 PART D – Discussion & 
Conclusions 
 
Discussion and Concluding Remarks 
A total of sixty five secondary metabolites were identified from the thirteen marine 
and terrestrial organisms investigated (Figure 1). HPLC-NMR was pivotal for the successful 
dereplication of the secondary metabolites in the chemical profiling approach adopted. In 
particular, HPLC-NMR was instrumental in the identification of an unstable compound that 
could not be isolated by off-line approaches. A comprehensive HPLC-NMR LOD study, 
whereby a gHMBCAD NMR spectrum was acquired on a HPLC-NMR system solely 
equipped with a 60 µL flow cell, was also achieved. 
 Of the sixty five compounds identified, fifty four were also isolated by off-line 
approaches. A total of twenty two new natural products and one new natural product 
derivative were identified (Figure 1). Seventeen distinct structure classes were identified 
during the course of these studies. The new compounds reported in this thesis are 
representative of seven different structure classes. Five previously known compounds are 
now reported as natural products for the first time. 
Of the fifty compounds assessed for their biological activity forty two displayed some 
anti-microbial activity (Figure 2), but none of the compounds displayed anti-fungal activity. 
 Nine compounds were completely characterised by 2D NMR spectroscopy for the 
first time. A total of five carbon and one proton NMR chemical shift reassignments were also 
made for four of the compounds isolated.  
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 Figure 1: Total number of compounds identified. 
 
 
Figure 2: Number of marine and terrestrial compounds displaying anti-biotic activity. 
While the aim of the thesis was to discover new natural products, rather than to 
explore why these compounds are produced, it can be assumed that the secondary metabolites 
isolated would serve a particular function. However, is not known whether this would be for 
a chemical defence or to promote reproduction or cell function.  
The overall chemical diversity displayed between marine and terrestrial specials was 
extensive. Two plant specimens studied were of the same family (Haemodoraceae), which 
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produced different chemistry. Whilst the phenylphenalenones, oxabenzochrysenones and 
chromenes were common structural classes, the kangaroo paw (Macropidia fuliginosa) 
specimen produced several different structural classes including chalcones, resveratrol dimers 
and flavonoids. Likewise in Chapter 8, which detailed the chemical profiling of seven marine 
algae, three of the marine algae were of the Sargassum genus and two were of the 
Cystophora genus. Whilst the two Cystophora species produced similar chemistry, each of 
the three species of Sargassum produced unique chemistry. Both of these examples highlight 
the importance of investigating unstudied species, despite the amount of knowledge that may 
be known for the genus or family of the organism.  
The disk diffusion assay used in this thesis was employed to ascertain whether a 
particular natural product may display anti-microbial activity. While this particular method is 
suitable to establish whether a particular crude extract or compound may display anti-
microbial activity, the methodology does have limitations. In particular, the compounds being 
tested must be able to diffuse within the agar medium, otherwise no zone of inhibition will be 
observed. Furthermore, despite ampicillin being used as a general positive control in some of 
the assays conducted, no direct comparison of the potency can be made between the isolated 
compounds tested and ampicillin. Future work should involve further anti-microbial testing 
of compounds that displayed promising activity using a more sophisticated assay method. 
Modern methods such as a tetrazolium or similar colorimetric cell proliferation assay would 
be ideal as the diffusion characteristic of the isolated compounds would not be an issue, and 
the potency of compound could be expressed as an MIC50 value, which in turn could be 
directly compared to other available anti-microbial drugs (Chand, Lusunzi, Veal, Williams, & 
Karuso, 1994; Mann & Markham, 1998). 
Many of the compounds identified in this thesis conform to Lipinski’s Rule of 5 
(Lipinski, Lombardo, Dominy, & Feeney, 1997), in that they contain properties which may 
suggest they could be converted into an orally available drug. Whilst the water-octanol 
partition co-efficient was not measured for any of the compounds identified, it can be 
determined which of the compounds conform to Lipinski’s three remaining rules. Providing 
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any of the compounds conforms to all of the three remaining rules, it could potentially be 
considered as a suitable orally available drug. Of all of the 65 compounds identified, 60 
conform to all three of Lipinski’s remaining rules, which include having a molecular weight 
less than 500 Da, containing no more than ten oxygen or nitrogen atoms, and having no more 
than five nitrogen-hydrogen or oxygen-hydrogen bonds. These compounds should be 
subjected to further biological activity studies, from which any compounds displaying potent 
activity could be prioritised as a drug lead. Compounds 1, 38 and 61 (see table below) either 
have a molecular weight greater than 500 Da, contain more than ten oxygen or nitrogen 
atoms, or contain more than five nitrogen-hydrogen or oxygen-hydrogen bonds. If the water-
octanol partition co-efficient of these compounds is less than five, these compounds still 
conform to Lipinski’s rules, however if the co-efficient is greater than five, these compounds 
must be excluded. Compounds 39 and 40 (see table below) do not conform to Lipinski’s rules 
and must also be excluded.  
A variant of Lipinski’s Rule of 5 exists, known as The Rule of 3, which determines 
whether a compound is a suitable drug-lead (Congreve, Carr, Murray, & Jhoti, 2003). The 
Rule of 3 dictates that a drug-lead compound should have a molecular weight less than 300 
Da, contain no more than three oxygen or nitrogen atoms, no more than three nitrogen-
hydrogen or oxygen-hydrogen bonds, and display a water-octanol partition co-efficient of 
less than three. Again whilst the water-octanol partition co-efficients were not measured, it 
can be determined which of the compounds comply with the remaining rules. Fourteen of the 
compounds identified (2-4, 10, 24, 25, 30, 31, 44-46, 62, 64 and 65-see table below) comply 
with the remaining rules and therefore represent potential drug-leads. Twelve other 
compounds (5-11, 17-19, 32 and 63-see table below) do not conform to one of the remaining 
rules. Providing these compounds display a water-octanol partition co-efficient of less than 
three, they would also represent potential drug-leads.  
The meroditerpenoids (5-16) were the most unstable structure class isolated in this 
thesis, in particular the hydroquinones which oxidised within a few days, even when stored at 
-80 °C. The phloroglucinols (47-60) which were isolated from several algae degraded after 
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approximately two weeks at -20 °C. The majority of the terrestrial natural products isolated 
were stable when stored at -20 °C and did not show any signs of degradation even after one 
year post isolation. In terms of bioavailability, it could be proposed that, once again, the 
meroditerpenoids and phloroglucinols would be the most unstable. This is attributed to the 
fact that they often contain functional groups such as alcohols and ketones, along with double 
bonds, which could be rapidly metabolised in vivo.  
This thesis has illustrated that for the dereplication of natural products, the use of 
HPLC-NMR should be implemented in more instances. While the use of UV and MS data, 
from hyphenated techniques such as HPLC-MS in particular, has been widely adopted to 
prioritise and dereplicate samples, the use of these two pieces of data may, in more instances 
than not, fail to provide key structural information which can be used to determine if a 
particular crude extract or fraction contains a possible new compound. The information 
obtained from HPLC-NMR analysis provides a wealth of structural knowledge and should be 
widely implemented, in conjunction with a complementary technique such as HPLC-MS. In 
most chapters in this thesis, dereplication using HPLC-NMR together with HPLC-MS was 
able to deduce the identity of many components. However, if HPLC-MS had solely been 
used, as is the case for many dereplication studies, the identity of these components would 
have not been possible.  
This thesis has also identified particular areas that should prioritised for future 
research. Compounds which showed promising anti-bacterial activity, in particular the 
oxabenzochrysenones, phenylphenalenones, and compound 39, should be further evaluated 
using more a sophisticated assay method such as a colorimetric cell proliferation assay. Many 
of the species investigated represent members of the Sargassum and Cystophora genera 
which produced an abundance of new chemical entities. This highlights the fact that these 
two genera should continue to be evaluated for further new chemistry. Two of the Australian 
plants studied are endemic to Western Australia which is an area of Australia with high 
biodiversity and remains understudied by natural product chemists. This should become an 
area for targeted research as should the study of Australian plants which may have been used 
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by the Australian Aborigines. The diversity present in the oceans and in marine invertebrates 
was exemplified in the study of a number of marine algae in this thesis and so the study of 
southern Australian marine invertebrates should also continue utilising efficient dereplication 
strategies such as those employed in this thesis. The MeOH crude extract of the bulbs of the 
kangaroo paw specimen (Macropidia fuliginosa) should be re-investigated as it displayed 
inhibitory activity against the MRSA bacterium. None of the compounds isolated from the 
MeOH extract described in this thesis displayed activity against MRSA. Either a synergistic 
effect is operating, or the compound responsible for the activity was not isolated. For this 
reason, this should be re-explored in an effort to deduce which of the two possibilities 
accounts for the activity displayed by the crude extract. 
The table that follows provides a summary for each of the compounds identified. 
Compounds are arranged by chemical structure class and by molecular weight and also 
provided are the details of the source organism. 
Page 166
Su
m
m
ar
y 
of
 C
om
po
un
ds
 Id
en
tif
ie
d 
 # 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Pyrano
[3,2-b]
pyrany
l Vinyl 
Acetyle
nes 
1 
O
B
r
O
B
r
NN
N
N H
O
(4
,4
'-d
ib
ro
m
o-
5-
et
hy
l-5
'-(
(Z
)-
pe
nt
-2
-e
n-
4-
yn
yl
)o
ct
ah
yd
ro
[2
,2
']-
bi
fu
ra
n
 
M
W
 5
70
 
[α
]25 365 +
16
.4
 
 
L.
 e
la
ta
 
- 
N
ew
 d
er
iv
at
iv
e 
11
 
 
 
 
 
 
 
 
Fatty A
cids 
2 
H
O
O
lin
ol
ei
c 
ac
id
 
M
W
 2
80
 
L.
 b
ir
nb
au
m
ii 
S.
 a
ur
eu
s, 
 S
. 
py
og
en
es
 
K
no
w
n 
7 
3 
H
O
O
ol
ei
c 
ac
id
 
M
W
 2
82
 
L.
 b
ir
nb
au
m
ii 
P.
 a
er
ug
in
os
a 
K
no
w
n 
7 
4 
H
3C
O
O
m
et
hy
l l
in
ol
ea
te
 
M
W
 2
94
 
L.
 b
ir
nb
au
m
ii 
S.
 a
ur
eu
s, 
P.
 
ae
ru
gi
no
sa
, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
7 
 
 
 
 
 
 
 
 
Merod
iterpen
oids 
5 
O O
sa
rg
aq
ui
no
ne
 
M
W
 3
94
 
S.
 p
ar
ad
ox
um
 
P.
 a
er
ug
in
os
a 
K
no
w
n,
  
ca
rb
on
 N
M
R
 
re
as
si
gn
m
en
t 
9 
 
 
  
 
 
 
 
Pa
ge
 1
67
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Merod
iterpen
oids (c
ont.) 
6 
C
H
O
OO
sa
rg
aq
ui
na
l
 
M
W
 4
08
 
S.
 p
ar
ad
ox
um
 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n 
9 
7 
C
H
O
O
H
O
H
sa
rg
ah
yd
ro
qu
in
al
 
M
W
 4
10
 
S.
 p
ar
ad
ox
um
 
- 
N
ew
, i
de
nt
ifi
ed
 
by
 H
PL
C
-N
M
R
 
9 
8 
O O
O
H
pa
ra
do
xq
ui
no
ne
 
M
W
 4
10
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
N
ew
 
9 
9 
O O
C
H
2O
H
2-
[1
1-
(h
yd
ro
xy
m
et
hy
l)-
3,
7,
15
-tr
im
et
hy
l-
2,
6,
10
,1
4-
he
xa
de
ca
te
tra
en
-1
-y
l]-
6-
m
et
hy
l-1
,4
-b
en
zo
qu
in
on
e
 
M
W
 4
10
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n 
9 
10
 
O
H
O
H
O
H
pa
ra
do
xh
yd
ro
qu
in
on
e
 
M
W
 4
12
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
N
ew
 
9 
 
     
 
 
 
 
 
Pa
ge
 1
68
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Merod
iterpen
oids (c
ont.) 
11
 
O
H
O
H
C
H
2O
H
2-
[1
1-
(h
yd
ro
xy
m
et
hy
l)-
3,
7,
15
-tr
im
et
hy
l-
2,
6,
10
,1
4-
he
xa
de
ca
te
tra
en
-1
-y
l]-
6-
m
et
hy
l-1
,4
-b
en
ze
ne
di
ol
 
M
W
 4
12
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n 
9 
12
 
OO
C
O
O
H
sa
rg
aq
ui
no
ic
 a
ci
d
 
M
W
 4
24
 
S.
 p
ar
ad
ox
um
 
S.
 a
ur
eu
s, 
S.
 
au
re
us
 M
R
SA
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n 
9 
13
 
O
H
O
H
C
O
O
H
sa
rg
ah
yd
ro
qu
in
oi
c 
ac
id
 
M
W
 4
26
 
S.
 p
ar
ad
ox
um
 
S.
 a
ur
eu
s, 
S.
 
au
re
us
 M
R
SA
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 c
ar
bo
n 
N
M
R
 
re
as
si
gn
m
en
t 
9 
14
 
O
O
H
O
C
H
2O
H
fa
lla
qu
in
on
e
 
M
W
 4
26
 
[α
]25 𝐷 +
31
.4
 
S.
 p
ar
ad
ox
um
 
P.
 a
er
ug
in
os
a 
K
no
w
n 
9 
15
 
O
H
O
H
O
H
C
H
2O
H
fa
lla
hy
dr
oq
ui
no
ne
 
M
W
 4
28
 
[α
]25 𝐷 +
45
.1
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 c
ar
bo
n 
an
d 
pr
ot
on
 
N
M
R
 
re
as
si
gn
m
en
t 
9 
16
 
O
O
H
O
C
H
2O
H
pa
ra
do
xq
ui
no
l
 
M
W
 4
40
 
[α
]25 𝐷 +
48
.5
 
S.
 p
ar
ad
ox
um
 
S.
 p
yo
ge
ne
s 
N
ew
 
9 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
Pa
ge
 1
69
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Tocotr
ienols 
17
 
(R
)-
δ -
to
co
tri
en
ol
O
H
O
 
M
W
 3
96
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
S.
 c
f f
al
la
x 
- 
K
no
w
n 
8,
 1
0 
18
 
C
H
O
O
H
O
9-
(6
-h
yd
ro
xy
2,
8-
di
m
et
hy
l2
H
-1
-b
en
zo
py
ra
n-
2-
yl
)-
6-
m
et
hy
l-2
-(
4-
m
et
hy
l-3
-p
en
te
n-
1-
yl
)-
2,
6-
no
na
di
en
al
 
M
W
 4
08
 
S.
 p
ar
ad
ox
um
 
- 
K
no
w
n 
9 
19
 
(R
)-
γ -
to
co
tri
en
ol
O
H
O
 
M
W
 4
10
 
C
. m
on
ili
fe
ra
 
- 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n 
fr
om
 
m
ar
in
e 
so
ur
ce
 
10
 
 
 
 
 
 
 
 
Chrom
enes 
20
 
O
O
O
2-
ph
en
yl
na
ph
th
al
ic
 a
nh
yd
rid
e
 
M
W
 2
74
 
M
. f
ul
ig
in
os
a 
P.
 a
er
ug
in
os
a 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n 
5 
 
 
       
 
 
 
 
Pa
ge
 1
70
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Chrom
enes (c
ont.) 
21
 
O
O
O
C
H
3
ha
em
od
or
di
on
e
O
 
M
W
 3
04
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i 
N
ew
 
6 
22
 
O
O
O
C
H
3
H
O
O
H
ha
em
od
or
di
ol
 
M
W
 3
22
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
S.
 
ae
ru
gi
no
sa
, 
S.
 p
yo
ge
ne
s 
N
ew
 
6 
23
 
O
O
O
H
3C
O
O
C
H
3
5,
6-
di
m
et
ho
xy
-7
-p
he
ny
l-1
H
,3
H
-
na
ph
th
o[
1,
8-
cd
]p
yr
an
-1
,3
-d
io
ne
 
M
W
 3
34
 
H
. s
pi
ca
tu
m
 
- 
K
no
w
n 
6 
 
 
 
 
 
 
 
Oxaben
zochry
senone
s 
24
 
O
O
O
H
5-
hy
dr
ox
y-
1H
-n
ap
ht
ho
[2
,1
,8
-m
na
]
xa
nt
he
n-
1-
on
e
 
M
W
 2
86
 
H
. s
pi
ca
tu
m
 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n,
 fi
rs
t 
2D
 N
M
R
 
ch
ar
ac
te
ris
at
io
n 
6 
 
 
 
 
 
 
 
Pa
ge
 1
71
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Oxaben
zochry
senone
s (cont
.) 
25
 
O
O
O
C
H
3
5-
m
et
ho
xy
-1
H
-n
ap
ht
ho
[2
,1
,8
-m
na
]
xa
nt
he
n-
1-
on
e
 
M
W
 3
00
 
H
. s
pi
ca
tu
m
 
S.
 a
ur
eu
s, 
S.
 
au
re
us
 M
R
SA
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n 
6 
26
 
O
O
O
H
O
C
H
3
5-
hy
dr
ox
y-
2-
m
et
ho
xy
-6
-
ox
ab
en
zo
[d
ef
]c
hr
ys
en
e-
1-
on
e
 
M
W
 3
16
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
P.
 
ae
ru
gi
no
sa
, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
6 
27
 
O
O
O
H
H
O
H
O
ha
em
of
lu
or
on
e 
A
 
M
W
 3
18
 
M
. f
ul
ig
in
os
a 
P.
 a
er
ug
in
os
a 
K
no
w
n 
5 
28
 
O
H
O
H
O
O
H
O
ha
em
of
lu
or
on
e 
B
 
M
W
 3
18
 
M
. f
ul
ig
in
os
a 
P.
 a
er
ug
in
os
a 
K
no
w
n 
5 
 
 
  
 
 
 
 
Pa
ge
 1
72
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Oxaben
zochry
senone
s (cont
.) 
29
 
O
O
O
C
H
3
O
C
H
3
2,
5-
di
m
et
ho
xy
-1
H
-n
ap
ht
ho
[2
,1
,8
-m
na
]
xa
nt
he
n-
1-
on
e
 
M
W
 3
30
 
H
. s
pi
ca
tu
m
 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n,
 fi
rs
t 
2D
 N
M
R
 
ch
ar
ac
te
ris
at
io
n 
6 
 
Phenyl
phenal
enones
 
30
 
O
fu
lig
in
on
e
 
M
W
 2
56
 
M
. f
ul
ig
in
os
a 
S.
 p
yo
ge
ne
s 
N
ew
 
5 
31
 
O
O
H
an
ig
or
uf
on
e
 
M
W
 2
72
 
M
. f
ul
ig
in
os
a 
- 
K
no
w
n 
5 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
  
 
  
 
 
 
 
Pa
ge
 1
73
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phenyl
phenal
enones
 (cont.)
 
32
 
O
O
C
H
3
H
3C
O
2,
6-
di
m
et
ho
xy
-9
-p
he
ny
l-1
H
-p
he
na
le
n-
1-
on
e
 
M
W
 3
16
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
P.
 
ae
ru
gi
no
sa
, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
6 
33
 
H
3C
O
O
H
O
H
O
fu
lig
in
ol
 
M
W
 3
18
 
M
. f
ul
ig
in
os
a 
S.
 p
yo
ge
ne
s 
N
ew
 
5 
34
 
O
O
C
H
3
O
H
H
3C
O
ha
em
ox
ip
hi
do
ne
 
M
W
 3
32
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
S.
 
au
re
us
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
N
ew
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
Pa
ge
 1
74
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phenyl
phenal
enones
 (cont.)
 
35
 
O
O
H
H
3C
O
ha
em
od
or
on
olO
C
H
3
 
M
W
 3
32
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
S.
 
au
re
us
, 
S.
 a
ur
eu
s 
M
R
SA
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
N
ew
 
6 
36
 
O
O
C
H
3
O
C
H
3
H
3C
O
2,
5,
6-
tri
m
et
ho
xy
-9
-p
he
ny
l-1
H
-p
he
na
le
n-
1-
on
e
 
M
W
 3
46
 
H
. s
pi
ca
tu
m
 
E.
 c
ol
i, 
S.
 
au
re
us
 M
R
SA
, 
P.
 a
er
ug
in
os
a,
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 
is
ol
at
io
n,
 fi
rs
t 
2D
 N
M
R
 
ch
ar
ac
te
ris
at
io
n 
6 
37
 
H
3C
O
O
H
O
H
O
ch
lo
ro
fu
lig
in
ol
C
l
 
M
W
 3
52
 
M
. f
ul
ig
in
os
a 
S.
 p
yo
ge
ne
s 
N
ew
 
5 
 
 
        
 
 
 
 
Pa
ge
 1
75
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Chalco
nes 
38
 
is
os
al
ip
ur
po
si
de
O
H
O
H
O
O
O
H
O
O
H
H
O
H
OH
O
 
M
W
 4
34
 
M
. f
ul
ig
in
os
a 
P.
 a
er
ug
in
os
a 
K
no
w
n 
5 
Flavon
oids 
39
 
6'
'-(
p -
hy
dr
ox
yc
in
na
m
at
e)
 s
al
ip
ur
po
si
de
O
O O
O
H
H
O
O
O
H
O
O
O
H
O
H
H
O
 
M
W
 5
80
 
M
. f
ul
ig
in
os
a 
E.
 c
ol
i, 
P.
 a
er
ug
in
os
a,
 
S 
py
og
en
es
 
K
no
w
n 
5 
40
 
ru
tin
O
H
O
H
OO
H
O
O
O
H
O
H
O
O
H
O
H
O
O
O
H
O
H
O
H
 
M
W
 6
10
 
[α
]22 𝐷 +
1.
4 
M
. f
ul
ig
in
os
a 
- 
K
no
w
n 
5 
 
 
    
 
 
 
 
Pa
ge
 1
76
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Resver
atrol D
imers 
41
 
O
O
H
C
H
O
H
O H
O
O
H
fu
lig
in
os
in
 A
 
M
W
 3
62
 
M
. f
ul
ig
in
os
a 
S.
 a
ur
eu
s, 
S.
 p
yo
ge
ne
s 
N
ew
 
5 
42
 
O
O
H
H
O H
O
O
H
fu
lig
in
os
in
 B
O
C
H
3
O
C
H
3
 
M
W
 4
08
 
M
. f
ul
ig
in
os
a 
- 
N
ew
 
5 
43
 
O
O
H
H
O H
O
O
H
an
ig
op
re
is
si
n 
A
O
H
 
M
W
 4
52
 
M
. f
ul
ig
in
os
a 
S.
 a
ur
eu
s, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
5 
 
 
        
  
 
 
 
Pa
ge
 1
77
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Cinnam
ic Acid
 Deriva
tives 
44
 
H
O
O
O
C
H
3
m
et
hy
l t
ra
ns
- p
-c
ou
m
ar
at
e
 
M
W
 1
78
 
M
. f
ul
ig
in
os
a 
S.
 a
ur
eu
s, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
5 
45
 
H
O
O
C
H
3
O
m
et
hy
l c
is
- p
-c
ou
m
ar
at
e
 
M
W
 1
78
 
M
. f
ul
ig
in
os
a 
S.
 a
ur
eu
s, 
S.
 p
yo
ge
ne
s 
K
no
w
n 
5 
Acenap
hthylen
es 
46
 
O
O
fu
lig
in
os
on
e
 
M
W
 2
58
 
M
. f
ul
ig
in
os
a 
S.
 a
ur
eu
s, 
P.
 a
er
ug
in
os
a 
N
ew
 
5 
Phloro
glucino
ls 
47
 
O
H
O O
H
H
O
m
on
ilif
er
an
on
e 
D
 
M
W
 3
60
 
C
. m
on
ili
fe
ra
 
S.
 p
yo
ge
ne
s 
N
ew
 
10
 
48
 
a
b
O
H
H
O
O
H
O
a+
b 
= 
5
1-
(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)h
ex
ad
ec
ad
ie
n-
1-
on
e
(u
nk
no
w
n 
do
ub
le
 b
on
d 
po
si
tio
ns
)
 
M
W
 3
60
 
S.
 c
f f
al
la
x 
- 
N
ew
 
8 
 
 
  
 
 
 
 
Pa
ge
 1
78
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phloro
glucino
ls (con
t.) 
49
 
O
O
H
H
O
O
H
1-
(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)-
6Z
,9
Z,
12
Z,
15
Z-
oc
ta
de
ca
te
tra
en
-1
-o
ne
 
M
W
 3
84
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
C
. r
et
ro
fle
xa
, 
S.
 c
f f
al
la
x 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n 
8,
 1
0 
50
 
O
O
H
H
O
O
H
m
on
ilif
er
an
on
e 
C
 
M
W
 3
86
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a 
- 
N
ew
 
10
 
51
 
O
H
O O
H
H
O
m
on
ilif
er
an
on
e 
A
 
M
W
 3
86
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
C
. r
et
ro
fle
xa
, 
S.
 c
f f
al
la
x 
- 
N
ew
 
8,
 1
0 
52
 
1-
(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)o
ct
ad
ec
ad
ie
n-
1-
on
e
(u
nk
no
w
n 
do
ub
le
 b
on
d 
po
si
tio
ns
)
a
b
O
H
H
O
O
H
O
a+
b 
= 
7
 
M
W
 3
88
 
C
. r
et
ro
fle
xa
, 
C
. s
ub
fa
rc
in
at
a 
- 
N
ew
 
8 
53
 
O
O
H
H
3C
O
O
H
1-
(2
,6
-d
ih
yd
ro
xy
-4
-m
et
ho
xy
ph
en
yl
)-
6Z
,9
Z,
12
Z,
15
Z-
oc
ta
de
ca
te
tra
en
-1
-o
ne
 
M
W
 3
98
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
S.
 c
f f
al
la
x 
S.
 a
ur
eu
s, 
P.
 a
er
ug
in
os
a 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n 
8,
 1
0 
 
 
      
 
 
 
 
Pa
ge
 1
79
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phloro
glucino
ls (con
t.) 
54
 
9-
hy
dr
ox
y-
1-
(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)-
6Z
,1
0E
,1
2Z
,1
5Z
-o
ct
ad
ec
at
et
ra
en
-1
-o
ne
O
H
H
O
O
H
O
O
H
 
M
W
 4
00
 
C
. m
on
ili
fe
ra
 
C
. r
et
ro
fle
xa
 
S.
 p
yo
ge
ne
s 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n 
8,
 1
0 
55
 
1-
(2
,6
-d
ih
yd
ro
xy
-4
-m
et
ho
xy
ph
en
yl
)o
ct
ad
ec
at
rie
n-
1-
on
e
(u
nk
no
w
n 
do
ub
le
 b
on
d 
po
si
tio
ns
)
O
H
H
3C
O
O
H
O
a
b
a+
b 
= 
4
 
M
W
 4
00
 
C
. s
ub
fa
rc
in
at
a 
- 
N
ew
 
8 
56
 
O
H
H
O
O
H
O
O
H
re
tro
fle
xa
no
ne
 
M
W
 4
02
 
C
. r
et
ro
fle
xa
 
- 
N
ew
 
8 
57
 
O
H
O O
H
H
O 1-
(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)-
5Z
,8
Z,
11
Z,
14
Z,
17
Z-
ei
co
sa
pe
nt
ae
n-
1-
on
e
 
M
W
 4
10
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
C
. r
et
ro
fle
xa
 
- 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n 
8,
 1
0 
58
 
O
H
O O
H
H
O
m
on
ilif
er
an
on
e 
B
 
M
W
 4
12
 
C
. m
on
ili
fe
ra
, 
C
. s
ub
fa
rc
in
at
a,
 
C
. r
et
ro
fle
xa
, 
S.
 c
f f
al
la
x 
S.
 p
yo
ge
ne
s 
N
ew
 
8,
 1
0 
 
 
      
 
 
 
 
Pa
ge
 1
80
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phloro
glucino
ls (con
t.) 
59
 
O
O
H
H
3C
O
O
H
O
H
9-
hy
dr
ox
y-
1-
(2
,6
-d
ih
yd
ro
xy
-4
-m
et
ho
xy
ph
en
yl
)-
6Z
,1
0Z
,1
2Z
,1
5Z
-o
ct
ad
ec
at
et
ra
en
-1
-o
ne
 
M
W
 4
14
 
C
. m
on
ili
fe
ra
 
- 
K
no
w
n 
10
 
60
 
O
O
H
H
O
O
H
O
H
15
-h
yd
ro
xy
-1
-(2
,4
,6
-tr
ih
yd
ro
xy
ph
en
yl
)-
5Z
,8
Z,
11
Z,
13
E,
17
Z-
ei
co
sa
pe
nt
ae
n-
1-
on
e
 
M
W
 4
26
 
C
. m
on
ili
fe
ra
 
- 
K
no
w
n,
 fi
rs
t 2
D
 
N
M
R
 
ch
ar
ac
te
ris
at
io
n,
 
ca
rb
on
 
re
as
si
gn
m
en
t 
10
 
 
 
 
 
 
 
 
Xantho
phylls 
61
 
O
O
H
O
O
O
H
O
al
l-t
ra
ns
-fu
co
xa
nt
hi
n
 
M
W
 6
58
 
S.
 v
es
tit
um
, 
H
. p
se
ud
os
pi
ca
ta
 
- 
K
no
w
n 
8 
 
 
 
 
 
 
 
Phenol
ic Acid
s 
62
 
H
O
6-
un
de
cy
ls
al
ic
yl
ic
 a
ci
d
C
O
O
H
 
M
W
 2
92
 
S.
 d
ec
ip
ie
ns
 
- 
K
no
w
n 
8 
63
 
H
O
C
O
O
H
6-
tri
de
cy
ls
al
ic
yl
ic
 a
ci
d
 
M
W
 3
20
 
S.
 d
ec
ip
ie
ns
 
- 
K
no
w
n 
8 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Pa
ge
 1
81
# 
St
ru
ct
ur
e 
an
d 
N
am
e 
Pr
op
er
tie
s 
So
ur
ce
 
A
ct
iv
ity
 
C
om
m
en
t 
C
ha
pt
er
 
Phenol
s 
64
 
H
O
3-
un
de
cy
lp
he
no
l
 
M
W
 2
48
 
S.
 d
ec
ip
ie
ns
 
- 
K
no
w
n 
8 
Resorc
inols 
65
 
H
O
5-
un
de
cy
lre
so
rc
in
ol
O
H
 
M
W
 2
64
 
S.
 d
ec
ip
ie
ns
 
- 
K
no
w
n 
8 
 R
ef
er
en
ce
s 
C
ha
nd
, S
., 
Lu
su
nz
i, 
I.,
 V
ea
l, 
D
. A
., 
W
ill
ia
m
s, 
L.
 R
., 
&
 K
ar
us
o,
 P
. (
19
94
). 
R
ap
id
 sc
re
en
in
g 
of
 th
e 
an
tim
ic
ro
bi
al
 a
ct
iv
ity
 o
f e
xt
ra
ct
s a
nd
 n
at
ur
al
 p
ro
du
ct
s. 
Jo
ur
na
l o
f 
An
tib
io
tic
s, 
47
(1
1)
, 1
29
5-
13
04
.  
C
on
gr
ev
e,
 M
ile
s, 
C
ar
r, 
R
ob
in
, M
ur
ra
y,
 C
hr
is
, &
 Jh
ot
i, 
H
ar
re
n.
 (2
00
3)
. A
 ‘R
ul
e 
of
 T
hr
ee
’ f
or
 fr
ag
m
en
t-b
as
ed
 le
ad
 d
is
co
ve
ry
? 
D
ru
g 
D
is
co
ve
ry
 T
od
ay
, 8
(1
9)
, 8
76
-
87
7.
  
Li
pi
ns
ki
, C
hr
is
to
ph
er
 A
., 
Lo
m
ba
rd
o,
 F
ra
nc
o,
 D
om
in
y,
 B
er
yl
 W
., 
&
 F
ee
ne
y,
 P
au
l J
. (
19
97
). 
Ex
pe
rim
en
ta
l a
nd
 c
om
pu
ta
tio
na
l a
pp
ro
ac
he
s t
o 
es
tim
at
e 
so
lu
bi
lit
y 
an
d 
pe
rm
ea
bi
lit
y 
in
 d
ru
g 
di
sc
ov
er
y 
an
d 
de
ve
lo
pm
en
t s
et
tin
gs
. A
dv
an
ce
d 
D
ru
g 
D
el
iv
er
y 
Re
vi
ew
s, 
23
(1
-3
), 
3-
25
.  
M
an
n,
 C
.M
., 
&
 M
ar
kh
am
, J
. L
. (
19
98
). 
A
 n
ew
 m
et
ho
d 
fo
r d
et
er
m
in
in
g 
th
e 
m
in
im
um
 in
hi
bi
to
ry
 c
on
ce
nt
ra
tio
n 
of
 e
ss
en
tia
l o
ils
. J
ou
rn
al
 o
f A
pp
lie
d 
M
ic
ro
bi
ol
og
y,
 
84
(4
), 
53
8-
54
4.
  
  
Pa
ge
 1
82
APPENDIX A 
Supplementary Information for HPLC-NMR Limit of 
Detection Studies  
 
This appendix contains further information relevant to the HPLC-NMR limit of 
detection studies as outlined in Chapter 4. 
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Limit of Detection Studies for Application to Natural Product 
Identification using High Performance Liquid Chromatography 
coupled to Nuclear Magnetic Resonance Spectroscopy 
Robert Brkljača and Sylvia Urban*
School of Applied Sciences (Discipline of Chemistry), Health Innovations Research Institute (HIRi) 
RMIT University, GPO Box 2476V Melbourne, Victoria 3001, Australia). 
Supporting Information  
S1. NMR data of methylparaben acquired by stop-flow HPLC-NMR and by conventional off-line NMR 
analyses. 
S2. WET1D Proton NMR spectra (obtained from stop-flow HPLC-NMR mode) of methylparaben 
(amounts of 0.5, 0.7, 1, 5, 10, 15, 25, 50, 200, 500 and 1000 µg injected, 500 MHz, 50% CH3CN/D2O). 
S3. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (5 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S4. WET1D Proton NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben 
(500 MHz, 50% CH3CN/D2O). 
S5. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (5 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S6. gCOSY NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben (500 
MHz, 50% CH3CN/D2O). 
S7. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (50 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S8. HSQCAD NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben (500 
MHz, 50% CH3CN/D2O). 
S9. gHMBCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (250 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S10. gHMBCAD NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben 
(500 MHz, 50% CH3CN/D2O). 
S11. NMR data of rhodamine B acquired by stop-flow HPLC-NMR and by conventional off-line NMR 
analyses. 
S12. WET1D Proton NMR spectra (obtained from stop-flow HPLC-NMR mode) of rhodamine B 
(amounts of 25, 50, 100, 250, 500 and 1000 µg injected, 500 MHz, 50% CH3CN/D2O). 
S13. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (50 
µg injected, 500 MHz, 50% CH3CN/D2O). 
S14. WET1D Proton NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B 
(500 MHz, 50% CH3CN/D2O). 
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S15. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (250 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S16. gCOSY NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
S17. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (500 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S18. HSQCAD NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
S19. gHMBCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (1000 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
S20. gHMBCAD NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
S21. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 1 at 
9.59 mins (3520 µg of the crude extract of C. subfarcinata injected, 500 MHz, 75% CH3CN/D2O). 
S22. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 1 at 9.59 mins 
(500 MHz, 75% CH3CN/D2O). 
S23. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 1 at 9.59 
mins (500 MHz, 75% CH3CN/D2O). 
S24. gHMBCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 1 at 9.59 
mins (500 MHz, 75% CH3CN/D2O). 
S25. High resolution negative ESI-MS of component 1 at 9.59 mins obtained from HRESILC-MS. 
S26. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 2 at 
13.05 mins (3520 µg of the crude extract of C. subfarcinata injected, 500 MHz, 75% CH3CN/D2O). 
S27. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 2 at 13.05 mins 
(500 MHz, 75% CH3CN/D2O). 
S28. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of component 2 at 13.05 
mins (500 MHz, 75% CH3CN/D2O). 
S29. High resolution negative ESI-MS of component 2 at 13.05 mins obtained from HRESILC-MS. 
 
*Corresponding author. Tel: +61 3 9925 3376; Fax: +61 3 9925 3747 
E-mail address: sylvia.urban@rmit.edu.au (S. Urban). 
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 S2. WET1D Proton NMR spectra (obtained from stop-flow HPLC-NMR mode) of methylparaben 
(amounts of 0.5, 0.7, 1, 5, 10, 15, 25, 50, 200, 500 and 1000 µg injected, 500 MHz, 50% CH3CN/D2O). 
 
1 ug (scale x30) 
5 ug (scale x30) 
1000 ug 
500 ug 
200 ug 
50 ug 
15 ug 
10 ug 
0.7 ug (scale x30) 
0.5 ug (scale x30) 
25 ug 
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S3. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (5 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S4. WET1D Proton NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben 
(500 MHz, 50% CH3CN/D2O). 
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 S5. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (5 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S6. gCOSY NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben (500 
MHz, 50% CH3CN/D2O)). 
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S7. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (50 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S8. HSQCAD NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben (500 
MHz, 50% CH3CN/D2O). 
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S9. gHMBCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of methylparaben (250 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S10. gHMBCAD NMR spectrum (obtained from conventional off-line NMR mode) of methylparaben 
(500 MHz, 50% CH3CN/D2O). 
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 S12. WET1D Proton NMR spectra (obtained from stop-flow HPLC-NMR mode) of rhodamine B 
(amounts of 25, 50, 100, 250, 500 and 1000 µg injected, 500 MHz, 50% CH3CN/D2O). 
50 ug 
100 ug 
250 ug 
500 ug 
1000 ug 
25 ug 
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S13. WET1D Proton NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (50 
µg injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S14. WET1D Proton NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B 
(500 MHz, 50% CH3CN/D2O). 
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 S15. gCOSY NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (250 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
S16. gCOSY NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
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S17. HSQCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (500 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S18. HSQCAD NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
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S19. gHMBCAD NMR spectrum (obtained from stop-flow HPLC-NMR mode) of rhodamine B (1000 µg 
injected, 500 MHz, 50% CH3CN/D2O). 
 
 
S20. gHMBCAD NMR spectrum (obtained from conventional off-line NMR mode) of rhodamine B (500 
MHz, 50% CH3CN/D2O). 
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APPENDIX B 
Supplementary Information for the Study of the Australian plant 
Macropidia fuliginosa 
 
This appendix contains further information relevant to the chemical investigation 
conducted on the flowers and bulbs of the Australian plant Macropidia fuliginosa as outlined 
in Chapter 5. 
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Supporting Information  
 
S1. Extracted UV profile of compound eluting at 2.45 mins (rutin (4)) from HPLC. 
S2. High resolution negative ESI-MS of compound eluting at 2.45 mins (rutin (4)) from HPLC-MS.  
S3. Extracted UV profile of compound eluting at 3.74 mins (haemofluorone A (1)) from HPLC. 
S4. High resolution negative ESI-MS of compound eluting at 3.74 mins (haemofluorone A (1)) from 
HPLC-MS. 
S5. Extracted UV profile of compound eluting at 4.44 mins (haemofluorone B (2)) from HPLC. 
S6. High resolution negative ESI-MS of compound eluting at 4.44 mins (haemofluorone B (2)) from 
HPLC-MS. 
S7. Extracted UV profile of compound eluting at 15.05 mins (compound 8) from HPLC. 
S8. High resolution negative ESI-MS of compound eluting at 15.05 mins (compound 8) from HPLC-MS. 
S9. Stop-flow WET1D Proton NMR spectrum of compounds eluting at (3.28 mins) (fuliginosin A (12) 
and B (13)). 
S10. On-flow WET1D Proton NMR spectrum of compound eluting at 4.11 mins (anigopreissin A (5)). 
S11. On-flow WET1D Proton NMR spectrum of compound eluting at 4.11 mins (anigopreissin A (5)). 
S12. High resolution negative ESI-MS of compound eluting at 4.11 mins (anigopreissin A (5)) from 
HPLC-MS. 
S13. Stop-flow WET1D Proton NMR spectrum of compound eluting at 11.31 mins (fuliginosone (14)). 
S14. Expansion of Stop-flow WET1D Proton NMR spectrum of compound eluting at 11.31 mins 
(fuliginosone (14)). 
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S15. High resolution negative ESI-MS of compound eluting at 11.31 mins (fuliginosone (14)) from 
HPLC-MS. 
S16. Stop-flow WET1D Proton NMR spectrum of compound eluting at 12.35 mins (compound 6). 
S17. Expansion of Stop-flow WET1D Proton NMR spectrum of compound eluting at 12.35 mins 
(compound 6). 
S18. gCOSY NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 12.35 mins 
(compound 6). 
S19. HSQCAD NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 12.35 mins 
(compound 6). 
S20. Expansion of HSQCAD NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 
12.35 mins (compound 6). 
S21. High resolution negative ESI-MS of compound eluting at 12.35 mins (compound 6) from HPLC-
MS. 
S22. Stop-flow WET1D Proton NMR spectrum of compound eluting at 19.11 mins (anigorufone (7)). 
S23. Expansion of Stop-flow WET1D Proton NMR spectrum of compound eluting at 19.11 mins 
(anigorufone (7)). 
S24. gCOSY NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 19.11 mins 
(anigorufone (7)). 
S25. HSQCAD NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 19.11 mins 
(anigorufone (7)). 
S26. Expansion of HSQCAD NMR spectrum (from stop-flow HPLC-NMR) of compound eluting at 
19.11 mins (anigorufone (7)). 
S27. High resolution negative ESI-MS of compound eluting at 19.11 mins (anigorufone (7)) from HPLC-
MS. 
S28. 1H NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
S29. gCOSY NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
S30. HSQCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
S31. Expansion of HSQCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
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S32. gHMBCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
S33. Expansion of gHMBCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin A (12). 
S34. High resolution negative ESI-MS of fuliginosin A (12). 
S35. 1H NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S36. Expansion of 1H NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S37. gCOSY NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S38. HSQCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S39. Expansion of HSQCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S40. gHMBCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S41. Expansion of gHMBCAD NMR spectrum (500 MHz, d6-DMSO) of fuliginosin B (13). 
S42. High resolution negative ESI-MS of fuliginosin B (13). 
S43. 1H NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S44. Expansion of 1H NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S45. 13C NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S46. gCOSY NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S47. HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S48. Expansion of HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S49. gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S50. Expansion of gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginosone (14). 
S51. High resolution negative ESI-MS of fuliginosone (14). 
S52. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
fuliginosone (14). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
S53. 1H NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S54. Expansion of 1H NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S55. gCOSY NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
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S56. HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S57. Expansion of HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S58. gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S59. Expansion of gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginone (15). 
S60. Single irradiation nOe NMR spectrum (500 MHz, CDCl3) of fuliginone (15) showing the irradiation 
of δH 7.17 (H-3). 
S61. Single irradiation nOe NMR spectrum (500 MHz, CDCl3) of fuliginone (15) showing the irradiation 
of δH 7.72 (H-4). 
S62. High resolution positive ASAP-MS of fuliginone (15). 
S63. 1H NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S64. Expansion of 1H NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S65. 13C NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S66. gCOSY NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S67. HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S68. Expansion of HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S69. gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S70. Expansion of gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16). 
S71. 1H NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol (17). 
S72. Expansion of 1H NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol (17). 
S73. gCOSY NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol (17). 
S74. HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol (17). 
S75. Expansion of HSQCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol 
(17). 
S76. gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol (17). 
S77. Expansion of gHMBCAD NMR spectrum (500 MHz, CDCl3) of fuliginol (16) and chlorofuliginol 
(17). 
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S78. High resolution negative ESI-MS of fuliginol (16) and chlorofuliginol (17). 
S79. Atomic coordinates ( x 104)for fuliginol (16) and chlorofuliginol (17) and equivalent isotropic 
displacement parameters (Å2x 103)for fuliginol (16) and chlorofuliginol (17). U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
 
*Corresponding author. Tel: +61 3 9925 3376; Fax: +61 3 9925 3747 
E-mail address: sylvia.urban@rmit.edu.au (S. Urban). 
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S52. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 
fuliginosone (14). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 6572(3) -827(3) 4452(1) 25(1) 
C(2) 7571(3) -1319(3) 4710(1) 27(1) 
C(3) 9216(3) -1187(3) 4652(1) 29(1) 
C(4) 9827(3) -560(3) 4351(1) 27(1) 
C(5) 8819(2) -25(3) 4078(1) 24(1) 
C(6) 9260(2) 632(3) 3753(1) 26(1) 
C(7) 8145(3) 1018(3) 3509(1) 25(1) 
C(8) 6493(2) 822(3) 3566(1) 23(1) 
C(9) 6029(2) 232(3) 3887(1) 23(1) 
C(10) 7182(2) -181(3) 4138(1) 22(1) 
C(11) 4830(3) -864(3) 4417(1) 27(1) 
C(12) 4479(2) -250(3) 4041(1) 25(1) 
C(13) 5370(3) 1239(3) 3286(1) 24(1) 
C(14) 5701(3) 686(3) 2952(1) 28(1) 
C(15) 4688(3) 1130(3) 2685(1) 32(1) 
C(16) 3349(3) 2150(3) 2749(1) 33(1) 
C(17) 2993(3) 2697(3) 3079(1) 30(1) 
C(18) 3993(3) 2241(3) 3346(1) 26(1) 
O(1) 3821(2) -1277(2) 4619(1) 35(1) 
O(2) 3174(2) -301(2) 3918(1) 34(1) 
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S79. Atomic coordinates ( x 104)for fuliginol (16) and chlorofuliginol (17) and equivalent isotropic 
displacement parameters (Å2x 103)for fuliginol (16) and chlorofuliginol (17). U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 7429(6) 4440(4) 5709(4) 33(1) 
C(2) 7287(6) 3404(4) 6613(4) 31(1) 
C(3) 7335(6) 3718(4) 7906(4) 38(1) 
C(4) 7600(7) 5004(4) 8186(4) 41(1) 
C(5) 7738(7) 6007(4) 7304(4) 40(1) 
C(6) 7612(6) 5762(4) 6070(4) 34(1) 
C(7) 7691(6) 6845(4) 5159(4) 36(1) 
C(8) 7599(6) 6522(4) 3860(4) 36(1) 
C(10) 7324(6) 4181(4) 4422(4) 34(1) 
C(11) 7081(6) 2913(4) 4076(4) 37(1) 
C(12) 6971(6) 1879(4) 4946(4) 32(1) 
C(13) 7105(6) 2088(4) 6194(4) 33(1) 
C(14) 7054(7) 2761(4) 8990(4) 43(1) 
C(15) 5285(8) 2303(5) 9402(4) 50(1) 
C(16) 5002(10) 1505(5) 10464(5) 67(2) 
C(17) 6447(12) 1160(6) 11109(5) 77(2) 
C(18) 8166(12) 1615(6) 10702(5) 75(2) 
C(19) 8483(9) 2431(5) 9643(4) 55(1) 
C(20) 8800(7) 289(4) 7047(4) 44(1) 
O(1) 7787(5) 8022(3) 5423(3) 47(1) 
O(2) 7662(5) 7548(3) 3033(3) 45(1) 
O(3) 6748(5) 646(3) 4543(3) 40(1) 
O(4) 6982(4) 996(3) 6974(3) 38(1) 
C(9) 7451(6) 5270(4) 3524(4) 37(1) 
Cl 7444(3) 4912(2) 1958(2) 41(1) 
C(9') 7451(6) 5270(4) 3524(4) 37(1) 
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APPENDIX C 
Supplementary Information for the Study of the Australian Plant 
Haemodorum spicatum 
 
This appendix contains further information relevant to study of the Australian plant 
Haemodorum spicatum as described in Chapter 6. 
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HPLC-NMR and HPLC-MS Profiling and Bioassay-Guided Identification 
of Secondary Metabolites from the Australian Plant Haemodorum 
spicatum 
 
 
Robert Brkljača and Sylvia Urban* 
School of Applied Sciences (Discipline of Chemistry), Health Innovations Research Institute (HIRi) 
RMIT University, GPO Box 2476V Melbourne, Victoria 3001, Australia). 
 
Supporting Information  
S1. Extracted UV trace from HPLC-NMR for peak A (Rt = 4.8 min) (1). 
S2. Extracted UV trace from HPLC-NMR for peak B (Rt = 5.1 min) (5). 
S3. Extracted UV trace from HPLC-NMR for peak C (Rt = 5.9 min)(11). 
S4. Extracted UV trace from HPLC-NMR for peak D (Rt = 7.0 min) (8). 
S5. Extracted UV trace from HPLC-NMR for peak E (Rt = 7.9 min) (12). 
S6. Extracted UV trace from HPLC-NMR for peak F (Rt = 9.9 min). 
S7. Extracted UV trace from HPLC-NMR for peak G (Rt = 16.9 min) (2). 
S8. Extracted UV trace from HPLC-NMR for peak H (Rt = 19.5 min) (3). 
S9. Extracted UV trace from HPLC-NMR for peak I (Rt = 23.0 min) (13). 
S10. 
1
H NMR spectrum (500 MHz, CDCl3) of haemoxiphidone (8). 
S11. gCOSY NMR spectrum (500 MHz, CDCl3) of haemoxiphidone (8). 
S12. gHSQCAD NMR spectrum (500 MHz, CDCl3) of haemoxiphidone (8). 
S13. gHMBC NMR spectrum (500 MHz, CDCl3) of haemoxiphidone (8). 
S14. Single irradiation nOe NMR spectrum (500 MHz, CDCl3) of haemoxiphidone (8).showing the 
irradiation of H 8.32 (H-7). 
S15. High resolution positive ESI-MS of haemoxiphidone (8). 
S16. 
1
H NMR spectrum (500 MHz, CDCl3) of haemodordione (13). 
S17. 
13
C NMR spectrum (125 MHz, CDCl3) of haemodordione (13). 
S18. gCOSY NMR spectrum (500 MHz, CDCl3) of haemodordione (13). 
S19. gHSQCAD NMR spectrum (500 MHz, CDCl3) of haemodordione (13). 
S20. gHMBC NMR spectrum (500 MHz, CDCl3) of haemodordione (13). 
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S21. High resolution positive ESI-MS of haemodordione (13). 
S22. 
1
H NMR spectrum (500 MHz, CDCl3) of haemodordiol (16). 
S23. gCOSY NMR spectrum (500 MHz, CDCl3) of haemodordiol (16). 
S24. gHSQCAD NMR spectrum (500 MHz, CDCl3) of haemodordiol (16). 
S25. gHMBC NMR spectrum (500 MHz, CDCl3) of haemodordiol (16). 
S26. High resolution ASAP-MS of haemodordiol (16). 
S27. 
1
H NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S28. gCOSY NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S29. gHSQCAD NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S30. gHMBC NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S31. NOESY NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S32. Expansion of NOESY NMR spectrum (500 MHz, CDCl3) of haemodoronol (17). 
S33. High resolution positive ESI-MS of haemodoronol (17). 
*Corresponding author. Tel: +61 3 9925 3376; Fax: +61 3 9925 3747 
E-mail address: sylvia.urban@rmit.edu.au (S. Urban). 
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APPENDIX D 
Supplementary Information for the Dereplication Studies 
Conducted on Seven Marine Algae 
 
This appendix contains further information relevant to the dereplication studies 
(HPLC-NMR & HPLC-MS) conducted on seven marine algae as given in Chapter 8. 
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Figure S1. Extracted UV profile of compound eluting at 2.29 min (2) from HPLC-NMR  
(S. decipiens). 
Figure S2. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
2.29 min (2) (S. decipiens). 
Figure S3. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compounds eluting at  
2.29 (2) and 2.44 min (3) (peaks diffused during stop-flow analysis) (S. decipiens). 
Figure S4. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compounds eluting at 2.29 (2) 
and 2.44 min (3) (peaks diffused during stop-flow analysis) (S. decipiens). 
Figure S5. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compounds eluting at 2.29 
(2) and 2.44 min (3) (peaks diffused during stop-flow analysis) (S. decipiens). 
Figure S6. High resolution negative ESI-MS of compound eluting at 2.29 min (2) from  
HPLC-MS (S. decipiens).  
Figure S7. NMR data for compound eluting at 2.29 min (2) (S. decipiens). 
Figure S8. Extracted UV profile of compound eluting at 2.44 min (3) from HPLC-NMR  
(S. decipiens). 
Figure S9. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
2.44 min (3) (S. decipiens). 
Figure S10. High resolution negative ESI-MS of compound eluting at 2.44 min (3) from  
HPLC-MS (S. decipiens).  
Figure S11. NMR data for compound eluting at 2.44 min (3) (S. decipiens). 
Figure S12. Extracted UV profile of compound eluting at 3.42 min (11) from HPLC-NMR  
(C. retroflexa). 
Figure S13. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
3.42 min (11) (C. retroflexa). 
Figure S14. High resolution negative ESI-MS of compound eluting at 3.42 min (11) from HPLC-MS 
(C. retroflexa).  
Figure S15. NMR data for compound eluting at 3.42 min (11) (C. retroflexa). 
Figure S16. Extracted UV profile of compound eluting at 3.55 min (1) from HPLC-NMR  
(S. decipiens). 
Figure S17. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
3.55 min (1) (S. decipiens). 
Figure S18. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
3.55 min (1) (S. decipiens). 
Figure S19. High resolution negative ESI-MS of compound eluting at 3.55 min (1) from  
HPLC-MS (S. decipiens).  
Figure S20. NMR data for compound eluting at 3.55 min (1) (S. decipiens). 
Figure S21. Extracted UV profile of compound eluting at 4.45 min (16) from HPLC-NMR  
(C. retroflexa). 
Figure S22. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
4.45 min (16) (C. retroflexa). 
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Figure S23. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
4.45 min (16) (C. retroflexa). 
Figure S24. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 4.45 
min (16) (C. retroflexa). 
Figure S25. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 4.45 
min (16) (C. retroflexa). 
Figure S26. High resolution negative ESI-MS of compound eluting at 4.45 min (16) from HPLC-MS 
(C. retroflexa).  
Figure S27. Extracted UV profile of compound eluting at 5.00 min from HPLC-NMR (Laurencia sp.). 
Figure S28. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
5.00 min (Laurencia sp.). 
Figure S29. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
5.00 min (Laurencia sp.). 
Figure S30. Extracted UV profile of compound eluting at 6.05 min from HPLC-NMR (Laurencia sp.). 
Figure S31. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
6.05 min (Laurencia sp.). 
Figure S32. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
6.05 min (Laurencia sp.). 
Figure S33. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 6.05 
min (Laurencia sp.). 
Figure S34. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 6.05 
min (Laurencia sp.). 
Figure S35. Extracted UV profile of compound eluting at 6.70 min from HPLC-NMR (Laurencia sp.). 
Figure S36. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
6.70 min (Laurencia sp.). 
Figure S37. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
6.70 min (Laurencia sp.). 
Figure S38. Extracted UV profile of compound eluting at 7.87 min (4) from HPLC-NMR  
(S. decipiens). 
Figure S39. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
7.87 min (4) (S. decipiens). 
Figure S40. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
7.87 min (4) (S. decipiens). 
Figure S41. High resolution negative ESI-MS of compound eluting at 7.87 min (4) from  
HPLC-MS (S. decipiens).  
Figure S42. NMR data for compound eluting at 7.87 min (4) (S. decipiens). 
Figure S43. Extracted UV profile of compound eluting at 9.98 min (12) from HPLC-NMR  
(C. retroflexa). 
Figure S44. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
9.98 min (12) (C. retroflexa). 
Figure S45. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at  
9.98 min (12) (C. retroflexa). 
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Figure S46. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 9.98 
min (12) (C. retroflexa). 
Figure S47. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 9.98 
min (12) (C. retroflexa). 
Figure S48. High resolution negative ESI-MS of compound eluting at 9.98 min (12) from HPLC-MS 
(C. retroflexa). 
Figure S49. NMR data for compound eluting at 9.98 min (12) (C. retroflexa). 
Figure S50. Extracted UV profile of compound eluting at 12.95 min (13) from HPLC-NMR  
(C. retroflexa). 
Figure S51. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
12.95 min (13) (C. retroflexa). 
Figure S52. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 12.95 min 
(13) (C. retroflexa). 
Figure S53. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 12.95 
min (13) (C. retroflexa). 
Figure S54. High resolution negative ESI-MS of compound eluting at 12.95 min (13) from HPLC-MS 
(C. retroflexa). 
Figure S55. NMR data for compound eluting at 12.95 min (13) (C. retroflexa). 
Figure S56. Extracted UV profile of compound eluting at 13.65 min (17) from HPLC-NMR  
(S. cf. fallax). 
Figure S57. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
13.65 min (17) (S. cf. fallax). 
Figure S58. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 13.65 min 
(17) (S. cf. fallax). 
Figure S59. High resolution negative ESI-MS of compound eluting at 13.65 min (17) from HPLC-MS 
(S. cf. fallax). 
Figure S60. Extracted UV profile of compound eluting at 14.53 min (5) from HPLC-NMR  
(H. pseudospicata). 
Figure S61. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
14.53 min (5) (H. pseudospicata). 
Figure S62. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 14.53 min 
(5) (H. pseudospicata). 
Figure S63. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 14.53 
min (5) (H. pseudospicata). 
Figure S64. ROESYAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 14.53 
min (5) (H. pseudospicata). 
Figure S65. High resolution negative ESI-MS of compound eluting at 14.53 min (5) from HPLC-MS 
(H. pseudospicata). 
Figure S66. High resolution positive ESI-MS of compound eluting at 14.53 min (5) from  
HPLC-MS (H. pseudospicata). 
Figure S67. NMR data for compound eluting at 14.53 min (5) (H. pseudospicata). 
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Figure S68. Extracted UV profile of compound eluting at 15.50 min (20) from HPLC-NMR  
(S. cf. fallax). 
Figure S69. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
15.50 min (20) (S. cf. fallax). 
Figure S70. High resolution negative ESI-MS of compound eluting at 15.50 min (20) from HPLC-MS 
(S. cf. fallax).  
Figure S71. NMR data for compound eluting at 15.50 min (20) (S. cf. fallax). 
Figure S72. Extracted UV profile of compound eluting at 20.15 min (21) from HPLC-NMR  
(C. retroflexa). 
Figure S73. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
20.15 min (21 (C. retroflexa)). 
Figure S74. High resolution negative ESI-MS of compound eluting at 20.15 min (21) from HPLC-MS 
(C. retroflexa).  
Figure S75. NMR data for compound eluting at 20.15 min (21) (C. retroflexa). 
Figure S76. Extracted UV profile of compound eluting at 21.62 min (14) from HPLC-NMR  
(S. cf. fallax). 
Figure S77. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
21.62 min (14) (S. cf. fallax). 
Figure S78. High resolution negative ESI-MS of compound eluting at 21.62 min (14) from HPLC-MS 
(S. cf. fallax).  
Figure S79. NMR data for compound eluting at 21.62 min (14) (S. cf. fallax). 
Figure S80. Extracted UV profile of compound eluting at 22.96 min (18) from HPLC-NMR  
(C. subfarcinata). 
Figure S81. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
22.96 min (18) (C. subfarcinata). 
Figure S82. High resolution negative ESI-MS of compound eluting at 22.96 min (18) from HPLC-MS 
(C. subfarcinata).  
Figure S83. Extracted UV profile of compound eluting at 23.16 min from HPLC-NMR  
(C. retroflexa). 
Figure S84. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
23.16 min (C. retroflexa). 
Figure S85. Extracted UV profile of compound eluting at 26.71 min from HPLC-NMR  
(H. pseudospicata). 
Figure S86. Extracted UV profile of compound eluting at 30.27 min from HPLC-NMR  
(H. pseudospicata). 
Figure S87. Extracted UV profile of compound eluting at 33.40 min (19) from HPLC-NMR  
(C. subfarcinata). 
Figure S88. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
33.40 min (19) (C. subfarcinata). 
Figure S89. High resolution negative ESI-MS of compound eluting at 33.40 min (19) from HPLC-MS 
(C. subfarcinata).  
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Figure S90. Extracted UV profile of compound eluting at 60.80 min (15) from HPLC-NMR  
(S. cf. fallax). 
Figure S91. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
60.80 min (15) (S. cf. fallax). 
Figure S92. NMR data for compound eluting at 60.80 min (15) (S. cf. fallax). 
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Figure S6. High resolution negative ESI-MS of compound eluting at 2.29 min (2) from 
HPLC-MS (S. decipiens). 
Position δC a, mult. δH (J in Hz) gCOSY gHMBCAD 
1 119.6, s 
2 162.0, s 
3 114.7, d 7.47, d (8.0) 4 - 
4 131.4, d 7.94, dd (8.0, 8.0) 3, 5 2, 6 
5 121.9, d 7.45, d (8.0) 4 1, 3 
6 147.2, s 
7 ND
1′ 35.5, t 3.87, t (7.5) 2′ 1, 5, 6, 2′, 3′ 
2′ 32.7, t 2.35, m 1′ 3′, 4′ 
3′ 30.2, t 2.10, m 4′, 5′ 
4′ 30.2, t 2.10, m 3′, 5′, 6′ 
5′ 30.2, t 2.10, m 3′, 4′, 6′, 7′ 
6′ 30.2, t 2.10, m 4′, 5′, 7′, 8′ 
7′ 30.2, t 2.10, m 5′, 6′, 8′ 
8′ 30.2, t 2.10, m 6′, 7′ 
9′ 32.5, t 2.10, m 7′, 8′ 
10′ 23.2, t 2.10, m 11′ 8′ 
11′ 14.3, q 1.71, t (6.0) 10′ 9′, 10′ 
2-OH ND
7-OH ND
Referenced to 75% CH3CN/D2O; a Carbon assignments based on HSQCAD and gHMBCAD NMR 
experiments; ND Not Detected. 
Figure S7. NMR data for compound eluting at 2.29 min (2) (S. decipiens). 
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Figure S8. Extracted UV profile of compound eluting at 2.44 min (3) from HPLC-NMR 
(S. decipiens). 
Figure S9. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 2.44 min (3) (S. decipiens). 
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Figure S10. High resolution negative ESI-MS of compound eluting at 2.44 min (3) from 
HPLC-MS (S. decipiens). 
Position δC a, mult. δH (J in Hz) gCOSY gHMBCAD 
1 162.0, s 
2 ND 6.31, s
3 147.2, s 
4 121.9, d 7.45, d (8.5) 5 6 
5 131.5, d 7.94, dd (8.5, 9.0) 4, 6 1, 3 
6 114.7, d 7.47, d (9.0)* 5 
1′ 35.5, t 3.87, t (7.5) 2′ 3, 4, 2′, 3′ 
2′ 32.7, t 2.35, m 1′ 3′, 4′ 
3′ 30.2, t 2.10, m 4′, 5′ 
4′ 30.2, t 2.10, m 3′, 5′, 6′ 
5′ 30.2, t 2.10, m 3′, 4′, 6′, 7′ 
6′ 30.2, t 2.10, m 4′, 5′, 7′, 8′ 
7′ 30.2, t 2.10, m 5′, 6′, 8′ 
8′ 30.2, t 2.10, m 6′, 7′ 
9′ 32.5, t 2.10, m 7′, 8′ 
10′ 23.2, t 2.10, m 11′ 8′ 
11′ 14.3, q 1.71, t (6.0) 10′ 9′, 10′ 
1-OH ND
Referenced to 75% CH3CN/D2O; a Carbon assignments based on HSQCAD and gHMBCAD NMR 
experiments; ND Not Detected; * Signals overlapped. 
Figure S11. NMR data for compound eluting at 2.44 min (3) (S. decipiens). 
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Position δH (J in Hz) 
1
2 3.86, t (7.5) 
3 2.45, p (7.5) 
4 2.21, p (7.5) 
5 3.10, dt (7.5, 9.5) 
6 6.10–6.34, m
7 6.10–6.34, m
8 3.73, dd (7.0, 7.5) 
9 4.95, dt (14.0, 7.0) 
10 6.48, dd (15.0, 7.0) 
11 7.32, dd (15.0, 11.0) 
12 6.78, dd (11.0, 10.5) 
13 6.10–6.34, m
14 SS
15 6.10–6.34, m
16 6.10–6.34, m
17 SS
18 1.76, t (7.5) 
1′
2′
3′ 6.69, s
4′
5′ 6.69, s
6′
9-OH ND
2′-OH ND
4′-OH ND
6′-OH ND
Referenced to D2O (δH 4.64 ppm); SS Signal suppressed; ND Not Detected. 
Figure S15. NMR data for compound eluting at 3.42 min (11) (C. retroflexa).
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Position δH (J in Hz) gCOSY 
1
2
3 7.48, d (8.0) 4 
4 7.96, dd (7.5, 8.0) 3, 5 
5 7.47, d (7.5) 4 
6
7
1′ 3.87, t (8.5) 2′ 
2′ 2.36, m 1′ 
3′ 2.11, m
4′ 2.11, m
5′ 2.11, m
6′ 2.11, m
7′ 2.11, m
8′ 2.11, m
9′ 2.11, m
10′ 2.11, m
11′ 2.11, m
12′ 2.11, m 13′ 
13′ 1.72, t (7.5) 12′ 
2-OH ND
7-OH ND
Referenced to 75% CH3CN/D2O; ND Not Detected. 
Figure S20. NMR data for compound eluting at 3.55 min (1) (S. decipiens). 
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Figure S23. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
4.45 min (16) (C. retroflexa). 
Figure S24. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting 
at 4.45 min (16) (C. retroflexa). 
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Figure S25. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 4.45 min (16) (C. retroflexa). 
Figure S26. High resolution negative ESI-MS of compound eluting at 4.45 min (16) from 
HPLC-MS (C. retroflexa). 
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Figure S27. Extracted UV profile of compound eluting at 5.00 min from HPLC-NMR 
(Laurencia sp.). 
Figure S28. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 5.00 min (Laurencia sp.). 
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Figure S29. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
5.00 min (Laurencia sp.). 
Figure S30. Extracted UV profile of compound eluting at 6.05 min from HPLC-NMR 
(Laurencia sp.). 
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Figure S31. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 6.05 min (Laurencia sp.). 
Figure S32. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
6.05 min (Laurencia sp.). 
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Figure S33. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting 
at 6.05 min (Laurencia sp.). 
Figure S34. gHMBCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 6.05 min (Laurencia sp.). 
Page 358
Mar. Drugs 2015, 13 
Figure S35. Extracted UV profile of compound eluting at 6.70 min from HPLC-NMR 
(Laurencia sp.). 
Figure S36. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 6.70 min (Laurencia sp.). 
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Figure S37. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
6.70 min (Laurencia sp.). 
Figure S38. Extracted UV profile of compound eluting at 7.87 min (4) from 
HPLC-NMR (S. decipiens). 
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Figure S39. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 7.87 min (4) (S. decipiens). 
Figure S40. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
7.87 min (4) (S. decipiens). 
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Figure S41. High resolution negative ESI-MS of compound eluting at 7.87 min (4) from 
HPLC-MS (S. decipiens). 
Position δH (J in Hz) gCOSY 
1
2 6.93, s
3
4 7.00, s
5
6 7.00, s
1′ 3.27, t (7.5) 2′ 
2′ 2.38, m 1′ 
3′ 2.11, m
4′ 2.11, m
5′ 2.11, m
6′ 2.11, m
7′ 2.11, m
8′ 2.11, m
9′ 2.11, m
10′ 2.11, m 11′ 
11′ 1.72, t (6.5) 10′ 
1-OH ND
3-OH ND
Referenced to 75% CH3CN/D2O; ND Not Detected. 
Figure S42. NMR data for compound eluting at 7.87 min (4) (S. decipiens).
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Position δH (J in Hz) δC, mult.a gCOSY gHMBCAD 
1 207.2, s
2 3.87, t (7.5) 44.3, t 3 1, 3, 4 
3 2.46, p (7.5) 25.1, t 2, 4 5 w 
4 2.23, p (7.5) 30.0, t 3 
5 SS 30.4, t
6 6.18–6.28, m 128.9, d 8 
7 6.18–6.28, m 128.9, d 8 
8 3.64, m 26.2, t 7, 9 6, 10 
9 6.18–6.28, m 128.9, d 8 11 
10 6.18–6.28, m 128.9, d 11 8 
11 3.64, m 26.2, t 10, 12 9, 13 
12 6.18–6.28, m 128.9, d 11 14 
13 6.18–6.28, m 128.9, d 14 11 
14 3.64, m 26.2, t 13, 15 12 
15 6.18–6.28, m 128.9, d 14 
16 6.18–6.28, m 132.7, d 14 
17 SS 21.1, t
18 1.76, t (7.0) 14.6, q 16, 17 
1′ 105.0, s
2′ 164.9, s
3′ 6.69, s 95.7, d 1′, 2′, 4′, 6′ 
4′ 164.9, s
5′ 6.69, s 95.7, d 
6′ 164.9, s
2′-OH ND 
4′-OH ND 
6′-OH ND 
Referenced to D2O (δH 4.64 ppm); a carbon assignments based on HSQCAD and gHMBCAD NMR 
experiments; w indicates weak or long range correlation; SS Signal suppressed; ND Not Detected. 
Figure S49. NMR data for compound eluting at 9.98 min (12) (C. retroflexa). 
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Figure S52. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
12.95 min (13) (C. retroflexa). 
Figure S53. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting 
at 12.95 min (13) (C. retroflexa). 
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Figure S54. High resolution negative ESI-MS of compound eluting at 12.95 min (13) from 
HPLC-MS (C. retroflexa). 
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Position δH (J in Hz) δC, mult.a gCOSY
1
2 3.88, t (7.0) 43.8, t 3 
3 2.55, m 25.3, t 2, 4 
4 3.00, m ND 3
5 6.19, m 128.9, d
6 6.19, m 128.9, d 7
7 3.60–3.70, m 26.2, t 6, 8 
8 6.19, m 128.9, d 7
9 6.19, m 128.9, d 10
10 3.60–3.70, m 26.2, t 9, 11 
11 6.19, m 128.9, d  10 
12 6.19, m 128.9, d 13
13 3.60–3.70, m 26.2, t 12, 14 
14 6.19, m 128.9, d 13
15 6.19, m 128.9, d 16
16 3.60–3.70 26.2, t 15, 17 
17 6.19, m 128.9, d 16
18 6.19, m 128.9, d
19 SS ND
20 1.76, t (7.5) 14.4, q 
1′ ND
2′ ND
3′ 6.69, s 95.6, d 
4′ ND
5′ 6.69, s 95.6, d 
6′ ND
2′-OH ND
4′-OH ND
6′-OH ND
Referenced to D2O (δH 4.64 ppm); a carbon assignments based on HSQCAD NMR experiments; SS Signal 
suppressed; ND Not Detected. 
Figure S55. NMR data for compound eluting at 12.95 min (13) (C. retroflexa). 
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Figure S56. Extracted UV profile of compound eluting at 13.65 min (17) from 
HPLC-NMR (S. cf. fallax). 
Figure S57. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 13.65 min (17) (S. cf. fallax). 
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Figure S58. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
13.65 min (17) (S. cf. fallax). 
Figure S59. High resolution negative ESI-MS of compound eluting at 13.65 min (17) from 
HPLC-MS (S. cf. fallax). 
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Figure S60. Extracted UV profile of compound eluting at 14.53 min (5) from 
HPLC-NMR (H. pseudospicata). 
Figure S61. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 14.53 min (5) (H. pseudospicata). 
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Figure S62. gCOSY NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting at 
14.53 min (5) (H. pseudospicata). 
Figure S63. HSQCAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound eluting 
at 14.53 min (5) (H. pseudospicata). 
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Figure S64. ROESYAD NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 14.53 min (5) (H. pseudospicata). 
Figure S65. High resolution negative ESI-MS of compound eluting at 14.53 min (5) from 
HPLC-MS (H. pseudospicata). 
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Figure S66. High resolution positive ESI-MS of compound eluting at 14.53 min (5) from 
HPLC-MS (H. pseudospicata). 
Position δCa, mult. δH (J in Hz) gCOSY Roesyad 
1 ND
2a 
ND 
SS
2b SS
3 ND 4.46, m
4a 
ND 
SS
4b SS
5 ND
6 ND
7a 
ND 
3.40, d (18.5) 
7b SS
8 ND
9 ND
10 ND 8.16, d (10.5) 11 7a, 12 
Figure S67. Cont. 
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11 ND 7.54, m 10, 12 
12 ND 7.65, m 10, 14 
13 ND
14 ND 7.33, d (10.5) 15 12, 15′ 
15 ND 7.58, m 14 14′ 
16 24.7, CH3 1.82, s
17 28.2, CH3 1.73, s
18 21.0, CH3 2.01, s
19 ND SS
20 ND SS
1′ ND
2a′ 
ND 
2.29, m 2b′ 16′ 
2b′ 2.04b
3′ ND 6.12, m 2a′, 4b′
4a′ 
ND 
2.51, m 4b′
4b′ 3.02b
5′ ND
6′ ND
7′ ND
8′ 103.4, CH 6.92, s 10′ 
9′ ND
10′ ND 7.01, d (11.5) 11′, 19′ 8′, 12′ 
11′ ND 7.53, m 10′, 12′ 19′ 
12′ ND 7.23, d (15.0) 10′, 14′ 
13′ ND
14′ ND 7.16, d (12.0) 15′
15′ ND 7.69, m 14′
16′ 29.2, CH3 2.16, s
17′ 32.3, CH3 1.89, s 
18′ 30.9, CH3 2.12, s
19′ ND 2.67b
20′ ND SS
21′ ND
22′ ND SS
3-OH ND
5′-OH ND
Referenced to 75% CH3CN/D2O; a Carbon assignments based on HSQCAD NMR experiment; b Proton 
assignment based on gCOSY experiment; ND Not Detected; SS Signal suppressed. 
Figure S67. NMR data for compound eluting at 14.53 min (5) (H. pseudospicata). 
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Figure S68. Extracted UV profile of compound eluting at 15.50 min (20) from HPLC-NMR 
(S. cf. fallax). 
Figure S69. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 15.50 min (20) (S. cf. fallax). 
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Figure S70. High resolution negative ESI-MS of compound eluting at 15.50 min (20) from 
HPLC-MS (S. cf. fallax). 
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Position δH (J in Hz) 
1
2 3.88, t (7.5) 
3 2.48, p (7.5) 
4 2.25, p (7.5) 
5 SS
6 6.20, m
7 6.20, m
8 3.65, m
9 6.20, m
10 6.20, m
11 3.65, m
12 6.20, m
13 6.20, m
14 SS
15 2.11–2.16, m
16 2.11–2.16, m
17 2.11–2.16, m
18 1.71, t (7.0) 
1′
2′
3′ 6.71, s
4′
5′ 6.71, s
6′
1′-OH ND
4′-OH ND
6′-OH ND
Referenced to 75% CH3CN/D2O; SS Signal suppressed; ND Not Detected. 
Figure S71. NMR data for compound eluting at 15.50 min (20) (S. cf. fallax). 
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Figure S74. High resolution negative ESI-MS of compound eluting at 20.15 min (21) from 
HPLC-MS (C. retroflexa). 
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Position δH (J in Hz) 
1
2 3.91, t (7.0) 
3 2.55 , m
4 SS
5 6.16–6.24, m
6 6.16–6.24, m
7 3.66, m
8 6.16–6.24, m
9 6.16–6.24, m
10 3.66, m
11 6.16–6.24, m
12 6.16–6.24, m
13 3.66, m
14 6.16–6.24, m
15 6.16–6.24, m
16 SS
17 SS
18 SS
19 SS
20 1.72, t (7.0) 
1′
2′
3′ 6.72, s
4′
5′ 6.72, s
6′
2′-OH ND
4′-OH ND
6′-OH ND
Referenced to D2O (δH 4.64 ppm); SS Signal suppressed; ND Not Detected. 
Figure S75. NMR data for compound eluting at 20.15 min (21) (C. retroflexa). 
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Figure S76. Extracted UV profile of compound eluting at 21.62 min (14) from HPLC-NMR 
(S. cf. fallax). 
Figure S77. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 21.62 min (14) (S. cf. fallax). 
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Figure S78. High resolution negative ESI-MS of compound eluting at 21.62 min (14) from 
HPLC-MS (S. cf. fallax). 
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Position δH (J in Hz) 
1
2 3.91, t (8.0) 
3 2.49, m
4 2.25, m
5 2.40, m *
6 6.21, m
7 6.21, m
8 3.66, m
9 6.21, m
10 6.21, m
11 3.66, m
12 6.21, m
13 6.21, m
14 3.66, m
15 6.21, m
16 6.21, m
17 SS *
18 1.78, t (7.5) 
1′
2′
3′ 6.81, s
4′
5′ 6.81, s
6′
1′-OH ND
4′-OCH3 SS
6′-OH ND
Referenced to 75% CH3CN/D2O; * signals interchangeable; SS Signal suppressed; ND Not Detected. 
Figure S79. NMR data for compound eluting at 21.62 min (14) (S. cf. fallax). 
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Mar. Drugs 2015, 13 
Figure S90. Extracted UV profile of compound eluting at 60.80 min (15) from HPLC-NMR 
(S. cf. fallax). 
Figure S91. WET1D Proton NMR spectrum (500 MHz, 75% CH3CN/D2O) of compound 
eluting at 60.80 min (15) (S. cf. fallax). 
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Position δH (J in Hz) 
1
2
3 SS
4 3.51, t (7.0) 
5 7.20, s
6
7 7.28, s
8
9
10
1′ SS
2′ SS
3′ 5.97, t (7.0) 
4′
5′ SS
6′ SS
7′ 5.92, m
8′
9′ SS
10′ SS
11′ 5.92, m
12′
2-CH3 2.08, s
8-CH3 SS
4′-CH3 2.41, s
8′-CH3 2.42, s*
12a′-CH3 2.40, s*
12b′-CH3 2.49, s
6-OH ND
Referenced to 75% CH3CN/D2O; * Signals interchangeable. 
Figure S92. NMR data for compound eluting at 60.80 min (15) (S. cf. fallax). 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
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APPENDIX E 
Supplementary Information for the Study of the Australian 
Marine Brown Alga Sargassum paradoxum 
 
This appendix contains further information relevant to the study of the Australian 
marine brown alga Sargassum paradoxum as outlined in Chapter 9. 
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Supplementary Information 
 
Figure S1. Bioassay-guided isolation scheme for S. paradoxum. 
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Table S1. NMR data (500 MHz, CDCl3) of 2-[11-(hydroxymethyl)-3,7,15-trimethyl-
2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzenediol (6). 
 
 
Position δC a, mult δH (J in Hz) gCOSY gHMBC 
1 146.4, s    
2 127.6, s    
3 114.0, d 6.46, d (2.5) 5, 1′ 1, 4, 5, 1′ 
4 149.0, s    
5 115.5, d 6.50, d (2.5) 3, 7 1, 3, 4, 7 
6 125.5, s    
7 16.1, q 2.18, s 5 1, 5, 6 
1′ 30.0, t 3.28, d (7.0) 3, 2′, 4′ 
w, 18′ w 1, 2, 3, 2′, 3′ 
2′ 122.0, d 5.26, t (7.0) 1′, 4′, 18′ 1′, 4′, 18′ 
3′ 138.1, s    
4′ 39.5, t 2.08, m 1′ w 5′, 18′ 
5′ 26.1, t 2.13, m  4′, 7′ 
6′ 124.4, d 5.09, m  4′, 5′, 19′ 
7′ 135.1, s    
8′ 39.8, t 2.00, m 9′ 7′, 9′, 10′ 19′ 
9′ 26.1, t 2.13, m 8′ 7′, 10′ 
10′ 128.9, d 5.30, t (7.5) 9′, 20′ 8′, 9′, 12′, 20′ 
11′ 138.2, s    
12′ 35.2, t 2.12, m  11′, 13′, 14′ 
13′ 27.1, t 2.11, m  11′, 12′, 14′, 15′ 
14′ 124.4, d 5.09, m 13′, 16′, 17′  
15′ 131.8, s    
16′ 17.7, q 1.60, s 13′ 14′, 15′, 17′ 
17′ 25.7, q 1.68, s 13′, 14′ 14′, 15′, 16′ 
18′ 16.2, q 1.75, s 1′, 2′ 2′, 3′, 4′ 
19′ 16.1, q 1.59, s 5′, 6′ 7′, 8′ 
20′ 60.4, t 4.11, s 10′ 10′, 11′, 12′ 
1-OH  ND b   
4-OH  ND b   
20′-OH  ND b   
a Carbon assignments made on the basis of gHSQCAD and gHMBCAD experiments. b indicates signal not 
detected. w Indicates weak or long range correlation. 
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Table S2. NMR data (500 MHz, CDCl3) of 2-[11-(hydroxymethyl)-3,7,15-trimethyl-
2,6,10,14-hexadecatetraen-1-yl]-6-methyl-1,4-benzoquinone (12). 
 
 
Position δC a, mult δH (J in Hz) gCOSY gHMBCAD bsNOESY 
1 188.0, s     
2 148.5, s     
3 132.3, d 6.46, bs 5, 1′ 1, 4, 5  
4 188.0, s     
5 133.2, d 6.54, bs 3, 7 1, 3, 4  
6 145.9, s     
7 16.0, q 2.05, s 5 1, 5, 6  
1′ 27.5, t 3.13, d (7.5) 3, 2′, 18′ 1, 2, 3, 2′, 3′  
2′ 118.1, d 5.15, t (7.5) 1′, 18′ 1′, 4′, 18′ 5, 1′, 4′ 
3′ 139.8, s     
4′ 39.6, t 2.07, m  2′, 3′, 5′, 18′  
5′ 26.2, t 2.11, m 6′, 18′ w, 19′ w 3′, 4′, 6′  
6′ 124.2, d 5.10, m 5′ 4′, 5′, 19′ 5′, 8′ 
7’ 135.1, s     
8′ 39.8, t 2.01, m  6′, 10′  
9′ 26.2, t 2.16, m 10′ 8′, 10′, 11′  
10′ 128.5, d 5.30, t (7.0) 9′, 20′ 8′, 9′, 12′, 20′ 12′ 
11′ 138.4, s     
12′ 35.2, t 2.12, m  11′, 13′, 14′, 15′  
13′ 27.1, t 2.12, m  14′, 17′ w 11′, 12′, 14′, 15′  
14′ 124.2, d 5.10, m  13′, 16′  17′ 
15′ 131.7, s     
16′ 17.7, q 1.60, s  14′, 15′  
17′ 25.7, q 1.68, s 13′ w 14′, 15′, 16′  
18′ 16.1, q 1.61, s  2′, 3′  
19′ 16.1, q 1.61, s    
20′ 60.3, t 4.11, s  10′, 11′, 12′  
20′-OH  ND b    
a Carbon assignments made on the basis of gHSQCAD and gHMBCAD experiments. b indicates signal not 
detected. c bs stands for band selective (Selective NOESY experiment). w Indicates weak or long range 
correlation. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
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APPENDIX F 
Supplementary Information for the dereplication and structural 
identification studies of marine algae of the genus Cystophora 
 
This appendix contains further information relevant to the dereplication (HPLC-NMR 
& HPLC-MS) and structural identification studies  conducted of marine algae of the 
Cystophora genus as described in Chapter 10. 
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Supporting Information Available 
S1. Extracted UV profile (70% CH3CN/D2O) of 1 from HPLC-NMR. 
S2. Stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of 1. 
S3. gCOSY NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 1. 
S4. gHSQCAD NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 1. 
S5. gHMBC NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 1. 
S6. High resolution negative ESI-MS of 1 from HPLC-MS. 
S7. Extracted UV profile (70% CH3CN/D2O) of 2 from HPLC-NMR. 
S8. Stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of 2. 
S9. gCOSY NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 2. 
S10. High resolution negative ESI-MS of 2 from HPLC-MS. 
S11. Extracted UV profile (70% CH3CN/D2O) of 3 from HPLC-NMR. 
S12. Stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of 3. 
S13. gCOSY NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 3. 
S14. High resolution negative ESI-MS of 3 from HPLC-MS. 
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S15. Extracted UV profile (75% CH3CN/D2O) of 4 from HPLC-NMR. 
S16. Stop-flow WET1D Proton NMR spectrum (75% CH3CN/D2O) of 4. 
S17. gCOSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of 4. 
S18. HSQCAD NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of 4. 
S19. gHMBCAD NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of 4. 
S20. High resolution negative ESI-MS of 4 from HPLC-MS. 
S21. Extracted UV profile (70% CH3CN/D2O) of 5 from HPLC-NMR. 
S22. Stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of 5. 
S23. gCOSY NMR spectrum (70% CH3CN/D2O) (from stop-flow HPLC-NMR) of 5. 
S24. High resolution negative ESI-MS of 5 from HPLC-MS. 
S25. Extracted UV profile (75% CH3CN/D2O) of 6 from HPLC-NMR. 
S26. Stop-flow WET1D Proton NMR spectrum (75% CH3CN/D2O) of 6. 
S27. gCOSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of 6. 
S28. High resolution negative ESI-MS of 6 from HPLC-MS. 
S29. Extracted UV profile (75% CH3CN/D2O) of 7 from HPLC-NMR. 
S30. Stop-flow WET1D Proton NMR spectrum (75% CH3CN/D2O) of 7. 
S31. gCOSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of 7. 
S32. Extracted UV profile (75% CH3CN/D2O) of 8 from HPLC-NMR. 
S33. Stop-flow WET1D Proton NMR spectrum (75% CH3CN/D2O) of moniliferanone A (8). 
S34. gCOSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of moniliferanone A (8). 
S35. 1D TOCSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of moniliferanone A 
(8). 
S36. HSQCAD NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of moniliferanone A 
(8). 
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S37. Expanded stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of moniliferanone A (8) 
and moniliferanone C (11) showing relative intensities from C. monilifera. 
S38. Expanded stop-flow WET1D Proton NMR spectrum (70% CH3CN/D2O) of moniliferanone A (8) 
and moniliferanone C (11) showing relative intensities from C. subfarcinata. 
S39. High resolution negative ESI-MS of moniliferanone A (8) from HPLC-MS. 
S40. Extracted UV profile (75% CH3CN/D2O) of 9 from HPLC-NMR. 
S41. Stop-flow WET1D Proton NMR spectrum (75% CH3CN/D2O) of moniliferanone B (9). 
S42. gCOSY NMR spectrum (75% CH3CN/D2O) (from stop-flow HPLC-NMR) of moniliferanone B (9). 
S43. High resolution negative ESI-MS of moniliferanone B (9) from HPLC-MS. 
S44. 1H NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and C (11) mixture. 
S45. 13C NMR spectrum (125 MHz, CDCl3) of moniliferanone A (8) and C (11) mixture. 
S46. gCOSY NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and C (11) mixture. 
S47. gHSQCAD NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and C (11) mixture. 
S48. gHMBC NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and C (11) mixture. 
S49. Expanded 1H NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and moniliferanone C (11) 
showing relative intensities from C. monilifera. 
S50. Expanded 1H NMR spectrum (500 MHz, CDCl3) of moniliferanone A (8) and moniliferanone C (11) 
showing relative intensities from C. subfarcinata. 
S51. High resolution negative ESI-MS of moniliferanone A (8) and C (11) mixture. 
S52. 1H NMR spectrum (500 MHz, CDCl3) of moniliferanone B (9). 
S53. gCOSY NMR spectrum (500 MHz, CDCl3) of moniliferanone B (9). 
S54. gHSQCAD NMR spectrum (500 MHz, CDCl3) of moniliferanone B (9). 
S55. gHMBC NMR spectrum (500 MHz, CDCl3) of moniliferanone B (9). 
S56. High resolution negative ESI-MS of moniliferanone B (9). 
S57. 1H NMR spectrum (500 MHz, CDCl3) of moniliferanone D (12). 
S58. gCOSY NMR spectrum (500 MHz, CDCl3) of moniliferanone D (12). 
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S59. gHSQCAD NMR spectrum (500 MHz, CDCl3) of moniliferanone D (12). 
S60. gHMBC NMR spectrum (500 MHz, CDCl3) of moniliferanone D (12). 
S61. High resolution negative ESI-MS of moniliferanone D (12). 
*Corresponding author. Tel: +61 3 9925 3376; Fax: +61 3 9925 3747 
E-mail address: sylvia.urban@rmit.edu.au (S. Urban). 
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